Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.73 - u-Plasminogen activator

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abdominal Abscess
Percutaneous treatment of intrabdominal abscess: urokinase versus saline serum in 100 cases using two surgical scoring systems in a randomized trial.
[Utility of urokinase in percutaneous drainage treatment of intra-abdominal abscesses.]
Abortion, Habitual
Could the defects in the endometrial extracellular matrix during the implantation be a cause for impaired fertility?
Abscess
Adjuvant urokinase therapy in percutaneous drainage of a multiloculated splenic abscess.
Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat.
Cutaneous infiltrates of histiocytosis X contain plasminogen activator-bearing epidermotropic dendritic cells different from Langerhans cells.
Effect of intracavitary injection of urokinase in the experimentally induced early pyogenic liver abscess of the rabbit.
Fluid flow during percutaneous drainage procedures: an in vitro study of the effects of fluid viscosity, catheter size, and adjunctive urokinase.
Intracavitary urokinase for enhancement of percutaneous abscess drainage: phase II trial.
Intraperitoneal thrombolytic agents in relapsing or persistent peritonitis of patients on continuous ambulatory peritoneal dialysis.
Percutaneous treatment of intrabdominal abscess: urokinase versus saline serum in 100 cases using two surgical scoring systems in a randomized trial.
Safety of intracavitary urokinase with percutaneous abscess drainage.
Ultrasound-guided drainages and sclerotherapy.
Use of urokinase in percutaneous drainage of large breast abscesses.
Young Investigator Award. In vivo treatment of infected prosthetic graft material with urokinase: an animal model.
[Usefulness of urokinase in intraabdominal abscesses.]
Acantholysis
American Academy of Dermatology 1999 Awards for Young Investigators in Dermatology. Pemphigus vulgaris IgG regulates expression of urokinase receptor and junctional proteins that may contribute to acantholysis.
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Functional involvement of urokinase-type plasminogen activator receptor in pemphigus acantholysis.
In vivo studies on the involvement of urokinase in pemphigus acantholysis.
Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG.
Pemphigus IgG induces expression of urokinase plasminogen activator receptor on the cell surface of cultured keratinocytes.
Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice.
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Role of plasminogen activator in pemphigus vulgaris.
Strict correlation between uPAR and plakoglobin expression in pemphigus vulgaris.
Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis.
[The role of urokinase-type plasminogen activator in the pathogenesis of pemphigus]
Acidosis
A new approach to the treatment of experimental septic shock.
Acquired Immunodeficiency Syndrome
Altered levels of urokinase on monocytes and in serum of children with AIDS; effects on lymphocyte activation and surface marker expression.
Dysregulated proteolysis in AIDS.
The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.
Acute Coronary Syndrome
Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase.
Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of acute coronary syndrome.
Safety and efficacy of abciximab use in conjunction with intracoronary urokinase in patients requiring angioplasty.
Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes.
Soluble Urokinase Plasminogen Activator Receptor for Risk Prediction in Patients Admitted with Acute Chest Pain.
[Urokinase-type plasminogen activator and its inhibitor type 1 in the diagnosis of evolving complications in coronary heart disease]
Acute Kidney Injury
Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
Acute renal allograft dysfunction in the setting of deep venous thrombosis: a case of successful urokinase thrombolysis and a review of the literature.
Cell Cycle Biomarkers and Soluble Urokinase-Type Plasminogen Activator Receptor for the Prediction of Sepsis-Induced Acute Kidney Injury Requiring Renal Replacement Therapy: A Prospective, Exploratory Study.
Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery.
Endarterial urokinase in childhood hemolytic uremic syndrome.
Postpartum acute renal failure: possible role for endarterial urokinase.
RAGE and ?V?3-integrin are essential for suPAR signaling in podocytes.
Soluble Urokinase Receptor and Acute Kidney Injury.
Soluble Urokinase Receptor and Acute Kidney Injury. Reply.
Urokinase (UK) activity in acute renal failure.
[Physiopathology of urokinase excretion as studied on the model of acute kidney failure]
[Urokinase (UK) activity in acute renal failure]
[Urokinase excretion and fibrinolysis in consumption coagulopathy and acute kidney failure]
Acute Lung Injury
Association between urokinase haplotypes and outcome from infection-associated acute lung injury.
Hyaluronan fragments induce plasminogen activator inhibitor-1 and inhibit urokinase activity in mouse alveolar macrophages: a potential mechanism for impaired fibrinolytic activity in acute lung injury.
Induction of urokinase-type plasminogen activator receptor by IL-1 beta.
Involvement of the urokinase kringle domain in lipopolysaccharide-induced acute lung injury.
Lack of durable protection against cotton smoke-induced acute lung injury in sheep by nebulized single chain urokinase plasminogen activator or tissue plasminogen activator.
Nebulization of Single-Chain Tissue-Type and Single-Chain Urokinase Plasminogen Activator for Treatment of Inhalational Smoke-Induced Acute Lung Injury.
Post-transcriptional regulation of urokinase-type plasminogen activator receptor expression in lipopolysaccharide-induced acute lung injury.
The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability.
Urokinase Plasminogen Activator Regulates Pulmonary Arterial Contractility and Vascular Permeability in Mice.
Urokinase-type plasminogen activator (uPA) induces pulmonary microvascular endothelial permeability through low density lipoprotein receptor-related protein (LRP)-dependent activation of endothelial nitric-oxide synthase.
Urokinase-Type Plasminogen Activator Inhibits Efferocytosis of Neutrophils.
Wood Bark Smoke Induces Lung and Pleural Plasminogen Activator Inhibitor 1 and Stabilizes its mRNA in Porcine Lung Cells.
Acute-On-Chronic Liver Failure
Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure.
Adenocarcinoma
2,3,7,8-Tetrachlorodibenzo-p-dioxin increases mRNA levels for interleukin-1beta, urokinase plasminogen activator, and tumor necrosis factor-alpha in human uterine endometrial adenocarcinoma RL95-2 cells.
Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I).
Antigen expression associated with lymph node metastasis in gastric adenocarcinomas.
Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells.
Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues.
Correlation between urokinase-type plasminogen activator production and the metastasizing ability of two murine mammary adenocarcinomas.
Detection of cathepsin B, plasminogen activators and plasminogen activator inhibitor in human non-small lung cancer cell lines.
Dexamethasone decreases urokinase plasminogen activator mRNA stability in MAT 13762 rat mammary carcinoma cells.
Early detection of pancreatic cancers in liquid biopsies by ultrasensitive fluorescence nanobiosensors.
Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group.
Enhancement of urokinase-type plasminogen activator activity during the growth of a murine mammary adenocarcinoma.
Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma.
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinoma.
Expression of cancer stem cell markers is prognostic in metastatic gastroesophageal adenocarcinoma.
Expression of ETS-1 is correlated with urokinase-type plasminogen activator and poor prognosis in pulmonary adenocarcinoma.
Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.
Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
Helicobacter pylori induces plasminogen activator inhibitor 2 in gastric epithelial cells through nuclear factor-kappaB and RhoA: implications for invasion and apoptosis.
High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma.
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer.
Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma.
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas.
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.
Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by basic fibroblast growth factor and transforming growth factor beta.
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
Overproduction of urokinase-type plasminogen activator is regulated by phospholipase D- and protein kinase C-dependent pathways in murine mammary adenocarcinoma cells.
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer.
Plasminogen Activation System in Rectal Adenocarcinoma.
Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
Plasminogen activator profiles in neoplastic tissues of the human colon.
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Plasminogen activators in (pre)malignant conditions of the colorectum.
Plasminogen activators in oesophageal carcinoma.
Post-transcriptional regulation of urokinase plasminogen activator gene expression occurs in the nucleus of BC1 rat mammary tumor cells.
Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction, and cardia evaluated by uPAR-immunohistochemistry.
Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.
Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Purification and characterization of an inhibitor of plasminogen activator released by rat mammary adenocarcinoma cells.
Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells.
Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells.
Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery.
Selective loss of TGFbeta Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines.
Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction.
Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.
The first international urokinase/warfarin trial in colorectal cancer.
The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma.
TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells.
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma.
Urokinase-type plasminogen activator activity increases during the growth of two murine mammary adenocarcinomas with different metastasizing abilities.
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.
Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro.
Adenocarcinoma of Lung
Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines.
Enhanced urokinase-type plasminogen activator activity by extracellular matrix protein obtained from highly metastatic human lung adenocarcinoma cell line.
HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression.
Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma.
Intrabronchial orthotopic propagation of human lung adenocarcinoma--characterizations of tumorigenicity, invasion and metastasis.
Pharmacokinetics of single chain forms of urokinase-type plasminogen activator.
Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator.
Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures.
The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
Urokinase-type plasminogen activator and its specific receptor in high metastatic and non-metastatic cell lines derived from human lung adenocarcinoma.
Adenoma
A urokinase-type plasminogen activator deficiency diminishes the frequency of intestinal adenomas in Apc(Min/+) mice.
Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas.
Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors.
Effect of anthraquinone-laxatives on the proliferation and urokinase secretion of normal, premalignant and malignant colonic epithelial cells.
Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum.
Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Plasmin-catalyzed proteolysis in colorectal neoplasia.
Role of urokinase in colorectal neoplasia.
The expression of p53, Ki-67 and urokinase plasminogen activator receptor in colorectal adenomas with true invasion and pseudoinvasion.
The Plasminogen System in Microdissected Colonic Mucosa Distant from an Isolated Adenoma.
Tumor-promoter-enhanced destruction of noninvasive human benign colon tumor cells by cocultivated carcinoma cells.
Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Urokinase secretion from human colon carcinomas induced by endogenous diglycerides.
Adenomatous Polyposis Coli
Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme.
Adenomatous Polyps
BMP pathway suppression is an early event in inflammation-driven colon neoplasmatogenesis of uPA-deficient mice.
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?
Plasminogen activators in human colorectal neoplasia.
Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme.
AIDS Dementia Complex
The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.
Airway Obstruction
Plastic bronchitis occurring late after the Fontan procedure: treatment with aerosolized urokinase.
[Plastic bronchitis. A case report and review of the literature]
Albuminuria
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
Alopecia
Enoxaparin-induced alopecia in patients with cerebral venous thrombosis.
Alveolar Bone Loss
Association of gene polymorphisms for plasminogen activators with alveolar bone loss.
Alzheimer Disease
A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimer's disease.
Association of late-onset Alzheimer disease with a genotype of PLAU, the gene encoding urokinase-type plasminogen activator on chromosome 10q22.2.
Association of tagSNPs in the urokinase-plasminogen activator (PLAU) gene with Alzheimer's disease and associated quantitative traits.
Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene.
Excessive urokinase-type plasminogen activator activity in the euglobulin fraction of patients with Alzheimer-type dementia.
Genetic association of urokinase-type plasminogen activator gene rs2227564 site polymorphism with sporadic Alzheimer's disease in the Han Chinese population.
Meta-analysis of the association between urokinase-plasminogen activator gene rs2227564 polymorphism and Alzheimer's disease.
The urokinase-plasminogen activator (PLAU) gene is not associated with late onset Alzheimer's disease.
The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-epsilon4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma Abeta(1-42) level.
Ameloblastoma
Presence of Myofibroblasts and Expression of Matrix Metalloproteinase-2 (MMP-2) in Ameloblastomas Correlate with Rupture of the Osseous Cortical.
Amnesia
[FDG-PET in an amnestic and hypersomnic patient with bilateral paramedian thalamic infarction]
Amyloidosis
Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review.
Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase.
[Fibrinolytic activity of the urine during chronic glomerulonephritis and amyloidosis]
[Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis]
Amyotrophic Lateral Sclerosis
A role for the urokinase-type plasminogen activator system in amyotrophic lateral sclerosis.
The urokinase system of plasminogen activator plays a role in amyotrophic lateral sclerosis (ALS) pathogenesis.
Anaphylaxis
Alteplase use for prevention of central line occlusion in a preterm infant.
Clinical utility of novel agents in the treatment of central venous catheter occlusion.
Highly probable anaphylactic reaction to systemic thrombolytic therapy with high dose urokinase in a child with a prosthetic valve.
Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase.
Pulsus paradoxus in anaphylactic shock due to urokinase administration.
Rational treatment of empyema in children.
The management of anaphylactoid reactions to urokinase.
Treatment of urokinase-related anaphylactoid reaction with intravenous famotidine.
Urokinase protocol for free-flap salvage following prolonged venous thrombosis.
[An allergic reaction due to i.v. urokinase administration]
[Cannulation of the internal jugular vein with 2 silastic catheters. A new method of vascular access for hemodialysis]
[Thrombolysis with Urokinase after anaphylaxis caused by streptokinase treatment (author's transl)]
Anemia
Bone Marrow Urokinase Plasminogen Activator Receptor Levels are Associated with the Progress of Multiple Myeloma.
Anemia, Aplastic
Properties of urokinase type-plasminogen activator found in chest fluid.
Anemia, Iron-Deficiency
Bone Marrow Urokinase Plasminogen Activator Receptor Levels are Associated with the Progress of Multiple Myeloma.
Anencephaly
Amniotic fluid fibrinolytic system in fetal neural tube defects.
Aneurysm
A multimodal concept in patients after severe aneurysmal subarachnoid hemorrhage: results of a controlled single centre prospective randomized multimodal phase I/II trial on cerebral vasospasm.
Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease.
Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms.
Angiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice.
Association between urokinase-plasminogen activator gene T4065C polymorphism and risk of mitral valve prolapse.
Case presentations of neuroradiologic interventions for acute cerebrovascular disease.
Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall.
Extracellular proteolysis in the development and progression of atherosclerosis.
Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis.
Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses.
Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins.
Multiple coronary artery aneurysms in an adult associated with extensive thrombus formation resulting in acute myocardial infarction: successful treatment with intracoronary urokinase, intravenous heparin, and oral anticoagulation.
Outcome after Preoperative or Intraoperative Use of Intra-arterial Urokinase Thrombolysis for Acute Popliteal Artery Thrombosis and Leg Ischemia.
Popliteal venous aneurysm with pulmonary embolism.
Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1.
Rebleeding from a vertebral artery dissecting aneurysm after endovascular internal trapping: adverse effect of intrathecal urokinase injection or incomplete occlusion?-case report-.
Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor.
Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis evaluation in transgenic animals.
Serine proteases and cardiac function.
Soluble urokinase plasminogen activator receptor in patients with abdominal aortic aneurysm.
Success of thrombolysis as a predictor of outcome in acute thrombosis of popliteal aneurysms.
Vascular aneurysms: a perspective.
[Effects of urokinase type plasminogen activator and plasminogen activator inhibitor-1 expressions on the formation of aneurysm of perimembranous ventricular septal defect].
[Radiological interventional procedures for the acute abdomen]
Aneurysm, Dissecting
Rebleeding from a vertebral artery dissecting aneurysm after endovascular internal trapping: adverse effect of intrathecal urokinase injection or incomplete occlusion?-case report-.
Aneurysm, False
Distal embolization from an unsuspected external iliac artery pseudoaneurysm: diagnosis during urokinase infusion.
Aneurysm, Ruptured
Development of a kit to treat subarachnoid hemorrhage by intrathecal simple urokinase infusion (ITSUKI) therapy: preliminary results in patients with World Federation of Neurological Surgery (WFNS) grade V subarachnoid hemorrhage.
Microcatheter intrathecal urokinase infusion into cisterna magna for prevention of cerebral vasospasm: preliminary report.
Angina Pectoris
Antithrombotic treatment in stable coronary syndromes: long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris.
Chronic-intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris--a pilot study.
Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a randomized dose-response trial.
Long-term Urokinase Therapy and Isovolemic Hemodilution: A Clinical and Hemodynamic Comparison in Patients with Refractory Angina Pectoris.
Spinal cord stimulation: a comparison of efficacy versus other novel treatments for refractory angina pectoris.
Urokinase-type plasminogen activator system predicts risk of cardiovascular events in patients with angina pectoris: results of the ECAPTURE study. European Concerted Action on Prevention from Thrombosis by URokinase Enhancement.
[Antithrombotic therapy in chronic coronary syndromes--value of thrombocyte aggregation inhibition, anticoagulation and chronic thrombolysis]
[Assessment of the anti-ischemic effect in patients with therapy refractory angina pectoris in end-stage coronary heart disease--results of chronic intermittent urokinase therapy]
[Chronic intermittent urokinase therapy in inoperable end-stage coronary disease with therapy refractory angina pectoris symptoms]
[Chronic intermittent urokinase therapy in therapy-refractory angina pectoris]
[Chronic intermittent urokinase therapy: anti-ischemic and hemodynamic effects]
[Conservative therapeutic approaches in terminal coronary heart disease. Chronic intermittent urokinase therapy]
[Rheological determinants of end-organ damage]
Angina, Stable
Plasma urokinase antigen and C-reactive protein predict angina recurrence after coronary angioplasty.
Angina, Unstable
Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA Trial. TAUSA Investigators. Thrombolysis and Angioplasty in Unstable Angina trial.
Adjunctive thrombolytic therapy for angioplasty in ischemic rest angina: results of a double-blind randomized pilot study.
Effects of urokinase and heparin on minimal cross-sectional area of the culprit narrowing in unstable angina pectoris.
Intracoronary urokinase as an adjunct to percutaneous transluminal coronary angioplasty in patients with complex coronary narrowings or angioplasty-induced complications.
Randomized clinical trial of urokinase versus heparin in unstable angina.
Randomized trial of thrombolysis versus heparin in unstable angina.
Safety and efficacy of urokinase during elective coronary angioplasty.
Thrombolytic therapy in refractory unstable angina: the role of Holter monitoring.
Urokinase plus heparin versus aspirin in unstable angina and non-Q-wave myocardial infarction.
Use of urokinase in unstable angina.
[Effect of low molecular weight heparin on unstable angina]
Angioedema
Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase.
Angioedemas, Hereditary
Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema.
Ankylosis
Biological activities of phosphocitrate: a potential meniscal protective agent.
Anterior Spinal Artery Syndrome
Anterior spinal artery syndrome.
Anthrax
A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.
Antitumor efficacy of a urokinase activation-dependent anthrax toxin.
Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.
Imaging specific cell surface protease activity in living cells using reengineered bacterial cytotoxins.
Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).
Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis.
Antiphospholipid Syndrome
Fatal cerebral infarction in an asymptomatic young patient with primary antiphospholipid syndrome.
Antithrombin III Deficiency
Fibrinolytic therapy for renal vein thrombosis in the child.
Aortic Aneurysm
Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms.
Aortic Aneurysm Rupture After Urokinase Treatment for Acute Limb Ischemia in Two Patients After EVAR.
Inhibitors of urokinase type plasminogen activator and cytostatic activity from crude plants extracts.
Aortic Aneurysm, Abdominal
Angiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice.
Soluble urokinase plasminogen activator receptor in patients with abdominal aortic aneurysm.
The controversial role of the urokinase system in abdominal aortic aneurysm formation and rupture.
Urokinase-Type Plasminogen Activator Deficiency in Bone Marrow-Derived Cells Augments Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms.
Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm.
[Expression of urokiase-type plasminogen activator and matrix metalloproteinases in human tissue of abdominal aortic aneurysm]
Aortic Rupture
Aortic Aneurysm Rupture After Urokinase Treatment for Acute Limb Ischemia in Two Patients After EVAR.
Aortic Valve Stenosis
Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).
SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis.
Appendicitis
Can serum soluble urokinase plasminogen activator receptor be an effective marker in the diagnosis of appendicitis and differentiation of complicated cases?
Diagnostic Value of Serum Urokinase-Type Plasminogen Activator Receptor in Children With Acute Appendicitis.
Progress of tissue injury in appendicitis involves the serine proteases uPA and PAI-1.
The diagnostic value of serum urokinase-type plasminogen activator receptor in acute appendicitis.
Arachnoiditis
Intrathecal urokinase as a treatment for intraventricular hemorrhage in the preterm infant.
The effect of urokinase in preventing the formation of epidural fibrosis and/or leptomeningeal arachnoiditis.
Arterial Occlusive Diseases
Initial results of reteplase in the treatment of acute lower extremity arterial occlusions.
Low-dose intermittent urokinase therapy in chronic symptomatic end-stage arterial disease--clinical relevance for patients with coronary artery disease or peripheral arterial occlusive disease.
The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.
Thrombolytic therapy in peripheral arterial occlusive disease: mechanisms of action and drugs available.
[Experience with urokinase in chronic arterial occlusive disease and long-standing phlebothrombosis]
[Intraarterial urokinase infusion therapy for arterial occlusive disease of the pelvis and extremities with special reference to short-term high dose infusion]
[Results of in situ arterial thrombolysis by the combination of urokinase and lysyl plasminogen in acute arterial occlusive diseases of the lower limbs]
[Short-term intra-arterial infusion with ultrahigh-dose urokinase in treatment of peripheral arterial occlusive disease]
Arteriovenous Fistula
Comparative efficacy and safety of local and peripheral venous thrombolytic therapy with urokinase for thrombosed hemodialysis arteriovenous fistulas.
Local fibrinolysis in native arteriovenous fistulas of haemodialysis patients.
Urokinase treatment for arteriovenous fistulae declotting in dialyzed patients.
Arteriovenous Malformations
Assessment of Complication Types and Rates Related to Diagnostic Angiography and Interventional N euroradiologic Procedures. A Four Year Review (1993-1996).
Intra-arterial urokinase for treatment of retrograde thrombosis following resection of an arteriovenous malformation. Case report.
Arthritis
Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation.
Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis.
Antibody-Mediated Neutralization of uPA Proteolytic Function Reduces Disease Progression in Mouse Arthritis Models.
Arthritis simulating thrombosis on urokinase scan.
Cathepsin B and cystatin C play an inflammatory role in gouty arthritis of the knee.
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Expression of the VEGF receptor-3 in osteoarthritic chondrocytes: stimulation by interleukin-1 beta and association with beta 1-integrins.
Identification and preclinical development of an anti-proteolytic uPA antibody for rheumatoid arthritis.
Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer.
Plasminogen activators in synovial fluid and plasma from patients with arthritis.
SURVIVIN IS AN ESSENTIAL MEDIATOR OF ARTHRITIS INTERACTING WITH UROKINASE SIGNALLING.
The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis.
Tissue-type plasminogen activator deficiency exacerbates arthritis.
Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis.
Urokinase-type plasminogen activator and arthritis progression: contrasting roles in systemic and monoarticular arthritis models.
Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement.
Arthritis, Experimental
Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis.
Antibody-Mediated Neutralization of uPA Proteolytic Function Reduces Disease Progression in Mouse Arthritis Models.
Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis.
Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells.
Arthritis, Gouty
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Arthritis, Infectious
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Arthritis, Rheumatoid
Antisense oligonucleotides against the urokinase receptor: a therapeutic strategy for the control of cell invasion in rheumatoid arthritis and cancer.
Antisense targeting of the urokinase receptor blocks urokinase-dependent proliferation, chemoinvasion, and chemotaxis of human synovial cells and chondrocytes in vitro.
Association between urokinase gene 3'-UTR T/C polymorphism and Chinese patients with rheumatoid arthritis in Taiwan.
Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis.
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis.
Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.
Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis.
Double-blind controlled assessment of the effect of intra-articular hydrocortisone and urokinase in rheumatoid arthritis.
Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
Exacerbation of antigen-induced arthritis in urokinase-deficient mice.
Increased proteolytic activity on the surface of monocytes from patients with rheumatoid arthritis.
Intra-articular urokinase in rheumatoid arthritis.
Plasminogen activators in synovial fluid and plasma from patients with arthritis.
Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis.
Release of the Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) by Activated Neutrophils in Rheumatoid Arthritis.
Serum levels of the soluble urokinase plasminogen activator receptor (suPAR) correlates with disease activity in early rheumatoid arthritis and reflects joint damage over time.
Significance of serine proteinase and matrix metalloproteinase systems in the destruction of human articular cartilage.
Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission.
Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population.
Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.
Suppression of urokinase-type plasminogen activator mRNA levels in human fibrosarcoma cells and synovial fibroblasts by anti-inflammatory glucocorticoids.
The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets.
Urokinase in rheumatoid arthritis: causal or coincidental?
Urokinase-mediated fibrinolysis in the synovial fluid of rheumatoid arthritis patients may be affected by the inactivation of single chain urokinase type plasminogen activator by thrombin.
Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement.
[Analysis of blood coagulation and fibrinolysis in rheumatoid arthritis using the urokinase activated thromboelastography]
[Blood coagulation, fibrinolysis and various values of Lansbury's activity index in rheumatoid arthritis patients]
[Levels of matrix metalloproteinase-3 and urokinase-type plasminogen activator in knee synovial fluids from patients with rheumatoid arthritis and osteoarthritis]
[Membrane and cytoplasmic expression of urokinase-type plasminogen activator receptor in synovial tissues of rheumatoid arthritis patients]
Aspergillosis
Invasive aspergillosis in leukemic children.
Asthma
Airway and peripheral uPAR is elevated in asthma, and identifies a severe, non-atopic subset of patients.
Association of urokinase-type plasminogen activator with asthma and atopy.
Cigarette Smoke Induces uPAR in Vivo and Isoforms Selectively Contribute to Bronchial Epithelial Phenotype.
Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge.
Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model.
Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients.
Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling.
PLAUR polymorphisms and lung function in UK smokers.
PLAUR polymorphisms are associated with asthma, PLAUR levels, and lung function decline.
Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy.
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
The biomarkers suPAR and blood eosinophils are associated with hospital readmissions and mortality in asthma - a retrospective cohort study.
Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma.
Urokinase-type plasminogen activator modulates airway eosinophil adhesion in asthma.
[The fibrinolytic system of bronchial asthma patients in the late terms of pregnancy]
Astrocytoma
Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells.
Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo.
Increased expression of low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor in human malignant astrocytomas.
Protein Kinase C-{alpha} Mediated Regulation of Low-Density Lipoprotein Receptor Related Protein and Urokinase Increases Astrocytoma Invasion.
Radiation-induced blood-brain barrier damage in astrocytoma: relation to elevated gelatinase B and urokinase.
Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma.
Urokinase induces receptor mediated brain tumor cell migration and invasion.
Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain.
Atherosclerosis
Automated, PCR-RFLP genotyping of the urokinase gene.
Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).
Extracellular proteolysis in the development and progression of atherosclerosis.
Fatty acids differentially modify the expression of urokinase type plasminogen activator receptor in monocytes.
Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis.
Hepatic Overexpression of Soluble Urokinase Receptor (uPAR) Suppresses Diet-Induced Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (LDLR-/-) Mice.
Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease.
Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow.
Inhibitor of plasminogen activator in human arterial wall. I. Histochemical study.
Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.
Level of Macrophage uPA Expression Is an Important Determinant of Atherosclerotic Lesion Growth in Apoe-/- Mice.
Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death.
Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins.
Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro.
Native atherosclerosis and vein graft arterialization: association with increased urokinase receptor expression in vitro and in vivo.
Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice.
Reduced beta3-endonexin levels are associated with enhanced urokinase-type plasminogen activator receptor expression in ApoE-/- mice.
Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor.
Relation of urokinase-type plasminogen activator expression to presence and severity of atherosclerotic lesions in human coronary arteries.
Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias.
Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis evaluation in transgenic animals.
Significant association of urokinase plasminogen activator Pro141Leu with serum lipid profiles in a Japanese population.
Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.
Successful silencing of plasminogen activator inhibitor-1 in human vascular endothelial cells using small interfering RNA.
The urokinase system in the pathogenesis of atherosclerosis.
The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.
Thrombosis and atherosclerosis.
Urokinase plasminogen activator (uPA) stimulates cholesterol biosynthesis in macrophages through activation of SREBP-1 in a PI3-kinase and MEK-dependent manner.
Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism.
Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-?B pathway in osteoclasts.
Urokinase receptor surface expression regulates monocyte migration and is associated with accelerated atherosclerosis.
Urokinase-type plasminogen activator downregulates paraoxonase 1 expression in hepatocytes by stimulating peroxisome proliferator-activated receptor-? nuclear export.
[Increase of the membrane-bound urokinase level in monocytes from patients with atherosclerosis is accompanied by decrease of urokinase-induced myocyte migration]
[Plasminogen activator of urokinase-type: mechanisms of involvement in vessel remodeling and angiogenesis, gene therapy approaches to ischemia]
Atrial Fibrillation
Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation.
Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation.
Low level of low-density lipoprotein cholesterol is related with increased hemorrhagic transformation after acute ischemic cerebral infarction.
Management of acute superior mesenteric artery occlusion.
Preoperative Levels of the Soluble Urokinase-Type Plasminogen Activator Receptor as Predictor for New Episodes of Atrial Fibrillation After Vascular Surgery.
Randomized clinical stroke trials in 2007.
Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Predictor of Incident Atrial Fibrillation.
Autoimmune Diseases
Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study.
The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosis.
Bacteremia
A prospective double-blind randomized trial of urokinase flushes to prevent bacteremia resulting from luminal colonization of subcutaneous central venous catheters.
Antibiotic lock with vancomycin and urokinase can successfully treat colonized central venous catheters in pediatric cancer patients.
Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome.
Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia.
Failure of urokinase to resolve Broviac catheter-related bacteremia in children.
Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.
Persistent catheter-related bacteremia: clearance with antibiotics and urokinase.
Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias.
Urokinase in the treatment of bacteremia and candidemia in patients with right atrial catheters.
Bacterial Infections
Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.
Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes.
Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis.
Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD.
The urokinase receptor. A cell surface, regulated chemokine.
Behcet Syndrome
Urokinase plasminogen activator receptor levels in Behcet's disease.
Bile Duct Diseases
[SPECTROPHOTOMETRIC AND COLORIMETRIC DETERMINATION OF UROKINASE IN THE BLOOD OF PATIENTS WITH LIVER AND BILE DUCT DISEASES.]
Biliary Atresia
Elevation of serum urokinase plasminogen activator receptor and liver stiffness in postoperative biliary atresia.
Hepatocytes buried in the cirrhotic livers of patients with biliary atresia proliferate and function in the livers of urokinase-type plasminogen activator-NOG mice.
Biliary Tract Neoplasms
Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.
Blindness
Comparison of intra-arterial thrombolysis with conventional treatment in patients with acute central retinal artery occlusion.
Blister
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Hemorrhagic bullae as a complication of urokinase therapy for hemodialysis catheter thrombosis.
Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice.
Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann.
Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.
[Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients]
Bloom Syndrome
Biological activities of phosphocitrate: a potential meniscal protective agent.
Bone Resorption
Bone resorption and response to calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor.
Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
The role of the plasminogen system in bone resorption in vitro.
Thrombomodulin is synthesized by osteoblasts, stimulated by 1,25-(OH)2D3 and activates protein C at their cell membrane.
uPA Attenuated LPS-induced Inflammatory Osteoclastogenesis through the Plasmin/PAR-1/Ca(2+)/CaMKK/AMPK Axis.
Brain Death
Fatal cerebral infarction in an asymptomatic young patient with primary antiphospholipid syndrome.
Brain Edema
Correlation of tumor plasminogen activator with peritumoral cerebral edema. A CT and biochemical study.
Surgical improvement of brain edema related to hypertensive intracerebral hemorrhage.
Brain Infarction
Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate.
Brain Injuries
Coagulopathy in the Setting of Mild Traumatic Brain Injury: Truths and Consequences.
Decreased levels of active uPA and KLK8 assessed by [(111) In]MICA-401 binding correlate with the seizure burden in an animal model of temporal lobe epilepsy.
Deficiency of urokinase-type plasminogen activator and its receptor affects social behavior and increases seizure susceptibility.
Future Perspectives on the Fibrinolytic Therapy of Intracerebral Hemorrhages.
Stereotactic cisternal lavage in patients with aneurysmal subarachnoid hemorrhage with urokinase and nimodipine for the prevention of secondary brain injury (SPLASH): study protocol for a randomized controlled trial.
The effects of blood pressure and urokinase on brain injuries after experimental cerebral infarction in rats.
Tissue plasminogen activator-independent roles of neuroserpin in the central nervous system.
Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window.
uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK.
Urokinase plasminogen activator impairs SNP and PGE2 cerebrovasodilation after brain injury through activation of LRP and ERK MAPK.
Urokinase-type plasminogen activator regulates neurodegeneration and neurogenesis but not vascular changes in the mouse hippocampus after status epilepticus.
Brain Injuries, Traumatic
Altered NO function contributes to impairment of uPA and tPA cerebrovasodilation after brain injury.
Epileptogenesis after traumatic brain injury in Plau-deficient mice.
Brain Ischemia
Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate.
Stenting as a Rescue Treatment After Failure of Mechanical Thrombectomy for Anterior Circulation Large Artery Occlusion.
Urokinase-type Plasminogen Activator Promotes Synaptic Recovery in the Ischemic Brain.
[Effects of rhubarb aglycone combined with thrombolysis on brain microvascular basement membrane impairment in rats with thrombus-occluded cerebral ischemia].
[Protective effects of Ginkgo biloba extract on focal cerebral ischemia and thrombogenesis of carotid artery in rats]
Brain Neoplasms
A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors.
Different types of plasminogen activator activity in human brain tumours: relation with peritumoral oedema?
Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors.
Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.
Metastatic brain tumour and fibrinopeptides.
Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours.
Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.
Purification and characterization of the plasminogen activator secreted by a rat brain tumor cell line in culture.
Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin.
Trial of anticancer pellet in malignant brain tumours; 5 FU and urokinase embedded in silastic.
Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity.
Urokinase induces receptor mediated brain tumor cell migration and invasion.
Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain.
Urokinase-derived peptide UP-7 suppresses tumor angiogenesis and metastasis through inhibition of FAK activation.
Urokinase-targeted fusion by oncolytic Sendai virus eradicates orthotopic glioblastomas by pronounced synergy with interferon-? gene.
[Treatment of brain tumors with anticancer pellet--experimental and clinical study (author's transl)]
Breast Cyst
Urokinase and tissue-type plasminogen activators are present in breast cyst fluids.
Breast Neoplasms
(-)-Epigallocatechin gallate derivatives reduce the expression of both urokinase plasminogen activator and plasminogen activator inhibitor-1 to inhibit migration, adhesion, and invasion of MDA-MB-231 cells.
A high cytosol value of urokinase-type plasminogen activator (uPA) may be predictive of early relapse in primary breast cancer.
A novel approach for identification of tumor-associated antigens expressed on the surface of tumor cells.
A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo.
A personalized approach to cancer treatment: how biomarkers can help.
A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue.
A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols.
A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen.
Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression.
Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells.
Alpha(v) integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells.
An Activatable Polymeric Reporter for Near-Infrared Fluorescent and Photoacoustic Imaging of Invasive Cancer.
An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
An Au-Se nanoprobe for the evaluation of the invasive potential of breast cancer cells via imaging the sequential activation of uPA and MMP-2.
An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.
Anti-metastatic effect of Smilax china L. extract on MDA-MB-231 cells.
Anti-urokinase-type plasminogen activator monoclonal antibodies inhibit the proliferation of human breast cancer cell lines in vitro.
Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer.
Antigen levels of urokinase type plasminogen activator and its inhibitors in primary breast cancer.
Antimetastatic Potential of PAI-1-Specific RNA Aptamers.
Assessment of c-erbB2 and vascular endothelial growth factor mRNA expression in fine-needle aspirates from early breast carcinomas: pre-operative determination of malignant potential.
Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.
Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer.
Binding of urokinase to specific receptor sites on human breast cancer membranes.
Biochemical markers in breast cancer: which ones are clinically useful?
Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma.
Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
Biological mechanisms in breast cancer invasiveness: relevance to preventive interventions.
Biomarkers associated with breast cancer are associated with obesity.
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice.
Breast cancer statistics and markers.
Calcitonin inhibits invasion of breast cancer cells: Involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment.
Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells.
Cell Signaling by Urokinase-type Plasminogen Activator Receptor Induces Stem Cell-like Properties in Breast Cancer Cells.
Cell surface expression of urokinase receptor in normal mammary epithelial cells and breast cancer cell lines.
Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer.
Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
Changes in uPA, PAI-1, and TGF-? Production during Breast Cancer Cell Interaction with Human Mesenchymal Stroma/Stem-Like Cells (MSC).
Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures.
Characterization of cancer cell lines established from two human metastatic breast cancers.
Clinical implications of urokinase and tissue type plasminogen activators and their inhibitor (PAI-1) in breast cancer tissue.
Clinical relevance of biologic factors in male breast cancer.
Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
Clinical relevance of the urokinase plasminogen activator system in breast cancer.
Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
Clinical uses of tumor markers: a critical review.
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
Clinicopathologic analysis of macrophage infiltrates in breast carcinoma.
Co-expression of urokinase with haptoglobin in human carcinomas.
Combined effect of green tea and Ganoderma lucidum on invasive behavior of breast cancer cells.
Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells.
Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma.
Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues.
Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients.
Comparison of the tumor associated proteases cathepsin D (CATH D) and urokinase-type plasminogen activator (uPA) in cytosols of human breast cancer patients.
Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay.
Conditionally activating optical contrast agent with enhanced sensitivity via gold nanoparticle plasmon energy transfer: feasibility study.
Confocal fluorescence microscopy of urokinase plasminogen activator receptor and cathepsin D in human MDA-MB-231 breast cancer cells migrating in reconstituted basement membrane.
Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma.
Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
Curcumin inhibits metastatic progression of breast cancer cell through suppression of urokinase-type plasminogen activator by NF-kappa B signaling pathways.
Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness.
Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.
Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells.
Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.
Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma.
Design and testing of a packaged microfluidic cell for the multiplexed electrochemical detection of cancer markers.
Design, synthesis, and characterization of urokinase plasminogen-activator-sensitive near-infrared reporter.
Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients.
Development of U11-functionalized gold nanoparticles for selective targeting of urokinase plasminogen activator receptor-positive breast cancer cells.
Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer.
Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
Disregulation of urokinase plasminogen activator gene in breast cancer.
Docosahexaenoic Acid Downregulates EGF-Induced Urokinase Plasminogen Activator and Matrix Metalloproteinase 9 Expression by Inactivating EGFR/ErbB2 Signaling in SK-BR3 Breast Cancer Cells.
Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection.
Effect of hypoxia on cellular adhesion to vitronectin and fibronectin.
Effect of macrophages on breast cancer cell proliferation, and on expression of hormone receptors, uPAR and HER-2.
Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231.
Effects of specific DNMT-gene depletion on cancer cell transformation and breast cancer cell invasion; towards selective DNMT inhibitors.
Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells.
EndoPredict versus uPA/PAI-1 in breast cancer: Comparison of markers and association with clinicopathological parameters.
Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR-4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression.
Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating alpha(v)beta5 vitronectin receptor cell surface expression.
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Enhanced Expression of Rab27A Gene by Breast Cancer Cells Promoting Invasiveness and the Metastasis Potential by Secretion of Insulin-Like Growth Factor-II.
Enhanced stability of urokinase-type plasminogen activator mRNA in metastatic breast cancer MDA-MB-231 cells and LLC-PK1 cells down-regulated for protein kinase C--correlation with cytoplasmic heterogeneous nuclear ribonucleoprotein C.
Enterolactone Suppresses Proliferation, Migration and Metastasis of MDA-MB-231 Breast Cancer Cells Through Inhibition of uPA Induced Plasmin Activation and MMPs-Mediated ECM Remodeling
Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue.
ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation.
Estradiol preferentially enhances extracellular tissue plasminogen activators of MCF-7 breast cancer cells.
European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer.
Evidence for the clinical use of tumour markers.
Exposure of mcf-7 breast cancer cells to electromagnetic fields up-regulates the plasminogen activator system.
Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Expression of cathepsin D, stromelysin-3, and urokinase by reactive stromal cells on breast carcinoma prognosis.
Expression of colony-stimulating factor-1 and its receptor (the protein product of c-fms) in invasive breast tumor cells. Induction of urokinase production via this pathway?
Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Expression of proteinases and inhibitors in human breast cancer progression and survival.
Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.
Expression of urokinase plasminogen activator (uPA) in the leukocytes and tissues of patients with benign and malignant breast lesions.
Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
Fibrinolytic Activity of Circulating Microvesicles Is Associated with Progression of Breast Cancer.
Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells.
Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression.
Glucocorticoid (GC)-mediated down-regulation of urokinase plasminogen activator expression via the serum and GC regulated kinase-1/forkhead box O3a pathway.
Green tea polyphenols modulate secretion of urokinase plasminogen activator (uPA) and inhibit invasive behavior of breast cancer cells.
Growth inhibition of MDA-MB-231 cell line by peptides designed based on uPA.
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer.
Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion.
High concentration of urokinase-type plasminogen activator receptor in the serum of women with primary breast cancer.
High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast.
High levels of cathepsin B predict poor outcome in patients with breast cancer.
High levels of uPA and PAI-1 predict a good response to anthracyclines.
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Hormonal modulation of plasminogen activator: an approach to prediction of human breast tumor responsiveness.
HPLC-MS/MS analysis of mesupron and its application to a pharmacokinetic study in rats.
Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity.
Human cytomegalovirus interleukin-10 enhances matrigel invasion of MDA-MB-231 breast cancer cells.
Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels.
Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer.
Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance.
Immunoassays of urokinase (uPA) and its type-1 inhibitor (PAI-1) in detergent extracts of breast cancer tissue.
Immunoelectron microscopy of the receptor for urokinase plasminogen activator and cathepsin D in the human breast cancer cell line MDA-MB-231.
Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours.
Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
Immunohistologic evaluation of invasion-associated proteases in breast carcinoma.
Impaired MicroRNA Processing Facilitates Breast Cancer Cell Invasion by Upregulating Urokinase-Type Plasminogen Activator Expression.
Impairment of breast cancer cell invasion by COX-2-specific inhibitor NS398: roles of CXCR4 and of uPA system.
In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells.
In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells.
In vitro suppression of urokinase plasminogen activator in breast cancer cells--a comparison of two antisense strategies.
In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis.
Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.
Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins.
Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.
Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells.
Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues.
Inhibition of breast carcinoma and trophoblast cell invasiveness by vascular endothelial growth factor.
Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator.
Inhibition of receptor-dependent urokinase signaling by specific Ser to Glu substitutions.
Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells.
Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
Inhibition of urokinase-type plasminogen activator expression by dihydroartemisinin in breast cancer cells.
Integrin ?3 and its ligand regulate the expression of uPA through p38 MAPK in breast cancer.
Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.
Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression.
Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.
Invasive capacity and regulation of urokinase-type plasminogen activator in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells, and a transfectant (S30) stably expressing ER.
Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA.
LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system.
Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.
Lipids isolated from bone induce the migration of human breast cancer cells.
Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.
Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence.
Mature breast adipocytes promote breast cancer cell motility.
Maximum effect of urokinase plasminogen activator inhibitors in the control of invasion and metastasis of rat mammary cancer.
Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer.
Metastatic effect of LY-6K gene in breast cancer cells.
Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells.
Molecular photoacoustic tomography of breast cancer using receptor targeted magnetic iron oxide nanoparticles as contrast agents.
MRTF-A and STAT3 promote MDA-MB-231 cell migration via hypermethylating BRSM1.
Multiparametric prognostic evaluation of biological factors in primary breast cancer.
Multiplex sensing of protease and kinase enzyme activity via orthogonal coupling of quantum dot-peptide conjugates.
N-Alkylisatin-Loaded Liposomes Target the Urokinase Plasminogen Activator System in Breast Cancer.
N-WASP activation by a beta1-integrin-dependent mechanism supports PI3K-independent chemotaxis stimulated by urokinase-type plasminogen activator.
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells.
New data on chemotherapy in the adjuvant setting.
New prognostic and predictive factors in breast cancer.
NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4.
Nimbolide inhibits invasion and migration, and down-regulates uPAR chemokine gene expression, in two breast cancer cell lines.
Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
NIR Fluorophore-Hollow Gold Nanosphere Complex for Cancer Enzyme-Triggered Detection and Hyperthermia.
Novel medicinal mushroom blend suppresses growth and invasiveness of human breast cancer cells.
Novel methods for the determination of the angiogenic activity of human tumors.
Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue.
Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
Optimized immunohistochemistry in combination with image analysis: A reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer.
Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells.
Osteopontin induces soluble urokinase-type plasminogen activator receptor production and release.
Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells.
Overexpression of PSMC2 promotes the tumorigenesis and development of human breast cancer via regulating plasminogen activator urokinase (PLAU).
Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes.
Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis.
Oxygen-mediated regulation of tumor cell invasiveness. Involvement of a nitric oxide signaling pathway.
PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.
Phellinus linteus suppresses growth, angiogenesis and invasive behaviour of breast cancer cells through the inhibition of AKT signalling.
Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator.
Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients.
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells.
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Plasminogen activator inhibitor-1 in cancer research.
Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.
Plasminogen activator system in human breast cancer.
Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients.
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer.
Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA.
Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR.
Prognosis and prediction of response in breast cancer: the current role of the main biological markers.
Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer.
Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours.
Prognostic importance of the uPa/PAI-1 complex in breast cancer.
Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer.
Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer.
Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.
Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer.
Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its receptor in breast cancer as measured by Northern blot analysis.
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
Prognostic Significance of the Urokinase Type PlasminogenActivator(u-PA) System in Node-Negative Breast Cancer.
Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Prognostic significance of tumor-related proteases as a function of the estrogen receptor status.
Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.
Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.
Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Protease nexin-1 expression is altered in human breast cancer.
Proteases as prognostic markers in cancer.
Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue.
Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts.
PTHrP [67-86] regulates the expression of stress proteins in breast cancer cells inducing modifications in urokinase-plasminogen activator and MMP-1 expression.
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Quantification of uPA receptor expression in human breast cancer cell lines by cRT-PCR.
Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells.
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients.
Recent advances in the field of anti-cancer immunotherapy.
Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients.
Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.
Relationship between Circulating Tumor Cells, Blood Coagulation, and Urokinase-Plasminogen-Activator System in Early Breast Cancer Patients.
Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes.
Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas.
Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis.
Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling.
RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells.
RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.
Role of IGF-1R in mediating breast cancer invasion and metastasis.
ROLE OF PLASMINOGEN ACTIVATOR INHIBITOR-1 IN UROKINASE'S PARADOXICAL IN VIVO TUMOR SUPPRESSING OR PROMOTING EFFECTS.
Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer.
Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer.
Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221.
Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.
Signalling networks associated with urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in breast cancer tissues: new insights from protein microarray analysis.
Sodium Salicylate Inhibits Urokinase Activity in MDA MB-231 Breast Cancer Cells.
Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.
Some pyrazole and pyrazolo[3,4-d]pyrimidine derivatives: synthesis and anticancer evaluation.
Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF-kappaB/AP-1-dependent and -independent pathways.
Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.
Stimulation of human breast carcinoma cell invasiveness and urokinase plasminogen activator activity by glucose deprivation.
Stimulation of urokinase-type plasminogen activator expression by blockage of E-cadherin-dependent cell-cell adhesion.
Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression.
Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype.
Suppression of FOXQ1 in benzyl isothiocyanate-mediated inhibition of epithelial-mesenchymal transition in human breast cancer cells.
Suppression of Proliferation and Invasive Behavior of Human Metastatic Breast Cancer Cells by Dietary Supplement BreastDefend.
Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor.
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428.
Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.
Suppressive effects of a proton beam on tumor growth and lung metastasis through the inhibition of metastatic gene expression in 4T1 orthotopic breast cancer model.
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.
Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells.
Synergistic induction of apoptosis by combination treatment with mesupron and auranofin in human breast cancer cells.
Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.
Synthesis and Characterization of an (111)In-Labeled Peptide for the in Vivo Localization of Human Cancers Expressing the Urokinase-Type Plasminogen Activator Receptor (uPAR).
Synthesis and in vivo preclinical evaluation of an (18)F labeled uPA inhibitor as a potential PET imaging agent.
Targeting a methioninase-containing fusion protein to breast cancer urokinase receptors inhibits growth and migration.
Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation.
Targeting uPAR with Antagonistic Recombinant Human Antibodies in Aggressive Breast Cancer.
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
TFRC and ACTB as the best reference genes to quantify Urokinase Plasminogen Activator in breast cancer.
The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer.
The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.
The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.
The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.
The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor.
The influence of opioids on urokinase plasminogen activator on protein and mRNA level in MCF-7 breast cancer cell line.
The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: a new avenue for breast cancer therapy.
The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer.
The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease.
The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer.
The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes.
The topology of plasminogen binding and activation on the surface of human breast cancer cells.
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.
The urokinase plasminogen activator system in breast cancer invasion and metastasis.
The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue.
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro.
Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.
Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
Tissue extraction procedures for investigation of urokinase plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in human breast carcinomas.
Tissue plasminogen activators in breast cancer.
Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation.
Transcriptomic pathway analysis of urokinase receptor silenced breast cancer cells: a microarray study.
Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells.
Transforming growth factor-beta 1, beta 2, and beta 3, urokinase and parathyroid hormone-related peptide expression in 8701-BC breast cancer cells and clones.
Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity.
Tumor markers in breast cancer- European Group on Tumor Markers recommendations.
Tumor markers in breast cancer--evaluation of their clinical usefulness.
Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer.
Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.
Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms.
Tumor-associated urokinase-type plasminogen activator: significance in breast cancer.
Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase.
uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer.
uPA-PAI-1 heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils.
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
Urokinase and macrophages in tumour angiogenesis.
Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells.
Urokinase expression in course of benign and malignant mammary lesions: comparison between nodular and healthy tissues.
Urokinase is a negative modulator of Egf-dependent proliferation and motility in the two breast cancer cell lines MCF-7 and MDA-MB-231.
Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer.
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.
Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.
Urokinase plasminogen activator and prognosis in breast cancer.
Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer.
Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer.
Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer.
Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer.
Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue.
Urokinase Plasminogen Activator Receptor (uPAR): A Potential Indicator of Invasion for In Situ Breast Cancer.
Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay.
Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease.
Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer.
Urokinase receptor expression is upregulated by cell culture sparsity in breast cancer cell line BT-20.
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.
Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer.
Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.
Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor.
Urokinase type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor 2 (HER2) expression in metastasis of breast cancer.
Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer.
Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay.
Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK).
Urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer: studies at both protein and mRNA level.
Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.
Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression.
Urokinase-type Plasminogen Activator and Plasminogen-activator-inhibitor Type 1 Predict Metastases in Good Prognosis Breast Cancer Patients.
Urokinase-type plasminogen activator antigen and early relapse in breast cancer.
Urokinase-type plasminogen activator in ascites obtained from the patient with mammary cancer.
Urokinase-type plasminogen activator induces proliferation in breast cancer cells.
Urokinase-type plasminogen activator receptor inhibits apoptosis in triple-negative breast cancer through miR-17/20a suppression of death receptors 4 and 5.
Urokinase-type plasminogen activator system and breast cancer (Review).
Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer.
Vasodilator-Stimulated Phosphoprotein (VASP) depletion from breast cancer MDA-MB-231 cells inhibits tumor spheroid invasion through downregulation of Migfilin, ?-catenin and urokinase-plasminogen activator (uPA).
Virtual Screening Targeting the Urokinase Receptor, Biochemical and Cell-Based Studies, Synthesis, Pharmacokinetic Characterization, and Effect on Breast Tumor Metastasis.
Visualizing Breast Cancer Cell Proliferation and Invasion for Assessing Drug Efficacy with a Fluorescent Nanoprobe.
Vitamin D3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture.
Vitronectin binding to urokinase receptor in human breast cancer.
Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.
[A plasminogen regulation system in brain tumors].
[Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system]
[Clinical and prognostic significance of tumor-associated proteases in gynecologic oncology]
[Clinical evaluation of various antineoplastic agents combined with urokinase--a comparison between urokinase from tissue culture (TCUK) and urine-derived urokinase (UUK)]
[D-dimer and plasminogen activator of the urokinase type: personal experiences with breast cancer]
[Experimental study of anti-metastasis effect of urokinase amino-terminal fragment gene on human breast cancer cells]
[Expression and significance of urokinase-type plasminogen activator in breast cancer]
[Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer]
[Relation between angiogenesis, fibrinolysis and invasion/metastasis in breast cancer]
[Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma]
Bronchial Spasm
Rigors and bronchospasm with urokinase after streptokinase.
Bronchitis
Plastic bronchitis occurring late after the Fontan procedure: treatment with aerosolized urokinase.
[Regulation of fibrinolysis by lymphocytes in inflammatory diseases of the bronchopulmonary system]
Bronchopulmonary Dysplasia
No association of urokinase gene 3'-UTR polymorphism with bronchopulmonary dysplasia for ventilated preterm infants.
Predictive value of soluble urokinase plasminogen activator receptor, soluble ST2, and IL-33 in bronchopulmonary dysplasia.
Brucellosis
[Can Mannose-Binding Lectin and Plasma Level of Soluble Urokinase Receptor be Used in Diagnosis and Treatment Monitorization of Brucellosis Patients?].
Budd-Chiari Syndrome
Budd-Chiari syndrome: early intervention with angioplasty and thrombolytic therapy.
Treatment of Budd-Chiari syndrome with urokinase following predilation in patients with old inferior vena cava thrombosis.
Urokinase treatment of Budd-Chiari syndrome.
Candidemia
Urokinase in the treatment of bacteremia and candidemia in patients with right atrial catheters.
Carcinogenesis
Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy.
Dietary Supplementation with Methylseleninic Acid Inhibits Mammary Tumorigenesis and Metastasis in Male MMTV-PyMT Mice.
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator Receptor.
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum.
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis.
Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model.
Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activator.
Novel patents and cancer therapies for transforming growth factor-beta and urokinase type plasminogen activator: potential use of their interplay in tumorigenesis.
Overexpression of PSMC2 promotes the tumorigenesis and development of human breast cancer via regulating plasminogen activator urokinase (PLAU).
Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carcinogenesis.
Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer.
Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
Predicting high risk disease using serum and DNA biomarkers.
Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
Screening and identification of hub genes in pancreatic cancer by integrated bioinformatics analysis.
Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance.
The effect of essential fatty acids on growth and urokinase-type plasminogen activator production in human prostate DU-145 cells.
The effect of gamma-linolenic acid and eicosapentaenoic acid on urokinase activity.
The plasminogen activator inhibitor "paradox" in cancer.
The Urokinase Receptor Supports Tumorigenesis of Human Malignant Pleural Mesothelioma Cells.
Tissue plasminogen activator-independent roles of neuroserpin in the central nervous system.
Urokinase-type plasminogen activator resulting from endometrial carcinogenesis enhances tumor invasion and correlates with poor outcome of endometrial carcinoma patients.
[Endothelial cell proteases and their modulation by platelets]
Carcinoma
(-)-Epigallocatechin-3-gallate (EGCG) inhibits HGF-induced invasion and metastasis in hypopharyngeal carcinoma cells.
A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma.
A novel 3-dimensional culture system as an in vitro model for studying oral cancer cell invasion.
A novel model for metastasis suppression involving regulation of nuclear precursor messenger-RNA stability.
ADAM-17 expression in breast cancer correlates with variables of tumor progression.
Altered expression of the urokinase receptor homologue, C4.4A, in invasive areas of human esophageal squamous cell carcinoma.
Amplification of the Urokinase-Type Plasminogen Activator Receptor (uPAR) Gene in Ductal Pancreatic Carcinomas Identifies a Clinically High-Risk Group.
Amurubicinol-induced eotaxin-3 expression in human NCI-H69 small cell lung carcinoma cells.
An immunohistochemical assessment of cathepsin D in gastric carcinoma: its impact on clinical prognosis.
An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture.
Angiostatin generation by human pancreatic cancer.
Anticancer evaluation of some newly synthesized N-nicotinonitrile derivative.
Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice.
Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Association of Urokinase Gene 3'-UTR T/C polymorphism with bladder cancer.
Augmented membrane type 1 matrix metalloproteinase (MT1-MMP):MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis.
Autocrine and paracrine regulation of tissue inhibitor of metalloproteinases, transin, and urokinase gene expression in metastatic and nonmetastatic mammary carcinoma cells.
Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors.
Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma.
Bound plasminogen is rate-limiting for cell-surface-mediated activation of plasminogen by urokinase.
Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.
Cell surface antigens in renal tumour cells: detection by immunoluminescence and enzymatic analysis.
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Changes in the expression of matrix proteases and of the transcription factor c-Ets-1 during progression of precancerous bronchial lesions.
Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder.
Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - ?1 (TGF-?1) and potential effects on migration and invasion.
Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Clinical relevance of urokinase-type plasminogen activator and its inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix.
Co-expression of urokinase with haptoglobin in human carcinomas.
Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma.
Comparative studies on urokinase and plasminogen activator from cultured pancreatic carcinoma.
Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues.
Connexin 32 down-regulates the fibrinolytic factors in metastatic renal cell carcinoma cells.
Constitutive expression and secretion of proteases in non-metastatic SP1 mammary carcinoma cells and its metastatic sublines.
Correlation between expression of urokinase-type plasminogen activator receptor and metastasis in gastric carcinoma.
Demonstration of a possible link between high grade malignancy in dimethylbenz[a]anthracene-induced rat mammary carcinoma and increased urokinase plasminogen activator content.
Deregulated activation of matriptase in breast cancer cells.
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma.
Determination of the effects of epidermal growth factor on urokinase secretion and urokinase receptor display in a well-differentiated human colon carcinoma cell line.
Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines.
Dexamethasone decreases urokinase plasminogen activator mRNA stability in MAT 13762 rat mammary carcinoma cells.
Different mechanisms contribute to simultaneous inhibition of urokinase and tissue-type plasminogen activators by glucocorticoids in human ovarian carcinoma cells.
Differential expression levels of urokinase-type plasminogen activator and cathepsin D in locally advanced laryngeal squamous cell carcinoma: clinical implications.
Differential expression of MMP and uPA systems and prognostic relevance of their expression in esophageal squamous cell carcinoma.
Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma.
Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines.
Diversity and modulation of plasminogen activator activity in human transitional carcinoma cell lines.
DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression.
Drug resistant tumor cells have increased levels of tumor markers for invasion and metastasis.
Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin B.
DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma.
Effect of anthraquinone-laxatives on the proliferation and urokinase secretion of normal, premalignant and malignant colonic epithelial cells.
Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines.
Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion.
Effect of urokinase on growth and metastases of rabbit V2 carcinoma.
Effect of urokinase on the proliferation of primary cultures of human prostatic cells.
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Effects of tranexamic acid and urokinase on hematogenous metastases of Lewis lung carcinoma in mice.
EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma.
ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts.
Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.
Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of alpha6beta1 integrin.
Ets2 transcription factor in normal and neoplastic human breast tissue.
Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a human colon cancer cell line.
Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma.
Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells In Vitro and In Vivo.
Expression and activation of proteases in co-cultures.
Expression and localization of urokinase-type plasminogen activator in human spinal column tumors.
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Expression of ETS-1 is correlated with urokinase-type plasminogen activator and poor prognosis in pulmonary adenocarcinoma.
Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population.
Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma.
Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.
Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Expression of the urokinase receptor regulates focal adhesion assembly and cell migration in adenoid cystic carcinoma cells.
Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion.
Expression of urokinase and urinary trypsin inhibitor in metastatic and non-metastatic murine Lewis lung carcinoma cells.
Expression of urokinase-type plasminogen activator and its receptor in squamous cell carcinoma of the oral tongue.
Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma.
Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas.
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Expression of urokinase-type plasminogen-activator in various human thyroid tissues.
Expression, subcellular distribution and plasma membrane binding of cathepsin B and gelatinases in bone metastatic tissue.
Fecal diglycerides as selective endogenous mitogens for premalignant and malignant human colonic epithelial cells.
Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells.
Fibrinolytic activity of in vitro cultivated human bladder cell lines.
Ganglioside GM3 promotes carcinoma cell proliferation via urokinase plasminogen activator-induced extracellular signal-regulated kinase-independent p70S6 kinase signaling.
Gastric mucosal plasminogen activators in Helicobacter pylori infection.
Glucocorticoid sensitivity of OVCA 433 human ovarian carcinoma cells: inhibition of plasminogen activators, cell growth, and morphological alterations.
Glutathione and glutathione S-transferases as early markers for ovarian carcinomas: case series.
Growth inhibition of vascular smooth muscle cells derived from urokinase receptor (u-PAR)-deficient mice in the presence of carcinoma cells.
Helicobacter pylori infection influences expression of genes related to angiogenesis and invasion in human gastric carcinoma cells.
Helicobacter pylori stimulates urokinase plasminogen activator receptor expression and cell invasiveness through reactive oxygen species and NF-kappaB signaling in human gastric carcinoma cells.
High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma.
High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent nongenomic effect on the plasma membrane.
Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression.
Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.
Immunohistochemical analysis of PAI-2 (plasminogen activator inhibitor type 2) and p53 protein in early gastric cancer patients with recurrence: a preliminary report.
Immunohistochemical Determination of ETS-1 Oncoprotein Expression in Urothelial Carcinomas of the Urinary Bladder.
Immunohistochemical expressions of uPA and its receptor uPAR and their prognostic significant in urinary bladder carcinoma.
Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Immunolocalization of the components of the plasminogen activating system in breast carcinoma tissue.
Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum.
Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture.
In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells.
In vitro plasminogen activator activity in human brain tumors.
In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate.
Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer.
Increased urokinase activity to antigen ratio in human renal-cell carcinoma.
Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells.
Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells.
Induction of urokinase activity and malignant phenotype in bladder carcinoma cells after transfection of the activated Ha-ras oncogene.
Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines.
Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo.
Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428.
Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model.
Inhibition of N-linked oligosaccharide processing in tumor cells is associated with enhanced tissue inhibitor of metalloproteinases (TIMP) gene expression.
Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system.
Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.
Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model.
Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.
Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase.
Invasive neoplastic uroepithelial cells express high-levels of urokinase receptor and plasminogen receptor, alpha-enolase.
Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells.
Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines.
Keratinocytes and head and neck squamous cell carcinoma cells regulate urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in fibroblasts.
Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Low interleukin-1alpha messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinoma.
Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin.
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Mechanisms of the development of osteoblastic metastases.
Melanocyte mediated paracrine induction of extracellular matrix degrading proteases in squamous cell carcinoma cells.
Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells.
Modulation of the plasminogen activator cascade during enhanced epidermal proliferation in vivo.
Modulation of the urokinase receptor in human colon cell lines by N,N-dimethylformamide.
Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.
Molecular cloning, sequencing, and expression in Escherichia coli of human preprourokinase cDNA.
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue.
Occurrence of components of fibrinolytic pathways in situ in laryngeal cancer.
Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells.
Paracrine factor and cell-cell contact-mediated induction of protease and c-ets gene expression in malignant keratinocyte/dermal fibroblast cocultures.
Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas.
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Plasma urokinase-type plasminogen activator correlates to bone scintigraphy in prostatic carcinoma.
Plasmin-catalyzed proteolysis in colorectal neoplasia.
Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens.
Plasminogen activators in human colorectal neoplasia.
Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining.
Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
Plasminogen activators in oesophageal carcinoma.
Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression.
Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells.
Post-transcriptional regulation of urokinase mRNA. Identification of a novel urokinase mRNA-binding protein in human lung epithelial cells in vitro.
Posttranscriptional regulation of urokinase receptor gene expression in human lung carcinoma and mesothelioma cells in vitro.
Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy.
Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma.
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer.
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus.
Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.
Prognostic value of the plasminogen activation system in patients with gastric carcinoma.
Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma.
Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.
Prognostic value of urokinase plasminogen activator for prostatic carcinoma.
PTHrP [67-86] regulates the expression of stress proteins in breast cancer cells inducing modifications in urokinase-plasminogen activator and MMP-1 expression.
Redundant regulation of urokinase plasminogen activator transcription by the two major isozymes of cAMP-dependent protein kinase.
Regulation of CSF-1 receptor expression.
Regulation of human squamous cell carcinoma plasma membrane associated urokinase plasminogen activator by epidermal growth factor.
Regulation of plasminogen activator activity in transitional carcinoma cell lines by wound site growth factors.
Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta.
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line.
Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene.
Regulation of urokinase-type plasminogen activator expression in squamous-cell carcinoma of the oral cavity.
Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells.
Relationship between plasma levels of components of the fibrinolytic system and acute-phase reactants in patients with uterine malignancies.
Relationship between plasminogen activators and stomach carcinoma stage.
Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival.
Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma.
Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Retinoic acid priming potentiates the induction of urokinase-type plasminogen activator by cyclic adenosine monophosphate in mouse mammary carcinoma cells.
RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo.
Role of urokinase in colorectal neoplasia.
Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Secretion of plasminogen activators by human colorectal and gastric tumor explants.
Semiautomatic landmark-based two-dimensional-three-dimensional image fusion in living mice: correlation of near-infrared fluorescence imaging of Cy5.5-labeled antibodies with flat-panel volume computed tomography.
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China.
Silencing of uPAR via RNA interference inhibits invasion and migration of oral tongue squamous cell carcinoma.
Simultaneous stimulation of urokinase and tissue-type plasminogen activators by phorbol esters in human ovarian carcinoma cells.
Sodium butyrate differentially modulates plasminogen activator inhibitor type-1, urokinase plasminogen activator, and its receptor in a human colon carcinoma cell.
Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.
Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report.
Some pyrazole and pyrazolo[3,4-d]pyrimidine derivatives: synthesis and anticancer evaluation.
Specific stimulation by estradiol of tissue-type plasminogen activator production in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.
Stimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors.
Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions.
Studies of possible mechanisms for the effect of urokinase therapy in small cell carcinoma of the lung.
Surface-bound plasmin induces selective proteolysis of insulin-like-growth-factor (IGF)-binding protein-4 (IGFBP-4) and promotes autocrine IGF-II bio-availability in human colon-carcinoma cells.
Synergistic transcriptional activation of the mouse urokinase plasminogen activator (uPA) gene and of its enhancer activator protein 1 (AP1) site by cAMP and retinoic acid.
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
T1 breast cancer: identification of patients at low risk of axillary lymph node metastases.
Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy.
The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase.
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
The malignant conversion step of mouse skin carcinogenesis.
The plasminogen activator inhibitor system in colon cancer cell lines is influenced by the CO(2) pneumoperitoneum.
The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report.
The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor.
The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells.
The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
The urokinase/PAI-2 complex: a new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein.
Tissue plasminogen activator activity in prostatic cancer.
Tissue plasminogen activator and urokinase in normal, dysplastic and cancerous squamous epithelium of the uterine cervix.
Transcription levels of invasion-related genes in prostate cancer cells are modified by inhibitors of tyrosine kinase.
Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.
Transcriptional induction of urokinase in cultured human kidney carcinoma cells by tetradecanoyl-phorbol-acetate.
Transforming growth factor-beta 1 is a potent inducer of plasminogen activator inhibitor type-1 in human glioblastoma and carcinoma cell lines.
Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo.
Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.
Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling.
Tumor necrosis factor stimulates urokinase-type plasminogen activator and inhibitor type 1 production in A549 lung carcinoma cells: treatment of monolayer and tridimensional cultures.
Tumor necrosis factor-alpha regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines.
Tumor-promoter-enhanced destruction of noninvasive human benign colon tumor cells by cocultivated carcinoma cells.
Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes.
Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma.
Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx.
uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery.
Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.
Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity.
Urokinase excretion in patients with carcinoma.
Urokinase expression by tumor suppressor protein p53: a novel role in mRNA turnover.
Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Urokinase plasminogen activator in ovarian cancer.
Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas.
Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC).
Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries.
Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma.
Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo.
Urokinase receptor up-regulation in head and neck squamous cell carcinoma.
Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Urokinase secretion from human colon carcinomas induced by endogenous diglycerides.
Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions.
Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas.
Urokinase-type plasminogen activator biosynthesis is induced by the EJ-Ha-ras oncogene in CL26 mouse colon carcinoma cells.
Urokinase-type plasminogen activator expression and proliferation stimulation in head and neck squamous cell carcinoma in vitro and in situ.
Urokinase-type plasminogen activator expression in human prostate carcinomas.
Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.
Urokinase-type plasminogen activator receptor expression in adenoid cystic carcinoma of the skull base.
Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
[Antisense RNA for urokinase receptor inhibits the invasiveness and metastasis of lung carcinoma]
[Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma]
[Effect of down regulation of laminin receptor on urokinase-type plasminogen activator expression in human bile duct carcinoma cells]
[Effect of hypoxia on the expression of urokinase-type plasminogen activator in human tongue squamous cell carcinoma cells (Tca8113)]
[Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]
[Expression of cyclooxygenase-2 and urokinase plasminogen activator in gastric carcinoma and the clinical significance thereof]
[Expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in gastric carcinoma]
[Expressions and clinical significance of urokinase-type activator (uPA) and uPA receptor (uPAR) in laryngeal squamous cell carcinoma]
[Expressions and clinical significance of urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) in tongue squamous cell carcinoma.]
[Gelatinases A and B and their endogenous regulators in the corpus uteri in squamous cell cervical carcinoma].
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[Matrix metalloproteinases 2 and 9, their endogenous regulators, and angiotensin-converting enzyme in cervical squamous cell carcinoma].
[Methylation status of uPA promoter in laryngeal squamous cell carcinoma]
[Multiple emboli from a cardiac metastasis of a renal-cell carcinoma]
[Pathogenesis and progression of scirrhous carcinoma]
[Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]
[Studies on alpha 2 macroglobulin deficiency in association with cancer metastasis]
[The effect of heat shock on the expression of urokinase-type plasminogen activator in human tongue squamous cell carcinoma cell line (Tca8113)]
[The expression and significance of urokinase-type plasminogen activator and its receptor in squamous cell carcinoma of hypopharynx]
[The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma]
[The expression of urokinase-type plasminogen activator in oral squamous cell carcinoma]
[The relationship between the activation of ERK and the up-regulation of uPA in laryngeal squamous cell carcinoma]
[The role of urokinase type plasminogen activator in invasion of bile duct carcinoma]
[The study of plasminogen activator in renal cell carcinoma with special remarks on urokinase type plasminogen activator]
[Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms]
[u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast]
[Urokinase-type plasminogen activator (uPA) and its inhibitor--new prognostic factors in oral squamous cell carcinoma]
[Value of p53, urokinase plasminogen activator, PAI-1 and Ki-67 in vulvar carcinoma]
Carcinoma in Situ
Changes in the expression of matrix proteases and of the transcription factor c-Ets-1 during progression of precancerous bronchial lesions.
T1 breast cancer: identification of patients at low risk of axillary lymph node metastases.
Carcinoma, Adenoid Cystic
Expression of the urokinase receptor regulates focal adhesion assembly and cell migration in adenoid cystic carcinoma cells.
Urokinase-type plasminogen activator receptor expression in adenoid cystic carcinoma of the skull base.
Carcinoma, Basal Cell
Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.
Expression, subcellular distribution and plasma membrane binding of cathepsin B and gelatinases in bone metastatic tissue.
Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin.
Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas.
Carcinoma, Ductal
High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast.
Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue.
Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization.
Carcinoma, Ductal, Breast
Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
Carcinoma, Hepatocellular
A regulatory element that mediates co-operation between a PEA3-AP-1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells.
Anti-invasion effects of 6-shogaol and 6-gingerol, two active components in ginger, on human hepatocarcinoma cells.
Baicalein Inhibits the Invasion and Metastatic Capabilities of Hepatocellular Carcinoma Cells via Down-Regulation of the ERK Pathway.
Cellular mechanisms of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MAPK signaling in hepatocellular carcinoma.
Characterization of the binding of plasminogen activators to plasma membranes from human liver.
Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma.
Dexamethasone induction of an inhibitor of plasminogen activator in HTC hepatoma cells.
Diagnostic efficacy of plasma urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in differentiation of hepatocellular carcinoma from cirrhosis.
Dioscorea nipponica Attenuates Migration and Invasion by Inhibition of Urokinase-Type Plasminogen Activator through Involving PI3K/Akt and Transcriptional Inhibition of NF-[Formula: see text]B and SP-1 in Hepatocellular Carcinoma.
Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase.
Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection.
Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma.
Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma.
Evaluation of the Association of Urokinase Plasminogen Activator System Gene Polymorphisms with Susceptibility and Pathological Development of Hepatocellular Carcinoma.
Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma.
Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma.
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma.
HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Hispolon suppresses SK-Hep1 human hepatoma cell metastasis by inhibiting matrix metalloproteinase-2/9 and urokinase-plasminogen activator through the PI3K/Akt and ERK signaling pathways.
Human HuH-7 hepatoma cells express urokinase and plasminogen activator inhibitor-1: identification, characterization and regulation by inflammatory mediators.
Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion.
Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
Korean Red Ginseng Suppresses Metastasis of Human Hepatoma SK-Hep1 Cells by Inhibiting Matrix Metalloproteinase-2/-9 and Urokinase Plasminogen Activator.
Licochalcone A Suppresses Migration and Invasion of Human Hepatocellular Carcinoma Cells through Downregulation of MKK4/JNK via NF-?B Mediated Urokinase Plasminogen Activator Expression.
MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells.
Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo.
Prognostic role of urokinase plasminogen activator in hepatocellular carcinoma: A protocol for systematic review and meta analysis.
Proteomic identification of LASP-1 down-regulation after RNAi urokinase silencing in human hepatocellular carcinoma cells.
Rationale for clinical trials of coagulation: reactive drugs in hepatocellular carcinoma.
Reactive oxygen species regulate the generation of urokinase plasminogen activator in human hepatoma cells via MAPK pathways after treatment with hepatocyte growth factor.
RNA interference against urokinase in hepatocellular carcinoma xenografts in nude mice.
Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma.
Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells.
Stable expression of antisense urokinase mRNA inhibits the proliferation and invasion of human hepatocellular carcinoma cells.
Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer.
Terminalia catappa attenuates urokinase-type plasminogen activator expression through Erk pathways in Hepatocellular carcinoma.
Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells.
Urokinase antigen in plasma of patients with liver cirrhosis and hepatoma.
Urokinase induces stromal cell-derived factor-1 expression in human hepatocellular carcinoma cells.
Urokinase plasminogen activator predicts poor prognosis in hepatocellular carcinoma.
Urokinase-type plasminogen activator (uPA) stimulates triglyceride synthesis in Huh7 hepatoma cells via p38-dependent upregulation of DGAT2.
Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells.
[Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients]
[Urokinase-type plasminogen activator (uPA), uPA receptor (uPA-R) and inhibitors (PA I -1) expression in hepatocellular carcinoma in relation to cancer invasion/metastasis and prognosis]
Carcinoma, Intraductal, Noninfiltrating
Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ.
Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ.
Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue.
Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue.
Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization.
Carcinoma, Large Cell
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Carcinoma, Lewis Lung
Effects of tranexamic acid and urokinase on hematogenous metastases of Lewis lung carcinoma in mice.
Expression of urokinase and urinary trypsin inhibitor in metastatic and non-metastatic murine Lewis lung carcinoma cells.
Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.
Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model.
Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.
Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model.
Regulation of CSF-1 receptor expression.
Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma.
Carcinoma, Neuroendocrine
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Carcinoma, Non-Small-Cell Lung
Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines.
Aeroallergen Der p 2 promotes motility of human non-small cell lung cancer cells via toll-like receptor-mediated up-regulation of urokinase-type plasminogen activator and integrin/focal adhesion kinase signaling.
Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer.
Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.
Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinoma.
Graphene nanosheets as an electric mediator for ultrafast sensing of urokinase plasminogen activator receptor-A biomarker of cancer.
Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients.
Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer.
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer.
Prognostic value of urokinase plasminogen activator system in non-small cell lung cancer: A systematic review and meta-analysis.
Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival.
The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC).
The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer.
Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer.
Urokinase plasminogen activator receptor induced non-small cell lung cancer invasion and metastasis requires NHE1 transporter expression and transport activity.
Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis.
[Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer]
Carcinoma, Ovarian Epithelial
Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression.
Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
In vitro invasion assays.
Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells.
Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC).
Urokinase plasminogen activator in ovarian cancer.
Urokinase Plasminogen Activator System Targeted Delivery of Nanobins as a Novel Ovarian Cancer Therapeutics.
Carcinoma, Papillary
Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid.
Immunohistochemical evaluation of urokinase plasminogen activator receptor in noninvasive and early invasive urothelial papillary neoplasia.
Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis.
Carcinoma, Renal Cell
Cell surface antigens in renal tumour cells: detection by immunoluminescence and enzymatic analysis.
Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues.
Connexin 32 down-regulates the fibrinolytic factors in metastatic renal cell carcinoma cells.
Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.
Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
Expression and localization of urokinase-type plasminogen activator in human spinal column tumors.
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells.
Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.
Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells.
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma.
Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
[The study of plasminogen activator in renal cell carcinoma with special remarks on urokinase type plasminogen activator]
Carcinoma, Small Cell
Studies of possible mechanisms for the effect of urokinase therapy in small cell carcinoma of the lung.
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Carcinoma, Squamous Cell
Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.
Clinical relevance of urokinase-type plasminogen activator and its inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix.
Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion.
Epidermal growth factor and 12-tetradecanoyl phorbol 13-acetate induction of urokinase in A431 cells.
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Expression of urokinase-type plasminogen activator and its receptor in squamous cell carcinoma of the oral tongue.
Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma.
Gangliosides inhibit urokinase-type plasminogen activator (uPA)-dependent squamous carcinoma cell migration by preventing uPA receptor/alphabeta integrin/epidermal growth factor receptor interactions.
Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.
Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines.
Keratinocytes and head and neck squamous cell carcinoma cells regulate urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in fibroblasts.
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Melanocyte mediated paracrine induction of extracellular matrix degrading proteases in squamous cell carcinoma cells.
Paracrine factor and cell-cell contact-mediated induction of protease and c-ets gene expression in malignant keratinocyte/dermal fibroblast cocultures.
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus.
Purification and characterization of single-chain urokinase-type plasminogen activator (pro-urokinase) from human A431 cells.
Regulation of human squamous cell carcinoma plasma membrane associated urokinase plasminogen activator by epidermal growth factor.
Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line.
Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene.
Separation and characterization of nonphosphorylated and serine-phosphorylated urokinase. Catalytic properties and sensitivity to plasminogen activator inhibitor type 1.
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China.
Silencing of uPAR via RNA interference inhibits invasion and migration of oral tongue squamous cell carcinoma.
Stimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors.
The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.
The Mr 17500 region of the A chain of urokinase is required for interaction with a specific receptor in A431 cells.
Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa.
Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx.
Urokinase receptor up-regulation in head and neck squamous cell carcinoma.
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
Urokinase-type plasminogen activator expression and proliferation stimulation in head and neck squamous cell carcinoma in vitro and in situ.
Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
[Effect of hypoxia on the expression of urokinase-type plasminogen activator in human tongue squamous cell carcinoma cells (Tca8113)]
[Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]
[Expressions and clinical significance of urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) in tongue squamous cell carcinoma.]
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[Matrix metalloproteinases 2 and 9, their endogenous regulators, and angiotensin-converting enzyme in cervical squamous cell carcinoma].
[Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]
[The effect of heat shock on the expression of urokinase-type plasminogen activator in human tongue squamous cell carcinoma cell line (Tca8113)]
[The expression and significance of urokinase-type plasminogen activator and its receptor in squamous cell carcinoma of hypopharynx]
Carcinoma, Transitional Cell
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Association of Urokinase Gene 3'-UTR T/C polymorphism with bladder cancer.
In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report.
[The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma]
Cardiomegaly
Serine proteases and cardiac function.
Cardiomyopathies
A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure.
Persistent plasminogen activator inhibitor 1 gene expression in cardiac transplant recipients with idiopathic dilated cardiomyopathy.
Cardiomyopathy, Dilated
ERK1/2 mediates the lipopolysaccharide-induced upregulation of FGF-2, uPA, MMP-2, MMP-9 and cellular migration in cardiac fibroblasts.
Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells.
Persistent plasminogen activator inhibitor 1 gene expression in cardiac transplant recipients with idiopathic dilated cardiomyopathy.
Cardiotoxicity
Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
Cardiovascular Diseases
Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals.
Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation.
Associations of suPAR with lifestyle and cardiometabolic risk factors.
Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.
Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study.
Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
Effect of simvastatin and ezetimibe on suPAR levels and outcomes.
Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor.
Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels.
Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase-type plasminogen activator receptor (suPAR) levels.
Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.
Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction.
Plasma soluble urokinase plasminogen activator receptor (suPAR) level is associated with myocardial impairment assessed with advanced echocardiography in Type 1 Diabetes Patients with normal ejection fraction and without known heart disease or end stage renal disease.
Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of acute coronary syndrome.
Prognostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity C-Reactive Protein on Postoperative Mortality in Patients Undergoing Elective On-Pump Cardiac Surgery.
Randomized clinical stroke trials in 2007.
Serine proteases and cardiac function.
Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity.
Sex- and age-related differences in the predictive capability of circulating biomarkers: from the MONICA 10 cohort.
Soluble urokinase plasminogen activation receptor - An emerging new biomarker of cardiovascular disease and critical illness.
Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.
Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism.
Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis.
Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease.
Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study.
Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema.
Streptokinase: An Efficient Enzyme in Cardiac Medicine.
Successful silencing of plasminogen activator inhibitor-1 in human vascular endothelial cells using small interfering RNA.
Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients.
Urokinase-type plasminogen activator system predicts risk of cardiovascular events in patients with angina pectoris: results of the ECAPTURE study. European Concerted Action on Prevention from Thrombosis by URokinase Enhancement.
Use of a proximity extension assay proteomics chip to discover new biomarkers associated with albuminuria.
Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention.
Carotid Artery Diseases
The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.
Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques.
Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
Urokinase-type plasminogen activator receptor is associated with macrophages and plaque rupture in symptomatic carotid atherosclerosis.
Carotid Stenosis
Percutaneous transluminal angioplasty for acute thrombotic occlusion of the cervical internal carotid artery using a perfusion balloon catheter.
Cataract
Sub-Tenon's urokinase injection-assisted vitrectomy in early treatment of suprachoroidal hemorrhage: Four cases report.
Catheter-Related Infections
Method using urokinase and an antibiotic to avoid device removal in central venous catheter-related infections.
Persistent catheter-related bacteremia: clearance with antibiotics and urokinase.
Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies.
Cellulitis
A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin.
Central Nervous System Diseases
Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.
Central Nervous System Neoplasms
Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms.
Use of urokinase in pediatric hematology/oncology patients.
Cerebral Hemorrhage
A review of stereotaxy and lysis for intracranial hemorrhage.
An effective treatment for cerebral hemorrhage: minimally invasive craniopuncture combined with urokinase infusion therapy.
Application of a rheolytic thrombectomy device in the treatment of dural sinus thrombosis: a new technique.
Bleeding complications after basilar artery fibrinolysis with tissue plasminogen activator.
Cerebral amyloid angiopathy-related intracerebral hemorrhage: Feasibility and safety of bedside catheter hematoma evacuation with urokinase.
Comparison of frame-based and frameless stereotactic hematoma puncture and subsequent fibrinolytic therapy for the treatment of supratentorial deep seated spontaneous intracerebral hemorrhage.
Efficacy of tissue plasminogen activator in the lysis of thrombosis of the cerebral venous sinus.
Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate.
Failure of peripheral arterial thrombolysis due to elevated plasminogen activator inhibitor type 1.
Frameless stereotactic aspiration for spontaneous intracerebral hemorrhage and subsequent fibrinolysis using urokinase.
In-Vitro Study of Urokinase Thrombolysis Following Stereotactic Aspiration of Intracerebral Hematoma.
Intra-Arterial Thrombolysis Improves the Prognosis of Acute Ischemic Stroke Patients without Large Vessel Occlusion.
Intracerebral hemorrhage complicating urokinase infusion into an occluded aortocoronary bypass graft.
Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke.
Management of non-traumatic intraventricular hemorrhage.
No exacerbation of perihematomal edema with intraclot urokinase in patients with spontaneous intracerebral hemorrhage.
Safety of thrombolytic therapy with urokinase or recombinant tissue plasminogen activator for peripheral arterial occlusion: a comprehensive compilation of published work.
Superior sagittal sinus thrombosis: a clinical and experimental study.
The release of thromboxane B2 and 6-keto-PGF1 alpha following pulmonary embolism.
Tissue-type plasminogen activator improves neurological functions in a rat model of thromboembolic stroke.
Urokinase vs Tissue-Type Plasminogen Activator for Thrombolytic Evacuation of Spontaneous Intracerebral Hemorrhage in Basal Ganglia.
Urokinase, a promising candidate for fibrinolytic therapy for intracerebral hemorrhage.
Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia.
[A case of successful thromobolytic therapy in a patient with cerebral embolism during angiography]
[New methods of intensive therapy in stroke: hemicraniectomy in patients with complete middle cerebral artery infarction and treatment of intracerebral and intraventricular hemorrhage with urokinase]
Cerebral Infarction
A clinical study of transcranial ultrasound as an adjuvant therapy for progressive cerebral infarction.
A pilot study of urokinase therapy in cerebral infarction.
Comparative study of intravenous thrombolysis with rt-PA and urokinase for patients with acute cerebral infarction.
Comparative study on the efficacy and safety of alteplase and urokinase in the treatment of acute cerebral infarction.
Controlled trial of combined urokinase and dextran sulfate therapy in patients with acute cerebral infarction.
Dynamic change of coagulation and anticoagulation markers of patients with acute cerebral infarction during intravenous urokinase thrombolysis.
Dynamical levels of plasma F(1+2) and D-dimer in patients with acute cerebral infarction during intravenous urokinase thrombolysis.
Effects of Intra-arterial Urokinase on a Non-human Primate Thromboembolic Stroke Model.
Evaluation of reperfusion and recovery of brain function before and after intracarotid arterial urokinase therapy in acute cerebral infarction with brain SPECT.
Fatal cerebral infarction in an asymptomatic young patient with primary antiphospholipid syndrome.
Impact of low-dose urokinase in peritoneal dialysis on serum oxidative stress, nitric oxide and endothelin in cerebral infarction complicated with uremia.
Influencing Factors of Recanalization after Intravenous Thrombolysis with Urokinase in Acute Cerebral Infarction Patients.
Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery.
Kawasaki Disease Complicated by Late-Onset Fatal Cerebral Infarction: A Case Report and Literature Review.
Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in early focal cerebral infarction following urokinase thrombolysis in rats.
Mechanically assisted intra-arterial thrombolysis in acute cerebral infarction.
Selective and superselective infusion of urokinase for embolic stroke.
Stroke research in China.
The effects of blood pressure and urokinase on brain injuries after experimental cerebral infarction in rats.
The serum levels of MMP-9, MMP-2 and vWF in patients with low doses of urokinase peritoneal dialysis decreased uremia complicated with cerebral infarction.
Treatment efficacy of arterial urokinase thrombolysis combined with mechanical thrombectomy for acute cerebral infarction and its influence on neuroprotective factors and factors for neurological injury.
Vasospasm prevention with postoperative intrathecal thrombolytic therapy: a retrospective comparison of urokinase, tissue plasminogen activator, and cisternal drainage alone.
[A case of unruptured A1 aneurysm causing ischemic compression to the medial proximal striate artery]
[Brain attack in Japan, now and future]
[Case of cholesterol crystal embolism occurring after treatment of cerebral infarction with urokinase]
[Clinical effects of sodium ozagrel and urokinase in patients with acute cerebral infarction in the territory of the internal carotid artery]
[Clinical study on ultra-early intravenous thrombolysis with high-dose urokinase in treatment of acute cerebral infarction]
[Endovascular embolization of cerebral arteriovenous malformation]
[Expression of urokinase-type plasminogen activator and its receptor in plasma of patients with cerebral infarction]
[Intraarterial injection of low molecular weight dextran and urokinase for acute cerebral infarction]
[Problems in urokinase therapy in cerebral infarction]
[Protective effects of Ginkgo biloba extract on focal cerebral ischemia and thrombogenesis of carotid artery in rats]
[Risk factors for intracerebral hemorrhage after intravenous thrombolysis in acute cerebral infarction]
[Studies on blood coagulation and fibrinolytic activities in the cases of cerebral infarction treated with urokinase. 2nd Report -- espeically changes of coagulofibrinolytic system before and after UK infusion (author's transl)]
[Studies on blood coagulation and fibrinolytic activities in the three cases of cerebral infarction treated with urokinase. 1st report--120,000 I.U. administrated-- (author's transl)]
[Successful treatment of thoracic drainage using urokinase for empyema in an elderly man].
[The treatment of acute cerebral infarction with urokinase and tissue plasminogen activator]
[Thrombolysis of cerebral thromboembolism by urokinase in an animal model]
[Thrombolytic agents in cerebral infarctions]
Cerebrovascular Disorders
Changes of the levels of antithrombin III in patients with cerebrovascular diseases.
Corrigendum to "Comparative Analysis of Fibrinolytic Properties of Alteplase, Tenecteplase and Urokinase in an in Vitro Clot Model of Intracerebral Haemorrhage. [Journal of Stroke and Cerebrovascular Diseases, Vol. 29, No. 9 (September), 2020: 105073]".
Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke.
Intraoperative high-dose regional urokinase infusion for cerebrovascular occlusion after carotid endarterectomy.
[Intraarterial urokinase infusion therapy with superselective catheterization for acute occlusive cerebrovascular disease]
Cervical Intraepithelial Neoplasia
Expression of MMP-2, MMP-9, and urokinase-type plasminogen activator in cervical intraepithelial neoplasia.
Cholangiocarcinoma
High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.
Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients.
Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer.
Cholecystitis
Hemorrhagic cholecystitis with hemobilia: treatment with percutaneous cholecystostomy and transcatheter urokinase.
Cholera
Isolation of a mutant LLC-PK1 cell line defective in hormonal responsiveness. A pleiotropic lesion in receptor function.
Modulations of functional activity in differentiated macrophages are accompanied by early and transient increase or decrease in c-fos gene transcription.
Cholesteatoma
Expression pattern of the plasminogen activator-plasmin system in human cholesteatoma.
Plasminogen activators in tissue extract of aural cholesteatoma.
Chondrosarcoma
CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells.
Expression and localization of urokinase-type plasminogen activator in human spinal column tumors.
Involvement of the soluble urokinase receptor in chondrosarcoma cell mobilization.
Kunitz-type protease inhibitor bikunin disrupts phorbol ester-induced oligomerization of CD44 variant isoforms containing epitope v9 and subsequently suppresses expression of urokinase-type plasminogen activator in human chondrosarcoma cells.
Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma.
Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells.
[New findings in orthopedic pathology]
Chordoma
Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma.
Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Choriocarcinoma
Inhibition of cytotrophoblastic (JEG-3) cell invasion by interleukin 12 involves an interferon gamma-mediated pathway.
Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells.
Protein C and its inhibitor in malignancy.
Choroidal Effusions
Sub-Tenon's urokinase injection-assisted vitrectomy in early treatment of suprachoroidal hemorrhage: Four cases report.
Choroidal Neovascularization
Effect of a novel octapeptide urokinase fragment, A6, on experimental choroidal neovascularization in the monkey.
Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model.
Role of urokinase inhibitors in choroidal neovascularization.
The Urokinase Receptor-Derived Peptide UPARANT Mitigates Angiogenesis in a Mouse Model of Laser-Induced Choroidal Neovascularization.
Chronic Limb-Threatening Ischemia
Effect of Systemic Urokinase Infusion After Lower Limb Percutaneous Transluminal Angioplasty on Limb Salvage Rate in Patients with Late-stage Critical Limb Ischemia.
Intermittent intravenous urokinase for critical limb ischemia in diabetic foot ulceration.
Chronic Urticaria
Blood urokinase plasminogen activator system in chronic urticaria.
Classical Swine Fever
Coordinated expression of vascular endothelial growth factor A and urokinase-type plasminogen activator contributes to classical swine fever virus Shimen infection in macrophages.
coagulation factor xiia deficiency
[Congenital deficiency of factor Xii and spontaenous venous thrombosis treated with urokinase]
Colitis
BMP pathway suppression is an early event in inflammation-driven colon neoplasmatogenesis of uPA-deficient mice.
Inflammation-driven colon neoplasmatogenesis in uPA-deficient mice is associated with an increased expression of Runx transcriptional regulators.
Inflammation-induced colon cancer in uPA-deficient mice is associated with a deregulated expression of Notch signaling pathway components.
Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization.
Colitis, Ulcerative
Abnormalities of the urokinase system in colonic crypt cells from patients with ulcerative colitis.
Use of thrombolytic therapy in cerebral venous sinus thrombosis with ulcerative colitis.
[Fibrinogen-guided thrombolysis with urokinase of a portal and mesenterial venous thrombosis during an acute episode of ulcerative colitis]
[Urokinase plasminogen activator (u-PA) and urokinase type plasminogen activator receptor (u-PAR) in children with ulcerative colitis.]
Colonic Diseases
Butyrate is a potent inhibitor of urokinase secretion by normal colonic epithelium in vitro.
Colonic Neoplasms
A pharmacological analysis of the cholinergic regulation of urokinase-type plasminogen activator secretion in the human colon cancer cell line, HT-29.
Amiloride modulates urokinase gene expression at both transcription and post-transcription levels in human colon cancer cells.
Aspirin upregulates expression of urokinase type plasminogen activator receptor (uPAR) gene in human colon cancer cells through AP1.
Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway.
beta-Catenin and NF-kappaB cooperate to regulate the uPA/uPAR system in cancer cells.
Chromosomal localization of the human urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 genes: implications in colorectal cancer.
Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.
Correlation between tumor proliferation and tumor tissue level of urokinase-type plasminogen activator.
Decreased urokinase receptor expression by overexpression of the plasminogen activator in a colon cancer cell line.
Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization.
Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness.
Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells.
Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade.
Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a human colon cancer cell line.
Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation.
Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma.
Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab.
Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis.
GATA6 promotes colon cancer cell invasion by regulating urokinase plasminogen activator gene expression.
Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells.
Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer.
Inflammation-induced colon cancer in uPA-deficient mice is associated with a deregulated expression of Notch signaling pathway components.
Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
Inhibition of colon cancer metastasis by a 3'- end antisense urokinase receptor mRNA in a nude mouse model.
Insensitivity of laminin degradation directed by receptor bound urokinase to PAI-1 in cultured colon cancer.
Integrated bioprocess for the production and isolation of urokinase from animal cell culture using supermacroporous cryogel matrices.
Interferon-alpha (Intron A) upregulates urokinase-type plasminogen activator receptor gene expression.
Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display.
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.
Lithocholic acid upregulates uPAR and cell invasiveness via MAPK and AP-1 signaling in colon cancer cells.
Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
Macrophage inhibitory cytokine-1 (MIC-1) and subsequent urokinase-type plasminogen activator mediate cell death responses by ribotoxic anisomycin in HCT-116 colon cancer cells.
Plasticity in Urokinase-Type Plasminogen Activator Receptor (uPAR) Display in Colon Cancer Yields Metastable Subpopulations Oscillating in Cell Surface uPAR Density--Implications in Tumor Progression.
Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation.
Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach.
Requirement of the enzymatic and signaling activities of plasmin for phorbol-ester-induced scattering of colon cancer cells.
Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.
Selective suicide gene therapy of colon cancer exploiting the urokinase plasminogen activator receptor promoter.
Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation.
Sodium butyrate inhibits expression of urokinase and its receptor mRNAs at both transcription and post-transcription levels in colon cancer cells.
Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis.
The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.
Transcriptional activation of the urokinase receptor gene in invasive colon cancer.
Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1.
Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
Urokinase-type plasminogen activator receptor regulates apoptotic sensitivity of colon cancer HCT116 cell line to TRAIL via JNK-p53 pathway.
Wnt/?-catenin signaling mediates the antitumor activity of magnolol in colorectal cancer cells.
[Assay and detection methods for urokinase-type plasminogen activator and its related-factors]
[The role of p38 MAPK in gastrin-induced u-PA expression in human colon cancer cells]
Colorectal Neoplasms
A C/T polymorphism in the urokinase-type plasminogen activator gene in colorectal cancer.
A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer.
A Preliminary Study of the Value of Plasma microRNA-193b and Soluble Urokinase-Type Plasminogen Activator Receptor in Identifying Patients with Early-Stage Colorectal Cancer and.
Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I).
Anti-cancer effect of Aquaporin 5 silencing in colorectal cancer cells in association with inhibition of Wnt/?-catenin pathway.
Antigen levels of the urokinase-type plasminogen activator and its gene polymorphisms in colorectal cancer.
Antigen levels of urokinase-type plasminogen activator receptor and its gene polymorphism related to microvessel density in colorectal cancer.
Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer.
Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system.
Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors.
Beta-catenin--a linchpin in colorectal carcinogenesis?
Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma.
Butyrate is a potent inhibitor of urokinase secretion by normal colonic epithelium in vitro.
Chromosomal localization of the human urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 genes: implications in colorectal cancer.
Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
Clinicopathologic significance of urokinase receptor- and MMP-9-positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogenous metastasis.
Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers.
Combined expression of urokinase-type plasminogen activator and proliferating cell nuclear antigen at the deepest invasive portion correlates with colorectal cancer prognosis.
Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression.
Correlation between metastatic potential and variants from colorectal tumor cell line HT-29.
Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization.
Enzymatic function of multiple origins regulates the progression of colorectal cancer and the development of metastases.
Epithelial and stromal cell urokinase plasminogen activator receptor expression differentially correlates with survival in rectal cancer stages B and C patients.
Evaluation of alpha 1-antitrypsin and the levels of mRNA expression of matrix metalloproteinase 7, urokinase type plasminogen activator receptor and COX-2 for the diagnosis of colorectal cancer.
Evidence for the clinical use of tumour markers.
Gelsolin Induces Colorectal Tumor Cell Invasion via Modulation of the Urokinase-Type Plasminogen Activator Cascade.
Gelsolin-Cu/ZnSOD interaction alters intracellular reactive oxygen species levels to promote cancer cell invasion.
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy.
Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.
Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.
Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers.
Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Novel Inhibitors of Urokinase-type Plasminogen Activators: 4-(3H-imidazo[4,5-b]pyridin-2-yl)-N-Substituted Benzamide and Benzamidine Compounds.
Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas.
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid.
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens.
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?
Plasminogen activators in human colorectal neoplasia.
Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.
Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
Prognostic role of urokinase plasminogen activator receptor in gastric and colorectal cancer: A systematic review and meta-analysis.
Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor.
Regional variations of urokinase-type plasminogen activator in human colorectal cancer: a quantitative study by image analysis.
Role of urokinase in colorectal neoplasia.
Role of urokinase, its receptor, and serpins in colorectal carcinoma.
Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.
Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas.
Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer.
Stromal cell-derived factor-1/CXC receptor 4 and b1 integrin interaction regulates urokinase-type plasminogen activator expression in human colorectal cancer cells.
Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect.
Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver.
The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study.
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.
The expression of urokinase type plasminogen activator is a novel prognostic factor in dukes B and C colorectal cancer.
The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology.
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
Urokinase receptor and colorectal cancer survival.
Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
Urokinase receptor genotypes in colorectal cancer.
Urokinase type plasminogen activator receptor expression in colorectal neoplasms.
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.
Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.
Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme.
Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer.
Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator.
[Comparative analysis of metastatic variants from the colorectal tumor cell line HT-29]
[Effect of jianpi-jiedu formula on tumor angiogenesis-relevant genes expression in colorectal cancer].
[Significance in gene expression of matrix metalloproteinase-9, urokinase-type plasminogen activator and tissue inhibitor of metalloproteinase for metastases of gastric and/or colo-rectal cancer]
[The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer]
Coma
Acute vertebral-basilar thrombosis. Angiologic-clinical comparison and therapeutic implications.
Endovascular thrombolysis in deep cerebral venous thrombosis.
Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial.
Management of primary intracerebral hematomas.
Thrombolytic therapy and posterior circulation extracranial-intracranial bypass for acute basilar artery thrombosis. Case report.
Twist drill craniostomy for traumatic acute subdural hematoma in the elderly: case series and literature review.
Urokinase treatment for severe neurological complications in a patient with thrombotic thrombocytopenic purpura.
[Multianalysis of short-term prognostic factors in surgical practices for hypertensive intracerebral hemorrhage]
Common Variable Immunodeficiency
Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency.
Communicable Diseases
Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Plasma Level of Soluble Urokinase-type Plasminogen Activator Receptor Predicts the Severity of Acute Alcohol Pancreatitis.
Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group.
Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection.
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.
suPAR as a prognostic biomarker in sepsis.
suPAR: the molecular crystal ball.
The Diagnostic and Prognostic Value of Supar in Patients With Sepsis: A Systematic Review and Meta-Analysis.
Conjunctivitis, Allergic
Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Corneal Neovascularization
The role of the fibrinolytic system in corneal angiogenesis.
Trehalose treatment accelerates the healing of UVB-irradiated corneas. Comparative immunohistochemical studies on corneal cryostat sections and corneal impression cytology.
Corneal Perforation
Immunohistochemical localization of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and ?2-antiplasmin in human corneal perforation: a case report.
Coronary Aneurysm
Intracoronary urokinase in Kawasaki disease: treatment and prevention of myocardial infarction.
[Clinical analysis of intravenous urokinase treatment of 10 cases with Kawasaki disease complicated with thrombus in coronary aneurysm]
Coronary Artery Disease
Antithrombotic treatment in stable coronary syndromes: long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris.
Automated, PCR-RFLP genotyping of the urokinase gene.
Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.
Chronic-intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris--a pilot study.
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease.
Increased Urokinase-Type Plasminogen Activator Receptor Expression on Circulating Monocytes Is Correlated with Clinical Instability and Long-Term Adverse Cardiac Events in Patients with Coronary Artery Disease.
Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a randomized dose-response trial.
Long-term Urokinase Therapy and Isovolemic Hemodilution: A Clinical and Hemodynamic Comparison in Patients with Refractory Angina Pectoris.
Low-dose intermittent urokinase therapy in chronic symptomatic end-stage arterial disease--clinical relevance for patients with coronary artery disease or peripheral arterial occlusive disease.
Multibiomarker analysis in patients with acute myocardial infarction.
Multimarker Approach to Identify Patients with Coronary Artery Disease at High Risk for Subsequent Cardiac Adverse Events: The Multi-Biomarker Study.
Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease.
Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients.
Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events.
Soluble Urokinase Plasminogen Activator Receptor Level Is an Independent Predictor of the Presence and Severity of Coronary Artery Disease and of Future Adverse Events.
Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease.
Soluble urokinase-type plasminogen activator receptor: a useful biomarker for coronary artery disease and clinical outcomes?
Stenting the stent: alternative strategy for treating in-stent restenosis.
SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease.
Urokinase plasminogen activator system in humans with stable coronary artery disease.
[Antithrombotic therapy in chronic coronary syndromes--value of thrombocyte aggregation inhibition, anticoagulation and chronic thrombolysis]
[Chronic intermittent urokinase therapy: anti-ischemic and hemodynamic effects]
[Clinical significance of the cardiovascular risk factor fibrinogen in secondary prevention]
[Risk factors for coronary artery disease stimulate urokinase receptor expression on monocytes]
Coronary Disease
Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase-type plasminogen activator receptor (suPAR) levels.
[Chronic intermittent urokinase therapy in inoperable end-stage coronary disease with therapy refractory angina pectoris symptoms]
[Chronic intermittent urokinase therapy in therapy-refractory angina pectoris]
[Conservative therapeutic approaches in terminal coronary heart disease. Chronic intermittent urokinase therapy]
[Relationship between atherosclerotic plaque characteristics and extracellular matrix metalloproteinase inducer and urokinase-type plasminogen activator in patients with coronary artery disease].
[Symptomatic therapy refractory myocardial ischemia in coronary heart disease. Chronic intermittent urokinase therapy and invasive therapeutic measures]
[Urokinase-type plasminogen activator and its inhibitor type 1 in the diagnosis of evolving complications in coronary heart disease]
Coronary Occlusion
Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
Intracoronary urokinase in acute myocardial infarction: prevalence of total coronary occlusion during the early hours, effects on myocardial infarct size and left ventricular function, and outcome of residual coronary stenosis.
Management of complicated coronary angioplasty by intracoronary urokinase and immediate re-angioplasty.
Myocardial infarction after cryoablation surgery for Wolff-Parkinson-White syndrome.
Pathomorphological changes in experimentally induced canine myocardial infarction.
Prolonged urokinase infusion for chronic total native coronary occlusions: clinical, angiographic, and treatment observations.
The use of urokinase in acute myocardial infarction: report of two cases.
Urokinase in thrombotic coronary occlusion.
Coronary Restenosis
Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis.
Coronary Stenosis
Intracoronary urokinase in acute myocardial infarction: prevalence of total coronary occlusion during the early hours, effects on myocardial infarct size and left ventricular function, and outcome of residual coronary stenosis.
Treatment of intracoronary thrombus with local urokinase infusion using a new, site-specific drug delivery system: the Dispatch catheter.
[Left ventricular asynergy in patients with impending myocardial infarction: two-dimensional echocardiographic assessment]
Coronary Thrombosis
A novel modified tissue-type plasminogen activator (t-PA), E6010, gradually increases coronary blood flow after thrombolysis compared with native t-PA, urokinase and balloon catheter occlusion-reperfusion.
Additional myocardial salvage by coadministration of the epoprostenol analog taprostene to recombinant single-chain urokinase-type plasminogen activator in a canine coronary thrombosis model.
Antiplatelet effects of urokinase and their clinical implications.
Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
Coronary thrombolysis. Comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase.
Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model.
Low-dose antithrombotic treatment in coronary thrombosis of kawasaki disease.
Low-dose i.v. urokinase for coronary thrombosis in Kawasaki disease.
Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.
[Comparison of the efficacy of intravenous urokinase and defibrase on 6-hour-old canine coronary thrombosis]
[Effects of intracoronary or intravenous urokinase on canine coronary thrombosis]
[Late effect of intracoronary urokinase. Apropos of a case of recurrent coronary thrombosis after angioplasty]
[Role of urokinase in the acute phase of myocardial infarction]
[Significance of coronary thrombosis for chronic myocardial ischemia]
COVID-19
Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study.
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients.
Evaluation of the relationship between KIM-1 and suPAR levels and clinical severity in COVID-19 patients: A different perspective on suPAR.
SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung.
Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department.
Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients.
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.
Unclear Issues Regarding COVID-19.
Craniocerebral Trauma
Effects of minimally invasive approaches on chronic subdural hematoma by novel YL-1 puncture needle and burr-hole methods.
Endovascular treatment of traumatic dural sinus thrombosis: case report.
Sagittal sinus thrombosis following minor head injury treated with continuous urokinase infusion.
[Monitoring of coagulation activity in cases with head injuries, with special reference to a urokinase resistance test]
Creutzfeldt-Jakob Syndrome
Cortical neurons of Creutzfeldt-Jakob disease patients express the urokinase-type plasminogen activator receptor.
Crohn Disease
Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
Cryptococcosis
Urokinase-type plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection.
Cystadenocarcinoma
Expression of urokinase-type plasminogen-activator (upa) and its receptor (upar) in human ovarian-cancer cells and in-vitro invasion capacity.
Cystic Fibrosis
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
Cysts
A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470.
Contrast-enhanced ultrasound evaluation of a refractory ovarian endometrial cyst and ultrasound-guided aspiration sclerotherapy using urokinase and lauromacrogol.
Drilling skull plus injection of urokinase in the treatment of epidural haematoma: a preliminary study.
Fluid characteristics of benign ovarian cysts: correlation with recurrence after puncture.
Medical therapy with tranexamic acid in autosomal dominant polycystic kidney disease patients with severe haematuria.
Novel Minimally Invasive Treatment Strategy for Acute Traumatic Epidural Hematoma: Endovascular Embolization Combined with Drainage Surgery and Use of Urokinase.
The urine urokinase concentration in end stage renal disease with acquired renal cyst.
Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
Darier Disease
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Death, Sudden, Cardiac
Circadian fluctuations in the efficacy of thrombolysis with streptokinase.
Dehydration
Resolution of proteinuria secondary to bilateral renal vein thrombosis after treatment with systemic thrombolytic therapy.
Dementia
Excessive urokinase-type plasminogen activator activity in the euglobulin fraction of patients with Alzheimer-type dementia.
The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.
Dementia, Vascular
Excessive urokinase-type plasminogen activator activity in the euglobulin fraction of patients with Alzheimer-type dementia.
Demyelinating Diseases
A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis.
Nerve lesions induced by macrophage activation.
Dermatitis Herpetiformis
Enhanced expression of interstitial collagenase, stromelysin-1, and urokinase plasminogen activator in lesions of dermatitis herpetiformis.
Urokinase plasminogen activator is expressed by basal keratinocytes before interstitial collagenase, stromelysin-1, and laminin-5 in experimentally induced dermatitis herpetiformis lesions.
Diabetes Mellitus
Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Deficiency of Urokinase Plasminogen Activator May Impair ? Cells Regeneration and Insulin Secretion in Type 2 Diabetes Mellitus.
Distribution of C-->T and T-->C polymorphisms of the urokinase-type plasminogen activator gene in children with type 1 diabetes mellitus and insulin resistance.
Insulin Treatment Forces Arteriogenesis in Diabetes Mellitus by Upregulation of the Early Growth Response-1 (Egr-1) Pathway in Mice.
Low level of low-density lipoprotein cholesterol is related with increased hemorrhagic transformation after acute ischemic cerebral infarction.
Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias.
Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.
Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus.
Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus.
[Case of cholesterol crystal embolism occurring after treatment of cerebral infarction with urokinase]
[Determination of efficacy of second application of Urokinase Medac in a diabetic foot syndrome].
[Urinary urokinase and blood fibrinolytic activity in patients with diabetes mellitus]
Diabetes Mellitus, Experimental
[Histidase and urokinase activity in the blood and liver of the rat in alloxan diabetes and the effect of insulin on their activities]
Diabetes Mellitus, Type 1
Distribution of C-->T and T-->C polymorphisms of the urokinase-type plasminogen activator gene in children with type 1 diabetes mellitus and insulin resistance.
Plasma soluble urokinase plasminogen activator receptor (suPAR) level is associated with myocardial impairment assessed with advanced echocardiography in Type 1 Diabetes Patients with normal ejection fraction and without known heart disease or end stage renal disease.
Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
Diabetes Mellitus, Type 2
Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Deficiency of Urokinase Plasminogen Activator May Impair ? Cells Regeneration and Insulin Secretion in Type 2 Diabetes Mellitus.
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.
Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes.
Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.
Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus.
The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status.
Diabetic Angiopathies
[Intra-arterial thrombolytic therapy of ischaemic complications of lower-limb diabetic angiopathy].
Diabetic Foot
Intermittent intravenous urokinase for critical limb ischemia in diabetic foot ulceration.
The role of soluble urokinase plasminogen activator receptor (suPAR) in the diagnostics of diabetic foot infection.
[Determination of efficacy of second application of Urokinase Medac in a diabetic foot syndrome].
[Regional intraosseous thrombolytic therapy in comprehensive treatment of patients with diabetic foot syndrome].
Diabetic Nephropathies
Diabetic nephropathy is associated with increased urine excretion of proteases plasmin, prostasin and urokinase and activation of amiloride-sensitive current in collecting duct cells.
Effect of urokinase on preservation of renal function in patients with diabetic nephropathy.
Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy.
RAGE and ?V?3-integrin are essential for suPAR signaling in podocytes.
Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes.
Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus.
Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.
Diabetic Retinopathy
Diabetic Retinopathy in the Spontaneously Diabetic Torii Rat: Pathogenetic Mechanisms and Preventive Efficacy of Inhibiting the Urokinase-Type Plasminogen Activator Receptor System.
The Urokinase Receptor-Derived Peptide UPARANT Recovers Dysfunctional Electroretinogram and Blood-Retinal Barrier Leakage in a Rat Model of Diabetes.
Thrombosis and Hemorrhage in Diabetic Retinopathy: A Perspective from an Inflammatory Standpoint.
[Urokinase therapy in diabetic retinopathy (author's transl)]
Digestive System Diseases
[Diagnostic values of alkaline phosphatase, histidase and urokinase in the bile in children with hepatobiliary diseases]
Diphtheria
A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts.
Contribution of plasminogen activator urokinase to in vitro cytotoxicity of diphtheria toxin.
Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13.
Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.
Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice.
Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.
Specific cleavage of diphtheria toxin by human urokinase.
Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.
Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.
The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells.
Disorders of Excessive Somnolence
[FDG-PET in an amnestic and hypersomnic patient with bilateral paramedian thalamic infarction]
Disseminated Intravascular Coagulation
Beneficial effects of urokinase on lipopolysaccharide-induced disseminated intravascular coagulation in rats: focus on organ function and endothelin levels.
Danger of urokinase as an anticoagulant with left ventricular assist devices.
Detection of low molecular weight urokinase in plasma of patient with acute pancreatitis followed by disseminated intravascular coagulation.
Disseminated intravascular coagulation. Heparin, anticoagulant and urokinase in experimental nephritic in mice.
Effect of urokinase on disseminated intravascular coagulation.
Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
Fibrinolytic agents: a new approach to the treatment of adult respiratory distress syndrome.
Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis.
Localization of tissue plasminogen activator on experimental thrombi in rats.
Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target?
Plasmin-alpha 2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis.
Unclear Issues Regarding COVID-19.
[Disseminated intravascular coagulation induced by endotoxin in rabbits: effect of treatment with t-PA and urokinase]
[Therapy of consumption coagulopathy and hyperfibrinolysis with urokinase in a case of acute promyelocytic leukemia]
[Urokinase excretion and fibrinolysis in consumption coagulopathy and acute kidney failure]
Drug-Related Side Effects and Adverse Reactions
Urokinase does not upregulate the vascular endothelial cell-mediated inflammatory response.
Duodenal Ulcer
Reduced tissue type plasminogen activator activity of the gastroduodenal mucosa in peptic ulcer disease.
Dyspnea
Randomised Controlled Trial of Urokinase versus Placebo for Non-draining Malignant Pleural Effusion.
[Successful thrombolysis of a thrombosed mitral valve prosthesis]
Eclampsia
Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia.
[Fibrinolysis in pregnancy toxemia]
Embolic Stroke
A case-control analysis of intra-arterial urokinase thrombolysis in acute cardioembolic stroke.
A Combined Treatment with Taurine and Intra-arterial Thrombolysis in an Embolic Model of Stroke in Rats: Increased Neuroprotective Efficacy and Extended Therapeutic Time Window.
Effect of intra-arterial tissue plasminogen activator and urokinase on autologous arterial emboli in the cerebral circulation of rabbits [corrected]
Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate.
Good clinical outcome in a patient with a large CT scan hypodensity treated with intra-arterial urokinase after an embolic stroke.
Intraoperative urokinase infusion for embolic stroke during carotid endarterectomy.
Selective and superselective infusion of urokinase for embolic stroke.
Tirofiban combined with urokinase selective intra-arterial thrombolysis for the treatment of middle cerebral artery occlusion.
Embolism
A new "wonder" drug to dissolve clots. The results of urokinase therapy in acute myocardial infarction, pulmonary embolism and deep vein thrombosis.
Carotid endarterectomy and intracranial thrombolysis: simultaneous and staged procedures in ischemic stroke.
Central venous line thrombosis in premature infants: a case management and literature review.
Combined modality of mechanical breakdown and intraembolus thrombolysis in failed systemic thrombolysis of subacute pulmonary embolism patients.
Coronary embolism following aortic and mitral valve replacement: successful management with abciximab and urokinase.
Cost-effectiveness of intra-arterial thrombolytic therapy.
Effect of urokinase on fibrinolysis and fibrinogenolysis.
Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism.
Experimental pulmonary embolus in the rat: a new in vivo model to test thrombolytic drugs.
Experimentally Induced Arterial Embolism by Hyaluronic Acid Injection: Clinicopathologic Observations and Treatment.
Experimentally Induced Arterial Embolism by Hyaluronic Acid Injection: Clinicopathological Observations and Treatment.
Fibrinolytic therapy for acute embolic stroke: intravenous, intracarotid, and intra-arterial local approaches.
Fibrinolytic therapy for upper-extremity arterial occlusions.
High-dose bolus injection of urokinase. Use during cardiopulmonary resuscitation for massive pulmonary embolism.
History and physical examination in acute pulmonary embolism in patients without preexisting cardiac or pulmonary disease.
Immediate postoperative thrombolytic therapy: an aggressive strategy for neurologic salvage when cerebral thromboembolism complicates carotid endarterectomy.
Intraarterial therapy for acute ischemic stroke: investigation of prognostic factors.
Intravenous Hyaluronidase with Urokinase as Treatment for Arterial Hyaluronic Acid Embolism.
Intravenous Hyaluronidase with Urokinase as Treatment for Rabbit Retinal Artery Hyaluronic Acid Embolism.
Lung endothelium targeting for pulmonary embolism thrombolysis.
Management of acute superior mesenteric artery occlusion.
Outcome in acute stroke with different intra-arterial infusion rate of urokinase on thrombolysis.
Percutaneous management of emboli associated with hot tip laser-assisted angioplasty.
Pulmonary embolus and Malassezia pulmonary infection related to urokinase therapy.
Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan.
Recanalization by mechanical embolus disruption during intra-arterial thrombolysis in the carotid territory.
Renal artery embolus treated with urokinase perfusion.
Reply: Intravenous Hyaluronidase with Urokinase as Treatment for Arterial Hyaluronic Acid Embolism.
Role of urokinase in the superior mesenteric artery embolism.
Safety and efficacy of urokinase during elective coronary angioplasty.
Successful intra-arterial fibrinolysis of the anterior choroidal artery in the acute stage of internal carotid artery occlusion: case report.
Successful intraarterial fragmentation and urokinase therapy in superior mesenteric artery embolisms.
Superior mesenteric arterial embolism: a retrospective study of local thrombolytic treatment with urokinase in West China.
Superior mesenteric arterial embolism: local fibrinolytic treatment with urokinase.
Superior mesenteric artery embolism: treatment with intraarterial urokinase.
Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus.
Thrombolytic therapy for catheter-related thrombosis.
Urokinase evaluated with the experimental radioactive embolus.
Urokinase in pulnonary embolism.
Urokinase resolution of impending paradoxic embolus in transit: evaluation by multiplane transesophageal echocardiography.
Urokinase thrombolysis as initial therapy for acute and non-acute ischemic extremities.
Urokinase treatment preserves endothelial and smooth muscle function in experimental acute arterial thrombosis.
[A case of inferior vena cava thrombosis associated with cholelithiasis demonstrated by ultrasonic examination]
[A case of renal artery embolism treated with urokinase]
[Arterial infusion therapy in mesenteric artery embolisms. A report of two cases treated by infusion therapy using only urokinase]
[Case of cholesterol crystal embolism occurring after treatment of cerebral infarction with urokinase]
[Comparative assessment of efficacy of local thrombolysis with various fibrinolytics].
[Drug therapy of pulmonary embolism]
[Experience with intra-arterial thrombolysis in patients with acute stroke]
[Intensive medical monitoring with transesophageal echocardiography in fulminant pulmonary embolism]
[Intra-arterial infusion with urokinase for embolism of the superior mesenteric artery]
[Intra-arterial perfusion with urokinase in embolism of the superior mesenteric artery]
[Local thrombolysis in renal artery embolism]
[Mechanical high speed analysis of acute thromboembolic occlusions of t he popliteal artery. Initial experiences with the Amplatz thrombectomy catheter]
[Multicenter study of 2 urokinase protocols in severe pulmonary embolism. Research Group on Urokinase and Pulmonary Embolism]
[Renal artery embolism treated with a continuous selective intra-arterial urokinase infusion therapy: a case report]
[Successful thrombolysis of a fulminant lung embolism during cardiopulmonary resuscitation]
[Systemic lysotherapy using recombinant tissue plasminogen activator for fulminant pulmonary embolism]
[Thrombus fragmentation and local lysis in extensive pulmonary embolisms]
[Treatment of a mesenteric artery embolism with local high-dosage urokinase administration]
Embolism, Air
Uncommon Occurrences of Air Embolism: Description of Cases and Review of the Literature.
Empyema
Community-acquired Pseudomonas aeruginosa pneumonia complicated with loculated empyema in an infant with selective IgA deficiency.
Comparison of urokinase and video-assisted thoracoscopic surgery for treatment of childhood empyema.
Computed tomography-guided catheter drainage with urokinase and ozone in management of empyema.
Empyema and effusion: outcome of image-guided small-bore catheter drainage.
Fibrinolysis with Lower Dose Urokinase in Patients with Complicated Parapneumonic Effusion.
Hyaluronic acid on the urokinase sustained release with a hydrogel system composed of poloxamer 407: HA/P407 hydrogel system for drug delivery.
Initial treatment of septated parapneumonic empyema with drainage plus fibrinolytic agents is equally effective as video-assisted thoracoscopic surgery, and is suitable as first-line therapy.
Intra-pleural fibrinolytic therapy vs. conservative management in the treatment of parapneumonic effusions and empyema.
Intracavitary urokinase therapy as an adjunct to percutaneous drainage in a patient with a multiloculated empyema.
Intrapleural alteplase in a patient with complicated pleural effusion.
Intrapleural fibrinolytic treatment of multiloculated thoracic empyemas.
Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial.
Intrapleural urokinase in the treatment of complicated parapneumonic pleural effusions and empyema.
Intrapleural urokinase treatment in children with complicated parapneumonic effusion.
Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. A randomized, double-blind study.
Intrapleural urokinase versus surgical management of childhood empyema.
Less is best? The impact of urokinase as the first line management of empyema thoracis.
Once-daily intrapleural urokinase treatment of complicated parapneumonic effusion in pediatric patients.
Phase 1 trial of intrapleural LTI-01; single chain urokinase in complicated parapneumonic effusions or empyema.
Randomised trial of intrapleural urokinase in the treatment of childhood empyema.
Role of Intrapleural Urokinase in Empyema Thoracis.
Role of routine computed tomography in paediatric pleural empyema.
Single-chain urokinase in empyema induced by Pasturella multocida.
The in vitro efficacy of varidase versus streptokinase or urokinase for liquefying thick purulent exudative material from loculated empyema.
Treatment of loculated pleural effusion with intrapleural urokinase in children.
Treatment of thoracic multiloculated empyemas with intracavitary urokinase: a prospective study.
Urokinase and VATS are equally effective for septated empyema.
Urokinase in the treatment of childhood empyema.
Urokinase versus VATS for treatment of empyema: a randomized multicenter clinical trial.
[Fibrinolysis with intracavitary urokinase in two cases of empyema drained percutaneously with computerized tomography]
[Intrathoracic washing with urokinase was effective for empyema with atelectasis].
[Successful treatment of thoracic drainage using urokinase for empyema in an elderly man].
[Two fibrinopulurent empyema cases--treatment with early mini-thoracotomy and transcatheter urokinase instillation]
[Usefulness of urokinase in multilocular pleural effusion]
Empyema, Pleural
Computed tomography-guided catheter drainage with urokinase and ozone in management of empyema.
Evaluation of a pediatric protocol of intrapleural urokinase for pleural empyema: A prospective study.
Intrapleural urokinase in the treatment of complicated parapneumonic pleural effusions and empyema.
Intrapleural urokinase therapy in a neonate with pleural empyema.
Once-daily intrapleural urokinase treatment of complicated parapneumonic effusion in pediatric patients.
The role of video-assisted thoracoscopic surgery in the treatment of parapneumonic empyema after the failure of fibrinolytics.
The use of urokinase for loculated thoracic empyema in children: a case report and review of the literature.
Use of urokinase in childhood pleural empyema.
Encephalitis
Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.
Encephalomyelitis, Autoimmune, Experimental
A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis.
Endocarditis
[Indications for the intra-arterial infusion of urokinase in the treatment of acute intestinal ischemia in patients with heart disease]
Endometrial Hyperplasia
Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Endometrial Neoplasms
A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study.
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Discordant expression of mRNA and protein for urokinase and tissue plasminogen activators (u-PA, t-PA) in endometrial carcinoma.
Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer.
Relationship between plasma levels of components of the fibrinolytic system and acute-phase reactants in patients with uterine malignancies.
Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Sex steroids regulate the expression of plasminogen activator inhibitor-1 (PAI-1) and its mRNA in uterine endometrial cancer cell line Ishikawa.
The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer.
Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma.
Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer.
Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer.
Urokinase-type plasminogen activator resulting from endometrial carcinogenesis enhances tumor invasion and correlates with poor outcome of endometrial carcinoma patients.
Endometriosis
Expression of angiogenic factors in endometriosis: relationship to fibrinolytic and metalloproteinase systems.
Expression of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis.
Extracellular matrix remodelling in the endometrium and its possible relevance to the pathogenesis of endometriosis.
Fibrinolytic factors in endometriotic tissue, endometrium, peritoneal fluid, and plasma from women with endometriosis and in endometrium and peritoneal fluid from healthy women.
Genetic Variants in Fibrinolytic System-Related Genes in Infertile Women With and Without Endometriosis.
In situ localization of mRNA for the fibrinolytic factors uPA, PAI-1 and uPAR in endometriotic and endometrial tissue.
Melatonin protects against endometriosis via regulation of matrix metalloproteinase-3 and an apoptotic pathway.
mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay.
Soluble urokinase-type plasminogen activator receptor is over-expressed in uterine endometrium from women with endometriosis.
Upregulation of CFTR in patients with endometriosis and its involvement in NF?B-uPAR dependent cell migration.
Urokinase-type plasminogen activator and insulin-like growth factor-binding protein 3 mRNA expression in endometriotic lesions and eutopic endometrium: implications for the pathophysiology of endometriosis.
Endotoxemia
Concurrent upregulation of urokinase plasminogen activator receptor and CD11b during tuberculosis and experimental endotoxemia.
Endotoxin stimulates expression of the murine urokinase receptor gene in vivo.
Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia.
Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia.
Enterocolitis, Necrotizing
The importance of biomarkers in neonatology.
Eosinophilia
Changes to plasminogen activators and matrix metalloproteinase-9 in dogs with toxocarosis.
Epilepsy
Increased expression of urokinase-type plasminogen activator receptor in the frontal cortex of patients with intractable frontal lobe epilepsy.
The relationship between levels of plasma-soluble urokinase plasminogen activator receptor (suPAR) and presence of migraine attack and aura.
The role of the urokinase receptor in epilepsy, in disorders of language, cognition, communication and behavior, and in the central nervous system.
Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies.
Urokinase-type plasminogen activator deficiency has little effect on seizure susceptibility and acquired epilepsy phenotype but reduces spontaneous exploration in mice.
Urokinase-Type Plasminogen Activator Receptor Modulates Epileptogenesis in Mouse Model of Temporal Lobe Epilepsy.
Epilepsy, Frontal Lobe
Increased expression of urokinase-type plasminogen activator receptor in the frontal cortex of patients with intractable frontal lobe epilepsy.
Epilepsy, Temporal Lobe
Urokinase-Type Plasminogen Activator Receptor Modulates Epileptogenesis in Mouse Model of Temporal Lobe Epilepsy.
Epiretinal Membrane
Plasminogen activation in epiretinal membranes.
Epistaxis
[The analysis of plasma Urokinase-type plasminogen activator and Urokinase-type plasminogen activator receptor which unknown factor nosebleed patients]
Erysipelas
[Bier's occlusion. An unjustly neglected therapeutic possibility in resistant tissue defects of the extremities]
Esophageal Neoplasms
High expression of uPA related to p38MAPK in esophageal cancer indicates poor prognosis.
Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.
Esophageal Squamous Cell Carcinoma
Altered expression of the urokinase receptor homologue, C4.4A, in invasive areas of human esophageal squamous cell carcinoma.
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Differential expression of MMP and uPA systems and prognostic relevance of their expression in esophageal squamous cell carcinoma.
Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma.
Essential Hypertension
Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease.
Exostoses
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Extranodal Extension
Urokinase-type plasminogen activator expression in human prostate carcinomas.
Eye Hemorrhage
[Treatment of traumatic hemophthalmos with intravitreal urokinase]
Eye Injuries, Penetrating
Effect of urokinase on posterior penetrating eye injuries.
Factor XII Deficiency
[Congenital deficiency of factor Xii and spontaenous venous thrombosis treated with urokinase]
Fatty Liver
Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.
Febrile Neutropenia
The diagnostic value of soluble urokinase plasminogen activator receptor compared with C-reactive protein and procalcitonin in children with febrile neutropenia.
The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.
Femoral Neuropathy
Femoral nerve palsy secondary to anticoagulant induced iliacus hematoma. A case report.
Fetal Diseases
[Myocardial infarction and thromboembolism during pregnancy]
Fetal Growth Retardation
Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: possible markers of placental function.
Fibrosarcoma
1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells.
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation.
Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines.
Enhanced expression of the urokinase-type plasminogen activator gene and reduced colony formation in soft agar by ectopic expression of PU.1 in HT1080 human fibrosarcoma cells.
External modulation of HT-1080 human fibrosarcoma cells improves urokinase production.
Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion.
Fiber-Reinforced Silk Composite for Enhanced Urokinase Production Using High-Density Perfusion Culture and Bioactive Molecule Supplementation.
Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.
Inhibition of experimental metastasis by enzyme inhibitors from microorganisms and plants.
Integrated bioprocess for the production and isolation of urokinase from animal cell culture using supermacroporous cryogel matrices.
Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin.
Localization of urokinase to focal adhesions by human fibrosarcoma cells synthesizing recombinant vitronectin.
New-generation multicistronic expression platform: pTRIDENT vectors containing size-optimized IRES elements enable homing endonuclease-based cistron swapping into lentiviral expression vectors.
Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.
Plasminogen activators in nude mice xenotransplanted with human tumorigenic cells.
Regulation of urokinase plasminogen activator by epigallocatechin-3-gallate in human fibrosarcoma cells.
Seahorse-derived peptide suppresses invasive migration of HT1080 fibrosarcoma cells by competing with intracellular ?-enolase for plasminogen binding and inhibiting uPA-mediated activation of plasminogen.
Secreted proteases. Regulation of their activity and their possible role in metastasis.
Soluble urokinase receptor from fibrosarcoma HT-1080 cells.
Supermacroporous cryogel matrix for integrated protein isolation. Immobilized metal affinity chromatographic purification of urokinase from cell culture broth of a human kidney cell line.
Suppression of urokinase-type plasminogen activator mRNA levels in human fibrosarcoma cells and synovial fibroblasts by anti-inflammatory glucocorticoids.
The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice.
Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Tumor necrosis factor-alpha regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines.
Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells.
Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components.
Foot Ulcer
The role of soluble urokinase plasminogen activator receptor (suPAR) in the diagnostics of diabetic foot infection.
Fragile X Syndrome
Urokinase plasminogen activator mediates changes in human astrocytes modeling fragile X syndrome.
Gallbladder Neoplasms
A MEK inhibitor (U0126) markedly inhibits direct liver invasion of orthotopically inoculated human gallbladder cancer cells in nude mice.
Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid.
Relationship between urokinase-type plasminogen activator receptor and vascular endothelial growth factor expression and metastasis of gallbladder cancer.
Gastrointestinal Hemorrhage
Recurrent gastrointestinal bleeding: use of thrombolysis with anticoagulation in diagnosis.
Gastrointestinal Neoplasms
Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers.
Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers.
gelatinase b deficiency
Plasmin and matrix metalloproteinases in vascular remodeling.
Giant Cell Tumor of Bone
[Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone]
Giant Cell Tumors
Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
[Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone]
Gingivitis
Salivary levels of MPO, MMP-8 and TIMP-1 are associated with gingival inflammation response patterns during experimental gingivitis.
Glaucoma
Intracameral urokinase for dissolution of fibrin or blood clots after glaucoma surgery.
Tissue and urokinase plasminogen activators instigate the degeneration of retinal ganglion cells in a mouse model of glaucoma.
Glaucoma, Neovascular
Two cases of frosted branch angiitis with central retinal vein occlusion.
[Two cases of frosted retinal angiitis with central retinal vein occlusion]
Glioblastoma
A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.
A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
A novel role for the urokinase-type plasminogen activator receptor in apoptosis of malignant gliomas.
A nutrient mixture inhibits glioblastoma xenograft U-87 MG growth in male nude mice.
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin.
A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.
Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro.
Cisplatin resistant glioblastoma cells may have increased concentration of urokinase plasminogen activator and plasminogen activator inhibitor type 1.
Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells.
Downregulation of urokinase-type plasminogen activator receptor (uPAR) induces caspase-mediated cell death in human glioblastoma cells.
Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin B.
Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
Epidermal growth factor receptor-mediated regulation of urokinase plasminogen activator expression and glioblastoma invasion via C-SRC/MAPK/AP-1 signaling pathways.
Expression and cellular localization of low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor in human glioblastoma in vivo.
Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.
Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13.
Improved positron emission tomography imaging of glioblastoma cancer using novel
Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors.
Intraventricular urokinase to treat a blocked ventriculoperitoneal shunt in a glioblastoma patient with leptomeningeal spread.
Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody.
Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Protein Kinase C-{alpha} Mediated Regulation of Low-Density Lipoprotein Receptor Related Protein and Urokinase Increases Astrocytoma Invasion.
Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.
Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines.
Sense p16 and antisense uPAR bicistronic construct inhibits angiogenesis and induces glioma cell death.
Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.
Sphingosine-1-phosphate regulates glioblastoma cell invasiveness through the urokinase plasminogen activator system and CCN1/Cyr61.
Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells.
Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth.
Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.
Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.
The role of proteolysis in tumor invasiveness in glioblastoma and metastatic brain tumors.
The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres.
Transforming growth factor-beta 1 is a potent inducer of plasminogen activator inhibitor type-1 in human glioblastoma and carcinoma cell lines.
Tristetraprolin Inhibits the Growth of Human Glioma Cells through Downregulation of Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor mRNAs.
Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion.
Urokinase induces receptor mediated brain tumor cell migration and invasion.
Urokinase plasminogen activator receptor and/or matrix metalloproteinase-9 inhibition induces apoptosis signaling through lipid rafts in glioblastoma xenograft cells.
Urokinase plasminogen activator, uPAR, MMP-2, and MMP-9 in the C6-glioblastoma rat model.
Urokinase-targeted fusion by oncolytic Sendai virus eradicates orthotopic glioblastomas by pronounced synergy with interferon-? gene.
Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.
[A plasminogen regulation system in brain tumors].
Glioma
A novel role for the urokinase-type plasminogen activator receptor in apoptosis of malignant gliomas.
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin.
Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth.
Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas.
Altered in vitro spreading and cytoskeletal organization in human glioma cells by downregulation of urokinase receptor.
Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors.
Co-depletion of cathepsin B and uPAR induces G0/G1 arrest in glioma via FOXO3a mediated p27 upregulation.
Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate.
Down-regulation of integrin alpha(v)beta(3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes.
Downregulation of uPARAP mediates cytoskeletal rearrangements and decreases invasion and migration properties in glioma cells.
Ebselen abrogates TNFalpha induced pro-inflammatory response in glioblastoma.
Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Epigallocatechin-3-gallate exhibits anti-tumor effect by perturbing redox homeostasis, modulating the release of pro-inflammatory mediators and decreasing the invasiveness of glioblastoma cells.
Ets-1 transcription factor-mediated urokinase-type plasminogen activator expression and invasion in glioma cells stimulated by serum and basic fibroblast growth factors.
Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
Expression and localisation of urokinase-type plasminogen activator gene in gliomas.
Expression and localization of urokinase-type plasminogen activator receptor in human gliomas.
Expression and significance of urokinase type plasminogen activator gene in human brain gliomas.
Expression and significance of urokinase-type plasminogen activator in human gliomas.
Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis.
Expression of dominant-negative form of Ets-1 suppresses fibronectin-stimulated cell adhesion and migration through down-regulation of integrin alpha5 expression in U251 glioma cell line.
Expression of the constitutively activated RelA/NF-kappaB in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion.
Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression.
Glioma cells deficient in urokinase plaminogen activator receptor expression are susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
High-molecular-weight serum protein complexes differentially promote cell migration and the focal adhesion localization of the urokinase receptor in human glioma cells.
In vitro inhibition of human malignant brain tumour cell line proliferation by anti-urokinase-type plasminogen activator monoclonal antibodies.
Increased expression of low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor in human malignant astrocytomas.
Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors.
Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells.
Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.
Invasion of brain tissue by primary glioma: evidence for the involvement of urokinase-type plasminogen activator as an activator of type IV collagenase.
Involvement of nitric oxide synthase in matrix metalloproteinase-9- and/or urokinase plasminogen activator receptor-mediated glioma cell migration.
Killing Glioma 'Stem-like' Cells via Drug-Induced Relocation of Endosomal Urokinase Proteins.
Mechanism of p27 upregulation induced by downregulation of cathepsin B and uPAR in glioma.
Mis-trafficking of endosomal urokinase proteins triggers drug-induced glioma nonapoptotic cell death.
Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells.
Molecular changes during the genesis of human gliomas.
Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
Prognostic role of urokinase-type plasminogen activator in human gliomas.
Protease nexin 1 is expressed in the human placenta.
Protease Nexin-1 affects the migration and invasion of C6 glioma cells through the regulation of urokinase Plasminogen Activator and Matrix Metalloproteinase-9/2.
Regulation of DNA repair mechanism in human glioma xenograft cells both in vitro and in vivo in nude mice.
Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines.
Retraction: Down-regulation of integrin ?v?3 expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes.
Retraction: Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas.
RNA interference-mediated simultaneous down-regulation of urokinase-type plasminogen activator receptor and cathepsin B induces caspase-8-mediated apoptosis in SNB19 human glioma cells.
Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo.
Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells.
Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism.
Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas.
Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences.
Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth.
Targeting of c-Met and Urokinase Expressing Human Glioma Cell Lines by Retrovirus Vector Displaying Single-Chain Variable Fragment Antibody.
The mechanical and pharmacological regulation of glioblastoma cell migration in 3D matrices.
The recombinant kringle domain of urokinase plasminogen activator inhibits in vivo malignant glioma growth.
Tristetraprolin Inhibits the Growth of Human Glioma Cells through Downregulation of Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor mRNAs.
Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor.
uPAR and cathepsin B downregulation induces apoptosis by targeting calcineurin A to BAD via Bcl-2 in glioma.
Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity.
Use of intrathecal urokinase in repeated shunt and external ventricular drain blockage from high CSF protein due to an optic pathway glioma.
Glomerulonephritis
Clinical effect of urokinase on chronic glomerulonephritis (group study).
Clinical significance of serum and urinary soluble urokinase receptor (suPAR) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese.
Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy.
Induction of urokinase receptor expression in nephrotoxic nephritis.
Levels of fibrinopeptide A (FPA) and fibrinopeptide B beta 15-42 (FPB beta) in urine and plasma after urokinase administration in patients with chronic glomerulonephritis.
mRNA expression of urokinase and plasminogen activator inhibitor-1 in human crescentic glomerulonephritis.
Plasminogen activator in nephrotic syndrome.
Prevention and treatment of experimental glomerulonephritis in mice by urokinase.
Tissue-type plasminogen activator and its inhibitor in human glomerulonephritis.
Urinary UK, t-PA and urinary trypsin inhibitor in health and glomerular diseases.
Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis.
Vitamin D and Glomerulonephritis.
[A role of fibrin deposits in the development of rabbit Masugi nephritis and effect of urokinase on the experimental glomerulonephritis (author's transl)]
[A study on the urokinase treatment in patients with glomerulonephritis and nephrotic syndrome]
[Effect of urokinase therapy in patients with glomerulonephritis and nephrotic syndrome. Trial at multiple institutes in Japan]
[Fibrinolytic activity of the urine during chronic glomerulonephritis and amyloidosis]
[The levels of fibrinopeptide A and fibrinopeptide B beta in the urine from patients with chronic glomerulonephritis during urokinase therapy]
[Treatment of rapid progressive glomerulonephritis (RPGN) with pulse methylprednisolone (MP) and urokinase (UK): a renal rebiopsy study]
[Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis]
Glomerulonephritis, IGA
Defibrination of intraglomerular fibrin deposits by urokinase in patients with IgA nephropathy.
Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy.
Effects of co-administration of urokinase and benazepril on severe IgA nephropathy.
In IgA Nephropathy, Glomerulosclerosis Is Associated with Increased Urinary CD80 Excretion and Urokinase-Type Plasminogen Activator Receptor-Positive Podocyturia.
Long-term effect of urokinase therapy in IgA nephropathy.
Pathological improvement of IgA nephropathy and Henoch-Schönlein purpura nephritis with urokinase therapy.
Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy.
Significant correlation between the immunofluorescence of alpha 2-plasmin inhibitor in glomeruli and the effects of urokinase therapy in patients with IgA nephropathy.
Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.
Urokinase-type plasminogen activator receptor in IgA nephropathy.
Vitamin D and Glomerulonephritis.
Glomerulonephritis, Membranous
Analysis of plasmin binding and urokinase activation of plasminogen bound to the Heymann nephritis autoantigen, gp330.
Effect of the nephritogenic autoantibody of Heymann's nephritis on plasminogen-binding to gp330 and activation by urokinase.
Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis.
Successful thrombolytic therapy in two patients with renal vein thrombosis.
Urokinase gene 3'-UTR T/C polymorphism is associated with malignancy and ESRD in idiopathic membranous nephropathy.
[A case of renal vein thrombosis and pulmonary embolism associated with diffuse membranous glomerulonephritis: the usefulness of low-molecular-weight heparin and urokinase therapy]
Glomerulosclerosis, Focal Segmental
1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuria.
A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease.
Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria.
Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?
Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.
CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
Circulating mediators of focal segmental glomerulosclerosis: soluble urokinase plasminogen activator receptor in context.
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
Clinical significance of serum and urinary soluble urokinase receptor (suPAR) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese.
Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis.
Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
Elevated soluble urokinase receptors in focal segmental glomerulosclerosis: a role for IL-2?
Erratum to: Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Focal Segmental Glomerulosclerosis Recurrence: Soluble Urokinase Receptor Left Out?
Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.
Further Evidence that the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.
Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis.
Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis.
Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.
Protein A immunoadsorption cannot significantly remove the soluble receptor of urokinase from sera of patients with recurrent focal segmental glomerulosclerosis.
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte ?3-integrin Activation.
Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis.
Serum suPAR levels are modulated by immunosuppressive therapy of minimal change nephrotic syndrome.
Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.
Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Soluble Urokinase Receptor and Chronic Kidney Disease.
Soluble urokinase receptor and focal segmental glomerulosclerosis.
Soluble urokinase receptor in a toddler with focal segmental glomerulosclerosis.
Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.
Soluble Urokinase Receptor Levels in Secondary Focal Segmental Glomerulosclerosis.
Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.
The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury.
The clinical pattern of nephrotic syndrome in children has no effect on the concentration of soluble urokinase receptor (suPAR) in serum and urine.
The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.
uPAR isoform 2 forms a dimer and induces severe kidney disease in mice.
Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
Urine But Not Serum Soluble Urokinase Receptor (suPAR) May Identify Cases of Recurrent FSGS in Kidney Transplant Candidates.
[Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome].
[Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis].
Granuloma
Detection of granuloma-associated plasminogen activator in experimental murine schistosomiasis.
Influence of hypercholesterolemia and cholesterol accumulation on rabbit carrageenan granuloma macrophage activation.
The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study.
Gray Platelet Syndrome
Advances in our understanding of the molecular basis of disorders of platelet function.
Guillain-Barre Syndrome
Role of the urokinase plasminogen activator system in patients with bacterial meningitis.
Hamartoma
[Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients]
Hantavirus Infections
Plasma levels of soluble urokinase-type plasminogen activator receptor associate with the clinical severity of acute puumala hantavirus infection.
Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection.
Head and Neck Neoplasms
Invasion and metastasis.
Overexpression of EMMPRIN Isoform 2 Is Associated with Head and Neck Cancer Metastasis.
Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.
Hearing Loss, Sudden
[Observation on large doses of urokinase in treatment of sudden deafness]
Heart Arrest
Post-mortem administration of urokinase in canine lung transplantation from non-heart-beating donors.
[Effect of urokinase on cerebral perfusion in rabbits after cardiopulmonary resuscitation].
Heart Block
Binding of anti-SSA antibodies to apoptotic fetal cardiocytes stimulates urokinase plasminogen activator (uPA)/uPA receptor-dependent activation of TGF-? and potentiates fibrosis.
Role of the urokinase plasminogen activator receptor in mediating impaired efferocytosis of anti-SSA/Ro-bound apoptotic cardiocytes: Implications in the pathogenesis of congenital heart block.
Heart Defects, Congenital
Late complication of classic Fontan operation: giant right atrial thrombus and massive pulmonary thromboembolism.
Heart Diseases
Lysis of left ventricular thrombus with urokinase in a patient with alcohol heart disease.
Plasma soluble urokinase plasminogen activator receptor (suPAR) level is associated with myocardial impairment assessed with advanced echocardiography in Type 1 Diabetes Patients with normal ejection fraction and without known heart disease or end stage renal disease.
Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease.
[Indications for the intra-arterial infusion of urokinase in the treatment of acute intestinal ischemia in patients with heart disease]
Heart Failure
Abnormalities of pathways of fibrin turnover in the human pleural space.
Circulating proteins as predictors of incident heart failure in the elderly.
COVID-19 and pneumonia: a role for the uPA/uPAR system.
Effect of vasoconstrictor coupling factor 6 on gene expression profile in human vascular endothelial cells: enhanced release of asymmetric dimethylarginine.
ERK1/2 mediates the lipopolysaccharide-induced upregulation of FGF-2, uPA, MMP-2, MMP-9 and cellular migration in cardiac fibroblasts.
Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation.
Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells.
Long-term outcome of patients with ST-segment elevation myocardial infarction treated with low-dose intracoronary thrombolysis during primary percutaneous coronary intervention: the 5-year results of the DISSOLUTION Trial.
Plasmin and matrix metalloproteinases in vascular remodeling.
Selective use of the intensive care unit after nonaortic arterial surgery.
Serine proteases and cardiac function.
Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure.
Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure.
Soluble urokinase-type plasminogen activator receptor strongly predicts global mortality in acute heart failure patients: insight from the STADE-HF registry.
Thrombolytic therapy in fulminant pulmonary thromboembolism.
[Conservative therapeutic approaches in terminal coronary heart disease. Chronic intermittent urokinase therapy]
[Treatment by urokinase of myocardial infarction and threatened infarction. Randomised study of 120 cases]
Heart Rupture
Plasmin and matrix metalloproteinases in vascular remodeling.
Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes.
HELLP Syndrome
Placental expression of proteases and their inhibitors in patients with HELLP syndrome.
Hemangioblastoma
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Hemangioma
Increased secretion of urokinase-type plasminogen activator by human lung microvascular endothelial cells.
The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study.
Hemangioma, Cavernous
A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470.
Hemangiosarcoma
Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors.
The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study.
Hematologic Neoplasms
Circulating Levels of Urokinase-Type Plasminogen Activator Receptor and D-Dimer in Patients With Hematological Malignancies.
Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies.
The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.
[The clinical value of soluble urokinase plasminogen activation receptor in febrile neutropenic patients with hematological malignancies after chemotherapy].
Hematoma, Subdural
Surviving the Largest Atypical Parasagittal Meningioma in a 2-Year-Old Child: A Case Report and a Brief Review of the Literature.
The Effectiveness of Subdural Drains Using Urokinase after Burr Hole Evacuation of Subacute Subdural Hematoma in Elderly Patients: A Prelimilary Report.
Treatment of a recurrent subdural hematoma using urokinase.
Hematoma, Subdural, Acute
Burr Hole Drainage with Urokinase Irrigation for the Treatment of Acute Subdural Hematoma: A Case Report.
Delayed Operation of Acute Subdural Hematoma in Subacute Stage by Trephine Drainage using Urokinase.
Hematoma, Subdural, Chronic
An improved electronic twist-drill craniostomy procedure with post-operative urokinase instillation in treating chronic subdural hematoma.
Prediction Models for Recurrence of Chronic Subdural Hematoma in Patients Underwent Twist-Drill Craniostomy Combined With Urokinase Instillation.
Hematuria
Abberant sex habits leading to acute limb ischemia and hematuria.
Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy.
Treatment of hematuria in a hemophiliac by epsilon aminocaproic acid with concomitant urokinase determination.
Urokinase, a scavenger of affected tubules in acute worsening during macroscopic hematuria of IgA nephropathy?
[Extensive cerebral venous thrombosis resistant to heparin: local fibrinolysis with urokinase]
[Hematuria due to increased urokinase activity. Its successful treatment with p-aminomethylbenzoic acid (PAMBA)]
[On the cure of renal hematuria by an inhibitor of fibrinolytic urokinase.]
[Treatment of hematuria in hemorrhagic diathesis by means of epsilon-aminocaproic acid with concomitant determination of urokinase]
Hemiplegia
Complex tumors of the glomus jugulare: criteria, treatment, and outcome.
[Successful treatment of thoracic drainage using urokinase for empyema in an elderly man].
Hemoglobinuria
A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria.
Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria.
Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity.
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes.
The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria.
Thrombolytic therapy for inferior vena cava thrombosis in paroxysmal nocturnal hemoglobinuria.
[Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria]
Hemoglobinuria, Paroxysmal
A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria.
Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria.
Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity.
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes.
The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria.
Thrombolytic therapy for inferior vena cava thrombosis in paroxysmal nocturnal hemoglobinuria.
[Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria]
Hemolytic-Uremic Syndrome
Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
Endarterial urokinase in childhood hemolytic uremic syndrome.
[Treatment of childhood hemolytic-uremic syndrome with urokinase. Cooperative controlled trial]
Hemophilia A
Platelet-delivered therapeutics.
Hemorrhagic Disorders
Superior mesenteric venous thrombosis treated by direct aspiration thrombectomy.
[Treatment of hematuria in hemorrhagic diathesis by means of epsilon-aminocaproic acid with concomitant determination of urokinase]
Hemorrhagic Fever with Renal Syndrome
[Clinical significance of urokinase and anticoagulant activity of the urine in patients suffering from hemorrhagic fever with renal syndrome]
Hemorrhagic Fever, Crimean
The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in Crimean-Congo hemorrhagic fever.
Hemothorax
Effectiveness of Delayed Intrapleural Alteplase Instillation for Infected Residual Traumatic Hemothorax. Case Report.
Intrapleural Fibrinolytic Therapy for Residual Coagulated Hemothorax After Lung Surgery.
Life-threatening hemothorax in a child following intrapleural administration of urokinase.
Urokinase application for hemothorax in pulmonary mucormycosis.
Hepatic Encephalopathy
[Clinical application and efficacy of TIPS combined with AngioJet mechanical thrombectomy for liver cirrhosis with extensive portal vein thrombosis].
Hepatitis
A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.
Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure.
Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
Serine proteases of the fibrinolysis pathway are not involved in lethal hepatitis and fibrinogen breakdown induced by tumor necrosis factor.
Hepatitis B
Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes.
Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes.
Hepatitis B virus inhibits liver regeneration via epigenetic regulation of urokinase-type plasminogen activator.
Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA.
Over-expression of uPA increases risk of liver injury in pAAV-HBV transfected mice.
Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.
Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology.
Hepatitis B, Chronic
Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.
Serum soluble urokinase-type plasminogen activator receptor and interferon-?-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B.
[Detection of plasma urokinase-type plasminogen activator and its receptor in acute or chronic hepatitis B patients and its clinical significance.]
[The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B]
Hepatitis C
Formulated Minimal-Length Synthetic Small Hairpin RNAs are Potent Inhibitors of Hepatitis C Virus in Mice with Humanized Livers.
Fragment-based drug discovery: opportunities for organic synthesis.
Practical Evaluation of a Mouse with Chimeric Human Liver Model for Hepatitis C Virus Infection Using an NS3-4A Protease Inhibitor.
Soluble urokinase plasminogen activator receptor in chronic hepatitis due to hepatitis C virus.
Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection.
Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology.
Hepatitis C, Chronic
Plasma and hepatic tissue levels of thrombomodulin, tissue factor, NFkappaB and nitric oxide in responders and nonresponders to IFNalpha therapy.
Hepatitis, Chronic
Soluble urokinase plasminogen activator receptor in chronic hepatitis due to hepatitis C virus.
Herpes Simplex
Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
Histiocytoma, Malignant Fibrous
Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
Histiocytosis, Langerhans-Cell
Cutaneous infiltrates of histiocytosis X contain plasminogen activator-bearing epidermotropic dendritic cells different from Langerhans cells.
HIV Infections
Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
Hodgkin Disease
Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and ?1 Integrin in Patients with Hodgkin's Lymphoma.
High-dose urokinase therapy for the lysis of a central venous catheter-related thrombus in a young patient with Hodgkin's disease.
[Value of the study of the activity of gamma-glutamyltransferase and urokinase for diagnosis of liver lesions in Hodgkin's disease]
Hyaline Membrane Disease
[Treatment of hyaline membrane disease with the plasminogen urokinase combination]
Hydatidiform Mole
Localization and significance of urokinase plasminogen activator and its receptor in placental tissue from intrauterine, ectopic and molar pregnancies.
Hydrocephalus
A study on the efficacy of intraventricular urokinase in the treatment of intraventricular haemorrhage.
Citrobacter koseri meningitis: A neurosurgical condition?
Efficacy and safety of intraventricular fibrinolytic therapy for post-intraventricular hemorrhagic hydrocephalus in extreme low birth weight infants: a preliminary clinical study.
Heron-mouth neuroendoscopic sheath-assisted neuroendoscopy plays critical roles in treating hypertensive intraventricular hemorrhage.
Intrathecal urokinase as a treatment for intraventricular hemorrhage in the preterm infant.
Intraventricular administration of urokinase as a novel therapeutic approach for communicating hydrocephalus.
Intraventricular urokinase for the treatment of posthemorrhagic hydrocephalus.
Intraventricular urokinase to treat a blocked ventriculoperitoneal shunt in a glioblastoma patient with leptomeningeal spread.
Lysis of intraventricular blood clot with urokinase in a canine model: Part 3. Effects of intraventricular urokinase on clot lysis and posthemorrhagic hydrocephalus.
Treatment of intraventricular hemorrhage in the premature infant with urokinase. A preliminary report.
Twist drill craniostomy for traumatic acute subdural hematoma in the elderly: case series and literature review.
uPA alleviates kaolin-induced hydrocephalus by promoting the release and activation of hepatocyte growth factor in rats.
Use of urokinase in the treatment of tuberculous meningitis hydrocephalus.
Hydronephrosis
[Renal and tissue fibrinolysis dysfunction in secondary pyelonephritis in children before and after the surgery]
Hypercholesterolemia
Influence of hypercholesterolemia and cholesterol accumulation on rabbit carrageenan granuloma macrophage activation.
Hyperemesis Gravidarum
Soluble urokinase-type plasminogen activator receptor (suPAR) and interleukin-6 levels in hyperemesis gravidarum.
Hyperemia
uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK.
Hyperglycemia
Factors predicting hemorrhagic complications after multimodal reperfusion therapy for acute ischemic stroke.
Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid.
Hyperlipidemias
Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis.
Hypersensitivity
Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase.
Intrapleural Fibrinolytic Therapy for Residual Coagulated Hemothorax After Lung Surgery.
Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion.
Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism.
Streptokinase and urokinase in the treatment of pulmonary thromboemboli; from a national cooperative study.
[An allergic reaction due to i.v. urokinase administration]
[Cardiovascular pharmacology (XIII). The efficacy of different thrombolytic drugs in the treatment of acute myocardial infarct]
[Comparison of clinical efficacy of thrombolytic drugs in patients with acute myocardial infarction]
[Thrombolysis with Urokinase after anaphylaxis caused by streptokinase treatment (author's transl)]
Hypertension
Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis.
Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats.
Down-regulation of UBA6 exacerbates brain injury by inhibiting the activation of Notch signaling pathway to promote cerebral cell apoptosis in rat acute cerebral infarction model.
Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura.
Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: possible markers of placental function.
Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion.
Serine proteases and cardiac function.
Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years.
Statistical analysis of visual prognosis following stellate ganglion block treatment on patients with retinal vessel obstruction.
Whole-blood fibrinolytic activity in normal and hypertensive pregnancies and its relation to the placental concentration of urokinase inhibitor.
[Case of cholesterol crystal embolism occurring after treatment of cerebral infarction with urokinase]
[Treatment of great hematoma in brain hemorrhage with multi-point puncture and continuous irrigation-draining]
Hypertension, Portal
[Expression of plasminogen activator system components in the gastric mucosa in portal hypertensive gastropathy].
Hypertension, Pulmonary
Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice.
Rapid reversal of canine thromboembolic pulmonary hypertension by bolus injection of the novel recombinant plasminogen activator BM 06.022.
Successful treatment of peripartum massive pulmonary embolism with extracorporeal membrane oxygenation and catheter-directed pulmonary thrombolytic therapy.
Use of thrombolytic drugs in non-coronary disorders.
Hypertension, Renovascular
Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease.
Hyperthyroidism
Tissue plasminogen activator (PA) and urokinase inhibitor in the tissue of neutral and hyperthyroid goitre.
Hyphema
Treatment of total hyphemas with urokinase.
Hypoalbuminemia
Resolution of protein-losing enteropathy with standard high molecular heparin and urokinase after Fontan repair in a patient with tricuspid atresia.
Hypotension
An autopsy case of vertebrobasilar dolichoectasia under hemodialysis due to autosomal dominant polycystic kidney disease.
Inhibition of integrin alphavbeta3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia.
Therapeutic approach to acute pulmonary embolism.
Thrombolytic therapy with urokinase for pulmonary embolism in patients with stable hemodynamics.
Treatment of myocardial infarction: hypotensive effect of different thrombolytic agents.
uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK.
[Comparison of clinical efficacy of thrombolytic drugs in patients with acute myocardial infarction]
Hypoxia, Brain
Inhibition of integrin alphavbeta3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia.
Idiopathic Pulmonary Fibrosis
Associations of Serological Biomarkers of sICAM-1, IL-1?, MIF, and su-PAR with 3-Month Mortality in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis.
The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF.
The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy.
IgA Vasculitis
Methylprednisolone pulse plus mizoribine in children with Henoch-Schoenlein purpura nephritis.
Infarction, Middle Cerebral Artery
A Combined Treatment with Taurine and Intra-arterial Thrombolysis in an Embolic Model of Stroke in Rats: Increased Neuroprotective Efficacy and Extended Therapeutic Time Window.
Elevation of mRNA levels of tissue-type plasminogen activator and urokinase-type plasminogen activator in hippocampus and cerebral cortex following middle cerebral artery occlusion in rats.
Evaluation of local intra-arterial fibrinolytic therapy for acute middle cerebral artery occlusion.
Neanthes japonica (Iznka) fibrinolytic enzyme reduced cerebral infarction, cerebral edema and increased antioxidation in rat models of focal cerebral ischemia.
Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan.
Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion.
Successful intra-arterial thrombolysis for acute ischemic stroke in the immediate postpartum period: case report.
Tirofiban combined with urokinase selective intra-arterial thrombolysis for the treatment of middle cerebral artery occlusion.
[Local therapeutic fibrinolysis in ischemic cerebrovascular insults: initial findings in 6 patients]
[New methods of intensive therapy in stroke: hemicraniectomy in patients with complete middle cerebral artery infarction and treatment of intracerebral and intraventricular hemorrhage with urokinase]
Infections
1C.01: SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR AS A PROGNOSTIC MARKER OF ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN A BLACK POPULATION.
4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia.
A C to T polymorphism of urokinase plasminogen activator (P141L) is associated with Helicobacter pylori infection.
A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters.
A novel orally available small molecule that inhibits hepatitis B virus expression.
A prospective double-blind randomized trial of urokinase flushes to prevent bacteremia resulting from luminal colonization of subcutaneous central venous catheters.
A prospective randomized trial of urokinase as an adjuvant in the treatment of proven Hickman catheter sepsis.
A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages.
Advances in parenteral nutrition.
Antigen-driven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA.
Application of the Ommaya reservoir in managing ventricular hemorrhage.
Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice.
Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas.
Cerebral amyloid angiopathy-related intracerebral hemorrhage: Feasibility and safety of bedside catheter hematoma evacuation with urokinase.
Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes.
Citrobacter koseri meningitis: A neurosurgical condition?
Clinical value of plasma soluble urokinase-type plasminogen activator receptor levels in term neonates with infection or sepsis: a prospective study.
Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection.
Coordinated expression of vascular endothelial growth factor A and urokinase-type plasminogen activator contributes to classical swine fever virus Shimen infection in macrophages.
Distinct Immune Imprints of Post-Liver Transplantation Hepatitis C Persist Despite Viral Clearance.
Effect of urokinase on the extracellular virulence properties of Pseudomonas aeruginosa and Burkholderia cepacia.
Effects of bacteria involved with the pathogenesis of infection-induced urolithiasis on the urokinase and sialidase (neuraminidase) activity.
Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome.
EMMPRIN (CD 147) is a central activator of extracellular matrix degradation by Chlamydia pneumoniae-infected monocytes. Implications for plaque rupture.
Evidence-based criteria for the choice and the clinical use of the most appropriate lock solutions for central venous catheters (excluding dialysis catheters): a GAVeCeLT consensus.
Exogenous rh-urokinase modifies inflammation and Pseudomonas aeruginosa infection in a rat chronic pulmonary infection model.
Granulocyte elastase, tumor necrosis factor-alpha and urokinase levels as prognostic markers in severe infection.
Griffithsin has antiviral activity against hepatitis C virus.
Helicobacter pylori induces plasminogen activator inhibitor 2 in gastric epithelial cells through nuclear factor-kappaB and RhoA: implications for invasion and apoptosis.
Helicobacter pylori interactions with plasminogen.
Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children.
Heron-mouth neuroendoscopic sheath-assisted neuroendoscopy plays critical roles in treating hypertensive intraventricular hemorrhage.
Hickman catheter for haemodialysis in paediatric patients.
High level synthesis and secretion of human urokinase using a late gene promoter of the Autographa californica nuclear polyhedrosis virus.
High pneumococcal DNA load, procalcitonin and suPAR levels correlate to severe disease development in patients with pneumococcal pneumonia.
Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure.
Intraperitoneal urokinase and oral rifampicin for persisting asymptomatic dialysate infection following acute coagulase-negative Staphylococcus peritonitis.
Intrapleural fibrinolytics combined with image-guided chest tube drainage for pleural infection.
Intrapleural use of urokinase and DNase in pleural infections managed with repeated thoracentesis: A comparative cohort study.
Intravenous catheter-related infections.
Laparoscopic implantation of the Tenckhoff catheter for the treatment of end-stage renal failure and congestive heart failure: experience with the pelvic fixation technique.
Late vascular occlusion of central lines in pediatric malignancies.
Levels of Soluble Urokinase Plasminogen Activator Receptor in Pediatric Lower Respiratory Tract Infections.
Long-term follow-up of upper extremity implanted venous access devices in oncology patients.
Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a randomized dose-response trial.
Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activator.
Manual Intrapleural Saline Flushing Plus Urokinase: A Potentially Useful Therapy for Complicated Parapneumonic Effusions and Empyemas.
Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury.
Osteopontin induces soluble urokinase-type plasminogen activator receptor production and release.
Plasma soluble urokinase plasminogen activator receptor in children with urinary tract infection.
Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia.
Practical Evaluation of a Mouse with Chimeric Human Liver Model for Hepatitis C Virus Infection Using an NS3-4A Protease Inhibitor.
Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies.
Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study.
Prospective randomized comparison of valved versus nonvalved peripherally inserted central vein catheters.
Pulmonary embolus and Malassezia pulmonary infection related to urokinase therapy.
Recruitment of Chlamydia pneumoniae-infected macrophages to the carotid artery wall in noninfected, nonatherosclerotic mice.
Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia.
Review and update of the use of urokinase in the prevention and management of CVAD-related complications in pediatric oncology patients.
Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias.
Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients.
Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.
Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection.
Serum soluble urokinase-type plasminogen activator receptor and interferon-?-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B.
Single-port laparoscopic insertion of peritoneal dialysis catheters in children.
Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population.
Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia.
Soluble Urokinase Plasminogen Activator Receptor Is a Predictor of Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection.
Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection.
Soluble urokinase-type plasminogen activator receptor (suPAR) as new biomarker of the prosthetic joint infection: correlation with inflammatory cytokines.
Soluble urokinase-type plasminogen activator receptor (suPAR) in patients with acute pancreatitis (AP) - Progress in prediction of AP severity.
Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study.
Structural determination of group A Streptococcal surface dehydrogenase and characterization of its interaction with urokinase-type plasminogen activator receptor.
The effect of perirenal puncture and drainage with urokinase treatment of perirenal hematoma complicated by infection: Two cases' report.
The effect of Plasmodium falciparum infection on expression of monocyte surface molecules.
The fibrinolytic system in dissemination and matrix protein deposition during a mycobacterium infection.
The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis.
The role of serum soluble urokinase-type plasminogen activator receptor in stable chronic obstructive pulmonary disease.
The role of soluble urokinase plasminogen activator receptor (suPAR) in the diagnostics of diabetic foot infection.
The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection.
Thrombolytic therapy for central venous catheter occlusion.
Thrombolytic therapy in acute stroke.
Treatment of posthemorrhagic hydrocephalus in the preterm infant with a ventricular access device.
Treatment of severe intraventricular hemorrhage by intraventricular infusion of urokinase.
Urokinase enhances the growth of Pseudomonas spp. in vitro under nonshaking (oxygen limited) conditions.
Urokinase in the treatment of bacteremia and candidemia in patients with right atrial catheters.
Urokinase plasminogen activator and TGF-beta production in immunosuppressed patients with and without P. Jiroveci infection.
Urokinase plasminogen activator receptor (uPAR; CD87) expression on monocytic cells and T cells is modulated by HIV-1 infection.
Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection.
Urokinase-Type Plasminogen Activator Inhibits Efferocytosis of Neutrophils.
Urokinase-type plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection.
Urokinase: a treatment for relapsing peritonitis due to coagulase-negative staphylococci.
Use of fibrinolytic agents to coat wire implants to decrease infection. An animal model.
Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study.
Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology.
Ventriculostomy and Infection: A 4-year-review in a local hospital.
[Cannulation of the internal jugular vein with 2 silastic catheters. A new method of vascular access for hemodialysis]
[Central venous access for hemodialysis: use and practice with the child in France]
[Effect of Zhibai Dihuang Pill on uPA of Uu-infection infertility patients].
[Use of central venous catheters implanted subcutaneously in children with neoplasms]
Infertility
Could the defects in the endometrial extracellular matrix during the implantation be a cause for impaired fertility?
Functionally inactive protein C inhibitor in seminal plasma may be associated with infertility.
Human seminal plasma fibrinolytic activity.
[Urokinase-type plasminogen activator improves the reproductive function of male rats]
Infertility, Male
Clinical Efficacy of Prodom-Assisted Urokinase in the Treatment of Male Infertility Caused by Impaired Semen Liquefaction.
Tissue-specific inhibition of urokinase-type plasminogen activator expression in the testes of mice by inducible lentiviral RNA interference causes male infertility.
[Effects of urokinase-type plasminogen activator on chemotactic responses of spermatozoa in vitro]
Inflammatory Bowel Diseases
Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease.
Influenza, Human
Cleavage activation of human-adapted influenza virus subtypes by kallikrein-related peptidases 5 and 12.
Insulin Resistance
Association analyses of porcine SERPINE1 reveal sex-specific effects on muscling, growth, fat accretion and meat quality.
Distribution of C-->T and T-->C polymorphisms of the urokinase-type plasminogen activator gene in children with type 1 diabetes mellitus and insulin resistance.
Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity.
Intracranial Aneurysm
A Less Invasive Strategy for Ruptured Cerebral Aneurysms with Intracerebral Hematomas: Endovascular Coil Embolization Followed by Stereotactic Aspiration of Hematomas Using Urokinase.
Intra-arterial infusion of tirofiban and urokinase for thromboembolic complications during coil embolization of ruptured intracranial aneurysms.
[Intrathecal irrigation with urokinase in ruptured cerebral aneurysm cases. Basic study and clinical application]
Intracranial Embolism
Cerebral embolism associated with left ventricular assist device support and successful therapy with intraarterial urokinase.
Endovascular treatment of acute embolism of the major cerebral arteries. The value of balloon disruption of the embolus.
Intravenous thrombolysis for pure pontine infarcts caused by cardiac myxoma: a case report and literature review.
The thrombolytic effect of lumbrokinase is not as potent as urokinase in a rabbit cerebral embolism model.
Intracranial Hemorrhage, Hypertensive
Clinical study on the early application and ideal dosage of urokinase after surgery for hypertensive intracerebral hemorrhage.
Intracranial Hemorrhages
A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators.
Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis.
Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate.
Free-hand bedside catheter evacuation of cerebellar hemorrhage.
Initial angiographic appearance of intracranial vascular occlusions in acute stroke as a predictor of outcome of thrombolysis: initial experience.
Intraarterial therapy for acute ischemic stroke: investigation of prognostic factors.
Lysis of intraventricular blood clot with urokinase in a canine model: Part 2. In vivo safety study of intraventricular urokinase.
Outcomes and Treatment Complications of Intravenous Urokinase Thrombolysis in Acute Ischemic Stroke in China.
Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone--a randomized pilot trial (the PROMPT Study). Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis.
The beneficial effect of intracarotid urokinase on acute stroke in a baboon model.
[Effectiveness of urokinase used in combination with batroxobin (DF-521) in rat model of focal cerebral ischemia-reperfusion]
[Endovascular embolization of cerebral arteriovenous malformation]
[Individualized endovascular treatment of cerebral venous thrombosis: analysis of 168 patients]
[Treatment of great hematoma in brain hemorrhage with multi-point puncture and continuous irrigation-draining]
Intracranial Hypertension
Superior sagittal sinus thrombus secondary to occult meningioma: a case report.
Intracranial Thrombosis
Changes of the levels of antithrombin III in patients with cerebrovascular diseases.
Oral urokinase: absorption, mechanisms of fibrinolytic enhancement and clinical effect on cerebral thrombosis.
Variations of alpha 2-plasmin inhibitor, antithrombin III, plasminogen in the serum of patients of cerebral thrombosis infused with urokinase.
[Experimental and clinical studies on oral urokinase and lysyl-plasminogen. Thrombolytic therapy for cerebral thrombosis]
[Thrombolytic therapy using urokinase in cerebral thrombosis (author's transl)]
Ischemic Attack, Transient
Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke.
Ischemic Stroke
A pilot study of a new thrombolytic agent for acute ischemic stroke in taiwan within a five-hour window.
Carotid endarterectomy and intracranial thrombolysis: simultaneous and staged procedures in ischemic stroke.
Case presentations of neuroradiologic interventions for acute cerebrovascular disease.
Clinical, Biochemical and Neuroimaging Parameters after Thrombolytic Therapy Predict Long-Term Stroke Outcome.
Combination of Polyethylene Glycol-Conjugated Urokinase Nanogels and Urokinase for Acute Ischemic Stroke Therapeutic Implications.
Comparison of intravenous and intra-arterial urokinase thrombolysis for acute ischaemic stroke.
Discovery of New Risk Markers for Ischemic Stroke Using a Novel Targeted Proteomics Chip.
Effect of one-shot intravenous 0.42 mega unit urokinase therapy in patients with acute ischemic stroke.
Effectiveness of intravenous r-tPA versus UK for acute ischaemic stroke: a nationwide prospective Chinese registry study.
Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate.
Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase.
Factors and outcomes associated with recanalization timing after thrombolysis.
Intra-Arterial Adjunctive Medications for Acute Ischemic Stroke During Mechanical Thrombectomy: A Meta-Analysis.
Intra-arterial adjuvant tirofiban after unsuccessful intra-arterial thrombolysis of acute ischemic stroke: preliminary experience in 16 patients.
Intra-arterial reteplase compared to urokinase for thrombolytic recanalization in acute ischemic stroke.
Intra-arterial thrombolysis in acute ischaemic stroke.
Intra-arterial thrombolysis of a distal internal carotid artery occlusion in an adolescent.
Intra-arterial urokinase for acute ischemic stroke: factors associated with complications.
Intra-carotid thrombolytic therapy in acute ischemic stroke of carotid arterial territory.
Intraarterial recombinant tissue plasminogen activator for ischemic stroke: an accelerating dosing regimen.
Intraarterial thrombolysis for treatment of acute stroke: experience in 26 patients with long-term follow-up.
Intraoperative high-dose regional urokinase infusion for cerebrovascular occlusion after carotid endarterectomy.
Intravenous glycoprotein IIb/IIIa inhibitor (tirofiban) followed by intra-arterial urokinase and mechanical thrombolysis in stroke.
Ischemic preconditioning as induction of ischemic tolerance after transient ischemic attacks in human brain: its clinical relevance.
Local intra-arterial thrombolysis in acute ischemic stroke.
Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan.
Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study.
Low-Dose Intra-Arterial Urokinase and Aggressive Mechanical Clot Disruption for Acute Ischemic Stroke after Failure of Intravenous Thrombolysis.
Low-dose tissue plasminogen activator is as effective as standard tissue plasminogen activator administration for the treatment of acute ischemic stroke.
Mechanical thrombolysis with adjuvant intraarterial urokinase for treatment of hyperacute ischemic stroke patients.
Neuroprotection by urokinase plasminogen activator in the hippocampus.
New grading system for angiographic evaluation of arterial occlusions and recanalization response to intra-arterial thrombolysis in acute ischemic stroke.
Outcome evaluation of intravenous infusion of urokinase for acute ischemic stroke.
Outcomes and Treatment Complications of Intravenous Urokinase Thrombolysis in Acute Ischemic Stroke in China.
Plasminogen activator inhibitor-1 promotes synaptogenesis and protects against A?(1-42)-induced neurotoxicity in primary cultured hippocampal neurons.
Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke.
Preliminary Efficacy Report of a Novel Thrombolytic Agent for Acute Ischaemic Stroke within a 5-Hour Window.
Rationale and design of a phase 3b, prospective, randomized, open label, blinded-endpoint, multicenter trial of the efficacy and safety of urokinase thrombolysis comparing with antiplatelet agents for patients with minor stroke.
Rescue therapy with local intra-arterial urokinase after poor clinical response with intravenous recombinant tissue plasminogen activator in acute ischaemic stroke.
Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke.
Safety and Angiographic Efficacy of Intra-Arterial Fibrinolytics as Adjunct to Mechanical Thrombectomy: Results from the INFINITY Registry.
Safety of High Doses of Urokinase and Reteplase for Acute Ischemic Stroke.
Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke.
Simple microwire and microcatheter mechanical thrombolysis with adjuvant intraarterial urokinase for treatment of hyperacute ischemic stroke patients.
Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
Soluble Urokinase-type Plasminogen Activator Receptor Predicts All-cause 5-Year Mortality in Ischemic Stroke and TIA.
Suppression of PKC-? attenuates TNF-?-evoked cerebral barrier breakdown via regulations of MMP-2 and plasminogen-plasmin system.
Symptomatic intracranial haemorrhage after intra-arterial thrombolysis in acute ischaemic stroke: assessment of 294 patients treated with urokinase.
The protective effect of polyethylene glycol-conjugated urokinase nanogels in rat models of ischemic stroke when administrated outside the usual time window.
Transgenic chickens expressing human urokinase-type plasminogen activator.
Urokinase Plasminogen Activator: A Potential Thrombolytic Agent for Ischaemic Stroke.
Urokinase-type plasminogen activator promotes dendritic spine recovery and improves neurological outcome following ischemic stroke.
Urokinase-type plasminogen activator receptor (uPAR) augments brain damage in a murine model of ischemic stroke.
[Experimental thrombolysis of thromboembolisms in the middle cerebral artery circulatory area]
Jaw Cysts
Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
Joint Diseases
Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis.
Significance of serine proteinase and matrix metalloproteinase systems in the destruction of human articular cartilage.
The urokinase-type plasminogen activator system and inflammatory joint diseases.
Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells.
Kallmann Syndrome
Cross-talk of anosmin-1, the protein implicated in X-linked Kallmann's syndrome, with heparan sulphate and urokinase-type plasminogen activator.
Keloid
Expression of urokinase-type plasminogen activator and its receptor in keloids.
Increased plasminogen activator inhibitor-1 in keloid fibroblasts may account for their elevated collagen accumulation in fibrin gel cultures.
Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts.
Keratitis, Herpetic
Analysis of fibronectin, plasminogen activators and plasminogen in tear fluid as markers of corneal damage and repair.
Kidney Calculi
Association of urokinase gene 3'-UTR polymorphism with calcium oxalate nephrolithiasis.
[Calcium kidney stones. Diagnostic and preventive prospects]
Kidney Cortex Necrosis
Local infusion of urokinase and heparin into renal arteries in impending renal cortical necrosis.
Kidney Diseases
Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.
Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children.
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction.
Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients.
Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels.
Non-immune cell-derived ICOS ligand functions as a renoprotective ?v?3 integrin-selective antagonist.
RAGE and ?V?3-integrin are essential for suPAR signaling in podocytes.
Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography.
Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit.
Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.
Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.
Soluble Urokinase Receptor and Acute Kidney Injury.
Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease.
Successful therapy with tonsillectomy for severe ISKDC grade VI Henoch-Schönlein purpura nephritis and persistent nephrotic syndrome.
The Associations of Plasma Biomarkers of Inflammation With Histopathologic Lesions, Kidney Disease Progression, and Mortality-The Boston Kidney Biopsy Cohort Study.
The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis.
Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.
[Studies on urokinase excretion in kidney diseases]
[Urokinase activity and fibrinolysis in kidney diseases]
[Urokinase excretion and fibrinolysis in infectious kidney diseases]
Kidney Diseases, Cystic
The urine urokinase concentration in end stage renal disease with acquired renal cyst.
Kidney Failure, Chronic
Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients.
Coagulation, fibrinolysis and fibrinolysis inhibitors in haemodialysis patients: contribution of arteriovenous fistula.
Fibrinolytic activity in end-stage renal disease.
Plasma soluble urokinase plasminogen activator receptor (suPAR) level is associated with myocardial impairment assessed with advanced echocardiography in Type 1 Diabetes Patients with normal ejection fraction and without known heart disease or end stage renal disease.
Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.
Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease.
The urine urokinase concentration in end stage renal disease with acquired renal cyst.
Urokinase gene 3'-UTR T/C polymorphism is associated with malignancy and ESRD in idiopathic membranous nephropathy.
[Case of cholesterol crystal embolism occurring after treatment of cerebral infarction with urokinase]
Kidney Neoplasms
Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Fibrinolysis-inhibitory activity of cultured human cancer cell lines.
Immunological analysis of plasminogen activators from cultured human cancer cells.
Laryngeal Neoplasms
[Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms]
Leg Ulcer
Differential effects of acute and chronic wound fluids on urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and tissue-type plasminogen activator in cultured human keratinocytes and fibroblasts.
Expression of tissue-type and urokinase-type plasminogen activator activities in chronic venous leg ulcers.
Plasminogen activators, venous leg ulcers and reepithelialization.
Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing.
Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers.
[Bier's occlusion. An unjustly neglected therapeutic possibility in resistant tissue defects of the extremities]
[Retrograde intravenous perfusion: technique and different variants]
[Urokinase in refractory lower leg ulcers: therapy with retrograde intravenous pressure infusion]
Leiomyoma
Insulin-like growth factors II exon 9 and E-cadherin-Pml I but not myeloperoxidase promoter-463, urokinase-ApaL I nor xeroderma pigmentosum polymorphisms are associated with higher susceptibility to leiomyoma.
Leiomyosarcoma
Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
Leukemia
A novel oncogenic role for urokinase receptor in leukemia cells: molecular sponge for oncosuppressor microRNAs.
Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients.
Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy.
Clinical and molecular features of papillary thyroid cancer in adolescents and young adults.
Design and testing of a packaged microfluidic cell for the multiplexed electrochemical detection of cancer markers.
Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.
Expression and functional role of urokinase-type plasminogen activator receptor (UPA-R; CD87) in normal and acute leukemia cells.
Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue.
FDP D-dimer induces the secretion of interleukin-1, urokinase-type plasminogen activator, and plasminogen activator inhibitor-2 in a human promonocytic leukemia cell line.
Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor.
High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia.
Increase in the D-dimer levels during treatment in patients with acute myelogenous leukemia.
Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins ?M?2 and ?V?3.
Leukemia inhibitory factor promote trophoblast invasion via urokinase-type plasminogen activator receptor in preeclampsia.
Osteopontin ablation ameliorates muscular dystrophy by shifting macrophages to a pro-regenerative phenotype.
Plasma urokinase-type plasminogen activator in patients with leukemias.
Plasminogen activator and its enhancement in differentiating mouse Friend erythroleukemia cells.
Plasminogen activator inhibitor-2 in patients with monocytic leukemia.
Plasminogen activators and their inhibitors in leukemic cell homogenates.
Production of an active urokinase by leukemia cells: a novel distinction from cell lines of solid tumors.
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Regulation and secretion of plasminogen activators and their inhibitors in a human leukemic cell line (K562).
Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia.
Stimulated production of urokinase and plasminogen activator inhibitor-2 by the human promyelocytic leukemia cell line HL-60.
Studies on the changes of uPA system in a co-culture model of bone marrow stromal cells-leukemia cells.
Urinary trypsin inhibitor efficiently inhibits urokinase production in tumor necrosis factor-stimulated cells.
[Establishment of urokinase receptor gene antisense RNA transfer system and its application in leukemia research]
[Therapy of consumption coagulopathy and hyperfibrinolysis with urokinase in a case of acute promyelocytic leukemia]
Leukemia, Monocytic, Acute
Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins ?M?2 and ?V?3.
Leukemia, Myeloid
Transcriptional regulation of urokinase-type plasminogen activator receptor by cyclic AMP in PL-21 human myeloid leukemia cells: comparison with the regulation by phorbol myristate acetate.
Urokinase-type plasminogen-activator (upa), a protease with cytokine-like activity in human hl-60 leukemic-cell line.
Leukemia, Myeloid, Acute
Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients.
Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy.
Flow cytometry evaluation of urokinase-type plasminogen activator receptor (UPA-R) in acute myeloid leukemia cells.
High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia.
Increase in the D-dimer levels during treatment in patients with acute myelogenous leukemia.
Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.
Matrix and serine protease expression during leukemic cell differentiation induced by aclacinomycin and all-trans-retinoic acid.
Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).
Plasminogen activators and their inhibitors in leukemic cell homogenates.
Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia.
Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia.
Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
Leukemia, Promyelocytic, Acute
Plasminogen activators and their inhibitors in leukemic cell homogenates.
[Therapy of consumption coagulopathy and hyperfibrinolysis with urokinase in a case of acute promyelocytic leukemia]
Leukocytosis
Role of the urokinase plasminogen activator system in patients with bacterial meningitis.
Leukopenia
The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report.
Lichen Sclerosus et Atrophicus
Do plasminogen activators play a role in lichen sclerosus?
Lipodystrophy
Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls.
Soluble Urokinase Plasminogen Activator Receptor (suPAR) is Associated with Metabolic Changes in HIV-1-Infected Africans: A Prospective Study.
Liver Abscess
Effect of intracavitary injection of urokinase in the experimentally induced early pyogenic liver abscess of the rabbit.
Liver Abscess, Pyogenic
Effect of intracavitary injection of urokinase in the experimentally induced early pyogenic liver abscess of the rabbit.
Liver Cirrhosis
Determination of plasma urokinase-type plasminogen activator antigen in patients with primary liver cancer: characterization as tumor-associated antigen and comparison with alpha-fetoprotein.
Diagnostic efficacy of plasma urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in differentiation of hepatocellular carcinoma from cirrhosis.
Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.
Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.
Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis.
Human urokinase-type plasminogen activator gene-modified bone marrow-derived mesenchymal stem cells attenuate liver fibrosis in rats by down-regulating the Wnt signaling pathway.
Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis.
Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy.
Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
Properties of urokinase type-plasminogen activator found in chest fluid.
Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection.
Transplantation of urokinase-type plasminogen activator gene-modified bone marrow-derived liver stem cells reduces liver fibrosis in rats.
Urokinase antigen in plasma of patients with liver cirrhosis and hepatoma.
Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGF.
[Effects of gene-transfected bone marrow-derived liver stem cell transplantation on accumulation of extracellular matrix in rats with liver fibrosis]
[Effects of Qinggan Huoxue Recipe and its separated recipes on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 fibrinolytic system in rats with alcoholic liver fibrosis]
[The plasma levels of urokinase plasminogen activator and plasminogen activator inhibitor-1 and the protein expressions of alpha-SMA and MMP-1 and TIMP-1 in patients with different grades of liver fibrosis]
[The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B]
Liver Cirrhosis, Alcoholic
Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.
Liver Cirrhosis, Biliary
Improved effects of viral gene delivery of human uPA plus biliodigestive anastomosis induce recovery from experimental biliary cirrhosis.
Liver Cirrhosis, Experimental
Urokinase plasminogen activator stimulates function of active forms of stromelysin and gelatinases (MMP-2 and MMP-9) in cirrhotic tissue.
Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGF.
Liver Diseases
Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma.
Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.
Morphological and microarray analyses of human hepatocytes from xenogeneic host livers.
Over-expression of uPA increases risk of liver injury in pAAV-HBV transfected mice.
Propagation of Human Hepatocytes in uPA/SCID Mice: Producing Chimeric Mice with Humanized Liver.
Serum soluble urokinase plasminogen activator receptor in alcoholics: relation to liver disease severity, fibrogenesis and alcohol use.
Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease.
Soluble Urokinase Receptor and Liver Disease.
Tissue-type plasminogen activator deficiency exacerbates cholestatic liver injury in mice.
Urokinase antigen in plasma of patients with liver cirrhosis and hepatoma.
[Urokinase in liver diseases]
Liver Failure
A fatal case of Behcet's disease.
Generation of hybrid hepatocytes by cell fusion from monkey embryoid body cells in the injured mouse liver.
Near completely humanized liver in mice shows human-type metabolic responses to drugs.
Liver Failure, Acute
Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure.
Liver Neoplasms
Determination of plasma urokinase-type plasminogen activator antigen in patients with primary liver cancer: characterization as tumor-associated antigen and comparison with alpha-fetoprotein.
Plumbagin inhibits invasion and migration of liver cancer HepG2 cells by decreasing productions of matrix metalloproteinase-2 and urokinase- plasminogen activator.
Some pyrazole and pyrazolo[3,4-d]pyrimidine derivatives: synthesis and anticancer evaluation.
Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer.
Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.
Lung Diseases
Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome.
Developmental expression of plasminogen activator inhibitor type 1 by human alveolar macrophages. Possible role in lung injury.
Lung Diseases, Interstitial
Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis.
Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs.
Lung Injury
A urokinase receptor mRNA binding protein from rabbit lung fibroblasts and mesothelial cells.
Association between urokinase haplotypes and outcome from infection-associated acute lung injury.
Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice.
Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells.
Induction of Tissue Factor by Urokinase in Lung Epithelial Cells and in the Lungs.
Involvement of urokinase in cigarette smoke extract-induced epithelial-mesenchymal transition in human small airway epithelial cells.
p53 and miR-34a Feedback Promotes Lung Epithelial Injury and Pulmonary Fibrosis.
Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin.
Regulation of lung injury and fibrosis by p53-mediated changes in urokinase and plasminogen activator inhibitor-1.
Role of p53-fibrinolytic system cross-talk in the regulation of quartz-induced lung injury.
Role of the urokinase-fibrinolytic system in epithelial-mesenchymal transition during lung injury.
The Contribution of the Urokinase Plasminogen Activator and the Urokinase Receptor to Pleural and Parenchymal Lung Injury and Repair: A Narrative Review.
The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system.
Urokinase Plasminogen Activator Receptor-Deficient Mice Demonstrate Reduced Hyperoxia-Induced Lung Injury.
[Experimental bleomycin lung injury and preventive effects of urokinase]
Lung Neoplasms
Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines.
Aeroallergen Der p 2 promotes motility of human non-small cell lung cancer cells via toll-like receptor-mediated up-regulation of urokinase-type plasminogen activator and integrin/focal adhesion kinase signaling.
Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition.
Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer.
Camptothecin induces urokinase-type plasminogen activator gene-expression in human RC-K8 malignant lymphoma and H69 small cell lung cancer cells.
Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: analysis by Northern blotting and in situ hybridization.
Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells.
Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients.
Detection of cathepsin B, plasminogen activators and plasminogen activator inhibitor in human non-small lung cancer cell lines.
Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.
Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.
ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts.
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinoma.
Fibrinolysis-inhibitory activity of cultured human cancer cell lines.
G-CSF increases secretion of urokinase-type plasminogen activator by human lung cancer cells.
Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells.
Graphene nanosheets as an electric mediator for ultrafast sensing of urokinase plasminogen activator receptor-A biomarker of cancer.
Immunological analysis of plasminogen activators from cultured human cancer cells.
Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients.
Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells.
Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells.
Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model.
Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.
Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer.
Peonidin 3-glucoside inhibits lung cancer metastasis by downregulation of proteinases activities and MAPK pathway.
Peroxiredoxin 6 promotes lung cancer cell invasion by inducing urokinase-type plasminogen activator via p38 kinase, phosphoinositide 3-kinase, and Akt.
Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro.
Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer.
Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer.
Prognostic value of urokinase plasminogen activator system in non-small cell lung cancer: A systematic review and meta-analysis.
Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival.
Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with {beta}1 integrins.
Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis.
Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.
Subpopulations of uPAR(+) contribute to vasculogenic mimicry and metastasis in large cell lung cancer.
Surface ?-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target.
The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC).
The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.
The effect of TNP-470 on cell proliferation and urokinase-type plasminogen activator and its inhibitor in human lung cancer cell lines.
The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer.
The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group.
Transcriptional regulation of urokinase receptor in high- (95D) and low-metastatic (95C) human lung cancer cells.
Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer.
Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment.
Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene.
Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors.
Urokinase combination chemotherapy in small cell lung cancer. A phase II study.
Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Urokinase plasminogen activator receptor induced non-small cell lung cancer invasion and metastasis requires NHE1 transporter expression and transport activity.
Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis.
Urokinase receptors in lung cancer and normal lung.
[Biological function of fusion protein ATF-PAI2CD]
[Clinical evaluation of various antineoplastic agents combined with urokinase--a comparison between urokinase from tissue culture (TCUK) and urine-derived urokinase (UUK)]
[Effects of MnSOD silence on in vitro tumorigenicity in NCI-H446 cells].
[Increase of cellular fibrinolysis in human lung cancer cell line by radiation: relationship between urokinase-type plasminogen activator (uPA) and metastasis and invasion]
[Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer]
[Urokinase plasminogen activator /U-PA/in blood of patients with lung cancer]
Lupus Erythematosus, Systemic
Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus.
Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Systemic Lupus Erythematosus Patients.
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.
Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
[Thrombolytic therapy with urokinase in two systemic lupus erythematosus patients with deep vein thrombosis]
Lupus Nephritis
Mycophenolate mofetil alleviates lupus nephritis through urokinase receptor signaling in a mice model.
Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis: a large cohort study from China.
Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity.
Vitamin D and Glomerulonephritis.
[The functional activity of plasminogen activators in the blood plasma and urine of patients with lupus nephritis]
Lyme Disease
Binding of human plasminogen and urokinase-type plasminogen activator to the Lyme disease spirochete, Borrelia burgdorferi.
The Urokinase Receptor (uPAR) Facilitates Clearance of Borrelia burgdorferi.
The urokinase receptor (uPAR) facilitates clearance of Borrelia burgdorferi.
Lymphatic Metastasis
Antigen expression associated with lymph node metastasis in gastric adenocarcinomas.
Clinical significance of urokinase-type plasminogen activator (uPA) in invasive cervical cancer of the uterus.
Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer.
Expression of HLA-DR and urokinase-type plasminogen activator in stage IV gastric cancer.
Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer.
High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast.
Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor.
Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
Isolated splenic metastasis of sigmoid colon cancer: a case report.
Plasminogen Activation System in Rectal Adenocarcinoma.
Sentinel Lymph Node-Targeted Therapy by Oncolytic Sendai Virus Suppresses Micrometastasis of Head and Neck Squamous Cell Carcinoma in an Orthotopic Nude Mouse Model.
Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.
Urokinase-type plasminogen activator resulting from endometrial carcinogenesis enhances tumor invasion and correlates with poor outcome of endometrial carcinoma patients.
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer]
Lymphoma
Amurubicinol-induced eotaxin-3 expression in human NCI-H69 small cell lung carcinoma cells.
Camptothecin induces urokinase-type plasminogen activator gene-expression in human RC-K8 malignant lymphoma and H69 small cell lung cancer cells.
Down-regulation of urokinase secretion from a human lymphoma cell line RC-K8 by dexamethasone without inducing plasminogen activator inhibitors.
Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue.
Induction of urokinase-type plasminogen activator by the anthracycline antibiotic in human RC-K8 lymphoma and H69 lung-carcinoma cells.
Inhibitory effect of a synthetic prostacyclin analogue, beraprost, on urokinase-type plasminogen activator expression in RC-K8 human lymphoma cells.
Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells.
Modulation of urokinase-type plasminogen activator gene expression by inflammatory cytokines in human pre-B lymphoma cell line RC-K8.
Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells.
Plasminogen activator inhibitor-2 in patients with monocytic leukemia.
Protein kinase activity-dependent inhibition of urokinase-type plasminogen activator gene transcription by cyclic AMP in human pre-B lymphoma cell line RC-K8.
Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
Lymphoma, Non-Hodgkin
Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma.
Successful treatment of veno-occlusive disease of the liver with urokinase in a patient with non-Hodgkin's lymphoma.
Macular Degeneration
Increased soluble urokinase plasminogen activator receptor (suPAR) levels in neovascular age-related macular degeneration: a role for inflammation in the pathogenesis of the disease?
Inhibitors of the proteolytic activity of urokinase type plasminogen activator.
Malaria
Correlation of biomarkers for parasite burden and immune activation with acute kidney injury in severe falciparum malaria.
Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice.
Elevated plasma urokinase receptor predicts low birth weight in maternal malaria.
Host urokinase-type plasminogen activator participates in the release of malaria merozoites from infected erythrocytes.
Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome.
Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection.
Malaria, Cerebral
Lesion associated expression of urokinase-type plasminogen activator receptor (uPAR, CD87) in human cerebral malaria.
Malaria, Falciparum
Host urokinase-type plasminogen activator participates in the release of malaria merozoites from infected erythrocytes.
Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection.
Measles
Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.
Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Medulloblastoma
Nuclear Translocation of Hand-1 Acts as a Molecular Switch to Regulate Vascular Radiosensitivity in Medulloblastoma Tumors: The Protein uPAR Is a Cytoplasmic Sequestration Factor for Hand-1.
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Urokinase-type plasminogen activator receptor (uPAR)-mediated regulation of WNT/?-catenin signaling is enhanced in irradiated medulloblastoma cells.
[Expression and significance of urokinase-type plasminogen activator in medulloblastoma]
Melanoma
Activation of pro-urokinase by the human T cell-associated serine proteinase HuTSP-1.
Alterations in endothelial cell proteinase and inhibitor polarized secretion following treatment with interleukin-1, phorbol ester, and human melanoma cell conditioned medium.
Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice.
Autotaxin stimulates urokinase-type plasminogen activator expression through phosphoinositide 3-kinase-Akt-nuclear [corrected] factor kappa B signaling cascade in human melanoma cells.
Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro.
Cambodian Phellinus linteus inhibits experimental metastasis of melanoma cells in mice via regulation of urokinase type plasminogen activator.
Characterization of plasminogen activator produced by an established cell line from human ovary.
Clearance of a novel recombinant tissue plasminogen activator in rabbits.
Co-localization of CD44 and urokinase-type plasminogen activator on the surface of human melanoma cells.
Comparative electrophoretic analysis of human and porcine plasminogen activators in SDS-polyacrylamide gels containing plasminogen and casein.
Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.
Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
Correlated suppression by 5-bromodeoxyuridine of tumorigenicity and plasminogen activator in mouse melanoma cells.
Cytokine-dependent invasiveness in B16 murine melanoma cells: role of uPA system and MMP-9.
De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation.
Decoy molecules based on PNA-DNA chimeras and targeting Sp1 transcription factors inhibit the activity of urokinase-type plasminogen activator receptor (uPAR) promoter.
Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression.
Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates.
Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro.
Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor.
Differentiation and the tumorigenic and metastatic phenotype of murine melanoma cells.
Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines.
EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.
Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.
Growth inhibition of vascular smooth muscle cells derived from urokinase receptor (u-PAR)-deficient mice in the presence of carcinoma cells.
High tPA-expression in primary melanoma of the limb correlates with good prognosis.
Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.
Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor.
Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis.
Immunological characterisation of plasminogen activators in the human vessel wall.
Immunological characterization of plasminogen activators in human mixed saliva.
Immunological comparison between human and rat plasminogen activators in blood and the vessel wall.
Importance of intramolecular interactions in the control of the fibrin affinity and activation of human plasminogen.
In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: radiation-induced increase in fraction of hypoxic cells and hypoxia-induced up-regulation of urokinase-type plasminogen activator receptor.
Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53.
Interleukin 1 preferentially stimulates the production of tissue-type plasminogen activator by human articular chondrocytes.
Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.
Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin.
Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR.
Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor.
Modulation of metastatic potential by cell surface urokinase of murine melanoma cells.
Modulation of the urokinase-type plasminogen activator receptor by the beta6 integrin subunit.
Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta1 integrins and the cytoskeleton.
Molecular species of plasminogen activators secreted by normal and neoplastic human cells.
New approaches to thrombolytic therapy.
New type of plasminogen activator produced by an established cell line from human ovary.
Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice.
Plasminogen activation in melanocytic neoplasia.
Plasminogen activators in human malignant melanoma.
Plasminogen activators in nude mice xenotransplanted with human tumorigenic cells.
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma.
Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.
Purification and properties of a plasminogen activator from cultured rat prostate adenocarcinoma cells.
Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3.
Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes.
Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes.
Secreted proteases. Regulation of their activity and their possible role in metastasis.
Serine enzymes released by cultured neoplastic cells.
Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest PAI-1 immunoassay evaluated.
Spitz naevi may express components of the plasminogen activation system.
Suppression of type I collagenase expression by antisense RNA in melanoma cells results in reduced synthesis of the urokinase-type plasminogen activator receptor.
Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.
Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions.
The plasminogen activation system in melanoma cell lines and in melanocytic lesions.
Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
uPAR controls vasculogenic mimicry ability expressed by drug-resistant melanoma cells.
uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients.
Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells.
Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Melanoma, Experimental
Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: lack of association with in vitro invasion.
Modulation of metastatic potential by cell surface urokinase of murine melanoma cells.
Melioidosis
Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis.
Meningioma
Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas.
Immunohistochemical expression of Ets-1 transcription factor and the urokinase-type plasminogen activator is correlated with the malignant and invasive potential in meningiomas.
Radiation-induced hypomethylation triggers urokinase plasminogen activator transcription in meningioma cells.
RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis.
RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth.
uPAR and cathepsin B shRNA impedes TGF-?1-driven proliferation and invasion of meningioma cells in a XIAP-dependent pathway.
[A plasminogen regulation system in brain tumors].
Meningitis
Biochemical and pathological evaluation of albendazole/thalidomide co-therapy against eosinophilic meningitis or meningoencephalitis induced by Angiostrongylus cantonensis.
Cerebrospinal fluid u-plasminogen activator and matrix metalloproteinase-9 levels in human eosinophilic meningitis associated with angiostrongyliasis.
Comparative efficacies of albendazole and the Chinese herbal medicine long-dan-xie-gan-tan, used alone or in combination, in the treatment of experimental eosinophilic meningitis induced by Angiostrongylus cantonensis.
Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome.
Elevation of plasminogen activators in cerebrospinal fluid of mice with eosinophilic meningitis caused by Angiostrongylus cantonensis.
Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome.
Treatment of intraventricular hemorrhage using urokinase.
Meningitis, Bacterial
Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome.
Role of the urokinase plasminogen activator system in patients with bacterial meningitis.
Meningitis, Pneumococcal
Urokinase-type plasminogen activator receptor regulates leukocyte recruitment during experimental pneumococcal meningitis.
Mesenteric Ischemia
Mesenteric venous thrombosis treated with urokinase via the superior mesenteric artery.
Transradial approach for transcatheter selective superior mesenteric artery urokinase infusion therapy in patients with acute extensive portal and superior mesenteric vein thrombosis.
Treatment of acute mesenteric venous thrombosis with transjugular intramesenteric urokinase infusion.
Urokinase therapy in mesenteric venous thrombosis: a case study.
Vasodilation, fibrinolysis, and thrombolysis with intraarterial infusion of urokinase in the canine superior mesenteric artery.
[A case of acute portal and mesenteric venous thrombosis treated with urokinase via superior mesenteric artery]
[Mesenteric ischemia diagnosed with Doppler ultrasonography and successfully treated with intra-arterial urokinase]
[Portal and superior mesenteric venous thrombosis treated with urokinase infusion via superior mesenteric artery]
[Transradial approach for transcatheter selective superior mesenteric artery urokinase infusion therapy in patients with acute extensive portal and superior mesenteric vein thrombosis].
Mesothelioma
A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells.
BioKnife, a uPA Activity-dependent Oncolytic Sendai Virus, Eliminates Pleural Spread of Malignant Mesothelioma via Simultaneous Stimulation of uPA Expression.
Intrapleural Urokinase Directly Under Medical Thoracoscopy for the Diagnosis of Malignant Pleural Mesothelioma With Severe Multiloculated Pleural Effusions.
Intrapleural urokinase directly under medical thoracoscopy for the diagnosis of tuberculous pleurisy.
Posttranscriptional regulation of urokinase receptor gene expression in human lung carcinoma and mesothelioma cells in vitro.
Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells.
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
The Urokinase Receptor Supports Tumorigenesis of Human Malignant Pleural Mesothelioma Cells.
Mesothelioma, Malignant
A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells.
BioKnife, a uPA Activity-dependent Oncolytic Sendai Virus, Eliminates Pleural Spread of Malignant Mesothelioma via Simultaneous Stimulation of uPA Expression.
Intrapleural Urokinase Directly Under Medical Thoracoscopy for the Diagnosis of Malignant Pleural Mesothelioma With Severe Multiloculated Pleural Effusions.
Intrapleural urokinase directly under medical thoracoscopy for the diagnosis of tuberculous pleurisy.
The Urokinase Receptor Supports Tumorigenesis of Human Malignant Pleural Mesothelioma Cells.
Urinary trypsin inhibitor suppresses migration of malignant mesothelioma.
Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis.
Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma.
Metabolic Syndrome
Association among Fibrinolytic Proteins, Metabolic Syndrome Components, Insulin Secretion, and Resistance in Schoolchildren.
Migraine Disorders
The relationship between levels of plasma-soluble urokinase plasminogen activator receptor (suPAR) and presence of migraine attack and aura.
MINOCA
Increased Inflammatory Activity in Patients 3 Months after Myocardial Infarction with Nonobstructive Coronary Arteries.
Mitral Valve Prolapse
Association between urokinase-plasminogen activator gene T4065C polymorphism and risk of mitral valve prolapse.
Mitral Valve Stenosis
[Case of mitral stenosis with regression and elimination of left atrial thrombus after combined therapy of urokinase, dipyridamole and aspirin]
Mouth Neoplasms
Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - ?1 (TGF-?1) and potential effects on migration and invasion.
Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metalloproteinases and urokinase-plasminogen activator.
Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor.
Plasminogen activation system in oral cancer: Relevance in prognosis and therapy (Review).
RNAi-mediated downregulation of urokinase plasminogen activator receptor inhibits proliferation, adhesion, migration and invasion in oral cancer cells.
Urokinase gene 3'-UTR T/C polymorphism is associated with oral cancer.
Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.
[Effect of hypoxia on the expression of urokinase-type plasminogen activator in human tongue squamous cell carcinoma cells (Tca8113)]
Mucocutaneous Lymph Node Syndrome
Intracoronary urokinase and post-thrombolytic regimen in an infant with Kawasaki disease and acute myocardial infarction.
Intracoronary urokinase in Kawasaki disease: treatment and prevention of myocardial infarction.
Low-dose i.v. urokinase for coronary thrombosis in Kawasaki disease.
Management of myocardial infarction in children with Kawasaki disease.
[Clinical analysis of intravenous urokinase treatment of 10 cases with Kawasaki disease complicated with thrombus in coronary aneurysm]
Mucormycosis
Urokinase application for hemothorax in pulmonary mucormycosis.
Multiple Endocrine Neoplasia Type 2a
[Systemic fibrinolysis following resuscitation or temporary electrostimulation]
Multiple Endocrine Neoplasia Type 2b
Intracoronary urokinase as an adjunct to percutaneous transluminal coronary angioplasty in patients with complex coronary narrowings or angioplasty-induced complications.
Multiple Myeloma
Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis.
Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression.
Bone Marrow Urokinase Plasminogen Activator Receptor Levels are Associated with the Progress of Multiple Myeloma.
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction.
Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
[Detection and clinical significance of plasma urokinase-type plasminogen activator and its soluble receptor in patients with multiple myeloma]
Multiple Sclerosis
Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis.
Inhibitors of urokinase type plasminogen activator and cytostatic activity from crude plants extracts.
Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system.
Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage.
Role of cytoskeletal elements in expression of monocyte urokinase plasminogen activator receptor, activation-associated antigen Mo3.
Multiple Sclerosis, Relapsing-Remitting
Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1).
Muscle Spasticity
Case presentations of neuroradiologic interventions for acute cerebrovascular disease.
Muscle Weakness
Kidney function estimates using cystatin C versus creatinine: Impact on medication prescribing in acutely hospitalized elderly patients.
Muscular Dystrophy, Duchenne
Cell invasion is affected by differential expression of the urokinase plasminogen activator/urokinase plasminogen activator receptor system in muscle satellite cells from normal and dystrophic patients.
Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system.
Myasthenia Gravis
Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study.
Myeloproliferative Disorders
Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism.
Myocardial Infarction
A clinicopathologic study of patients with hemorrhagic myocardial infarction treated with selective coronary thrombolysis with urokinase.
A comparative study on the effects of low dose of tPA and different regimens of intravenous urokinase in acute myocardial infarction.
A Double-Blind Multicenter Comparison of the Efficacy and Safety of Saruplase and Urokinase in the Treatment of Acute Myocardial Infarction: Report of the SUTAMI Study Group.
A new "wonder" drug to dissolve clots. The results of urokinase therapy in acute myocardial infarction, pulmonary embolism and deep vein thrombosis.
A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial.
A white flapping structure in the coronary artery lumen observed by angioscopy after coronary thrombolysis--is this the "ruptured atheroma" that initiated the acute myocardial infarction?
Accelerated ST-segment reduction after thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) compared to urokinase.
Acute myocardial infarction complicating recanalization of aortocoronary bypass grafts with urokinase therapy.
Acute myocardial infarction complicating urokinase infusion for total saphenous vein graft occlusion.
Acute myocardial infarction in a patient with essential thrombocythemia: successful treatment with percutaneous transluminal coronary recanalization.
Adjunctive abciximab improves outcomes during recanalization of totally occluded saphenous vein grafts using transluminal extraction atherectomy.
Angina preceding myocardial infarction and residual coronary narrowing after intracoronary thrombolysis.
Angiographic features in the infarct-related artery after intracoronary urokinase followed by prolonged anticoagulation. Role of ruptured atheromatous plaque and adherent thrombus in acute myocardial infarction in vivo.
Angiographic features of the coronary arteries during intracoronary thrombolysis.
Angiographic study of mutant tissue-type plasminogen activator versus urokinase for acute myocardial infarction.
Augmented plasma protein C activity after coronary thrombolysis with urokinase in patients with acute myocardial infarction.
Biochemical evaluation of low dose of urokinase in acute myocardial infarction. A double-blind study.
Bleeding after thrombolysis in acute myocardial infarction.
Cardiac rupture complicating hemorrhagic infarction after intracoronary thrombolysis.
Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.
Circadian fluctuations in the efficacy of thrombolysis with streptokinase.
Clinical characteristics of myocardial infarction following Kawasaki disease: report of 11 cases.
Clinical experience with urokinase in intracoronary thrombolysis.
Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
Clinical significance of early myocardial 99mTc-pyrophosphate uptake in patients with acute myocardial infarction.
Clinical study on the thrombolytic effect with different doses of urokinase in acute myocardial infarction. The Collaborative Research Group on Thrombolysis.
Clinical use of streptokinase and urokinase therapy for acute myocardial infarction.
Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.
Comparative efficacy of thrombolytic therapy for acute myocardial infarction in patients with and without chronic preinfarction angina.
Comparative tolerability profiles of thrombolytic agents. A review.
Comparison of catalytic activity and mass concentration of serum creatine kinase MB isoenzyme in the detection of coronary reperfusion in acute myocardial infarction after therapeutic thrombolysis.
Comparison of double bolus urokinase versus front-loaded alteplase regimen for acute myocardial infarction. Thrombolysis in Myocardial Infarction in Korea (TIMIKO) study group.
Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction. Urochinasi per via Sistemica nell'Infarto Miocardico (USIM) Collaborative Group.
Comparison of the Pharmacokinetics and Effects on the Hemostatic System of Saruplase and Urokinase in Patients with Acute Myocardial Infarction.
Complex formation between urokinase and plasma protein C inhibitor in vitro and in vivo.
Controlled trial of urokinase in myocardial infarction. A European Collaborative Study.
Coronary angiographic findings in infarct-related arteries following 1 month of medical treatment.
Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction.
Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: evidence for synergism of low dose urokinase.
Coronary thrombolysis in man with pro-urokinase: improved efficacy with low dose urokinase.
Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.
Coronary thrombolysis with intravenous urokinase in patients with acute myocardial infarction.
Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction.
Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
Coronary thrombolysis with urokinase infusion in acute myocardial infarction: multicenter study in Japan.
Defibrotide versus heparin in the prevention of coronary reocclusion after thrombolysis in acute myocardial infarction.
Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Addition to High-Sensitivity Troponin I in Early Diagnosis of Acute Myocardial Infarction.
Dipyridamole echocardiography test. A new tool for detecting jeopardized myocardium after thrombolytic therapy.
Dose of urokinase for intracoronary thrombolysis in patients with acute myocardial infarction.
Economic assessment of rheolytic thrombectomy versus intracoronary urokinase for treatment of extensive intracoronary thrombus: Results from a randomized clinical trial.
Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction.
Effects of coronary artery reperfusion on relation between creatine kinase-MB release and infarct size estimated by myocardial emission tomography with thallium-201 in man.
Effects of intracoronary thrombolysis therapy on left ventricular function after acute myocardial infarction.
Effects of intracoronary urokinase during acute myocardial infarction.
Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction.
Effects of lipoprotein(a) on thrombolysis.
Effects of patency of infarct-related coronary artery on acute outcome in acute myocardial infarction patients undergoing urokinase therapy. Collaborative Research Group on Thrombolysis.
Effects of percutaneous transluminal coronary angioplasty: intracoronary thrombolysis with urokinase in acute myocardial infarction.
Effects of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six-week left ventricular function. The TAMI Investigators. Thrombolysis and Angioplasty in Acute Myocardial Infarction.
Efficacy of intracoronary and intravenous urokinase in acute myocardial infarction.
Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction.
Emerging technologies in therapeutic ultrasound: thermal ablation to gene delivery.
ERK1/2 mediates the lipopolysaccharide-induced upregulation of FGF-2, uPA, MMP-2, MMP-9 and cellular migration in cardiac fibroblasts.
Evaluation of the patency rate of infarct-related artery after intravenous urokinase in acute myocardial infarction by 90 minutes angiography. Collaborative Group of Clinical Trial for Urokinase Therapy.
Experiences in intravenous urokinase treatment of 100 acute myocardial infarction patients]
Feasibility of urokinase in the treatment of acute myocardial infarction.
Febrile reaction associated with urokinase.
Femoral nerve palsy secondary to anticoagulant induced iliacus hematoma. A case report.
Fiber-Reinforced Silk Composite for Enhanced Urokinase Production Using High-Density Perfusion Culture and Bioactive Molecule Supplementation.
Fibrinolytic effects of pro-urokinase combined with low-dose urokinase compared to high-dose urokinase in patients with acute myocardial infarction.
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Fibrinolytic therapy urokinase for myocardial infarction.
Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction.
Hemostatic changes after thrombolytic therapy with saruplase (unglycosylated single-chain urokinase-type plasminogen activator) and urokinase (two-chain urokinase-type plasminogen activator).
High-dose intra-arterial urokinase for the treatment of hepatic artery thrombosis in liver transplantation.
HTUPA as a new thrombolytic agent for acute myocardial infarction: A multicenter, randomized study.
Human fibrinogen heterogeneity. A study of limited fibrinogen degradation.
Improved prognosis after coronary thrombolysis with urokinase in acute myocardial infarction.
Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase.
Indications for and limitations of coronary thrombolysis.
Influence of different start time of urokinase therapy after acute myocardial infarction efficacy of thrombolysis. The Collaborative Research Group on Thrombolysis.
Influence of the plasminogen activator system on necrosis in acute myocardial infarction: analysis of urokinase- and urokinase receptor-knockout mouse models.
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.
Intracoronary thrombolysis in patients with acute myocardial infarction: comparison of the efficacy of urokinase with streptokinase.
Intracoronary thrombolysis with urokinase in acute myocardial infarction. Effects on reperfusion and left ventricular wall motion.
Intracoronary urokinase and post-thrombolytic regimen in an infant with Kawasaki disease and acute myocardial infarction.
Intracoronary urokinase in acute myocardial infarction: prevalence of total coronary occlusion during the early hours, effects on myocardial infarct size and left ventricular function, and outcome of residual coronary stenosis.
Intracoronary urokinase in Kawasaki disease: treatment and prevention of myocardial infarction.
Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).
Intravenous recombinant tissue-type plasminogen activator (rt-PA) and urokinase (UK) in patients with evolving myocardial infarction--a multicenter double-blind, randomized trial in Japan.
Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
Intravenous urokinase in acute myocardial infarction.
Isoforms of creatine kinase isoenzymes in serum in acute myocardial infarction after intracoronary thrombolysis.
Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction.
Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate.
Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells.
Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study.
Long-term outcome of patients with ST-segment elevation myocardial infarction treated with low-dose intracoronary thrombolysis during primary percutaneous coronary intervention: the 5-year results of the DISSOLUTION Trial.
Long-term prognosis after thrombolytic therapy for acute myocardial infarction.
Low dose urokinase preactivated natural prourokinase for thrombolysis in acute myocardial infarction.
Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion.
Lysis of left ventricular thrombi with urokinase.
Lysis of mobile left ventricular thrombi during acute myocardial infarction with urokinase.
Management of myocardial infarction in children with Kawasaki disease.
Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study.
Multicenter clinical trial of thrombolytic therapy in 1,406 patients with acute myocardial infarction. Collaborative Group of Clinical Trial for Urokinase Therapy.
Multicenter dose-finding trial for thrombolysis with urokinase preactivated pro-urokinase (TCL 598) in acute myocardial infarction. German Preactivated Pro-Urokinase Study Group.
Multiple coronary artery aneurysms in an adult associated with extensive thrombus formation resulting in acute myocardial infarction: successful treatment with intracoronary urokinase, intravenous heparin, and oral anticoagulation.
Myocardial Infarction: Symptoms and Treatments.
Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice.
Peaking time of creatine-kinase MB in patients treated with urokinase or conventionally during acute myocardial infarction: is it really a clue to reperfusion?
Percutaneous transluminal coronary angioplasty, alone or in combination with urokinase therapy, during acute myocardial infarction.
Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction.
Plasmin and matrix metalloproteinases in vascular remodeling.
Platelet aggregation and thromboxane B2 release in patients with acute myocardial infarction--their relation to coronary patency.
Platelet-dependent thrombin generation after in vitro fibrinolytic treatment.
Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction.
Prevention of an early re-occlusion after thrombolytic therapy of acute myocardial infarction by ketanserin.
Procoagulant effects of thrombolytic therapy in acute myocardial infarction.
Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction.
Quantitation of infarct size in man by means of plasma enzyme levels.
Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group.
Randomized comparison of intracoronary tirofiban versus urokinase as an adjunct to primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: results of the ICTUS-AMI trial.
Randomized double-blind trial of intracoronary urokinase for acute myocardial infarction: multicenter study.
Randomized trial of thrombolysis versus heparin in unstable angina.
Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction.
Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used.
Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.
Relationship between preinfarction angina and time interval to reperfusion with thrombolytic therapy in acute myocardial infarction.
Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Report on the use of urokinase in acute myocardial infarction.
Results of high dose intravenous urokinase for acute myocardial infarction.
Ruptured arteriovenous malformation complicating thrombolytic therapy with tissue plasminogen activator.
Saruplase is a safe and effective thrombolytic agent; observations in 1,698 patients: results of the PASS study. Practical Applications of Saruplase Study.
Serum enzymes in acute myocardial infarction after intracoronary thrombolysis.
Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.
Soluble urokinase plasminogen activator receptor in one-year prediction of major adverse cardiac events in patients after first myocardial infarction treated with primary percutaneous coronary intervention.
Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction.
Spontaneous splenic rupture associated with thrombolytic therapy and/or concomitant heparin anticoagulation.
Successful surgical repair of left ventricular rupture after acute myocardial infarction.
SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease.
Systolic left ventricular function after reperfusion therapy for acute myocardial infarction. Analysis of determinants of improvement. The TAMI Study Group.
The co-operative action of hyaluronidase and urokinase on the isoproterenol-induced myocardial infarction in rats.
The feasibility of urokinase therapy in acute myocardial infarction.
The impact of thrombolytic therapy on hospital mortality from acute myocardial infarction in the Chinese in Hong Kong.
The intracoronary administration of urokinase following direct PTCA for acute myocardial infarction reduces early restenosis.
The role of macrophage-derived urokinase plasminogen activator in myocardial infarct repair Urokinase attenuates ventricular remodeling.
The role of the low-density lipoprotein receptor-related protein (LRP) in the plasma clearance and liver uptake of recombinant single-chain urokinase-type plasminogen activator in rats.
The use of urokinase in acute myocardial infarction: report of two cases.
Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
Thrombolytic Therapy for Acute Myocardial Infarction : A Review.
Thrombolytic therapy in acute myocardial infarction. A perspective.
Thrombolytic therapy with urokinase reduces increased circulating endothelial adhesion molecules in acute myocardial infarction.
Thrombolytic therapy: overview of results in major vascular occlusions.
Thrombolytic therapy: then and now.
Treatment of acute myocardial infarction with prolonged intracoronary urokinase delivery through intracoronary infusion catheter.
Treatment of myocardial infarction: hypotensive effect of different thrombolytic agents.
uPA, uPAR and TGF?? expression during early and late post myocardial infarction period in rat myocardium.
Urokinase plus heparin versus aspirin in unstable angina and non-Q-wave myocardial infarction.
Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction.
Urokinase therapy in the early stage of acute myocardial infarction.
Urokinase versus heparin in acute myocardial infarction: no difference?
Use of thrombolytic drugs in non-coronary disorders.
Use of urokinase in acute myocardial infarction.
Usefulness of coronary artery bypass graft surgery or percutaneous transluminal angioplasty after thrombolytic therapy.
Usefulness of Local Delivery of Thrombolytics Before Thrombectomy in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (the Delivery of Thrombolytics Before Thrombectomy in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention [DISSOLUTION] Randomized Trial).
Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention.
[1st results in thrombolitic treatment with urokinase in myocardial infarct and premonitory syndromes]
[A case of successful prevention of recurrent acute myocardial infarction by emergency aorto-coronary bypass grafting after PTCR and a high intravenous dose of urokinase]
[A double-blind comparative study of intracoronary administration of GE-0943 and urokinase: multicenter study]
[A study of a systemic fibrinolytic treatment of acute myocardial infarction. The effect of a moderate dose infusion of urokinase]
[Accelerated thrombolysis by liposomal-encapsulated urokinase in a canine model of acute myocardial infarction]
[An allergic reaction due to i.v. urokinase administration]
[Analysis of factors correlated to death and reinfarction in patients with acute myocardial infarction]
[Analysis of segmental kinetics of the left ventricle after intravenous administration of urokinase in the acute phase of myocardial infarction]
[Calcitonin gene-related peptide and thrombolysis]
[Clinical analysis of early stage thrombolytic therapy with venous urokinase for acute myocardial infarction in 24 cases]
[Coronary arteriographic findings during early hours of acute myocardial infarction: response to intracoronary injection of nitrates and urokinase (author's transl)]
[Coronary thrombolysis in acute myocardial infarction]
[Effects of intravenous urokinase infusion in acute myocardial infarction]
[Electro-mechanical dissociation concomitant with myocardial reperfusion in the acute phase of myocardial infarction]
[Elements of choice of thrombolytic agents in myocardial infarction]
[Emergency percutaneous transluminal coronary angioplasty for acute myocardial infarction]
[Evaluation of coronary reperfusion for acute myocardial infarction by emission CT using technetium-99m pyrophosphate]
[Fibrinolytic therapy in acute myocardial infarction. Coronarographic evaluation of short-term results]
[Fibrinolytic treatment of acute myocardial infarction (author's transl)]
[Hemodynamic effects of diltiazem in the subacute stage of myocardial infarct treated by thrombolysis]
[Incidence of residual thrombi following successful thrombolytic therapy in acute myocardial infarct and their significance for the rate of early re-occlusion. A report of a multicenter dose-finding study for thrombolytic therapy with urokinase preactivated natural prourokinase (TCL 598)]
[Intracoronary thrombolysis using urokinase in acute myocardial infarct]
[Intracoronary thrombolysis]
[Intracoronary thrombolytic therapy in Kawasaki disease and the usefulness of two-dimensional echocardiography in detecting intracoronary thrombi]
[Intracoronary thrombolytic treatment with urokinase in myocardial infarct: clinical angiographic findings and effects on left ventricular function]
[Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)]
[Intravenous short-term coronary thrombolysis by a high-dose urokinase in aged patients with acute myocardial infarction]
[Intravenous thrombolysis by urokinase in acute myocardial infarction]
[Intravenous thrombolysis with domestic urokinase in 40 cases of acute myocardial infarction]
[Kawasaki disease: new and important problems in cardiology]
[Lysis treatment of left ventricular thrombi. Acute and long-term results]
[Moderate doses of urokinase (UK) in the treatment of myocardial infarct and pulmonary embolism]
[Percutaneous transluminal coronary angioplasty in patients over 75 years old with acute myocardial infarct or unstable angina pectoris]
[Possibilities of early diagnosis of thromboembolic complications in myocardial infarct by means of biochemical methods]
[Results of local intracoronary fibrinolysis in acute myocardial infarct and the effects of reperfusion on the function of the left ventricle]
[Role of urokinase in the acute phase of myocardial infarction]
[Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy]
[Serial changes in hemostatic molecular markers after urokinase therapy of acute myocardial infarction]
[Short- and long-term mortality of intracoronary urokinase in acute myocardial infarction]
[Study on defibrinogenasing enhancing the thrombolytic effect of urokinase on acute myocardial infarction]
[Study on effect of shenmai injection in protecting myocardium against ischemia-reperfusion injury in thrombolytic therapy with urokinase for acute myocardial infarction patients evaluated by 99mTc-MIBI myocardial imaging]
[Systemic fibrinolysis following resuscitation or temporary electrostimulation]
[The course of residual stenosis after intracoronary thrombolysis]
[The dose of intracoronary urokinase infusion in acute myocardial infarct]
[The effects of coronary thrombolysis on the short- and long-term mortality in acute myocardial infarction]
[The effects of intravenous urokinase administration in patients with acute myocardial infarction]
[The evaluation of the therapeutic effect on acute myocardial infarction by radioisotope method--assessment of the intravenous injection of urokinase and comparison with the results of PTCR + PTCA]
[The evaluation of thrombolytic effect of snake venom antithrombus enzyme in treatment of acute myocardial infarction]
[The kinetics of plasma coagulation fibrinolysis levels in acute myocardial infarction before and after treatment with intravenous urokinase]
[The thrombolysis treatment of acute myocardial infarct at the site of the emergency. A randomized double-blind study]
[Thrombolytic effect of a moderate dose of urokinase in acute myocardial infarction]
[Treatment by urokinase of myocardial infarction and threatened infarction. Randomised study of 120 cases]
[Treatment of acute myocardial infarct by intracoronary thrombolysis and aortocoronary bypass]
[Treatment of acute myocardial infarction by thrombolytic therapy with large dosage of urokinase]
[Urokinase treatment of threatened and acute myocardial infarct]
[Use of urokinase in acute myocardial infarction]
[Usefulness and safety of intravenous thrombolytic therapy for elderly patients with acute myocardial infarction: relationship with cardiac rupture]
Myocardial Ischemia
Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a randomized dose-response trial.
Treatment of acute myocardial infarction with prolonged intracoronary urokinase delivery through intracoronary infusion catheter.
[Symptomatic therapy refractory myocardial ischemia in coronary heart disease. Chronic intermittent urokinase therapy and invasive therapeutic measures]
Myocarditis
Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis.
Myoma
The relationship between urokinase plasminogen activator/plasminogen activator inhibitor type-1 expression in myoma/myometrium and mechanism of uterine artery occlusion by laparoscopy for uterine myoma treatment.
Myositis
Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.
Myxoma
Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor.
Nasopharyngeal Carcinoma
Hispolon suppresses migration and invasion of human nasopharyngeal carcinoma cells by inhibiting the urokinase-plasminogen activator through modulation of the Akt signaling pathway.
Measurement of urokinase-type plasminogen activator activity in sera of nasopharyngeal carcinoma patients by an immunocapture assay.
The concentration of u-PA and PAI-1 antigen in tissue extracts of nasopharyngeal carcinoma.
Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.
Neonatal Sepsis
The importance of biomarkers in neonatology.
Neoplasm Metastasis
(-)-Epigallocatechin gallate derivatives reduce the expression of both urokinase plasminogen activator and plasminogen activator inhibitor-1 to inhibit migration, adhesion, and invasion of MDA-MB-231 cells.
(4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
(±)Equol inhibits invasion in prostate cancer DU145 cells possibly via down-regulation of matrix metalloproteinase-9, matrix metalloproteinase-2 and urokinase-type plasminogen activator by antioxidant activity.
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis.
A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts.
A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines.
A highly polymorphic CA/GT repeat in intron 3 of the human urokinase receptor gene (PLAUR).
A human monoclonal antibody scFv to urokinase plasminogen activator.
A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.
A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer.
A new prognostic strategy for gastric carcinoma: mRNA expression of tumor growth-related factors in endoscopic biopsy specimens.
A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
A novel model for metastasis suppression involving regulation of nuclear precursor messenger-RNA stability.
A novel peptide blocking cancer cell invasion by structure-based drug design.
A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site.
A pharmacological analysis of the cholinergic regulation of urokinase-type plasminogen activator secretion in the human colon cancer cell line, HT-29.
A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development.
A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix.
A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation.
A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis.
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
Activation of the anti-cancer agent upamostat by the mARC enzyme system.
Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines.
Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I).
Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression.
Amplification of the Urokinase-Type Plasminogen Activator Receptor (uPAR) Gene in Ductal Pancreatic Carcinomas Identifies a Clinically High-Risk Group.
Amplification of urokinase gene in prostate cancer.
An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.
An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.
Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells.
Anti-Invasion Effect of Crebanine and O-methylbulbocapnine from Stephania venosa via Down-Regulated MMPs and uPA.
Anti-invasive activity of synthetic serine protease inhibitors and its combined effect with a matrix metalloproteinase inhibitor.
Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: An orally active anti-cancer drug waiting for its call-of-duty?
Antigen expression associated with lymph node metastasis in gastric adenocarcinomas.
Antimetastatic Potential of Quercetin Analogues with Improved Pharmacokinetic Profile: Pharmacoinformatic Preliminary Study.
Antimetastatic Potentials of Phyllanthusurinaria L on A549 and Lewis Lung Carcinoma Cells via Repression of Matrix-Degrading Proteases.
Antimetastatic role of Smad4 signaling in colorectal cancer.
Antiprotease and antimetastatic activity of ursolic acid isolated from Salvia officinalis.
Antisense inhibition of urokinase: effect on malignancy in a human osteosarcoma cell line.
Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice.
Antitumor effects of the novel quinazolinone MJ-33: Inhibition of metastasis through the MAPK, AKT, NF-?B and AP-1 signaling pathways in DU145 human prostate cancer cells.
Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor.
Apigenin Suppresses the IL-1?-Induced Expression of the Urokinase-Type Plasminogen Activator Receptor by Inhibiting MAPK-Mediated AP-1 and NF-?B Signaling in Human Bladder Cancer T24 Cells.
Aspirin inhibits highly invasive prostate cancer cells.
Assessment of the interaction between urokinase and reactive site mutants of protein C inhibitor.
Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer.
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Autotaxin stimulates urokinase-type plasminogen activator expression through phosphoinositide 3-kinase-Akt-nuclear [corrected] factor kappa B signaling cascade in human melanoma cells.
Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9.
Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence.
Binding site of amiloride to urokinase plasminogen activator depends on species.
Bioconjugatable azo-based dark-quencher dyes: synthesis and application to protease-activatable far-red fluorescent probes.
Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.
Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse.
Calcitonin inhibits invasion of breast cancer cells: Involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Cambodian Phellinus linteus inhibits experimental metastasis of melanoma cells in mice via regulation of urokinase type plasminogen activator.
Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: analysis by Northern blotting and in situ hybridization.
Cancer invasion and metastasis: changing views.
Cancer metastasis: biological and clinical aspects.
Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment.
Caveolin-1-dependent and -independent uPAR signaling pathways contribute to ganglioside GT1b induced early apoptosis in A549 lung cancer cells.
cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Cell surface expression of urokinase receptor in normal mammary epithelial cells and breast cancer cell lines.
Cellular mechanisms of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MAPK signaling in hepatocellular carcinoma.
Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity.
Characterization of downstream Ras signals that induce alternative protease-dependent invasive phenotypes.
Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma.
Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.
Characterization of morphogenetic and invasive abilities of human mammary epithelial cells: correlation with variations of urokinase-type plasminogen activator activity and type-1 plasminogen activator inhibitor level.
Characterization of protease expression in human prostate-cancer cell-lines.
Characterization of the interaction between heterodimeric ?v?6 integrin and urokinase plasminogen activator receptor (uPAR) using functional proteomics.
Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
Chromosomal localization of the human urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 genes: implications in colorectal cancer.
Circulating Levels of Urokinase-Type Plasminogen Activator Receptor and D-Dimer in Patients With Hematological Malignancies.
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Clinical significance of the uPA system in gastric cancer with peritoneal metastasis.
Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
Clinical significance of urokinase-type plasminogen activator (uPA) in invasive cervical cancer of the uterus.
Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma.
Clinicopathologic significance of urokinase receptor- and MMP-9-positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogenous metastasis.
Clotting factors in tumour tissue: implications for cancer therapy.
Clustering of murine lung metastases reflects fractal nonuniformity in regional lung blood flow.
Co-expression of uPAR and CXCR4 promotes tumor growth and metastasis in small cell lung cancer.
Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.
Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma.
Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma.
Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.
Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
Correlation between expression of urokinase-type plasminogen activator receptor and metastasis in gastric carcinoma.
Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.
CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases.
CSF levels of growth factors and plasminogen activators in leptomeningeal metastases.
Cysteine and serine proteases in gastric cancer.
Defective cell migration in an ovarian cancer cell line is associated with impaired urokinase-induced tyrosine phosphorylation.
Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness.
Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor.
Detecting in vivo urokinase plasminogen activator activity with a catalyCEST MRI contrast agent.
Detection of cathepsin B, plasminogen activators and plasminogen activator inhibitor in human non-small lung cancer cell lines.
Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Dexamethasone plus Somatostatin-analog Manipulation as Bone Metastasis Microenvironment-targeting Therapy for the Treatment of Castration-resistant Prostate Cancer: A Meta-analysis of Uncontrolled Studies.
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer.
Dietary supplementation with methylseleninic acid, but not selenomethionine, reduces spontaneous metastasis of Lewis lung carcinoma in mice.
Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of Plasminogen Activator Inhibitor Type 2 (PAI-2) forms.
Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma.
Dihydromyricetin suppresses cell metastasis in human osteosarcoma through SP-1- and NF-?B-modulated urokinase plasminogen activator inhibition.
Direct evidence of the importance of vitronectin and its interaction with the urokinase receptor in tumor growth.
Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.
Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
Docosahexaenoic Acid Downregulates EGF-Induced Urokinase Plasminogen Activator and Matrix Metalloproteinase 9 Expression by Inactivating EGFR/ErbB2 Signaling in SK-BR3 Breast Cancer Cells.
Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.
Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells.
Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145.
Downregulation of Extracellular Matrix Metalloproteinase Inducer by scFv-M6-1B9 Intrabody Suppresses Cervical Cancer Invasion Through Inhibition of Urokinase-Type Plasminogen Activator.
Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer.
Downregulation of SPINK13 Promotes Metastasis by Regulating uPA in Ovarian Cancer Cells.
Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells.
Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin B.
Effect of urokinase on growth and metastases of rabbit V2 carcinoma.
Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis.
Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases.
Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.
Effects of tranexamic acid and urokinase on hematogenous metastases of Lewis lung carcinoma in mice.
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
Enhanced spontaneous metastasis in bikunin-deficient mice.
Enterolactone Suppresses Proliferation, Migration and Metastasis of MDA-MB-231 Breast Cancer Cells Through Inhibition of uPA Induced Plasmin Activation and MMPs-Mediated ECM Remodeling
Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metalloproteinases and urokinase-plasminogen activator.
Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation.
Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma.
Evolving role of uPA/uPAR system in human cancers.
Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma.
Explaining urokinase type plasminogen activator inhibition by amino-5-hydroxybenzimidazole and two naphthamidine-based compounds through quantum biochemistry.
Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Expression and purification of recombinant ATF-mellitin, a new type fusion protein targeting ovarian cancer cells, in P. pastoris.
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Expression of C4.4A, a structural uPAR homolog, reflects squamous epithelial differentiation in the adult mouse and during embryogenesis.
Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer.
Expression of HLA-DR and urokinase-type plasminogen activator in stage IV gastric cancer.
Expression of MMP-2, MMP-9, and urokinase-type plasminogen activator in cervical intraepithelial neoplasia.
Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.
Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Expression of urokinase-type plasminogen activator in an experimental model of hepatocarcinoma.
Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms.
Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer.
Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma.
Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma.
Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Expression of urokinase-type plasminogen-activator in various human thyroid tissues.
Expression, Purification, and Biological Characterization of The Amino-Terminal Fragment of Urokinase in Pichia pastoris.
Expression, subcellular distribution and plasma membrane binding of cathepsin B and gelatinases in bone metastatic tissue.
Extending preclinical models of skeletal manifestations of malignancy to the clinical setting.
Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis.
Extracellular signal-regulated kinase and AP-1 pathways are involved in reactive oxygen species-induced urokinase plasminogen activator receptor expression in human gastric cancer cells.
FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions.
Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules.
Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells.
Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications.
Fibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma.
First-in-human uPAR PET: Imaging of Cancer Aggressiveness.
Flavokawain B inhibits growth of human squamous carcinoma cells: Involvement of apoptosis and cell cycle dysregulation in vitro and in vivo.
FOXM1c Promotes Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis via Upregulation of Expression of the Urokinase Plasminogen Activator System.
Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion.
Gene expression in cancer cells is influenced by contact with bone cells in a novel coculture system that models bone metastasis.
Genetic down-regulation of phosphoinositide 3-kinase by bikunin correlates with suppression of invasion and metastasis in human ovarian cancer HRA cells.
Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.
Growth inhibition of MDA-MB-231 cell line by peptides designed based on uPA.
Growth of a human carcinoma (HEp3) in nude mice: rapid and efficient metastasis.
Guanidinobenzoatase and UPA in high-grade human astrocytomas and after xenografting cell suspensions into the rat cerebral cortex: proteases for metastasis and disease progression.
Heat shock proteins HSP70 and MRJ cooperatively regulate cell adhesion and migration through urokinase receptor.
Helicobacter pylori infection stimulates plasminogen activator inhibitor 1 production by gastric epithelial cells.
Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer.
Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase.
Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.
High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast.
High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.
High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.
High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma.
High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
Hispolon suppresses SK-Hep1 human hepatoma cell metastasis by inhibiting matrix metalloproteinase-2/9 and urokinase-plasminogen activator through the PI3K/Akt and ERK signaling pathways.
Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastases.
Host protein C inhibitor inhibits tumor growth, but promotes tumor metastasis, which is closely correlated with hypercoagulability.
Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor.
Icariside II from Epimedium koreanum inhibits hypoxia-inducible factor-1alpha in human osteosarcoma cells.
IL-1 beta induces urokinase-plasminogen activator expression and cell migration through PKC alpha, JNK1/2, and NF-kappaB in A549 cells.
Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop.
Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
In vitro and in vivo antimetastatic effects of Terminalia catappa L. leaves on lung cancer cells.
In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas.
Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis.
Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.
Increased surgical stress promotes tumor metastasis.
Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase.
Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Induction of urokinase-type plasminogen activator by lipopolysaccharide in PC-3 human prostatic cancer cells.
Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy.
Influence of drinking green tea on breast cancer malignancy among Japanese patients.
Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue.
Inhibiting tissue invasion and metastasis as targets for cancer therapy.
Inhibition of colon cancer metastasis by a 3'- end antisense urokinase receptor mRNA in a nude mouse model.
Inhibition of fibrinolysis by a synthetic urokinase inhibitor enhances lung colonization of metastatic murine mammary tumor cells.
Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator.
Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor.
Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model.
Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.
Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells.
Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.
Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.
Inhibition of Tumor Growth and Metastasis by ATF-Fc, an Engineered Antibody: Targeting Urokinase Receptor.
Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.
Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model.
Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, WXC-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases.
Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells.
Inhibitors of the protease domain of urokinase-type plasminogen activator.
Inhibitors of urokinase type plasminogen activator and cytostatic activity from crude plants extracts.
Inhibitory effect of a synthetic prostacyclin analogue, beraprost, on urokinase-type plasminogen activator expression in RC-K8 human lymphoma cells.
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Inhibitory effects of tanshinone II-A on invasion and metastasis of human colon carcinoma cells.
Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer.
Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.
Intrabronchial orthotopic propagation of human lung adenocarcinoma--characterizations of tumorigenicity, invasion and metastasis.
Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.
Invasion-Metastasis by Hepatocyte Growth Factor/c-Met Signaling Concomitant with Induction of Urokinase Plasminogen Activator in Human Pancreatic Cancer: Role as Therapeutic Target.
Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4.
Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cells.
Is inhibition process better described with MD(QM/MM) simulations? The case of urokinase type plasminogen activator inhibitors.
Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
Is urokinase gene 3'-UTR polymorphism associated with prostate cancer?
Isolated splenic metastasis of sigmoid colon cancer: a case report.
JNK Suppression is Essential for 17beta-Estradiol Inhibits Prostaglandin E2-Induced uPA and MMP-9 Expressions and Cell Migration in Human LoVo Colon Cancer Cells.
Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
Korean Red Ginseng Suppresses Metastasis of Human Hepatoma SK-Hep1 Cells by Inhibiting Matrix Metalloproteinase-2/-9 and Urokinase Plasminogen Activator.
Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma.
Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array.
Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system.
Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.
Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin.
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.
Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis.
Maximum effect of urokinase plasminogen activator inhibitors in the control of invasion and metastasis of rat mammary cancer.
Mechanisms of cancer prevention by green and black tea polyphenols.
Met-HGF/SF: tumorigenesis, invasion and metastasis.
Metastatic effect of LY-6K gene in breast cancer cells.
Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo.
MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells.
Mistletoe Extract Targets the STAT3-FOXM1 Pathway to Induce Apoptosis and Inhibits Metastasis in Breast Cancer Cells.
Modulation of growth and urokinase secretion by vasopressin and closely related nonapeptides in metastatic mouse mammary tumor cells.
Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human female cancer cell lines.
Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human glioblastoma cell lines.
Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.
Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
MRTF-A and STAT3 promote MDA-MB-231 cell migration via hypermethylating BRSM1.
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis.
Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
N-Alkylisatin-Loaded Liposomes Target the Urokinase Plasminogen Activator System in Breast Cancer.
N-WASP activation by a beta1-integrin-dependent mechanism supports PI3K-independent chemotaxis stimulated by urokinase-type plasminogen activator.
New ELISA for quantitation of human urokinase receptor (CD87) in cancer.
NF-kappaB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1alpha.
NFkappaB-dependent regulation of urokinase plasminogen activator by proanthocyanidin-rich grape seed extract: effect on invasion by prostate cancer cells.
Nimbolide inhibits invasion and migration, and down-regulates uPAR chemokine gene expression, in two breast cancer cell lines.
Novel protein interactors of urokinase-type plasminogen activator receptor.
Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo.
One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.
Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer.
Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells.
Overexpression of c-met Protein in Gastric Cancer and Role of uPAR as a Therapeutic Target.
Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma.
Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carcinogenesis.
Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis.
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
P38 MAPK pathway is involved in the urokinase plasminogen activator expression in human gastric SNU-638 cells.
p38? MAPK Mediates 17?-Estradiol Inhibition of MMP-2 and -9 Expression and Cell Migration in Human LoVo Colon Cancer Cells.
PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
PAI-1 and functional blockade of SNAI1 in breast cancer cell migration.
Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas.
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Plasminogen Activation System in Rectal Adenocarcinoma.
Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Plasminogen activator inhibitor (PAI) trap3, an exocellular peptide inhibitor of PAI-1, attenuates the rearrangement of F-actin and migration of cancer cells.
Plasminogen activator inhibitor 2 (PAI-2) is not inactivated by exposure to oxidants which can be released from activated neutrophils.
Plasminogen activator inhibitor type 2 in breast cancer.
Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis.
Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.
Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine.
Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer.
Plasminogen binding and cancer: promises and pitfalls.
PLOD3 promotes lung metastasis via regulation of STAT3.
Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma.
Preclinical evaluation of [(111) In]MICA-401, an activity-based probe for SPECT imaging of in vivo uPA activity.
Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy.
Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
Prevention of metastasis by inhibition of the urokinase receptor.
Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA).
Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.
Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.
Production of a urokinase plasminogen activator-IgG fusion protein (uPA-IgG) in the baculovirus expression system.
Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Prognostic relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinoma.
Prognostic role of urokinase-type plasminogen activator in human gliomas.
Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.
Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma.
Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.
Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer.
Prognostic value of urokinase-type plasminogen activators in gastric-cancer.
Prostate cancer cells show elevated urokinase receptor in a mouse model of metastasis.
Prostate-specific antigen activates single-chain urokinase-type plasminogen activator.
Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion.
Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1.
Protease nexin-1 expression is altered in human breast cancer.
Proteases as prognostic markers in cancer.
Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue.
Protein kinase C is inhibited by bisphosphonates in prostate cancer PC-3 cells.
Proteolytic enzymes in proliferation and neoplastic metastases formation.
Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy.
Quercetin Has Antimetastatic Effects on Gastric Cancer Cells via the Interruption of uPA/uPAR Function by Modulating NF-?b, PKC-?, ERK1/2, and AMPK?.
Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3).
Rapid detection of urokinase plasminogen activator using flexible paper-based graphene-gold platform.
Rapid identification of urokinase plasminogen activator inhibitors from Traditional Chinese Medicines based on ultrafiltration, LC-MS and in silico docking.
Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite.
Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice.
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines.
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo.
Regulation of Urokinase Production by Androgens in Human Prostate Cancer Cells: Effect on Tumor Growth and Metastases in Vivo1.
Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells.
Relationship between urokinase plasminogen activator receptor (uPAR) and the invasion of human prenatal hair follicle.
Relationship between urokinase-type plasminogen activator receptor and vascular endothelial growth factor expression and metastasis of gallbladder cancer.
Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer.
Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival.
Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Retraction: Small Interfering RNA-Directed Reversal of Urokinase Plasminogen Activator Demethylation Inhibits Prostate Tumor Growth and Metastasis.
Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis.
Revisiting the biological roles of PAI2 (SERPINB2) in cancer.
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo.
RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.
RNAi-mediated downregulation of urokinase plasminogen activator receptor inhibits proliferation, adhesion, migration and invasion in oral cancer cells.
ROC1 promotes the malignant progression of bladder cancer by regulating p-I?B?/NF-?B signaling.
Role of epigenetics in cancer initiation and progression.
Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies.
Role of urokinase in colorectal neoplasia.
Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Role of urokinase-type plasminogen activator and inhibitory effect of protease inhibitor in invasion and metastasis of pancreatic cancer.
Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221.
Secretion of urokinase and metalloproteinase-9 induced by staurosporine is dependent on a tyrosine kinase pathway in mammary tumor cells.
Selection criteria for epirubicin-based adjuvant chemotherapy in node-negative breast cancer.
Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis.
Sentinel Lymph Node-Targeted Therapy by Oncolytic Sendai Virus Suppresses Micrometastasis of Head and Neck Squamous Cell Carcinoma in an Orthotopic Nude Mouse Model.
Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers.
Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases.
Sex steroids regulate the expression of plasminogen activator inhibitor-1 (PAI-1) and its mRNA in uterine endometrial cancer cell line Ishikawa.
Significant association of urokinase plasminogen activator Pro141Leu with serum lipid profiles in a Japanese population.
Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.
siRNA-mediated downregulation of MMP-9 and uPAR in combination with radiation induces G2/M cell-cycle arrest in Medulloblastoma.
Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis.
Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease.
Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.
Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.
SPRY1 promotes the degradation of uPAR and inhibits uPAR-mediated cell adhesion and proliferation.
Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer.
Stromal cell-derived factor-1/CXC receptor 4 and b1 integrin interaction regulates urokinase-type plasminogen activator expression in human colorectal cancer cells.
Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect.
Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions.
Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
Structure of human urokinase plasminogen activator in complex with its receptor.
Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis.
Structure-based design, synthesis and SAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors.
Studies of possible mechanisms for the effect of urokinase therapy in small cell carcinoma of the lung.
Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin.
Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor.
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428.
Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.
Suppression of urokinase expression and tumor metastasis by bikunin overexpression [mini-review].
Suppression of Urokinase-Type Plasminogen Activator Receptor by Docosahexaenoic Acid Mediated by Heme Oxygenase-1 in 12-O-Tetradecanoylphorbol-13-Acetate-Induced Human Endothelial Cells.
Suppressive effects of a proton beam on tumor growth and lung metastasis through the inhibition of metastatic gene expression in 4T1 orthotopic breast cancer model.
Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Synthetic urokinase inhibitors as potential anti-invasive drugs.
Targeting Multiple Conformations Leads to Small Molecule Inhibitors of the uPAR•uPA Protein-Protein Interaction that Block Cancer Cell Invasion.
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.
Targeting uPA/uPAR in prostate cancer.
Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
Terminalia catappa attenuates urokinase-type plasminogen activator expression through Erk pathways in Hepatocellular carcinoma.
Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions.
The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice.
The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer.
The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer.
The effect of essential fatty acids on growth and urokinase-type plasminogen activator production in human prostate DU-145 cells.
The effect of gamma-linolenic acid and eicosapentaenoic acid on urokinase activity.
The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor.
The expression of urokinase type plasminogen activator is a novel prognostic factor in dukes B and C colorectal cancer.
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice.
The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
The influence of opioids on urokinase plasminogen activator on protein and mRNA level in MCF-7 breast cancer cell line.
The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase.
The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target.
The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells.
The pharmacological pathways of GnRH mediating the inhibition of mammary tumours: implications in humans and domestic animals.
The plasminogen activator inhibitor "paradox" in cancer.
The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer.
The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer.
The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor.
The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes.
The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis.
The role of proteolytic enzymes in cancer invasion and metastasis.
The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer.
The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.
The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products.
The uPA/uPA receptor system as a target for tumor therapy.
The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
The urokinase plasminogen activator binding to its receptor: a quantum biochemistry description within an in/homogeneous dielectric function framework with application to uPA-uPAR peptide inhibitors.
The urokinase plasminogen activator receptor as a gene therapy target for cancer.
The urokinase plasminogen activator system in breast cancer invasion and metastasis.
The urokinase plasminogen activator system in cancer: a putative therapeutic target?
The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis.
The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.
The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?
The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction.
The urokinase receptor as an entertainer of signal transduction.
The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.
The urokinase-system--role of cell proliferation and apoptosis.
The urokinase-type plasminogen activator system in cancer metastasis: a review.
The urokinase-type plasminogen activator system in prostate cancer metastasis.
The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group.
Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator.
Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells.
Transcriptional complexity and roles of Fra-1/AP-1 at the uPA/Plau locus in aggressive breast cancer.
Transcriptional regulation of the urokinase receptor (u-PAR)--a central molecule of invasion and metastasis.
Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.
Transforming growth factor-beta1-dependent activation of Smad2/3 and up-regulation of PAI-1 expression is negatively regulated by Src in SKOV-3 human ovarian cancer cells.
Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells.
Translational research on u-PAR.
Tspan9 inhibits the proliferation, migration and invasion of human gastric cancer SGC7901 cells via the ERK1/2 pathway.
Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment.
Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma.
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
uPA receptor expression in benign and malignant thyroid tumors.
uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions.
uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.
uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line.
uPAR induces expression of transforming growth factor ? and interleukin-4 in cancer cells to promote tumor-permissive conditioning of macrophages.
uPAR peptide antagonist alters regulation of MAP kinases and Bcl-2 family members in favor of apoptosis in MDA-MB-231 cell line.
uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery.
Upregulation of C4.4A expression during progression of melanoma.
Upregulation of circulating cytokeratin 20, urokinase plasminogen activator and C-reactive protein is associated with poor prognosis in gastric cancer.
Urokinase (u-PA) and the u-PA receptor. Modulation of in vitro invasiveness of human bladder cancer cell lines.
Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells.
Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
Urokinase induces stromal cell-derived factor-1 expression in human hepatocellular carcinoma cells.
Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo.
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.
Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.
Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer.
Urokinase plasminogen activator in ovarian cancer.
Urokinase plasminogen activator predicts poor prognosis in hepatocellular carcinoma.
Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.
Urokinase Plasminogen Activator Receptor (uPAR): A Potential Indicator of Invasion for In Situ Breast Cancer.
Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy.
Urokinase plasminogen activator receptor induced non-small cell lung cancer invasion and metastasis requires NHE1 transporter expression and transport activity.
Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease.
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice.
Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
Urokinase receptor deficiency results in EGFR-mediated failure to transmit signals for cell survival and neurite formation in mouse neuroblastoma cells.
Urokinase receptor expression is upregulated by cell culture sparsity in breast cancer cell line BT-20.
Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.
Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells.
Urokinase type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor 2 (HER2) expression in metastasis of breast cancer.
Urokinase type plasminogen activator receptor expression in colorectal neoplasms.
Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec.
Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.
Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo.
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.
Urokinase-type plasminogen activator activity increases during the growth of two murine mammary adenocarcinomas with different metastasizing abilities.
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.
Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Urokinase-type Plasminogen Activator and Plasminogen-activator-inhibitor Type 1 Predict Metastases in Good Prognosis Breast Cancer Patients.
Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas.
Urokinase-type plasminogen activator in carcinomatous pleural fluid.
Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.
Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications.
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.
Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
Urokinase-type plasminogen activator receptor (uPAR)-mediated regulation of WNT/?-catenin signaling is enhanced in irradiated medulloblastoma cells.
Urokinase-type plasminogen activator receptor expression in adenoid cystic carcinoma of the skull base.
Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.
Urokinase-type plasminogen activator receptor inhibits apoptosis in triple-negative breast cancer through miR-17/20a suppression of death receptors 4 and 5.
Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.
Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models.
Urokinase-type plasminogen activator resulting from endometrial carcinogenesis enhances tumor invasion and correlates with poor outcome of endometrial carcinoma patients.
Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases.
Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers.
Urokinase-type-plasminogen-activator (uPA) production by human breast (myo) fibroblasts in vitro: influence of transforming growth factor-beta(1) (TGF beta(1)) compared with factor(s) released by human epithelial-carcinoma cells.
Uterine fibrinolytic enzymes in endometrial cancer.
Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization.
Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator.
Virtual Screening Targeting the Urokinase Receptor, Biochemical and Cell-Based Studies, Synthesis, Pharmacokinetic Characterization, and Effect on Breast Tumor Metastasis.
[A plasminogen regulation system in brain tumors].
[Antisense inhibition of urokinase in a human osteosarcoma cell line]
[Antisense RNA for urokinase receptor inhibits the invasiveness and metastasis of lung carcinoma]
[Assay and detection methods for urokinase-type plasminogen activator and its related-factors]
[Cell phenotype determines PAI-1 antiproliferative effect - suppressed proliferation of the lung cancer but not prostate cancer cells]
[Correlation of p38 mitogen-activated protein kinase signal transduction pathway to uPA expression in breast cancer]
[Effect of hypoxia on the expression of urokinase-type plasminogen activator in human tongue squamous cell carcinoma cells (Tca8113)]
[Establishment of urokinase receptor gene antisense RNA transfer system and its application in leukemia research]
[Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer]
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[Increase of cellular fibrinolysis in human lung cancer cell line by radiation: relationship between urokinase-type plasminogen activator (uPA) and metastasis and invasion]
[Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer]
[Inhibitory effect of FOY-305 on liver metastasis of the pancreatic cancer]
[Multiple emboli from a cardiac metastasis of a renal-cell carcinoma]
[Prognostic role of cisteine and serin proteases in gastriC cancer]
[Significance in gene expression of matrix metalloproteinase-9, urokinase-type plasminogen activator and tissue inhibitor of metalloproteinase for metastases of gastric and/or colo-rectal cancer]
[Significance of urokinase and its inhibitors in the invasiveness and metastasing of malignant tumors].
[Study on cases of D dimer values were dissociated from FDP-E]
[The clinical prospects for the study of the plasminogen activation system in breast cancer]
[The expression of urokinase-type plasminogen activator in oral squamous cell carcinoma]
[The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer]
[Urokinase plasminogen activator /U-PA/in blood of patients with lung cancer]
[Urokinase-type plasminogen activator as a predictor for lymph nodes metastasis of uterine cervical cancer]
Neoplasm Micrometastasis
T1 breast cancer: identification of patients at low risk of axillary lymph node metastases.
Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma.
Neoplasm, Residual
Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.
The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?
Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.
Neoplasms
(4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
(68)Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
1C.01: SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR AS A PROGNOSTIC MARKER OF ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN A BLACK POPULATION.
2,3,7,8-Tetrachlorodibenzo-p-dioxin increases mRNA levels for interleukin-1beta, urokinase plasminogen activator, and tumor necrosis factor-alpha in human uterine endometrial adenocarcinoma RL95-2 cells.
3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
68Ga-labeled HBED-CC variant of uPAR targeting peptide AE105 compared with 68Ga-NODAGA-AE105.
A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification.
A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis.
A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.
A bisanthracycline (WP631) represses uPAR gene expression and cell migration of RKO colon cancer cells by interfering with transcription factor binding to a chromatin-accessible -148/-124 promoter region.
A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
A C to T polymorphism of urokinase plasminogen activator (P141L) is associated with Helicobacter pylori infection.
A C/T polymorphism in the urokinase-type plasminogen activator gene in colorectal cancer.
A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors.
A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts.
A Fluorescent Carbon Nanotube Sensor Detects the Metastatic Prostate Cancer Biomarker uPA.
A functional proteomics screen of proteases in colorectal carcinoma.
A gene expression signature that distinguishes desmoid tumours from nodular fasciitis.
A highly polymorphic CA/GT repeat in intron 3 of the human urokinase receptor gene (PLAUR).
A highly potential cleavable linker for tumor targeting antibody-chemokines.
A human monoclonal antibody scFv to urokinase plasminogen activator.
A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.
A labile repressor acts through the NFkB-like binding sites of the human urokinase gene.
A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer.
A Multiscale Mathematical Model of Tumour Invasive Growth.
A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer.
A new tagging system for production of recombinant proteins in Drosophila S2 cells using the third domain of the urokinase receptor.
A nomogram to predict individual prognosis in node-negative breast carcinoma.
A novel oncogenic role for urokinase receptor in leukemia cells: molecular sponge for oncosuppressor microRNAs.
A novel peptide blocking cancer cell invasion by structure-based drug design.
A novel tumor targeting drug carrier for optical imaging and therapy.
A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site.
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin.
A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo.
A personalized approach to cancer treatment: how biomarkers can help.
A pharmacological analysis of the cholinergic regulation of urokinase-type plasminogen activator secretion in the human colon cancer cell line, HT-29.
A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development.
A prospective audit evaluating use of urokinase in oncology patients with occluded central venous access devices.
A prospective double-blind randomized trial of urokinase flushes to prevent bacteremia resulting from luminal colonization of subcutaneous central venous catheters.
A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue.
A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth.
A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix.
A site for direct integrin ?v?6·uPAR interaction from structural modelling and docking.
A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway.
A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells.
A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation.
A suppressive role of mitogen inducible gene-2 in mesenchymal cancer cell invasion.
A suppressor of multiple extracellular matrix-degrading proteases and cancer metastasis.
A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.
A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial.
A8, an anti-uPA agonistic antibody, promotes metastasis of cancer cells via ERK pathway.
Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
Ab initio molecular simulations for proposing novel peptide inhibitors blocking the ligand-binding pocket of urokinase receptor.
Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease.
Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung.
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
Activation of CD95L fusion protein prodrugs by tumor-associated proteases.
Activation of cultured rat hepatic stellate cells by tumoral hepatocytes.
Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.
Activation of the acute inflammatory phase response in idiopathic nephrotic syndrome: association with clinicopathological phenotypes and with response to corticosteroids.
Activation of the anti-cancer agent upamostat by the mARC enzyme system.
Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.
Activation of uPAR is required for cigarette smoke extract-induced epithelial-mesenchymal transition in lung epithelial cells.
Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression.
Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth.
Adenovirus E1A orchestrates the urokinase-plasminogen activator system and upregulates PAI-2 expression, supporting a tumor suppressor effect.
Adenovirus E1A represses protease gene expression and inhibits metastasis of human tumor cells.
Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines.
Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth.
Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas.
Adjuvant Chemotherapy in Node-negative Breast Cancer: UPA/PAI-1 Determinations for 163 Cases.
Adjuvant treatment for complement activation increases the effectiveness of photodynamic therapy of solid tumors.
Alteration of the Methylation Status of Tumor-Promoting Genes Decreases Prostate Cancer Cell Invasiveness and Tumorigenesis In vitro and In vivo.
Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
Altered in vitro spreading and cytoskeletal organization in human glioma cells by downregulation of urokinase receptor.
Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion.
Amine-functionalized lanthanide-doped zirconia nanoparticles: optical spectroscopy, time-resolved fluorescence resonance energy transfer biodetection, and targeted imaging.
Amino-Terminal Fragment of Urokinase Inhibits Tumor Cell Invasion In Vitro and In Vivo: Respective Contribution of the Urokinase Plasminogen Activator Receptor-Dependent or -Independent Pathway.
Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors.
Amplification of the Urokinase-Type Plasminogen Activator Receptor (uPAR) Gene in Ductal Pancreatic Carcinomas Identifies a Clinically High-Risk Group.
Amplification of urokinase gene in prostate cancer.
Amurubicinol-induced eotaxin-3 expression in human NCI-H69 small cell lung carcinoma cells.
An anti-urokinase plasminogen activator receptor (uPAR) antibody: crystal structure and binding epitope.
An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.
An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
An increase in plasminogen activator mRNA occurs at an early stage in ethylnitrosourea-induced transformation of rat brain cells.
An inhibitor of urokinase and tissue plasminogen activators in Dunning R3327H prostate tumors of rats treated with D-Trp6-LH-RH.
An orthotopic floor-of-mouth cancer model allows quantification of tumor invasion.
Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator.
Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.
Anthrax toxin: structures, functions and tumour targeting.
Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells.
Anti-angiogenic effects of mangiferin and mechanism of action in metastatic melanoma.
Anti-Invasion Effect of Crebanine and O-methylbulbocapnine from Stephania venosa via Down-Regulated MMPs and uPA.
Anti-invasive activity of synthetic serine protease inhibitors and its combined effect with a matrix metalloproteinase inhibitor.
Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: An orally active anti-cancer drug waiting for its call-of-duty?
Antibiotic lock with vancomycin and urokinase can successfully treat colonized central venous catheters in pediatric cancer patients.
Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging.
Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer.
Anticancer evaluation of some newly synthesized N-nicotinonitrile derivative.
Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
Antigen levels of urokinase-type plasminogen activator receptor and its gene polymorphism related to microvessel density in colorectal cancer.
Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates.
Antimetastatic Potential of Quercetin Analogues with Improved Pharmacokinetic Profile: Pharmacoinformatic Preliminary Study.
Antimetastatic Potentials of Phyllanthusurinaria L on A549 and Lewis Lung Carcinoma Cells via Repression of Matrix-Degrading Proteases.
Antimetastatic role of Smad4 signaling in colorectal cancer.
Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR).
Antiprotease and antimetastatic activity of ursolic acid isolated from Salvia officinalis.
Antiprotease therapy in cancer: hot or not?
Antisense inhibition of urokinase: effect on malignancy in a human osteosarcoma cell line.
Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors.
Antisense oligonucleotides against the urokinase receptor: a therapeutic strategy for the control of cell invasion in rheumatoid arthritis and cancer.
Antitumor activity of the type 1 plasminogen activator inhibitor and cytotoxic conjugate in vitro.
Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer.
Antitumor effect and mechanism of action of a tumor-targeting recombinant human tumor necrosis factor-? fusion protein mediated by urokinase.
Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-?B, on glioblastoma.
Antitumor effects of Mucin 1/sec involves the modulation of urokinase-type plasminogen activator and signal transducer and activator of transcription 1 expression in tumor cells.
Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor.
Apigenin Suppresses the IL-1?-Induced Expression of the Urokinase-Type Plasminogen Activator Receptor by Inhibiting MAPK-Mediated AP-1 and NF-?B Signaling in Human Bladder Cancer T24 Cells.
Apoptosis Induced by Knockdown of uPAR and MMP-9 is Mediated by Inactivation of EGFR/STAT3 Signaling in Medulloblastoma.
Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
Aspirin inhibits highly invasive prostate cancer cells.
Assessment of breast cancer surgical margins with multimodal optical microscopy: A feasibility clinical study.
Assessment of Complication Types and Rates Related to Diagnostic Angiography and Interventional N euroradiologic Procedures. A Four Year Review (1993-1996).
Assessment of the interaction between urokinase and reactive site mutants of protein C inhibitor.
Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis.
Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer.
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer.
Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial.
Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer.
Autotaxin stimulates urokinase-type plasminogen activator expression through phosphoinositide 3-kinase-Akt-nuclear [corrected] factor kappa B signaling cascade in human melanoma cells.
Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system.
bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: involvement of ERK1/ERK2 activity.
Benzodiazepine-Associated Carcinogenesis: Focus on Lorazepam-Associated Cancer Biomarker Changes in Overweight Individuals.
Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9.
Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence.
Binding of urokinase-type plasminogen activator receptor (uPAR) to the mannose 6-phosphate/insulin-like growth factor II receptor: contrasting interactions of full-length and soluble forms of uPAR.
Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility.
Binding site of amiloride to urokinase plasminogen activator depends on species.
Biochemical and pathological evaluation of albendazole/thalidomide co-therapy against eosinophilic meningitis or meningoencephalitis induced by Angiostrongylus cantonensis.
Biochemical markers as a predictor for lymph-node involvement in patients with cervical-cancer of the uterus.
Bioconjugatable azo-based dark-quencher dyes: synthesis and application to protease-activatable far-red fluorescent probes.
Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
Biological implications of growth factors on the mechanism of invasion in gynecological tumor cells.
Biological significance of tissue plasminogen activator content in brain tumors.
Bioluminescence Imaging of Urokinase-Type Plasminogen Activator Activity in Vitro and in Tumors.
Biomarker profile in stable Fontan patients.
Biomarkers for predicting outcomes in chronic kidney disease.
Biomarkers of blood cadmium and incidence of cardiovascular events in non-smokers: results from a population-based proteomics study.
Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.
Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma.
Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors.
Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas.
Blockage of the urokinase receptor on the cell surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin.
Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells.
Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma.
Boosting the sensitivity of ligand-protein screening by NMR of long-lived states.
Borrelia burgdorferi and other bacterial products induce expression and release of the urokinase receptor (CD87).
Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia.
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.
Butyrate is a potent inhibitor of urokinase secretion by normal colonic epithelium in vitro.
Calcitonin stimulates the secretion of urokinase-type plasminogen activator from prostate cancer cells: its possible implications on tumor cell invasion.
Cambodian Phellinus linteus inhibits experimental metastasis of melanoma cells in mice via regulation of urokinase type plasminogen activator.
Can linoleic acid and gamma-linolenic acid be important in cancer treatment?
Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.
Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: analysis by Northern blotting and in situ hybridization.
Cancer cells release a covalent complex containing disulfide-linked domains from urinary plasminogen activator, neural cell adhesion molecule, and haptoglobin alpha and beta chains.
Cancer invasion and metastasis: changing views.
Cancer metastasis: biological and clinical aspects.
Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin.
Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo.
Carotenoids in Cancer Metastasis-Status Quo and Outlook.
Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma.
Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).
Caveolin-1-dependent and -independent uPAR signaling pathways contribute to ganglioside GT1b induced early apoptosis in A549 lung cancer cells.
CD87-positive tumor cells in bone marrow aspirates identified by confocal laser scanning fluorescence microscopy.
cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
CEA, EpCAM, ?v?6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy.
Cell biologic factors and cancer spread.
Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours.
Cell surface expression of urokinase receptor in normal mammary epithelial cells and breast cancer cell lines.
Cellular and extracellular plasminogen activator and inhibitor in an experimental tumour.
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer.
Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
Cellular mechanisms of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MAPK signaling in hepatocellular carcinoma.
Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients.
CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer.
Challenges for drug discovery - a case study of urokinase receptor inhibition.
Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.
Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures.
Characterisation of a Novel Fc Conjugate of Macrophage Colony-stimulating Factor.
Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells.
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in animals.
Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma.
Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.
Characterization of the interaction between heterodimeric ?v?6 integrin and urokinase plasminogen activator receptor (uPAR) using functional proteomics.
Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
CHK1 and RAD51 activation after DNA damage is regulated via urokinase receptor/TLR4 signaling.
Chromosomal localization of the human urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 genes: implications in colorectal cancer.
Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder.
Circulating intact and cleaved forms of the urokinase-type plasminogen activator receptor: biological variation, reference intervals and clinical useful cut-points.
Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.
Circulating proteins as predictors of incident heart failure in the elderly.
Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - ?1 (TGF-?1) and potential effects on migration and invasion.
Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway.
Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients.
Clinical features and prognostic factors in Covid-19: A prospective cohort study.
Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients.
Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer.
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer.
Clinical significance of plasma tissue factor pathway and urokinase-type plasminogen activator system in cancer patients.
Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients.
Clinical significance of the uPA system in gastric cancer with peritoneal metastasis.
Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer.
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
Clinicopathological significance of urokinase-type plasminogen activator genotypes in gastric cancer.
Clotting factors in tumour tissue: implications for cancer therapy.
Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.
Co-expression of uPAR and CXCR4 promotes tumor growth and metastasis in small cell lung cancer.
Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues.
Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression.
Colonic epithelial cell activation and the paradoxical effects of butyrate.
Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma.
Combined histomorphologic and immunohistochemical phenotype to predict the presence of vascular invasion in colon cancer.
Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma.
Commentary: targeting colorectal cancer through molecular biology.
Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis.
Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells.
Comparison of anti-invasive activity of parthenolide and 3-isopropyl-2-methyl-4-methyleneisoxazolidin-5-one (MZ-6)--a new compound with ?-methylene-?-lactone motif--on two breast cancer cell lines.
Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate.
Comparison of intraperitoneal anti-adhesive polysaccharides derived from Phellinus mushrooms in a rat peritonitis model.
Comparison of the effects of auranofin and retinoic acid on plasminogen activator activity of peritoneal macrophages and Lewis lung carcinoma cells.
Comparison of the tumor associated proteases cathepsin D (CATH D) and urokinase-type plasminogen activator (uPA) in cytosols of human breast cancer patients.
Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay.
Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.
Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
Computational Approaches and Analysis for a Spatio-Structural-Temporal Invasive Carcinoma Model.
Computer aided identification of small molecules disrupting uPAR/alpha5beta1--integrin interaction: a new paradigm for metastasis prevention.
Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment.
Constitutive expression and secretion of proteases in non-metastatic SP1 mammary carcinoma cells and its metastatic sublines.
Construction of Urokinase-Type Plasminogen Activator Receptor-Targeted Heterostructures for Efficient Photothermal Chemotherapy against Cervical Cancer To Achieve Simultaneous Anticancer and Antiangiogenesis.
Content and characterization of plasminogen activators in human lung tumors and normal lung tissue.
Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
Controlled release of PEG chain from gold nanorods: targeted delivery to tumor.
Cooperation between monocytes and breast cancer cells promotes factors involved in cancer aggressiveness.
Coordinate inhibition of plasminogen activator and tumor growth by hydrocortisone in mouse mammary carcinoma.
Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results.
Correction: Targeting Tumor Cell Invasion and Dissemination In Vivo by an Aptamer that Inhibits Urokinase-type Plasminogen Activator through a Novel Multifunctional Mechanism.
Correlates for disease progression and prognosis during concurrent HIV/TB infection.
Correlation between tumor proliferation and tumor tissue level of urokinase-type plasminogen activator.
Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells.
Correlation of tissue and blood plasminogen activation system in breast cancer.
Correlation of tumor plasminogen activator with peritumoral cerebral edema. A CT and biochemical study.
Crebanine, an aporphine alkaloid, sensitizes TNF-?-induced apoptosis and suppressed invasion of human lung adenocarcinoma cells A549 by blocking NF-?B-regulated gene products.
Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.
CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases.
Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA.
Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Cyclooxygenase-2 alters transforming growth factor-beta 1 response during intestinal tumorigenesis.
Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.
Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.
Cysteine and serine proteases in gastric cancer.
Cysteine peptidases and their inhibitors in breast and genital cancer.
Cytokine-regulated urokinase-type-plasminogen-activator (uPA) production by human breast fibroblasts in vitro.
Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.
Decoy molecules based on PNA-DNA chimeras and targeting Sp1 transcription factors inhibit the activity of urokinase-type plasminogen activator receptor (uPAR) promoter.
Decreased expression of intercellular adhesion molecule-1 (ICAM-1) and urokinase-type plasminogen activator receptor (uPAR) is associated with tumor cell spreading in vivo.
Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1).
Defective cell migration in an ovarian cancer cell line is associated with impaired urokinase-induced tyrosine phosphorylation.
Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
Deficiency of plasminogen activator inhibitor-2 results in accelerated tumor growth.
Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma.
Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.
Demonstration of a possible link between high grade malignancy in dimethylbenz[a]anthracene-induced rat mammary carcinoma and increased urokinase plasminogen activator content.
Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization.
Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness.
Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancer.
Deregulated activation of matriptase in breast cancer cells.
Deregulated Expression of Urokinase and its Inhibitor Type 1 in Prostate Cancer Cells: Role of Epigenetic Mechanisms.
Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype.
Design and testing of a packaged microfluidic cell for the multiplexed electrochemical detection of cancer markers.
Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents.
Design, synthesis, and characterization of urokinase plasminogen-activator-sensitive near-infrared reporter.
Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor.
Designing tracers for PET imaging of the urokinase-type plasminogen activator receptor from a cyclic uPA-derived peptide: first in vitro evaluations.
Detecting in vivo urokinase plasminogen activator activity with a catalyCEST MRI contrast agent.
Detection of in vivo enzyme activity with CatalyCEST MRI.
Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Detection of soluble urokinase receptor by immunoradiometric assay and its application in tumor patients.
Detection of the plasmin system in human mammary pathology using immunofluorescence.
Detection of the receptor for the human urokinase-type plasminogen activator using fluoresceinated uPA.
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
Development of AE147 Peptide-Conjugated Nanocarriers for Targeting uPAR-Overexpressing Cancer Cells.
Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners.
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer.
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: lack of association with in vitro invasion.
Differential effect of radiation on endothelial cell function in rectal cancer and normal rectum.
Differential effects of fibroblast growth factors on expression of genes of the plasminogen activator and insulin-like growth factor systems by human breast fibroblasts.
Differential expression levels of urokinase-type plasminogen activator and cathepsin D in locally advanced laryngeal squamous cell carcinoma: clinical implications.
Differential expression of angiogenic cytokines by cell lines and primary cultures of human prostate cancer.
Differential expression of c-jun and c-fos mRNAs in squamous cell carcinoma of the head and neck: associations with uPA, gelatinase B, and matrilysin mRNAs.
Differential expression of genes by tumor cells of a low or a high malignancy phenotype: The case of murine and human Ly-6 proteins.
Differential expression of genes by tumor cells of a low or a high malignancy phenotype: the case of murine and human Ly-6 proteins.
Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
Differential expression of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse skin after exposure to a tumor-promoting phorbol ester.
Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer.
Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
Differential regulation of plasminogen activators by epidermal growth factor in normal and neoplastic human urothelium.
Differential roles of uPAR in peritoneal ovarian carcinomatosis.
Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma.
Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
Direct evidence of the importance of vitronectin and its interaction with the urokinase receptor in tumor growth.
Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase.
Directed migration of murine and human tumor cells to collagenases and other proteases.
Discovering novel ligands for macromolecules using X-ray crystallographic screening.
Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.
Discovery of New Risk Markers for Ischemic Stroke Using a Novel Targeted Proteomics Chip.
Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion.
Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
Distinct Immune Imprints of Post-Liver Transplantation Hepatitis C Persist Despite Viral Clearance.
DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase): association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients.
Do plasminogen activators play a role in lichen sclerosus?
Docosahexaenoic Acid Downregulates EGF-Induced Urokinase Plasminogen Activator and Matrix Metalloproteinase 9 Expression by Inactivating EGFR/ErbB2 Signaling in SK-BR3 Breast Cancer Cells.
Docosahexaenoic Acid Inhibits Tumor Promoter-Induced Urokinase-Type Plasminogen Activator Receptor by Suppressing PKC?- and MAPKs-Mediated Pathways in ECV304 Human Endothelial Cells.
Does plasma urokinase antigen reflect tumor urokinase in prostatic carcinoma?
Down regulation of u-PA by a nutrient mixture in hemangioma (EOMA) cells by inducing caspase-dependent apoptosis.
Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation.
Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells.
Downregulation of angiogenic factors in Ewing tumor xenografts by the combination of human interferon-alpha or interferon-beta with ifosfamide.
Downregulation of Extracellular Matrix Metalloproteinase Inducer by scFv-M6-1B9 Intrabody Suppresses Cervical Cancer Invasion Through Inhibition of Urokinase-Type Plasminogen Activator.
Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer.
Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells.
Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma.
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells.
Downregulation of urokinase-type plasminogen activator receptor (uPAR) induces caspase-mediated cell death in human glioblastoma cells.
DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression.
Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin B.
DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo.
Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.
E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma.
Early detection of pancreatic cancers in liquid biopsies by ultrasensitive fluorescence nanobiosensors.
Early events of metastasis in the microcirculation involve changes in gene expression of cancer cells. Tracking mRNA levels of metastasizing cancer cells in the chick embryo chorioallantoic membrane.
Effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) on the liver metastasis of colon 26-L5 carcinoma cells.
Effect of antisense inhibition of Urokinase receptor on malignancy.
Effect of bFGF on invasion of ovarian cancer cells through the regulation of Ets-1 and urokinase-type plasminogen activator.
Effect of body-weight loading onto the articular cartilage on the occurrence of quinolone-induced chondrotoxicity in juvenile rats.
Effect of bone resorbing factors on u-PA and its specific receptor in osteosarcoma cell line.
Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion.
Effect of TGF-beta 1 and TNF-alpha on the plasminogen system of rat proximal tubular epithelial cells.
Effect of transforming growth factor-beta on plasminogen activator production of cultured human uveal melanoma cells.
Effect of urokinase on growth and metastases of rabbit V2 carcinoma.
Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis.
Effects of 1 year of exercise training versus combined exercise training and weight loss on body composition, low-grade inflammation and lipids in overweight patients with coronary artery disease: a randomized trial.
Effects of a highly controlled carbohydrate-reduced high-protein diet on markers of oxidatively generated nucleic acid modifications and inflammation in weight stable participants with type 2 diabetes; a randomized controlled trial.
Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases.
Effects of Coriandrum sativum on Migration and Invasion Abilities of Cancer Cells.
Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Effects of in vivo culture of murine mammary adenocarcinoma cells on tumor and metastatic growth.
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
Effects of macrophage-colony stimulating factor on human monocytes: induction of expression of urokinase-type plasminogen activator, but not of secreted prostaglandin E2, interleukin-6, interleukin-1, or tumor necrosis factor-alpha.
Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes.
Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Effects of sex steroids and growth factors on invasive activity and 5'-deoxy-5-fluorouridine sensitivity in ovarian adenocarcinoma OMC-3 cells.
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.
Effects of tranexamic acid and urokinase on hematogenous metastases of Lewis lung carcinoma in mice.
Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells.
Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin.
EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases.
EGFR and ?v?6 as Promising Targets for Molecular Imaging of Cutaneous and Mucosal Squamous Cell Carcinoma of the Head and Neck Region.
Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA).
Electroanalysis of pM-levels of urokinase plasminogen activator in serum by phosphorothioated RNA aptamer.
Elevated cell proliferation and VEGF production by high-glucose conditions in Müller cells involve XIAP.
Elevated levels of angiostatin in effusions from patients with malignant disease.
Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection.
Elevated levels of soluble urokinase receptor in serum from mycobacteria infected patients: still looking for a marker of treatment efficacy.
Elevated levels of urokinase-type plasminogen activator and its receptor during tumor growth in vivo.
Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.
Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera.
Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis.
Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer.
Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor.
ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients.
Elucidation of the Contribution of Active Site and Exosite Interactions to Affinity and Specificity of Peptidylic Serine Protease Inhibitors, using Non-natural Arginine Analogs.
EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression.
Endogenously produced urokinase amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes.
Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating alpha(v)beta5 vitronectin receptor cell surface expression.
Engineered Antibody Fragment against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography.
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
Enhanced spontaneous metastasis in bikunin-deficient mice.
Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness.
Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue.
Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells.
Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications.
Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application?
Epidermal growth factor receptor-mediated regulation of urokinase plasminogen activator expression and glioblastoma invasion via C-SRC/MAPK/AP-1 signaling pathways.
Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metalloproteinases and urokinase-plasminogen activator.
Epigenetic modification of transgenes under the control of the mouse mammary tumor virus LTR: tissue-dependent influence on transcription of the transgenes.
Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.
Epigenetic upregulation of urokinase plasminogen activator promotes the tropism of mesenchymal stem cells for tumor cells.
Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation.
Estimating the Roles of Protonation and Electronic Polarization in Absolute Binding Affinity Simulations.
Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: correlation with clinical outcome of anti-estrogen therapy.
Ets-1 positively regulates expression of urokinase-type plasminogen activator (uPA) and invasiveness of astrocytic tumors.
Evaluating the value of uPAR of serum and tissue on patients with cervical cancer.
Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX(®), clinicopathological markers and tumor cell dissemination in the blood and bone marrow.
Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma.
Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer.
Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and ?1 Integrin in Patients with Hodgkin's Lymphoma.
Evidence for the clinical use of tumour markers.
Evolving role of uPA/uPAR system in human cancers.
Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma.
Explaining urokinase type plasminogen activator inhibition by amino-5-hydroxybenzimidazole and two naphthamidine-based compounds through quantum biochemistry.
Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study.
Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma.
Expression and localisation of urokinase-type plasminogen activator gene in gliomas.
Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Expression and localization of urokinase-type plasminogen activator in human spinal column tumors.
Expression and localization of urokinase-type plasminogen activator receptor in human gliomas.
Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Expression and purification of recombinant ATF-mellitin, a new type fusion protein targeting ovarian cancer cells, in P. pastoris.
Expression of a novel factor, com1, in early tumor progression of breast cancer.
Expression of a urokinase-type plasminogen activator during tumor growth leads to angiogenesis via galanin activation in tumor-bearing mice.
Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis.
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Expression of C4.4A, a structural uPAR homolog, reflects squamous epithelial differentiation in the adult mouse and during embryogenesis.
Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer.
Expression of integrins, degradative enzymes and their inhibitors in uveal melanoma: differences between in vitro and in vivo expression.
Expression of MMP-2, MMP-9, and urokinase-type plasminogen activator in cervical intraepithelial neoplasia.
Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
Expression of plasminogen activators in basal cell carcinoma.
Expression of the constitutively activated RelA/NF-kappaB in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion.
Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: purification of the recombinant proteins and generation of polyclonal antibodies in chicken.
Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression.
Expression of the urokinase-type plasminogen activator receptor in human articular chondrocytes: association with caveolin and beta 1-integrin.
Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion.
Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study.
Expression of urokinase plasminogen activator (uPA) in the leukocytes and tissues of patients with benign and malignant breast lesions.
Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers.
Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells.
Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis.
Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors.
Expression of urokinase-type plasminogen activator and its receptor in squamous cell carcinoma of the oral tongue.
Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms.
Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer.
Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma.
Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma.
Expression of urokinase-type plasminogen activator receptor is increased during epileptogenesis in the rat hippocampus.
Expression of urokinase-type plasminogen activator, its receptor and type-1 plasminogen activator inhibitor is differently regulated by inhibitors of protein synthesis in human cancer cell lines.
Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma.
Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Expression of urokinase-type plasminogen-activator (upa) and its receptor (upar) in human ovarian-cancer cells and in-vitro invasion capacity.
Expression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: role of oxygenation status and tumour size.
Expression, Purification, and Biological Characterization of The Amino-Terminal Fragment of Urokinase in Pichia pastoris.
Extending preclinical models of skeletal manifestations of malignancy to the clinical setting.
Extracellular collagenases and the endocytic receptor, urokinase plasminogen activator receptor-associated protein/Endo180, cooperate in fibroblast-mediated collagen degradation.
Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis.
Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor.
Extracellular signal-regulated kinase and AP-1 pathways are involved in reactive oxygen species-induced urokinase plasminogen activator receptor expression in human gastric cancer cells.
FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions.
Fecal diglycerides as selective endogenous mitogens for premalignant and malignant human colonic epithelial cells.
Fibrin and Fibrinolysis in Cancer.
Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells.
Fibrinogen-fibrin transformation in situ in renal cell carcinoma.
Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
Fibrinolysis-inhibitory activity of cultured human cancer cell lines.
Fibrinolytic activity in human malignant tumors.
Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.
Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications.
Fibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma.
First-in-human uPAR PET: Imaging of Cancer Aggressiveness.
Flavokawain B inhibits growth of human squamous carcinoma cells: Involvement of apoptosis and cell cycle dysregulation in vitro and in vivo.
Flow cytofluorometry in tumour cell receptor analysis. Survey of the literature and recent developments concerning the urokinase-type plasminogen activator (uPA).
Fluorescent probes as tools to assess the receptor for the urokinase-type plasminogen activator on tumor cells.
Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.
Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.
Functional structure of the somatomedin B domain of vitronectin.
Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors.
Ganoderma lucidum: A rational pharmacological approach to surmount cancer.
Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion.
Gelsolin-Cu/ZnSOD interaction alters intracellular reactive oxygen species levels to promote cancer cell invasion.
Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs).
Gene expression patterns associated with the metastatic phenotype in rodent and human tumors.
Gene transfer of a soluble IL-1 type 2 receptor-Ig fusion protein improves cardiac allograft survival in rats.
Generation of antibodies to the urokinase receptor (uPAR) by DNA immunization of uPAR knockout mice: membrane-bound uPAR is not required for an antibody response.
Generation of high-affinity rabbit polyclonal antibodies to the murine urokinase receptor using DNA immunization.
Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies.
Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.
Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia.
Genistein reduces tumor necrosis factor alpha-induced plasminogen activator inhibitor-1 transcription but not urokinase expression in human endothelial cells.
Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels.
Germinated Brown Rice Attenuates Atherosclerosis and Vascular Inflammation in Low-Density Lipoprotein Receptor-Knockout Mice.
Glioma cells deficient in urokinase plaminogen activator receptor expression are susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
GPI-specific phospholipase D mRNA expression in tumor cells of different malignancy.
Granulocyte elastase, tumor necrosis factor-alpha and urokinase levels as prognostic markers in severe infection.
Grape seed extract suppresses MDA-MB231 breast cancer cell migration and invasion.
Graphene nanosheets as an electric mediator for ultrafast sensing of urokinase plasminogen activator receptor-A biomarker of cancer.
Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer.
Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.
Growth inhibition of MDA-MB-231 cell line by peptides designed based on uPA.
Growth of a human carcinoma (HEp3) in nude mice: rapid and efficient metastasis.
Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme.
Heat shock proteins HSP70 and MRJ cooperatively regulate cell adhesion and migration through urokinase receptor.
Helicobacter pylori Colonization Drives Urokinase Receptor (uPAR) Expression in Murine Gastric Epithelium During Early Pathogenesis.
Helicobacter pylori infection stimulates plasminogen activator inhibitor 1 production by gastric epithelial cells.
Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors.
Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer.
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer.
Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase.
Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells.
Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.
Heterogeneous distribution of macrophages, tumour necrosis factor alpha, tissue factor and fibrinolytic regulators in atherosclerotic vessels.
High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma.
High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.
High levels of cathepsin B predict poor outcome in patients with breast cancer.
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.
High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer.
High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma.
High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer.
High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
High-affinity urokinase receptor antagonists identified with bacteriophage peptide display.
HMG-CoA reductase inhibitors reduce matrix metalloproteinase-9 activity in human varicose veins.
Homocysteine inhibits the proliferation and invasive potential of HT-1080 human fibrosarcoma cells.
Host protein C inhibitor inhibits tumor growth, but promotes tumor metastasis, which is closely correlated with hypercoagulability.
HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI.
Human and canine mammary tumors: A role for urokinase plasminogen activator?
Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.
Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator.
Human primary colon carcinomas xenografted into nude mice. I. Characterization of plasminogen activators expressed by primary tumors and their xenografts.
Human prostate tumor angiogenesis in nude mice: metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells.
Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma.
Human sprouty1 suppresses urokinase receptor-stimulated cell migration and invasion.
Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.
Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels.
Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells.
Hyaluronan-oligosaccharide-induced transcription of metalloproteases.
Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid.
Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications.
Hypoxia Effects: Implications for Maspin Regulation of the uPA/uPAR Complex.
Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression.
Identification and preclinical development of an anti-proteolytic uPA antibody for rheumatoid arthritis.
Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (?M).
Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression.
Identification of differential pathways in papillary thyroid carcinoma utilizing pathway co-expression analysis.
Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography.
Identification of Ras suppressor-1 (RSU-1) as a potential breast cancer metastasis biomarker using a three-dimensional in vitro approach.
Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging.
IFN-gamma, tumor necrosis factor-alpha, and urokinase regulate the expression of urokinase receptors on human monocytes.
IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma.
IL-1 beta induces urokinase-plasminogen activator expression and cell migration through PKC alpha, JNK1/2, and NF-kappaB in A549 cells.
Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET.
Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: the role of mesothelial cells.
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response.
Immunohistochemical analysis of plasminogen activator expression in human colorectal carcinomas: correlation with CEA distribution and tumor cell kinetics.
Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours.
Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
Immunohistochemical Detection of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor in Canine Vascular Endothelial Tumours.
Immunohistochemical evaluation of urokinase plasminogen activator receptor in noninvasive and early invasive urothelial papillary neoplasia.
Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma.
Immunohistochemical expression of Ets-1 transcription factor and the urokinase-type plasminogen activator is correlated with the malignant and invasive potential in meningiomas.
Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
Immunohistochemical profile of cystosarcoma phyllodes of the breast: a study of 23 cases.
Immunologic detection of the cellular receptor for urokinase plasminogen activator.
Immunological analysis of plasminogen activators from cultured human cancer cells.
Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer.
Impact of Saskatoon berry powder on insulin resistance and relationship with intestinal microbiota in high fat-high sucrose diet-induced obese mice.
Impact of uPA system gene polymorphisms on the susceptibility of environmental factors to carcinogenesis and the development of clinicopathology of oral cancer.
Impaired MicroRNA Processing Facilitates Breast Cancer Cell Invasion by Upregulating Urokinase-Type Plasminogen Activator Expression.
Improved Immuno-PET Imaging of HER2-Positive Tumors in Mice: Urokinase Injection-Triggered Clearance Enhancement of 64Cu-Trastuzumab.
Improved positron emission tomography imaging of glioblastoma cancer using novel
In papillary thyroid carcinoma BRAF(V) (600E) is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
In vitro activity of probiotic Lactobacillus reuteri against gastric cancer progression by downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor gene expression.
In vitro and in vivo antimetastatic effects of Terminalia catappa L. leaves on lung cancer cells.
In vitro inhibition of human sarcoma cells' invasive ability by bis(5-amidino-2-benzimidazolyl)methane--a novel esteroprotease inhibitor.
In vitro receptor imaging for characterization of human solid tumors.
In vitro suppression of urokinase plasminogen activator in breast cancer cells--a comparison of two antisense strategies.
In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer.
In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase.
In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model.
In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion.
In-vivo imaging of tumor associated urokinase-type plasminogen activator activity.
Inactivation of human tumor cell pro-urokinase by granulocyte elastase.
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate.
Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas.
Increased cell-surface urokinase in advanced ovarian cancer.
Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas.
Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas.
Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis.
Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Increased plasminogen activator inhibition levels in malignancy.
Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.
Increased urokinase activity to antigen ratio in human renal-cell carcinoma.
Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis.
Indirect activation of blood coagulation in colon cancer.
Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer.
Inducible changes in cell size and attachment area due to expression of a mutant SWI/SNF chromatin remodeling enzyme.
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.
Induction of IL-8 and monoclyte chemoattractant protein-1 by doxorubicin in human small cell lung carcinoma cells.
Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells.
Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells.
Induction of Urokinase Activity by Retinoic Acid in Two Cell Lines of Neuronal Origin.
Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells.
Inflammation and post-operative recovery in patients undergoing total knee arthroplasty-secondary analysis of a randomized controlled trial.
Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer.
Inflammatory markers associated with abdominal aortic aneurysm.
Inflammatory mediators after endovascular aortic aneurysm repair.
Influence of drinking green tea on breast cancer malignancy among Japanese patients.
Influence of freeze-drying on the recovery of the tumour invasion markers uPA and PAI-1 from prostate cancer resections.
Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue.
Inhibition activities of natural products on serine proteases.
Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist.
Inhibition of fibrinolysis by a synthetic urokinase inhibitor enhances lung colonization of metastatic murine mammary tumor cells.
Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer.
Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.
Inhibition of human tumor cell-associated fibrinolysis by vascular bovine smooth muscle cells.
Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors.
Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor.
Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428.
Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones.
Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates.
Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.
Inhibition of nuclear factor-?B signaling suppresses Spint-1-deletion-induced tumor susceptibility in the ApcMin/+ model.
Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade.
Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif.
Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells.
Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.
Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
Inhibition of trypsin and urokinase by Cbz-amino(4-guanidinophenyl)methanephosphonate aromatic ester derivatives: the influence of the ester group on their biological activity.
Inhibition of Tumor Growth and Metastasis by ATF-Fc, an Engineered Antibody: Targeting Urokinase Receptor.
Inhibition of tumor implantation at sites of trauma by plasminogen activators.
Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.
Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model.
Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, WXC-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases.
Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells.
Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse.
Inhibitors of proteases as anticancer drugs.
Inhibitors of the protease domain of urokinase-type plasminogen activator.
Inhibitors of the proteolytic activity of urokinase type plasminogen activator.
Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.
Inhibitors of urokinase type plasminogen activator and cytostatic activity from crude plants extracts.
Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro.
Inhibitory effect of a synthetic prostacyclin analogue, beraprost, on urokinase-type plasminogen activator expression in RC-K8 human lymphoma cells.
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Inhibitory Effects of a Reengineered Anthrax Toxin on Canine Oral Mucosal Melanomas.
Inhibitory role of plasminogen activator inhibitor-1 in invasion and proliferation of HLE hepatocellular carcinoma cells.
Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.
Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.
Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA).
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
Interventions to obstructive long-term central venous catheter in cancer patients: a meta-analysis.
Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.
Intrapleural urokinase for the treatment of loculated malignant pleural effusions and trapped lungs in medically inoperable cancer patients.
Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
Invasion and metastasis.
Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display.
Invasion-Metastasis by Hepatocyte Growth Factor/c-Met Signaling Concomitant with Induction of Urokinase Plasminogen Activator in Human Pancreatic Cancer: Role as Therapeutic Target.
Invasive capacity of heterotopic endometrium.
Invasiveness of hepatocellular carcinoma cell lines: contribution of membrane-type 1 matrix metalloproteinase.
Inverse correlation between mRNA expression of plasminogen activator inhibitor-2 and lymph node metastasis in human breast cancer.
Involvement of fibronectin in the regulation of urokinase production and binding in murine mammary tumor cells.
Involvement of Platelets in Cancers.
Involvement of TNF-alpha in enhancement of invasion and metastasis of colon 26-L5 carcinoma cells in mice by social isolation stress.
Involvement of Urokinase-Type Plasminogen Activator System in Cancer: An Overview.
IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts.
Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cells.
Is inhibition process better described with MD(QM/MM) simulations? The case of urokinase type plasminogen activator inhibitors.
Is the circulating urokinase plasminogen activator upregulated by the circulating p105 fraction of the HER-2/neu proto-oncogene in patients with cervical cancer?
Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
Is urokinase gene 3'-UTR polymorphism associated with prostate cancer?
Isolated splenic metastasis of sigmoid colon cancer: a case report.
Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA.
JNK Suppression is Essential for 17beta-Estradiol Inhibits Prostaglandin E2-Induced uPA and MMP-9 Expressions and Cell Migration in Human LoVo Colon Cancer Cells.
JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation.
Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
Knock-down of calcitonin receptor expression induces apoptosis and growth arrest of prostate cancer cells.
Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters: a multicentre randomised comparison of urokinase versus heparin.
Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.
Lanthanide-doped NaScF4 nanoprobes: crystal structure, optical spectroscopy and biodetection.
Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array.
Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system.
Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.
Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus.
Local function of urokinase receptor at the adhesion contact sites of a metastatic tumor cell.
Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients.
Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas.
Loss of Inhibitor of Growth (ING-4) Is Implicated in the Pathogenesis and Progression of Human Astrocytomas.
Loss of mitochondrial DNA enhances angiogenic and invasive potential of hepatoma cells.
Loss of the metastatic phenotype by a human epidermoid carcinoma cell line, HEp-3, is accompanied by increased expression of tissue inhibitor of metalloproteinase 2.
Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.
Low molecular weight heparin suppresses tumor necrosis factor expression from deep vein thrombosis.
Low-dose urokinase infusions to treat fibrinous obstruction of venous access devices in cancer patients.
Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells.
Lysosome labilizers potentiate the antitumor effects of tumor necrosis factor-alpha.
Macrophage colony-stimulating factor could evaluate both disease activity and renal involvement in systemic lupus erythematosus.
Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase.
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
MAGE-A gene expression pattern in primary breast cancer.
Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ.
Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.
Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.
Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography.
Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer.
Markers of the uPA system and common prognostic factors in breast cancer.
Maspin inhibits cell migration in the absence of protease inhibitory activity.
Mathematical modeling of cancer cell invasion of tissue: biological insight from mathematical analysis and computational simulation.
Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions.
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.
Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.
Melanoma antigen-encoding gene-1 expression in invasive gastric carcinoma: correlation with stage of disease.
Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme.
Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways.
Mesenchymal stem cells from adipose and bone marrow promote angiogenesis via distinct cytokine and protease expression mechanisms.
Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer.
Metabolism and distribution of two highly potent and selective peptidomimetic inhibitors of matriptase.
Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice.
Metalloproteases and urokinase in angiogenesis and tumor progression.
Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
Metastatic behavior of prostatic tumor as influenced by the hematopoietic and hematogenous factors.
Metastatic brain tumour and fibrinopeptides.
Metastatic effect of LY-6K gene in breast cancer cells.
Methods to analyze the effects of the urokinase system on cancer cell adhesion, proliferation, migration, and signal transduction events.
Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo.
MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells.
Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.
Mistletoe Extract Targets the STAT3-FOXM1 Pathway to Induce Apoptosis and Inhibits Metastasis in Breast Cancer Cells.
MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate.
Modified Panax ginseng Extract Inhibits uPAR-Mediated ?[Formula: see text]?1-Integrin Signaling by Modulating Caveolin-1 to Induce Early Apoptosis in Lung Cancer Cells.
Modulation of growth and urokinase secretion by vasopressin and closely related nonapeptides in metastatic mouse mammary tumor cells.
Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells.
Modulation of the urokinase-type plasminogen activator receptor by the beta6 integrin subunit.
Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human female cancer cell lines.
Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human glioblastoma cell lines.
Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.
Modulation of urokinase-type plasminogen activator and metalloproteinase activities in cultured mouse mammary-carcinoma cells: enhancement by paclitaxel and inhibition by nocodazole.
Modulation of urokinase-type plasminogen activator gene expression by inflammatory cytokines in human pre-B lymphoma cell line RC-K8.
Modulation of urokinase-type plasminogen-activator expression by the wild-type and mutated p53 tumor-suppressor gene.
Modulations of functional activity in differentiated macrophages are accompanied by early and transient increase or decrease in c-fos gene transcription.
Modulators of the urokinase-type plasminogen activation system for cancer.
Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.
Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles.
Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer.
Molecular interactions in cancer cell metastasis.
Molecular mechanisms of anticancer activity of deoxyelephantopin in cancer cells.
Molecular mechanisms of malignant conversion in skin carcinogenesis.
Molecular mechanisms of protease-mediated tumor invasiveness.
Molecular modeling as a new approach to the development of urokinase inhibitors.
Molecular photoacoustic tomography of breast cancer using receptor targeted magnetic iron oxide nanoparticles as contrast agents.
Molecular regulation of an invasion-related molecule--options for tumour staging and clinical strategies.
Molecular targeted NIR-II probe for image-guided brain tumor surgery.
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Mortality and major complications after emergency laparotomy: A pilot study of risk prediction model development by preoperative blood-based immune parameters.
MUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-?B p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells.
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review).
Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.
Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer.
Multiparametric prognostic evaluation of biological factors in primary breast cancer.
Multiple forms of plasminogen activator in human breast tumors.
Multiple pathways of cell invasion are regulated by multiple families of serine proteases.
Multiscale Modelling of Cancer Response to Oncolytic Viral Therapy.
Mutant K-ras regulates cathepsin B localization on the surface of human colorectal carcinoma cells.
Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
Nanoparticle Binding to Urokinase Receptor on Cancer Cell Surface Triggers Nanoparticle Disintegration and Cargo Release.
Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells.
New cancer therapy using genetically-engineered oncolytic Sendai virus vector.
New ELISA for quantitation of human urokinase receptor (CD87) in cancer.
NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4.
NFkappaB-dependent regulation of urokinase plasminogen activator by proanthocyanidin-rich grape seed extract: effect on invasion by prostate cancer cells.
Nicotine stimulates urokinase-type plasminogen activator receptor expression and cell invasiveness through mitogen-activated protein kinase and reactive oxygen species signaling in ECV304 endothelial cells.
Nimbolide inhibits invasion and migration, and down-regulates uPAR chemokine gene expression, in two breast cancer cell lines.
Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
Node-Negative Breast Cancer: Which Patients Should Be Treated?
Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks.
Novel immunologic tolerance of human cancer cell xenotransplants in zebrafish.
Novel inhibitors of urokinase-type plasminogen activator and matrix metalloproteinase expression in metastatic cancer cell lines.
Novel patents and cancer therapies for transforming growth factor-beta and urokinase type plasminogen activator: potential use of their interplay in tumorigenesis.
Novel protein interactors of urokinase-type plasminogen activator receptor.
Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation.
Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue.
Nuclear Translocation of Hand-1 Acts as a Molecular Switch to Regulate Vascular Radiosensitivity in Medulloblastoma Tumors: The Protein uPAR Is a Cytoplasmic Sequestration Factor for Hand-1.
Occupancy of the cancer cell urokinase receptor (uPAR): effects of acid elution and exogenous uPA on cell surface urokinase (uPA).
Okadaic acid-dependent induction of the urokinase-type plasminogen activator gene associated with stabilization and autoregulation of c-Jun.
One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.
Optimization of construct design and fermentation strategy for the production of bioactive ATF-SAP, a saporin based anti-tumoral uPAR-targeted chimera.
Organization of GPI-anchored proteins at the cell surface and its physiopathological relevance.
Orientation-controlled conjugation of haloalkane dehalogenase fused homing peptides to multifunctional nanoparticles for the specific recognition of cancer cells.
Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management.
Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
Overexpression of forkhead box M1 and urokinase-type plasminogen activator in gastric cancer is associated with cancer progression and poor prognosis.
Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carcinogenesis.
Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis.
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
Overexpression of VEGF189 in breast cancer cells induces apoptosis via NRP1 under stress conditions.
p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells.
P38 MAPK pathway is involved in the urokinase plasminogen activator expression in human gastric SNU-638 cells.
p38? MAPK Mediates 17?-Estradiol Inhibition of MMP-2 and -9 Expression and Cell Migration in Human LoVo Colon Cancer Cells.
p53 and miR-34a Feedback Promotes Lung Epithelial Injury and Pulmonary Fibrosis.
p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
PAI-1 and functional blockade of SNAI1 in breast cancer cell migration.
PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells.
PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis.
Paracrine factor and cell-cell contact-mediated induction of protease and c-ets gene expression in malignant keratinocyte/dermal fibroblast cocultures.
Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression.
PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.
Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation.
Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinase-type plasminogen activator.
pH-Sensitive Shell-Core Platform Block DNA Repair Pathway To Amplify Irreversible DNA Damage of Triple Negative Breast Cancer.
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
Phorbol-ester-stimulated human lymphoid cell lines produce a plasminogen activator modulator inducing cell-bound urokinase-type plasminogen activator in malignant tumor cell lines.
PI3K, Erk signaling in BMP7-induced epithelial-mesenchymal transition (EMT) of PC-3 prostate cancer cells in 2- and 3-dimensional cultures.
Plasma level of soluble urokinase plasminogen activator receptor (suPAR) predicts long-term mortality after first acute alcohol-induced pancreatitis.
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Plasmin-tumour necrosis factor interaction in the ovulatory process.
Plasminogen activation in human leukemia and in normal hematopoietic cells.
Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior.
Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues.
Plasminogen activator content of gynecological tumors and their metastases.
Plasminogen activator inhibitor (PAI) trap3, an exocellular peptide inhibitor of PAI-1, attenuates the rearrangement of F-actin and migration of cancer cells.
Plasminogen activator inhibitor 2 (PAI-2) is not inactivated by exposure to oxidants which can be released from activated neutrophils.
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v)beta(5) integrin.
Plasminogen activator inhibitor type 2 in breast cancer.
Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis.
Plasminogen activator inhibitor-1 in cancer research.
Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.
Plasminogen activator inhibitor-2 in patients with monocytic leukemia.
Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.
Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.
Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors.
Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine.
Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer.
Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells.
Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
Plasminogen activator/plasminogen activator inhibitor-1 and cytokine modulation by the PROACT System.
Plasminogen activators and plasmin in lung cancer.
Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid.
Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas.
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?
Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype.
Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas.
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
Plasminogen binding and cancer: promises and pitfalls.
Plasticity in Urokinase-Type Plasminogen Activator Receptor (uPAR) Display in Colon Cancer Yields Metastable Subpopulations Oscillating in Cell Surface uPAR Density--Implications in Tumor Progression.
PLAU Promotes Cell Proliferation and Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma.
Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
PLOD3 promotes lung metastasis via regulation of STAT3.
Polymer Nanoparticles Mediated Codelivery of AntimiR-10b and AntimiR-21 for Achieving Triple Negative Breast Cancer Therapy.
Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.
Polymorphonuclear cells stimulate the migration and metastatic potential of rat sarcoma cells.
Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system.
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Post-transcriptional regulation of urokinase plasminogen activator gene expression occurs in the nucleus of BC1 rat mammary tumor cells.
Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Preclinical evaluation of [(111) In]MICA-401, an activity-based probe for SPECT imaging of in vivo uPA activity.
Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2.
Predicting the sites of metastases from lung cancer using molecular biologic markers.
Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
Presence of Myofibroblasts and Expression of Matrix Metalloproteinase-2 (MMP-2) in Ameloblastomas Correlate with Rupture of the Osseous Cortical.
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance.
Prevention of intraperitoneal adhesions and abscesses by polysaccharides isolated from Phellinus spp in a rat peritonitis model.
Prevention of metastasis by inhibition of the urokinase receptor.
Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA).
Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.
Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: impact of endotoxin and tumor necrosis factor-alpha.
Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.
Probing inhibitors binding to human urokinase crystals by Raman microscopy: implications for compound screening.
Production of a urokinase plasminogen activator-IgG fusion protein (uPA-IgG) in the baculovirus expression system.
Production of an active urokinase by leukemia cells: a novel distinction from cell lines of solid tumors.
Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.
Production of recombinant lethal factor of Bacillus anthracis in Bacillus subtilis.
Profibrinolytic properties characterize a stably transformed human endothelial cell line.
Profiling the evolution of human metastatic bladder cancer.
Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction, and cardia evaluated by uPAR-immunohistochemistry.
Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma.
Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer.
Prognostic relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinoma.
Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer.
Prognostic role of urokinase-type plasminogen activator in human gliomas.
Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients.
Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.
Prognostic significance of proteolytic enzymes in human brain tumors.
Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Prognostic significance of uPA and uPAR expression in patients with cervical cancer undergoing radiotherapy.
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.
Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC).
Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.
Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma.
Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.
Prognostic value of urokinase plasminogen activator system in non-small cell lung cancer: A systematic review and meta-analysis.
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.
Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer.
Proliferation of a human epidermal tumor cell line stimulated by urokinase.
Properties of urokinase type-plasminogen activator found in chest fluid.
Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study.
Prophylaxis with urokinase in pediatric oncology patients with central venous catheters.
Prostaglandin E2 regulates tumor angiogenesis in prostate cancer.
Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.
Prostate-specific antigen activates single-chain urokinase-type plasminogen activator.
Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth.
Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion.
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Proteases and metastasis: clinical relevance nowadays?
Proteases as prognostic markers in cancer.
Proteases associated with gynecological tumors.
Proteases in brain tumour progression.
Proteases in gastrointestinal neoplastic diseases.
Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.
Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue.
Protein C inhibitor inhibits breast cancer cell growth, metastasis and angiogenesis independently of its protease inhibitory activity.
Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection.
Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB.
Protein kinase C is inhibited by bisphosphonates in prostate cancer PC-3 cells.
Protein Kinase C Synergistically Stimulates Tumor Necrosis Factor-alpha-Induced Secretion of Urokinase-Type Plasminogen Activator in Human Dental Pulp Cells.
Proteinases, their inhibitors, and cytokine profiles in acute wound fluid.
Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.
Proteolysis in human breast and colorectal cancer.
Proteolytic and cellular death mechanisms in ovulatory ovarian rupture.
Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy.
Proteolytic enzymes in proliferation and neoplastic metastases formation.
Proteolytic mechanisms in the ovulatory folliculo-luteal transformation.
Proteolytic networks in cancer.
Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy.
Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach.
Proteomics Reveals Cell-Surface Urokinase Plasminogen Activator Receptor Expression Impacts Most Hallmarks of Cancer.
Pulmonary epithelial cell urokinase-type plasminogen activator. Induction by interleukin-1 beta and tumor necrosis factor-alpha.
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay.
Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion.
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Quercetin Has Antimetastatic Effects on Gastric Cancer Cells via the Interruption of uPA/uPAR Function by Modulating NF-?b, PKC-?, ERK1/2, and AMPK?.
Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3).
Radioimmunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures.
Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor.
RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases.
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Rapid detection of urokinase plasminogen activator using flexible paper-based graphene-gold platform.
Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes.
Rationale for clinical trials of coagulation: reactive drugs in hepatocellular carcinoma.
Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite.
Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor.
Recent advances in the field of anti-cancer immunotherapy.
Receptor for plasmin on human carcinoma cells.
Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.
Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice.
Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.
Reduced gene expression of bikunin as a prognostic marker for renal cell carcinoma.
Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy.
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Reduction of tumor-associated fibrinolytic-activity by antimetastatic dosages of 2 ru(ii)-dmso complexes in mice bearing lewis lung-carcinoma.
Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.
Regulation by interleukin-3 of human monocyte pro-inflammatory mediators. Similarities with granulocyte-macrophage colony-stimulating factor.
Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding.
Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma.
Regulation of cell signalling by uPAR.
Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Regulation of DNA repair mechanism in human glioma xenograft cells both in vitro and in vivo in nude mice.
Regulation of fibrin deposition by malignant mesothelioma.
Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines.
Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1).
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Regulation of tumor dormancy and role of microenvironment: a mathematical model.
Regulation of u-PAR gene expression by H2A.Z is modulated by the MEK-ERK/AP-1 pathway.
Regulation of urokinase plasminogen activator (uPA) activity by E-cadherin and hormones in mammary epithelial cells.
Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo.
Regulation of Urokinase Production by Androgens in Human Prostate Cancer Cells: Effect on Tumor Growth and Metastases in Vivo1.
Regulation of urokinase receptor mRNA stability by hnRNP C in lung epithelial cells.
Regulation of urokinase-type plasminogen activator expression in squamous-cell carcinoma of the oral cavity.
Regulatory Mechanism of Collagen Degradation by Keratocytes and Corneal Inflammation: The Role of Urokinase-Type Plasminogen Activator.
Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells.
Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.
Relationship between expression of plasminogen activator system and metastatic ability in human cancers.
Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes.
Relationship between plasma levels of components of the fibrinolytic system and acute-phase reactants in patients with uterine malignancies.
Relationship between tumorigenicity, in vitro invasiveness, and plasminogen activator production of human breast cell lines.
Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer.
Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Reprogramming urokinase into an antibody-recruiting anticancer agent.
Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor.
Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Retinoic acid priming potentiates the induction of urokinase-type plasminogen activator by cyclic adenosine monophosphate in mouse mammary carcinoma cells.
Retinoids inhibit protein kinase C-dependent transduction of 1,2-diglyceride signals in human colonic tumor cells.
Retraction: Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.
Retraction: Small Interfering RNA-Directed Reversal of Urokinase Plasminogen Activator Demethylation Inhibits Prostate Tumor Growth and Metastasis.
Retraction: Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas.
Retroviral display of urokinase-binding domain fused to amphotropic envelope protein.
Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis.
Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling.
Review and update of the use of urokinase in the prevention and management of CVAD-related complications in pediatric oncology patients.
Revisiting the biological roles of PAI2 (SERPINB2) in cancer.
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis.
RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo.
RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth.
RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.
Role of DHX33 in c-Myc-induced cancers.
Role of epigenetics in cancer initiation and progression.
Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
ROLE OF PLASMINOGEN ACTIVATOR INHIBITOR-1 IN UROKINASE'S PARADOXICAL IN VIVO TUMOR SUPPRESSING OR PROMOTING EFFECTS.
Role of protein kinase C in tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator.
Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer.
Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.
Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies.
Role of urokinase in colorectal neoplasia.
Role of urokinase inhibitors in choroidal neovascularization.
Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer.
Role of urokinase plasminogen activator receptor in gastric cancer: a potential therapeutic target.
Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Role of urokinase receptor in tumor progression and development.
Role of urokinase-type plasminogen activator and inhibitory effect of protease inhibitor in invasion and metastasis of pancreatic cancer.
Roles of the ovarian surface epithelium in ovulation and carcinogenesis.
Safety, dosimetry and tumor detection ability of 68Ga-NOTA-AE105 - a novel radioligand for uPAR PET imaging: first-in-humans study.
Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.
Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA/NHE1 Active and Single Target-Selective Inhibitors.
Secreted proteases. Regulation of their activity and their possible role in metastasis.
Secretion of plasminogen activators by human colorectal and gastric tumor explants.
Secretion of urokinase and metalloproteinase-9 induced by staurosporine is dependent on a tyrosine kinase pathway in mammary tumor cells.
Selection criteria for epirubicin-based adjuvant chemotherapy in node-negative breast cancer.
Selective Growth Inhibition of Cancer Cells by L-Methioninase-Containing Fusion Protein Targeted to the Urokinase Receptor.
Selective targeting of 2'-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro.
Self-assembled chitosan polymer intercalating peptide functionalized gold nanoparticles as nanoprobe for efficient imaging of urokinase plasminogen activator receptor in cancer diagnostics.
Self-Reported Fatigue Common among Optimally Treated HIV Patients: No Correlation with Cerebral FDG-PET Scanning Abnormalities.
Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
Separation, purification and N-terminal sequence analysis of a novel leupeptin-sensitive serine endopeptidase present in chemically induced rat mammary tumour.
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China.
Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin.
Serpins for diagnosis and therapy in cancer.
Serum biomarkers in the diagnosis of periprosthetic joint infection: consolidated evidence and recent developments.
Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers.
Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy.
Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma.
Signal transduction-mediated regulation of urokinase gene expression in human prostate cancer.
Signaling pathways responsible for cancer cell invasion as targets for cancer therapy.
Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with {beta}1 integrins.
Significant association of urokinase plasminogen activator Pro141Leu with serum lipid profiles in a Japanese population.
Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction.
Silencing of Growth Differentiation Factor-15 Promotes Breast Cancer Cell Invasion by Down-regulating Focal Adhesion Genes.
Silencing of uPAR via RNA interference inhibits invasion and migration of oral tongue squamous cell carcinoma.
Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.
Simultaneous downregulation of uPAR and MMP-9 induces overexpression of the FADD-associated protein RIP and activates caspase 9-mediated apoptosis in gliomas.
Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors.
Single-chain, urokinase-type plasminogen activator in a tumor model linked to metastatic potential.
siRNA-mediated downregulation of MMP-9 and uPAR in combination with radiation induces G2/M cell-cycle arrest in Medulloblastoma.
siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells.
Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta.
Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis.
Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
Smoking-induced changes in cancer-related factors in patients with upper tract urothelial cancer.
Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid.
Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cells.
Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.
Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis.
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations are Elevated in Patients with Neuroendocrine Malignancies.
Soluble urokinase plasminogen activator receptor (suPAR) is lower in disease-free patients but cannot rule out incident disease in patients with suspected cancer.
Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening.
Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population.
Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease.
Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.
Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study.
Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report.
Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia.
Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling.
Species specificity of amidine-based urokinase inhibitors.
Specific immunofluorimetric assay detecting the chemotactic epitope of the urokinase receptor (uPAR).
Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas.
Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.
SPRY1 promotes the degradation of uPAR and inhibits uPAR-mediated cell adhesion and proliferation.
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
Stable antisense RNA expression neutralizes the activity of low-density lipoprotein receptor-related protein and promotes urokinase accumulation in the medium of an astrocytic tumor cell line.
Stable expression of antisense urokinase mRNA inhibits the proliferation and invasion of human hepatocellular carcinoma cells.
Staurosporine stimulates expression of the urokinase-type (u-PA) plasminogen activator in LLC-PK1 cells.
Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules.
Stromal cell-derived factor-1/CXC receptor 4 and b1 integrin interaction regulates urokinase-type plasminogen activator expression in human colorectal cancer cells.
Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect.
Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression.
Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.
Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
Structural modification of protease inducible preprogrammed nanofiber precursor.
Structure and function analysis of urinary trypsin inhibitor (UTI): identification of binding domains and signaling property of UTI by analysis of truncated proteins.
Structure of human urokinase plasminogen activator in complex with its receptor.
Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis.
Structure-based design, synthesis and SAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors.
Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy.
Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite.
Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist.
Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.
Studies of possible mechanisms for the effect of urokinase therapy in small cell carcinoma of the lung.
Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy.
Subpopulations of uPAR(+) contribute to vasculogenic mimicry and metastasis in large cell lung cancer.
Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation.
suPAR, a soluble form of urokinase plasminogen activator receptor, inhibits human prostate cancer cell growth and invasion.
Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences.
Suppression of hepatocarcinoma model in vitro and in vivo by ECRG2 delivery using adenoviral vector.
Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin.
Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor.
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428.
Suppression of tumor growth and invasion in 9,10 dimethyl benz(a) anthracene induced mammary carcinoma by the plant bioflavonoid quercetin.
Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.
Suppression of urokinase expression and tumor metastasis by bikunin overexpression [mini-review].
Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade.
Suppression of Urokinase-Type Plasminogen Activator Receptor by Docosahexaenoic Acid Mediated by Heme Oxygenase-1 in 12-O-Tetradecanoylphorbol-13-Acetate-Induced Human Endothelial Cells.
Suppressive effects of a proton beam on tumor growth and lung metastasis through the inhibition of metastatic gene expression in 4T1 orthotopic breast cancer model.
Surgical treatment of tumor metastases: general considerations and results.
SV40 T/t-common polypeptide inhibits angiogenesis and growth of HER2-overexpressing human ovarian cancer.
Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth.
Synergistic inhibitory effects of an engineered antibody-like molecule ATF-Fc and trastuzumab on tumor growth and invasion in a human breast cancer xenograft mouse model.
Synthesis and Characterization of an (111)In-Labeled Peptide for the in Vivo Localization of Human Cancers Expressing the Urokinase-Type Plasminogen Activator Receptor (uPAR).
Synthesis and in vivo preclinical evaluation of an (18)F labeled uPA inhibitor as a potential PET imaging agent.
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Synthetic urokinase inhibitors as potential anti-invasive drugs.
Synthetic urokinase inhibitors as potential antitumor drugs.
Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
Systemic administration of anti-urokinase plasminogen activator receptor monoclonal antibodies induces hepatic fibrin deposition in tissue-type plasminogen activator deficient mice.
Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029.
T1 breast cancer: identification of patients at low risk of axillary lymph node metastases.
Targeted Delivery with Imaging Assessment of siRNA Expressing Nanocassettes into Cancer.
Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis.
Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin.
Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation.
Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells.
Targeting of the ?6 gene to suppress degradation of ECM via inactivation of the MAPK pathway in breast adenocarcinoma cells.
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.
Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.
Targeting the urokinase plasminogen activator receptor with synthetic self-assembly nanoparticles.
Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.
Targeting uPA/uPAR in prostate cancer.
Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance.
Targeting urokinase and the transferrin receptor with novel, anti-mitotic N-alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growth.
Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.
Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
TGF-?-mediated regulation of plasminogen activators is human telomerase reverse transcriptase dependent in cancer cells.
The anti-tumoral potential of the saporin-based uPAR-targeting chimera ATF-SAP.
The Apparent uPA/PAI-1 Paradox in Cancer: More than Meets the Eye.
The Association between Plasma Levels of Intact and Cleaved uPAR Levels and the Risk of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer.
The Associations of Plasma Biomarkers of Inflammation With Histopathologic Lesions, Kidney Disease Progression, and Mortality-The Boston Kidney Biopsy Cohort Study.
The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer.
The complete recanalization of PICC-related venous thrombosis in cancer patients: A series of case reports.
The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.
The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.
The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.
The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors.
The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer.
The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer.
The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.
The effect of EGFR-related tyrosine kinase activity inhibition on the growth and invasion mechanisms of prostate carcinoma cell lines.
The effect of essential fatty acids on growth and urokinase-type plasminogen activator production in human prostate DU-145 cells.
The effect of gamma-linolenic acid and eicosapentaenoic acid on urokinase activity.
The effect of platelets on invasiveness and protease production of human mammary tumor cells.
The effect of polysaccharides and carboxymethylcellulose combination to prevent intraperitoneal adhesion and abscess formation in a rat peritonitis model.
The effect of thrombospondin on invasion of fibrin gels by human A549 lung carcinoma.
The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.
The effect of TNP-470 on cell proliferation and urokinase-type plasminogen activator and its inhibitor in human lung cancer cell lines.
The effects of amino-acid mutations on specific interactions between urokinase-type plasminogen activator and its receptor: Ab initio molecular orbital calculations.
The expression of urokinase type plasminogen activator is a novel prognostic factor in dukes B and C colorectal cancer.
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice.
The importance of selected markers of inflammation and blood-brain barrier damage for short-term ischemic stroke prognosis.
The influence of opioid peptides on matrix metalloproteinase-9 and urokinase plasminogen activator expression in three cancer cell lines.
The influence of opioids on urokinase plasminogen activator on protein and mRNA level in MCF-7 breast cancer cell line.
The interaction between urokinase receptor and vitronectin in cell adhesion and signalling.
The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase.
The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer.
The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy.
The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target.
The p38 SAPK pathway is required for Ha-ras induced in vitro invasion of NIH3T3 cells.
The plasmin system in human colonic tumors: an immunofluorescence study.
The plasminogen activation system and its role in lung cancer. A review.
The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.
The plasminogen activation system in melanoma cell lines and in melanocytic lesions.
The plasminogen activator inhibitor "paradox" in cancer.
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.
The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
The Plasminogen System in Microdissected Colonic Mucosa Distant from an Isolated Adenoma.
The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis.
The possible role of angiogenesis in the metastatic potential of human melanoma. Clinicopathological aspects.
The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer.
The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer.
The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia.
The prognostic value of BCAR1 in patients with primary breast cancer.
The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer.
The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease.
The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).
The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer.
The protease inhibitor bikunin, a novel anti-metastatic agent.
The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style.
The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor.
The relationship of plasminogen activators and oncogenes to tumour invasion.
The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis.
The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model.
The role of Ly49E receptor expression on murine intraepithelial lymphocytes in intestinal cancer development and progression.
The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells.
The Role of Urokinase, Tumor Necrosis Factor, and Matrix Metalloproteinase-9 in Monocyte Activation.
The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer.
The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.
The Root Extract of Gentiana macrophylla Pall. Alleviates B19-NS1-Exacerbated Liver Injuries in NZB/W F1 Mice.
The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface.
The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products.
The uPA/uPA receptor system as a target for tumor therapy.
The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice.
The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
The urokinase plasminogen activator binding to its receptor: a quantum biochemistry description within an in/homogeneous dielectric function framework with application to uPA-uPAR peptide inhibitors.
The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer.
The urokinase plasminogen activator receptor as a gene therapy target for cancer.
The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer.
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.
The urokinase plasminogen activator system in breast cancer invasion and metastasis.
The urokinase plasminogen activator system in cancer: a putative therapeutic target?
The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis.
The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.
The Urokinase Plasminogen Activator System in Human Cancers: An Overview of Its Prognostic and Predictive Role.
The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
The urokinase plasminogen activator system: role in malignancy.
The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?
The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction.
The urokinase receptor and integrins in cancer progression.
The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition.
The urokinase receptor as a potential target in cancer therapy.
The urokinase receptor as an entertainer of signal transduction.
The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres.
The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.
The Urokinase Receptor Supports Tumorigenesis of Human Malignant Pleural Mesothelioma Cells.
The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications.
The urokinase receptor: involvement in cell surface proteolysis and cancer invasion.
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
The urokinase type of plasminogen activator in cancer of digestive tracts.
The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
The urokinase-system--role of cell proliferation and apoptosis.
The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies.
The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
The urokinase-type plasminogen activator system in cancer and other pathological conditions: introduction and perspective.
The urokinase-type plasminogen activator system in cancer metastasis: a review.
The urokinase-type plasminogen activator system in prostate cancer metastasis.
The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group.
The use of a uPAR-targeted probe for photothermal cancer therapy prolongs survival in a xenograft mouse model of glioblastoma.
Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.
Three types of human lung tumour cell lines can be distinguished according to surface expression of endogenous urokinase and their capacity to bind exogenous urokinase.
Three-dimensional type I collagen gel system containing MG-63 osteoblasts-like cells as a model for studying local bone reaction caused by metastatic cancer cells.
Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.
Thrombospondin-2 inhibits tumor cell invasion through the modulation of MMP-9 and uPA in pancreatic cancer cells.
Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
Tissue extraction procedures for investigation of urokinase plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in human breast carcinomas.
Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer.
Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator.
Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients.
Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
TMPRSS4 induces cancer cell invasion through pro-uPA processing.
TMPRSS4 upregulates uPA gene expression through JNK signaling activation to induce cancer cell invasion.
TMPRSS4: an emerging potential therapeutic target in cancer.
Toxicodendron vernicifluum Stokes extract inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice.
Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator protein-2alpha-related factor.
Transcatheter thrombolysis in cancer patients.
Transcription factor PEA3 participates in the induction of urokinase plasminogen activator transcription in murine keratinocytes stimulated with epidermal growth factor or phorbol-ester.
Transcriptional activation of the urokinase receptor gene in invasive colon cancer.
Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.
Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells.
Transcriptional complexity and roles of Fra-1/AP-1 at the uPA/Plau locus in aggressive breast cancer.
Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation.
Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.
Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells.
Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa.
Transforming growth factor-?, matrix metalloproteinases, and urokinase-type plasminogen activator interaction in the cancer epithelial to mesenchymal transition.
Transforming growth factor-beta 1, beta 2, and beta 3, urokinase and parathyroid hormone-related peptide expression in 8701-BC breast cancer cells and clones.
Transforming Growth Factor-Beta and Urokinase Type Plasminogen Interplay in Cancer.
Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.
Transforming Growth Factor-Beta Signaling Leads to uPA/PAI-1 Activation and Metastasis: A Study on Human Breast Cancer Tissues.
Transforming growth factor-beta stimulates urokinase expression in tumor-associated macrophages of the breast.
Transforming growth factor-beta1-dependent activation of Smad2/3 and up-regulation of PAI-1 expression is negatively regulated by Src in SKOV-3 human ovarian cancer cells.
Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells.
Translational research on u-PAR.
Triclosan inhibits tumor necrosis factor-alpha-stimulated urokinase production in human gingival fibroblasts.
Triptolide inhibits tumor promoter-induced uPAR expression via blocking NF-kappaB signaling in human gastric AGS cells.
Tristetraprolin: A novel target of diallyl disulfide that inhibits the progression of breast cancer.
Tspan9 inhibits the proliferation, migration and invasion of human gastric cancer SGC7901 cells via the ERK1/2 pathway.
Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.
Tumor cell surface-associated binding site for the M(r) 72,000 type IV collagenase.
Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells.
Tumor cell-expressed SerpinB2 is present on microparticles and inhibits metastasis.
Tumor cells secrete an angiogenic factor that stimulates basic fibroblast growth factor and urokinase expression in vascular endothelial cells.
Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling.
Tumor growth inhibition mediated by trypsin inhibitor or urokinase inhibitors.
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
Tumor necrosis factor ? stimulates expression and secretion of urokinase plasminogen activator in human dental pulp cells.
Tumor necrosis factor alpha, CYP 17, urokinase, and interleukin 10 gene polymorphisms in postmenopausal women: correlation to bone mineral density and susceptibility to osteoporosis.
Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells.
Tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by gamma-interferon.
Tumor necrosis factor induction of urokinase-type plasminogen activator in human endothelial cells.
Tumor necrosis factor regulation of endothelial cell extracellular proteolysis: the role of urokinase plasminogen activator.
Tumor necrosis factor stimulates urokinase-type plasminogen activator and inhibitor type 1 production in A549 lung carcinoma cells: treatment of monolayer and tridimensional cultures.
Tumor necrosis factor-alpha regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines.
Tumor necrosis factor-alpha stimulates the biosynthesis of matrix metalloproteinases and plasminogen activator in cultured human chorionic cells.
Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells: molecular basis linking ovulation and cancer risk.
Tumor promoter PMA stimulates the synthesis and secretion of mouse pro-urokinase in MSV-transformed 3T3 cells: this is mediated by an increase in urokinase mRNA content.
Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors.
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer.
Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.
Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.
Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
Tumor-associated soluble uPAR-directed endothelial cell motility and tumor angiogenesis.
Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.
Tumor-associated urokinase-type plasminogen activator: significance in breast cancer.
Tumoral and macrophage uPAR and MMP-9 contribute to the invasiveness of B16 murine melanoma cells.
Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer.
Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor.
Tumour cell u-PA as a cause of fibrinolytic bleeding in metastatic disease.
Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes.
Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1.
u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression.
Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator.
Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene.
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
uPA and uPA-receptor are involved in cancer-associated myeloid-derived suppressor cell accumulation.
uPA and uPAR contribute to NK cell invasion through the extracellular matrix.
uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer.
uPA receptor expression in benign and malignant thyroid tumors.
uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
uPA/PAI-1 ratios distinguish benign prostatic hyperplasia and prostate cancer.
uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo.
uPAR and cathepsin B inhibition enhanced radiation-induced apoptosis in gliomainitiating cells.
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.
uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions.
uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.
uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line.
uPAR induces expression of transforming growth factor ? and interleukin-4 in cancer cells to promote tumor-permissive conditioning of macrophages.
uPAR Knockout Results in a Deep Glycolytic and OXPHOS Reprogramming in Melanoma and Colon Carcinoma Cell Lines.
uPAR peptide antagonist alters regulation of MAP kinases and Bcl-2 family members in favor of apoptosis in MDA-MB-231 cell line.
uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180.
uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors.
uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
uPAR-deficient mouse keratinocytes fail to produce EGFR-dependent laminin-5, affecting migration in vivo and in vitro.
uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery.
uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection.
Upper tract urokinase instillation for nephrostomy tube patency.
Upregulation of circulating cytokeratin 20, urokinase plasminogen activator and C-reactive protein is associated with poor prognosis in gastric cancer.
Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice.
Urinary trypsin inhibitor efficiently inhibits urokinase production in tumor necrosis factor-stimulated cells.
Urokinase (u-PA) and the u-PA receptor. Modulation of in vitro invasiveness of human bladder cancer cell lines.
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
Urokinase activity in corneal fibroblasts may be modulated by DNA damage and secreted proteins.
Urokinase and macrophages in tumour angiogenesis.
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors.
Urokinase and tissue plasminogen activators and their PAI-1 inhibitor in tumors of patients with oral mucosal cancer: relationship with the main clinical morphological factors.
Urokinase and type I plasminogen activator inhibitor production by normal human hepatocytes: modulation by inflammatory agents.
Urokinase Exerts Antimetastatic Effects by Dissociating Clusters of Circulating Tumor Cells-Letter.
Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells.
Urokinase expression by tumor suppressor protein p53: a novel role in mRNA turnover.
Urokinase expression in course of benign and malignant mammary lesions: comparison between nodular and healthy tissues.
Urokinase expression in mononuclear phagocytes: cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha.
Urokinase gene 3'-UTR T/C polymorphism is associated with malignancy and ESRD in idiopathic membranous nephropathy.
Urokinase gene 3'-UTR T/C polymorphism is associated with oral cancer.
Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer.
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.
Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer.
Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer.
Urokinase plasminogen activator expression by primary and HPV 16-transformed keratinocytes.
Urokinase plasminogen activator in ovarian cancer.
Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer.
Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain.
Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer.
Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.
Urokinase Plasminogen Activator Receptor (uPAR): A Potential Indicator of Invasion for In Situ Breast Cancer.
Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy.
Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma.
Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes.
Urokinase Plasminogen Activator Receptor-Mediated Targeting of a Stable Nanocomplex Coupled with Specific Peptides for Imaging of Cancer.
Urokinase Plasminogen Activator Receptor-PET with (68)Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand.
Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer.
Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma.
Urokinase plasminogen activator system as a potential target for cancer therapy.
Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay.
Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease.
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy.
Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice.
Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth.
Urokinase receptor antagonists: novel agents for the treatment of cancer.
Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer.
Urokinase receptor deficiency results in EGFR-mediated failure to transmit signals for cell survival and neurite formation in mouse neuroblastoma cells.
Urokinase receptor expression is upregulated by cell culture sparsity in breast cancer cell line BT-20.
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.
Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis.
Urokinase receptor is a key player in tumour progression.
Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression.
Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598.
Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.
Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells.
Urokinase receptor mRNA stability involves tyrosine phosphorylation in lung epithelial cells.
Urokinase Receptor Promotes Skin Tumor Formation by Preventing Epithelial Cell Activation of Notch1.
Urokinase receptor up-regulation in head and neck squamous cell carcinoma.
Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells.
Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells.
Urokinase receptors in lung cancer and normal lung.
Urokinase secretion from human colon carcinomas induced by endogenous diglycerides.
Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels.
Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines.
Urokinase type plasminogen activator and the molecular mechanisms of its regulation in cancer.
Urokinase type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor 2 (HER2) expression in metastasis of breast cancer.
Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer.
Urokinase type plasminogen activator receptor expression in colorectal neoplasms.
Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.
Urokinase-dependent cell surface proteolysis and cancer.
Urokinase-dependent human vascular smooth muscle cell adhesion requires selective vitronectin phosphorylation by ectoprotein kinase CK2.
Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid.
Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec.
Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay.
Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.
Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas.
Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo.
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK).
Urokinase-type plasminogen activator activity increases during the growth of two murine mammary adenocarcinomas with different metastasizing abilities.
Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.
Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression.
Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.
Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
Urokinase-type plasminogen activator expression in human prostate carcinomas.
Urokinase-type plasminogen activator in carcinomatous pleural fluid.
Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.
Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells.
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction.
Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications.
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.
Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.
Urokinase-type plasminogen activator receptor (uPAR)-mediated regulation of WNT/?-catenin signaling is enhanced in irradiated medulloblastoma cells.
Urokinase-type plasminogen activator receptor expression in adenoid cystic carcinoma of the skull base.
Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models.
Urokinase-type plasminogen activator regulates neurodegeneration and neurogenesis but not vascular changes in the mouse hippocampus after status epilepticus.
Urokinase-type plasminogen activator resulting from endometrial carcinogenesis enhances tumor invasion and correlates with poor outcome of endometrial carcinoma patients.
Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor.
Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers.
Urokinase-type-plasminogen-activator (uPA) production by human breast (myo) fibroblasts in vitro: influence of transforming growth factor-beta(1) (TGF beta(1)) compared with factor(s) released by human epithelial-carcinoma cells.
Use of urokinase in pediatric hematology/oncology patients.
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.
Uterine fibrinolytic enzymes in endometrial cancer.
Utility of Serum and Urine uPAR Levels for Diagnosis of Breast Cancer.
Vasodilator-Stimulated Phosphoprotein (VASP) depletion from breast cancer MDA-MB-231 cells inhibits tumor spheroid invasion through downregulation of Migfilin, ?-catenin and urokinase-plasminogen activator (uPA).
Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines.
Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells.
Weight loss is superior to exercise in improving the atherogenic lipid profile in a sedentary, overweight population with stable coronary artery disease: A randomized trial.
Whole genome expression analysis for biologic rational pathway modeling: application in cancer prognosis and therapy prediction.
Zinc phthalocyanine conjugated with the amino-terminal fragment of urokinase for tumor-targeting photodynamic therapy.
[Antisense inhibition of urokinase in a human osteosarcoma cell line]
[Assay and detection methods for urokinase-type plasminogen activator and its related-factors]
[Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma]
[Autocrine-generated matrix metalloproteinases of tumor cells and the cascade network of protease activation mediated by membrane associated urokinase-type plasminogen activator: involvement in the degradation of extracellular matrices]
[Cell phenotype determines PAI-1 antiproliferative effect - suppressed proliferation of the lung cancer but not prostate cancer cells]
[Correlation between the expression of urokinase-type plasminogen activator, E-cadherin and malignancy in gastric cancer]
[Correlation of p38 mitogen-activated protein kinase signal transduction pathway to uPA expression in breast cancer]
[Effect of inhalation of aerosolized unfractioned heparin on peri alveolar coagulability and inflammatory response in endotoxin induced acute lung injury rat model.]
[Effect of urokinase on the tumor blood flow studied by Xenon-133 method (author's transl)]
[Effects of urokinase on the transfer of 1-hexylcarbamoyl-5-fluorouracil (HCFU) into the blood, bile and pancreatic juice]
[Endothelial cell proteases and their modulation by platelets]
[Establishment of urokinase receptor gene antisense RNA transfer system and its application in leukemia research]
[Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients]
[Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer]
[Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone]
[Fibrin deposition and fibrinolysis in the pathogenesis of pulmonary fibrosis]
[Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients]
[Immunohistochemical evidences of prognostic parameters associated with tumor development of pulmonary adenocarcinoma]
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[Increase of cellular fibrinolysis in human lung cancer cell line by radiation: relationship between urokinase-type plasminogen activator (uPA) and metastasis and invasion]
[Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis]
[Modern prospects for molecular-biochemical methods for evaluating biological "behavior" of breast neoplasms]
[Molecular mechanism of liver metastasis from colorectal cancer]
[Molecular pathways of pancreatic carcinogenesis]
[Molecular structure of the receptor for urokinase plasminogen activator and its physiological modulation of a tumor cell line]
[New molecular targets in pancreatic cancer]
[Plasminogen activator system and its clinical significance in patients with a malignant disease].
[Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases]
[Prognostic factors and therapeutic strategy of breast cancer]
[Prognostic factors in carcinoma of the breast. Thereupon depends success of the treatment]
[Prognostic implications of biologic markers in intracranial meningiomas: 120 cases]
[Prognostic role of cisteine and serin proteases in gastriC cancer]
[Prognostic value of immunohistochemical determination of urokinase plasminogen activator in primary breast cancers]
[Regulation of angiogenesis and tumor growth]
[Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis]
[Significance in gene expression of matrix metalloproteinase-9, urokinase-type plasminogen activator and tissue inhibitor of metalloproteinase for metastases of gastric and/or colo-rectal cancer]
[Significance of urokinase and its inhibitors in the invasiveness and metastasing of malignant tumors].
[Study on cases of D dimer values were dissociated from FDP-E]
[Test for urokinase-type plasminogen activator inhibitor of edible plants in vitro]
[The clinical prospects for the study of the plasminogen activation system in breast cancer]
[The expression of urokinase-type plasminogen activator in oral squamous cell carcinoma]
[The location of components of fibrinolytic system in laryngeal cancer]
[The urokinase-type plasminogen activator system and its role in tumor progression].
[Tumor affinity of 99mTc-labeled radiopharmaceuticals, 99mTc-Sn-urokinase and 99mTc-Sn-mannitol]
[Tumor metastasis and the fibrinolytic system]
[uPA expression of gastric cancer cell lines and its correlation with peritoneal seeding]
[Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer]
[Urokinase plasminogen activation system and its role in cancer progression]
[Urokinase plasminogen activator /U-PA/in blood of patients with lung cancer]
[Urokinase-type plasminogen activator (uPA) and its inhibitor--new prognostic factors in oral squamous cell carcinoma]
[Urokinase-type plasminogen activator (uPA), uPA receptor (uPA-R) and inhibitors (PA I -1) expression in hepatocellular carcinoma in relation to cancer invasion/metastasis and prognosis]
[Urokinase-type plasminogen activator antigen as a prognostic factor in bladder cancer]
[Urokinase-type plasminogen activator as a predictor for lymph nodes metastasis of uterine cervical cancer]
[Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma]
Neoplasms, Germ Cell and Embryonal
A personalized approach to cancer treatment: how biomarkers can help.
Evidence for the clinical use of tumour markers.
Neoplasms, Squamous Cell
Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Neoplastic Cells, Circulating
Molecular interactions in cancer cell metastasis.
Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells.
Nephritis
Analysis of urinary and circulating FDP subfragments and subunits: application of the western-blot technique.
Comparative effects of heparin, urokinase, and ancrod on intraglomerular coagulation induced in progressive Masugi nephritis.
Effect of the nephritogenic autoantibody of Heymann's nephritis on plasminogen-binding to gp330 and activation by urokinase.
Effects of fibrinolytic treatment on rabbit Masugi nephritis.
Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study.
Efficacy of methylprednisolone and urokinase pulse therapy for severe Henoch-Schönlein nephritis.
Induction of urokinase receptor expression in nephrotoxic nephritis.
Methylprednisolone pulse plus mizoribine in children with Henoch-Schoenlein purpura nephritis.
Pathological improvement of IgA nephropathy and Henoch-Schönlein purpura nephritis with urokinase therapy.
Successful therapy with tonsillectomy for severe ISKDC grade VI Henoch-Schönlein purpura nephritis and persistent nephrotic syndrome.
Therapy for children with henoch-schonlein purpura nephritis: a systematic review.
[A role of fibrin deposits in the development of rabbit Masugi nephritis and effect of urokinase on the experimental glomerulonephritis (author's transl)]
[Combined use of heparin and urokinase in the patients with nephritis resistant to the conventional treatment and the significance of alpha 2-plasmin inhibitor in the therapy (author's transl)]
[Comparative effects of ancrod, urokinase and heparin on intraglomerular coagulation induced by progressive Masugi nephritis (author's transl)]
[Effect of urokinase on renal structure and function in experimental immune nephritis]
[Fibrin deposits in Masugi nephritis and effects of urokinase, non-steroidal anti-inflammatory agents, anti-inflammatory enzymes and prostaglandins]
[Functional state of the kidneys in experimental immune nephritis during the use of heparin, urokinase and uroplasmin]
[Significance of the markers of endothelial dysfunction and hemorheological disorders for assessing the activity and prognosis of chronic glomerulonephritis]
[State of the thrombin-plasmin system in nephrotoxic nephritis treated with heparin, urokinase, and uroplasmin]
Nephritis, Interstitial
[The fibrinolytic system in uric acid dysmetabolism]
Nephrolithiasis
Association of urokinase gene 3'-UTR polymorphism with calcium oxalate nephrolithiasis.
[Urinary urokinase and blood fibrinolytic activity in patients with nephrolithiasis and other urinary tract diseases]
Nephrosis, Lipoid
CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
CD80, suPAR and Nephrotic Syndrome in a case of NPHS2 mutation.
Circulating Permeability Factors in Idiopathic Nephrotic Syndrome and Focal Segmental Glomerulosclerosis.
Nephrotic syndrome complicated with portal, splenic, and superior mesenteric vein thrombosis.
Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis.
Urokinase treatment of pulmonary artery thrombosis complicating the pediatric nephrotic syndrome.
Nephrotic Syndrome
Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.
CD80, suPAR and Nephrotic Syndrome in a case of NPHS2 mutation.
Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.
Circulating Permeability Factors in Idiopathic Nephrotic Syndrome and Focal Segmental Glomerulosclerosis.
Clinical significance of serum and urinary soluble urokinase receptor (suPAR) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese.
Evaluation of serum soluble urokinase plasminogen activator receptor as a marker for steroid-responsiveness in children with primary nephrotic syndrome.
Hemostatic abnormalities in nephrotic syndrome.
High dose urokinase against massive pulmonary embolism in nephrotic syndrome.
Plasmin in nephrotic urine activates the epithelial sodium channel.
Plasminogen activator in nephrotic syndrome.
Regulation of sodium transport by ENaC in the kidney.
Relationship between soluble urokinase-type plasminogen activator receptor and serum biomarkers of endothelial activation in patients with idiopathic nephrotic syndrome.
Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children.
Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.
Simultaneous renal arterial and venous thrombosis associated with idiopathic nephrotic syndrome: treatment with intra-arterial urokinase.
Successful therapy with tonsillectomy for severe ISKDC grade VI Henoch-Schönlein purpura nephritis and persistent nephrotic syndrome.
The clinical pattern of nephrotic syndrome in children has no effect on the concentration of soluble urokinase receptor (suPAR) in serum and urine.
The glomerular permeability factors in idiopathic nephrotic syndrome.
Urokinase and AT-III concentrate treatment in inferior vena cava thrombosis associated with nephrotic syndrome.
Urokinase treatment of pulmonary artery thrombosis complicating the pediatric nephrotic syndrome.
Urokinase-type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)-mediated sodium retention in experimental nephrotic syndrome.
[A study on the urokinase treatment in patients with glomerulonephritis and nephrotic syndrome]
[Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome].
[Effect of urokinase therapy in patients with glomerulonephritis and nephrotic syndrome. Trial at multiple institutes in Japan]
[Nephrotic syndrome complicated with intracranial venous thrombosis treated with urokinase: report of 5 cases]
[Primary nephrotic syndrome treated with urokinase--a report of 20 cases]
[Successful lysis therapy in acute unilateral renal vein thrombosis]
Nervous System Diseases
[Intra-arterial fibrinolysis in acute thrombosis of the basilar artery]
Nervous System Neoplasms
Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms.
Neuralgia
Induction of plasminogen activator inhibitor-1 and -2 in dorsal root ganglion neurons after peripheral nerve injury.
Neuroblastoma
Changes in gene expression of kringle domain-containing proteins in murine brains and neuroblastoma cells infected by prions.
Characterization and partial purification of the plasminogen activator from human neuroblastoma cell line, SK-N-SH. A comparison with human urokinase.
CRISPR/Cas9 nickase mediated targeting of urokinase receptor gene inhibits neuroblastoma cell proliferation.
Downregulation of uPAR promotes urokinase translocation into the nucleus and epithelial to mesenchymal transition in neuroblastoma.
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis.
Urokinase receptor deficiency results in EGFR-mediated failure to transmit signals for cell survival and neurite formation in mouse neuroblastoma cells.
Neurodegenerative Diseases
Organization of GPI-anchored proteins at the cell surface and its physiopathological relevance.
Neuroinflammatory Diseases
Suppression of PKC-? attenuates TNF-?-evoked cerebral barrier breakdown via regulations of MMP-2 and plasminogen-plasmin system.
The fibrinolytic system: A new target for treatment of depression with psychedelics.
Neurologic Manifestations
Effects of Intra-arterial Urokinase on a Non-human Primate Thromboembolic Stroke Model.
The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.
Twist drill craniostomy for traumatic acute subdural hematoma in the elderly: case series and literature review.
Neurosyphilis
Cytokines in cerebrospinal fluid of neurosyphilis patients: Identification of Urokinase plasminogen activator using antibody microarrays.
Nevus
[Histochemical studies of transepidermal elimination of nevus cells in nevus cell nevi of the corium]
Nevus, Blue
Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Non-alcoholic Fatty Liver Disease
Changes in the levels of endothelium-derived coagulation parameters in nonalcoholic fatty liver disease.
Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.
Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease.
Non-ST Elevated Myocardial Infarction
Multibiomarker analysis in patients with acute myocardial infarction.
Obesity
A superactive leptin antagonist alters metabolism and locomotion in high leptin mice.
Association analyses of porcine SERPINE1 reveal sex-specific effects on muscling, growth, fat accretion and meat quality.
Influence of t-pA and u-PA on adipose tissue development in a murine model of diet-induced obesity.
Inhibition of Plasminogen Activator Inhibitor-1 Activation Suppresses High Fat Diet-Induced Weight Gain via Alleviation of Hypothalamic Leptin Resistance.
Plasma levels of soluble urokinase plasminogen activator receptor (suPAR) and high-sensitivity C-reactive protein after Roux-en-Y gastric bypass or sleeve gastrectomy: a 1-year prospective observational study.
Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss.
Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity.
Odontogenic Tumors
Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
Osteoarthritis
Antisense targeting of the urokinase receptor blocks urokinase-dependent proliferation, chemoinvasion, and chemotaxis of human synovial cells and chondrocytes in vitro.
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Construction and verification of the targeted uPA-shRNA lentiviral vector and evaluation of the transfection and silencing rate.
Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.
Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues.
Effects of different molecular weight hyaluronan products on the expression of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis.
Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
Establishment of a rat model of lumbar facet joint osteoarthritis using intraarticular injection of urinary plasminogen activator.
Expression of stromelysin and urokinase type plasminogen activator protein in resection specimens and biopsies at different stages of osteoarthritis of the knee.
Expression of the urokinase-type plasminogen activator receptor in human articular chondrocytes: association with caveolin and beta 1-integrin.
Glucosamine sulfate suppresses the expressions of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis.
Increased proteolytic activity on the surface of monocytes from patients with rheumatoid arthritis.
Interleukin-1beta-induced expression of the urokinase-type plasminogen activator receptor and its co-localization with MMPs in human articular chondrocytes.
Naproxen, meloxicam and methylprednisolone inhibit urokinase plasminogen activator and inhibitor and gelatinases expression during the early stage of osteoarthritis.
Significance of serine proteinase and matrix metalloproteinase systems in the destruction of human articular cartilage.
Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts.
Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis.
Urokinase plasminogen activator system in synovial fibroblasts from osteoarthritis patients: modulation by inflammatory mediators and neuropeptides.
Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Variation patterns of two degradation enzyme systems in articular cartilage in different stages of osteoarthritis: regulation by dehydroepiandrosterone.
[Expression of urokinase-type plasminogen activator and its receptor protein in synovial tissues from osteoarthritis]
[Levels of matrix metalloproteinase-3 and urokinase-type plasminogen activator in knee synovial fluids from patients with rheumatoid arthritis and osteoarthritis]
[Study of molecular mechanisms of fuyuan capsule, icariin and arasaponin R1 in treatment of osteoarthritis].
Osteoarthritis, Knee
Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans.
Expression of stromelysin and urokinase type plasminogen activator protein in resection specimens and biopsies at different stages of osteoarthritis of the knee.
Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis.
Osteomyelitis
The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine.
Osteoporosis
Tumor necrosis factor alpha, CYP 17, urokinase, and interleukin 10 gene polymorphisms in postmenopausal women: correlation to bone mineral density and susceptibility to osteoporosis.
Osteosarcoma
Antisense inhibition of urokinase: effect on malignancy in a human osteosarcoma cell line.
Binding and activation of plasminogen on the surface of osteosarcoma cells.
Dihydromyricetin suppresses cell metastasis in human osteosarcoma through SP-1- and NF-?B-modulated urokinase plasminogen activator inhibition.
Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines.
Function of hepatocyte growth factor in gastric cancer proliferation and invasion.
Glucocorticoid regulation of plasminogen activator inhibitor-1 messenger ribonucleic acid and protein in normal and malignant rat osteoblasts.
Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells.
Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line.
Plasminogen activator regulation in osteoblasts: parathyroid hormone inhibition of type-1 plasminogen activator inhibitor and its mRNA.
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha.
Regulation of the production of plasminogen activators by bone resorption enhancing and inhibiting factors in three types of osteoblast-like cells.
Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2.
Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1.
The course of fibrinolytic proteins in children with malignant bone tumours.
The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model.
The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells.
[Antisense inhibition of urokinase in a human osteosarcoma cell line]
Out-of-Hospital Cardiac Arrest
The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study.
Ovarian Hyperstimulation Syndrome
Concentration of soluble urokinase plasminogen activator receptor (suPAR) in the pre-ovulatory follicular fluid is associated with development of ovarian hyperstimulation syndrome during ovarian stimulation.
Ovarian Neoplasms
A kunitz-type protease inhibitor bikunin disrupts ligand-induced oligomerization of receptors for transforming growth factor (TGF)-beta and subsequently suppresses TGF-beta signalings.
A Kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor-beta 1 signaling cascade.
A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer.
A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation.
Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice.
Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer.
Comparing SILAC and two-dimensional gel electrophoresis image analysis for profiling urokinase plasminogen activator signaling in ovarian cancer cells.
Critical involvement of ILK in TGFbeta1-stimulated invasion/migration of human ovarian cancer cells is associated with urokinase plasminogen activator system.
Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1).
Designing tracers for PET imaging of the urokinase-type plasminogen activator receptor from a cyclic uPA-derived peptide: first in vitro evaluations.
Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma.
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Effect of bFGF on invasion of ovarian cancer cells through the regulation of Ets-1 and urokinase-type plasminogen activator.
EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
Evidence for the clinical use of tumour markers.
Expression and anticancer activity analysis of recombinant human uPA1?43-melittin.
Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
GPI-specific phospholipase D mRNA expression in tumor cells of different malignancy.
High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.
High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer.
Increased cell-surface urokinase in advanced ovarian cancer.
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells.
Induction of c-fos Gene Expression by Urokinase-Type Plasminogen Activator in Human Ovarian Cancer Cells.
Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B.
Inhibition of lysophosphatidic acid receptor-2 expression by RNA interference decreases lysophosphatidic acid-induced urokinase plasminogen activator activation, cell invasion, and migration in ovarian cancer SKOV-3 cells.
Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.
Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.
Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.
Lysophosphatidic acid signaling in ovarian cancer.
Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer.
Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase.
Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice.
Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
Overexpression of a hybrid gene consisting of the amino-terminal fragment of urokinase and carboxyl-terminal domain of bikunin suppresses invasion and migration of human ovarian cancer cells in vitro.
Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.
Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
Proteases as prognostic markers in cancer.
Protein C and its inhibitor in malignancy.
Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.
Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.
Self-assembled chitosan polymer intercalating peptide functionalized gold nanoparticles as nanoprobe for efficient imaging of urokinase plasminogen activator receptor in cancer diagnostics.
Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.
SPARC ameliorates ovarian cancer-associated inflammation.
Suppression of urokinase expression and invasion by a soybean Kunitz trypsin inhibitor are mediated through inhibition of Src-dependent signaling pathways.
Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways.
Suppression of urokinase expression and tumor metastasis by bikunin overexpression [mini-review].
Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor kappaB activation and subsequently suppressed ovarian cancer dissemination.
Suppression of urokinase-type plasminogen activator expression from human ovarian cancer cells by urinary trypsin inhibitor.
Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells.
Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells.
Tumor markers for ovarian cancer.
Upregulation of bikunin in tumor-infiltrating macrophages as a factor of favorable prognosis in ovarian cancer.
Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.
Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
Urokinase plasminogen activator in ovarian cancer.
Urokinase Plasminogen Activator System Targeted Delivery of Nanobins as a Novel Ovarian Cancer Therapeutics.
Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence.
[Study of the effect of TF/FVIIa complex on the expression of u-PAR mRNA in human ovarian cancer]
Overweight
The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status.
Pancreatic Neoplasms
Action of antiproteases on pancreatic cancer cells.
Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system.
Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells.
Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer.
Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer.
Expression of kallikrein 7 diminishes pancreatic cancer cell adhesion to vitronectin and enhances urokinase-type plasminogen activator receptor shedding.
FOXM1c Promotes Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis via Upregulation of Expression of the Urokinase Plasminogen Activator System.
Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells.
Imaging of human pancreatic cancer xenografts by single-photon emission computed tomography with (99m)Tc-Hynic-PEG-AE105.
Inhibition and mechanism of action of a protease inhibitor in human pancreatic cancer cells.
Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Invasion-Metastasis by Hepatocyte Growth Factor/c-Met Signaling Concomitant with Induction of Urokinase Plasminogen Activator in Human Pancreatic Cancer: Role as Therapeutic Target.
Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles.
Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.
Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice.
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer.
Pre-clinical Study of (213)Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer.
Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.
Role of urokinase-type plasminogen activator and inhibitory effect of protease inhibitor in invasion and metastasis of pancreatic cancer.
TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system.
Thrombospondin-2 inhibits tumor cell invasion through the modulation of MMP-9 and uPA in pancreatic cancer cells.
Transcriptional silencing of ETS-1 efficiently suppresses angiogenesis of pancreatic cancer.
Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery.
Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models.
Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.
[Inhibitory effect of FOY-305 on liver metastasis of the pancreatic cancer]
Pancreatitis
Correlation of Serum and Ascitic Fluid Soluble Form Urokinase Plasminogen Activator Receptor Levels With Patient Complications, Disease Severity, Inflammatory Markers, and Prognosis in Patients With Severe Acute Pancreatitis.
Detection of low molecular weight urokinase in plasma of patient with acute pancreatitis followed by disseminated intravascular coagulation.
Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis.
Neutrophil to lymphocyte ratio at the early phase of acute pancreatitis correlates with serum urokinase-type plasminogen activator receptor and interleukin 6 and predicts organ failure.
Plasma level of soluble urokinase plasminogen activator receptor (suPAR) predicts long-term mortality after first acute alcohol-induced pancreatitis.
Plasma Level of Soluble Urokinase-type Plasminogen Activator Receptor Predicts the Severity of Acute Alcohol Pancreatitis.
Serum Urokinase-Type Plasminogen Activator Receptor Does Not Outperform C-Reactive Protein and Procalcitonin as an Early Marker of Severity of Acute Pancreatitis.
Soluble urokinase plasminogen activator receptor associates with higher risk, advanced disease severity as well as inflammation, and might serve as a prognostic biomarker of severe acute pancreatitis.
Soluble urokinase-type plasminogen activator receptor (suPAR) in patients with acute pancreatitis (AP) - Progress in prediction of AP severity.
The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
The role of soluble urokinase plasminogen activator receptor (SuPAR) as an indicator of the severity of acute pancreatitis
Pancreatitis, Acute Necrotizing
The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
Pancreatitis, Chronic
Enhanced urokinase plasminogen activation in chronic pancreatitis suggests a role in its pathogenesis.
Papilledema
Ischemic optic neuropathy in a female carrier with Fabry's disease.
The modality of huoxue-huayu in treatment of retinal vein occlusion.
Papilloma
Immunohistochemical evaluation of urokinase plasminogen activator receptor in noninvasive and early invasive urothelial papillary neoplasia.
Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice.
Paralysis
Intraarterial therapy for acute ischemic stroke: investigation of prognostic factors.
Parasitemia
Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection.
Paresis
[Clinical effects of urokinase and sodium ozagrel in patients with acute symptomatic lacunar infarction]
Pediatric Obesity
Serum levels of soluble urokinase plasminogen activator receptor as a new inflammatory marker in adolescent obesity.
Pelvic Inflammatory Disease
Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
Pemphigoid Gestationis
An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid.
Pemphigoid, Bullous
Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes.
Plasminogen activation in bullous pemphigoid immunohistology reveals urokinase type plasminogen activator, its receptor and plasminogen activator inhibitor type-2 in lesional epidermis.
Pemphigus
American Academy of Dermatology 1999 Awards for Young Investigators in Dermatology. Pemphigus vulgaris IgG regulates expression of urokinase receptor and junctional proteins that may contribute to acantholysis.
Functional involvement of urokinase-type plasminogen activator receptor in pemphigus acantholysis.
In vivo studies on the involvement of urokinase in pemphigus acantholysis.
Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG.
No activation of urokinase plasminogen activator by anti-desmoglein 3 monoclonal IgG antibodies in cultured human keratinocytes.
Pemphigus IgG induces expression of urokinase plasminogen activator receptor on the cell surface of cultured keratinocytes.
Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice.
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Plasmin induces acantholysis in skin organ cultures.
Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann.
Strict correlation between uPAR and plakoglobin expression in pemphigus vulgaris.
Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis.
UVB increases urokinase-type plasminogen activator receptor (uPAR) expression.
[The role of urokinase-type plasminogen activator in the pathogenesis of pemphigus]
Pemphigus, Benign Familial
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Peptic Ulcer
The release of thromboxane B2 and 6-keto-PGF1 alpha following pulmonary embolism.
Pericardial Effusion
Prevention of pericardial constriction by transcatheter intrapericardial fibrinolysis with urokinase.
Pericarditis
Intrapericardial infusion of urokinase for the treatment of purulent pericarditis.
Intrapericardial urokinase irrigation and systemic corticosteroids: an alternative to pericardectomy for persistent fibrino-purulent pericarditis.
Prevention of pericardial constriction by transcatheter intrapericardial fibrinolysis with urokinase.
Treatment of exudative fibrinous pericarditis with intrapericardial urokinase.
Pericarditis, Constrictive
Treatment of exudative fibrinous pericarditis with intrapericardial urokinase.
Periodontal Diseases
Association of gene polymorphisms for plasminogen activators with alveolar bone loss.
Differential uPA Expression by TGF-{beta}1 in Gingival Fibroblasts.
Plasmin is essential in preventing periodontitis in mice.
Periodontitis
Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase-type plasminogen activator receptor (suPAR) levels.
Porphyromonas gingivalis-derived RgpA-Kgp Complex Activates the Macrophage Urokinase Plasminogen Activator System: IMPLICATIONS FOR PERIODONTITIS.
Soluble urokinase-type plasminogen activator receptor is associated with signs of periodontitis in adolescents.
Peripheral Arterial Disease
Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
Cost-effectiveness of urokinase and alteplase for treatment of acute peripheral artery disease: comparison in a decision analysis model.
Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes.
Peripheral Nerve Injuries
Crohn's disease but not chronic ulcerative colitis induces the expression of PAI-1 in enteric neurons.
Peripheral Vascular Diseases
Peripheral intra-arterial thrombolytic therapy for acute arterial occlusion.
Relative cost-effectiveness of urokinase versus streptokinase in the treatment of peripheral vascular disease.
Urokinase infusion in total occlusion of peripheral vascular disease.
Using efficacy, safety, and cost data to support a formulary decision regarding thrombolytic therapy.
Peritonitis
Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat.
Candidate host marker for peritoneal dissemination.
Evidence for peritonitis treatment and prophylaxis: Indications for the use of urokinase in peritoneal dialysis-associated peritonitis.
Intraperitoneal thrombolytic agents in relapsing or persistent peritonitis of patients on continuous ambulatory peritoneal dialysis.
Intraperitoneal urokinase and oral rifampicin for persisting asymptomatic dialysate infection following acute coagulase-negative Staphylococcus peritonitis.
Laparoscopic implantation of the Tenckhoff catheter for the treatment of end-stage renal failure and congestive heart failure: experience with the pelvic fixation technique.
Peritoneal fluid neutrophil counts and cultures after intraperitoneal infusion of urokinase for relapsing serratia peritonitis.
Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients.
Successful use of recombinant tissue plasminogen activator in a patient with relapsing peritonitis.
Tenckhoff catheter replacement or intraperitoneal urokinase: a randomised trial in the management of recurrent continuous ambulatory peritoneal dialysis (CAPD) peritonitis.
Treatment for peritoneal dialysis-associated peritonitis.
Treatment of relapsing peritonitis in pediatric patients on peritoneal dialysis.
Treatment of resistant peritonitis in continuous ambulatory peritoneal dialysis with intraperitoneal urokinase: a double-blind clinical trial.
Urokinase for recurrent CAPD peritonitis.
Urokinase-type plasminogen activator receptor plays a role in neutrophil migration during lipopolysaccharide-induced peritoneal inflammation but not during Escherichia coli-induced peritonitis.
Urokinase: a treatment for relapsing peritonitis due to coagulase-negative staphylococci.
Use of intraperitoneal urokinase for resistant bacterial peritonitis in continuous ambulatory peritoneal dialysis.
Use of streptokinase or urokinase in recurrent CAPD peritonitis.
[Peritoneal dialysis catheter sterilization by urokinase administration in case of relapsing peritonitis: About four observations].
Pheochromocytoma
The urokinase plasminogen activator receptor (UPAR) is preferentially induced by nerve growth factor in PC12 pheochromocytoma cells and is required for NGF-driven differentiation.
Phlebitis
Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients.
Thrombolytic therapy for catheter-related thrombosis.
[Phlebitis of the legs. Comparison of streptokinase and urokinase therapy]
Pituitary ACTH Hypersecretion
Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Pituitary Neoplasms
Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
plasmin deficiency
Serine proteases, inhibitors and receptors in renal fibrosis.
Pleural Diseases
Asbestos upregulates expression of the urokinase-type plasminogen activator receptor on mesothelial cells.
Effects of intrapleural heparin or urokinase on the extent of tetracycline-induced pleural disease.
Pleural Effusion
A study of loculated tuberculous pleural effusions treated with intrapleural urokinase.
Diagnostic value of suPAR in differentiating noncardiac pleural effusions from cardiac pleural effusions.
Elevated levels of angiostatin in effusions from patients with malignant disease.
Evaluation of a pediatric protocol of intrapleural urokinase for pleural empyema: A prospective study.
Evolving experience in the management of pleural empyema.
Fibrinolytic and inflammatory processes in pleural effusions.
Image-guided drainage of complicated pleural effusions and adjunctive use of intrapleural urokinase. What would Hippocrates think?
Intra-pleural fibrinolytic therapy vs. conservative management in the treatment of parapneumonic effusions and empyema.
Intrapleural alteplase in a patient with complicated pleural effusion.
Intrapleural fibrinolysis in the management of empyemas and haemothoraces. Our experience.
Intrapleural Fibrinolysis with Urokinase Versus Alteplase in Complicated Parapneumonic Pleural Effusions and Empyemas: A Prospective Randomized Study.
Intrapleural instillation of urokinase in the treatment of loculated pleural effusions in children.
Intrapleural Urokinase Directly Under Medical Thoracoscopy for the Diagnosis of Malignant Pleural Mesothelioma With Severe Multiloculated Pleural Effusions.
Intrapleural urokinase directly under medical thoracoscopy for the diagnosis of tuberculous pleurisy.
Intrapleural urokinase in the treatment of complicated parapneumonic pleural effusions and empyema.
Intrapleural urokinase in the treatment of loculated pleural effusions.
Intrapleural urokinase treatment in children with complicated parapneumonic effusion.
Proteolytic Regulation of Epithelial Sodium Channels by Urokinase Plasminogen Activator: CUTTING EDGE AND CLEAVAGE SITES.
Streptokinase and urokinase for the treatment of pleural effusions and empyemas.
The effects of urokinase instillation therapy via percutaneous transthoracic catheter in loculated tuberculous pleural effusion: a randomized prospective study.
Transcatheter instillation of urokinase into loculated pleural effusion: analysis of treatment effect.
Transcatheter intracavitary fibrinolysis of loculated pleural effusions: experience in 102 patients.
Transcatheter intrapleural urokinase for loculated pleural effusion.
Treatment of complicated pleural effusion with intracavitary urokinase in children.
Treatment of loculated pleural effusion with intrapleural urokinase in children.
Treatment of loculated pleural effusions with transcatheter intracavitary urokinase.
[Drainage of loculated and/or multiloculated pleural effusions using a small caliber catheter and urokinase (pleuro-fibrinolysis)]
[Intrapleural urokinase in the treatment of parapneumonic effusions]
[The study of intrapleural urokinase in the prevention of pleural thickening and loculated effusions by tuberculous pleurisy]
[Urokinase in the treatment of complicated pleural effusion]
[Use of intrapleural urokinase in children]
[Usefulness of urokinase in multilocular pleural effusion]
Pleural Effusion, Malignant
Erratum: Randomized Controlled Trial of Urokinase versus Placebo for Nondraining Malignant Pleural Effusion.
Intrapleural urokinase for the treatment of loculated malignant pleural effusions and trapped lungs in medically inoperable cancer patients.
Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study.
Randomised Controlled Trial of Urokinase versus Placebo for Non-draining Malignant Pleural Effusion.
Using urokinase to treat malignant pleural effusions.
Pleurisy
Properties of urokinase type-plasminogen activator found in chest fluid.
Single-chain urokinase alone or complexed to its receptor in tetracycline-induced pleuritis in rabbits.
Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles.
Pneumoconiosis
Gene polymorphisms of fibrinolytic enzymes in coal workers' pneumoconiosis.
Pneumonia
Angiostrongylus cantonensis: Induction of urokinase-type PA and degradation of type IV collagen in rat lung granulomatous fibrosis.
Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Level as a Predictor of the Severity of Community-Acquired Pneumonia.
Properties of urokinase type-plasminogen activator found in chest fluid.
Regulation of urokinase receptor mRNA stability by hnRNP C in lung epithelial cells.
Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients.
Selective use of the intensive care unit after nonaortic arterial surgery.
Soluble receptor for urokinase plasminogen activator in community-acquired pneumonia in children.
Soluble urokinase plasminogen activator receptor: an indicator of pneumonia severity in children.
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.
The plasminogen activation system: new targets in lung inflammation and remodeling.
The role of the soluble urokinase plasminogen activator (suPAR) in children with pneumonia.
Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia.
Urokinase receptor mRNA stability involves tyrosine phosphorylation in lung epithelial cells.
Urokinase-Type Plasminogen Activator Inhibits Efferocytosis of Neutrophils.
[Regulation of fibrinolysis by lymphocytes in inflammatory diseases of the bronchopulmonary system]
Pneumonia, Bacterial
Procoagulant and fibrinolytic activities in bronchoalveolar fluid of HIV-positive and HIV-negative patients.
Pneumonia, Pneumococcal
Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia.
Pneumonia, Ventilator-Associated
Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis.
Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia.
Pneumoperitoneum
The plasminogen activator inhibitor system in colon cancer cell lines is influenced by the CO(2) pneumoperitoneum.
Pneumothorax
Use of urokinase in childhood pleural empyema.
Polycystic Kidney Diseases
Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.
Polycystic Kidney, Autosomal Dominant
Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.
Polycythemia
Overexpression of PRV-1 gene in polycythemia rubra vera and essential thrombocythemia.
Polycythemia Vera
Overexpression of PRV-1 gene in polycythemia rubra vera and essential thrombocythemia.
Right hepatic artery thrombosis in an essential polycythemia vera patient following pancreato-biliary surgery for severe pancreatitis.
Postthrombotic Syndrome
[Thrombolysis in deep venous thrombosis: critical review]
Pre-Eclampsia
Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors.
Hyperglycemia impairs cytotrophoblast function via stress signaling.
Leukemia inhibitory factor promote trophoblast invasion via urokinase-type plasminogen activator receptor in preeclampsia.
Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: possible markers of placental function.
Serum soluble urokinase plasminogen activator receptor (suPAR) in early pregnancy prior to clinical onset of preeclampsia.
Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia.
The fibrinolytic system in pre-eclampsia.
The role of placental urokinase inhibitor in toxemia of pregnancy.
Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia.
Urinary coagulation-fibrinolysis, kallirein-kinin systems and kininase in cases of preclampsia.
[Fibrinolytic therapy for toxemia of late pregnancy--experimental studies of pregnant rabbits treated with urokinase]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy.
[The use of urokinase and ammonium chloride in unblocking a central venous catheter in a child with acute lymphoblastic leukemia]
Pregnancy, Ectopic
Immunohistochemical localization of urokinase-type plasminogen activator and the plasminogen activator inhibitors 1 and 2 in early human implantation sites.
Pressure Ulcer
Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Priapism
[Embolization of the bilateral internal pudendal arteries for intractable priapism in a child with chronic myelogenous leukemia]
Primary Myelofibrosis
Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera.
Prolactinoma
Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Prostatic Diseases
Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
Prostatic Hyperplasia
Effect of urokinase on the proliferation of primary cultures of human prostatic cells.
Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue.
In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer.
Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues.
Post-operative blood loss after transurethral prostatectomy is dependent on in situ fibrinolysis.
Prognostic value of urokinase plasminogen activator for prostatic carcinoma.
Tissue plasminogen activator activity in prostatic cancer.
Prostatic Intraepithelial Neoplasia
Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion.
Prostatic Neoplasms
(±)Equol inhibits invasion in prostate cancer DU145 cells possibly via down-regulation of matrix metalloproteinase-9, matrix metalloproteinase-2 and urokinase-type plasminogen activator by antioxidant activity.
213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model.
A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines.
A piece in prostate cancer puzzle: Future perspective of novel molecular signatures.
A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis.
Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
Amplification and overexpression of Elongin C gene discovered in prostate cancer by cDNA microarrays.
Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors.
Amplification of urokinase gene in prostate cancer.
An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells.
Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer.
Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor.
Application of in-gel protease assay in a biological sample: characterization and identification of urokinase-type plasminogen activator (uPA) in secreted proteins from a prostate cancer cell line PC-3.
Aspirin Inhibits IKK-?-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.
Cadherin switching and activation of beta-catenin signaling underlie proinvasive actions of calcitonin-calcitonin receptor axis in prostate cancer.
Calcitonin increases tumorigenicity of prostate cancer cells: evidence for the role of protein kinase A and urokinase-type plasminogen receptor.
Calcitonin receptor-stimulated migration of prostate cancer cells is mediated by urokinase receptor-integrin signaling.
Calcitonin stimulates the secretion of urokinase-type plasminogen activator from prostate cancer cells: its possible implications on tumor cell invasion.
CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer.
Characterization of protease expression in human prostate-cancer cell-lines.
Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer.
Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Decreased expression of the low-density lipoprotein receptor-related protein-1 (LRP-1) in rats with prostate cancer.
Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.
Deregulated Expression of Urokinase and its Inhibitor Type 1 in Prostate Cancer Cells: Role of Epigenetic Mechanisms.
Dexamethasone plus Somatostatin-analog Manipulation as Bone Metastasis Microenvironment-targeting Therapy for the Treatment of Castration-resistant Prostate Cancer: A Meta-analysis of Uncontrolled Studies.
Differential expression of uPA in an aggressive (DU 145) and a nonaggressive (1013L) human prostate cancer xenograft.
Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway.
Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer.
Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145.
Dual regulation of urokinase gene expression in human prostate cancer.
Effect of hepatocyte growth factor on invasion of prostate cancer cell lines.
Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases.
Effects of hepatocyte growth factor on urokinase-type plasminogen activator (uPA) and uPA receptor in DU145 prostate cancer cells.
Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue.
Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer.
Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer.
Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA).
Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.
Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer.
Explication of the roles of prostate health index (PHI) and urokinase plasminogen activator (uPA) as diagnostic and predictor tools for prostate cancer in equivocal PSA range of 4-10 ng/mL.
Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.
Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines.
Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers.
Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer.
Expression of urokinase-type plasminogen activator system in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Extending preclinical models of skeletal manifestations of malignancy to the clinical setting.
Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer.
First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.
Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
Ganoderma lucidum inhibits proliferation and induces apoptosis in human prostate cancer cells PC-3.
Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer.
Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications.
Imaging Active Urokinase Plasminogen Activator in Prostate Cancer.
Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET.
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer.
Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis.
Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase.
Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3.
Induction of urokinase-type plasminogen activator by lipopolysaccharide in PC-3 human prostatic cancer cells.
Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells.
Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer.
Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade.
Inhibitors of tyrosine kinase inhibit the production of urokinase plasminogen activator in human prostatic cancer cells.
Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer.
Integrin alpha6 cleavage: a novel modification to modulate cell migration.
Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4.
Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines.
Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cells.
Is urokinase gene 3'-UTR polymorphism associated with prostate cancer?
Lycopene increases urokinase receptor and fails to inhibit growth or connexin expression in a metastatically passaged prostate cancer cell line: a brief communication.
Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis.
Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo.
New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer.
New circulating biomarkers for prostate cancer.
NFkappaB-dependent regulation of urokinase plasminogen activator by proanthocyanidin-rich grape seed extract: effect on invasion by prostate cancer cells.
Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells.
Nutraceutical inhibitors of urokinase: potential applications in prostate cancer prevention and treatment.
Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion.
Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment.
Other biomarkers for detecting prostate cancer.
Pamidronate down-regulates urokinase-type plasminogen activator expression in PC-3 prostate cancer cells.
PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives.
PET Tracers Beyond FDG in Prostate Cancer.
PKD2 and PKD3 Promote Prostate Cancer Cell Invasion via uPA by Shifting Balance Between NF-?B and HDAC1.
Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer.
Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence.
Predicting high risk disease using serum and DNA biomarkers.
Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer.
Prognostic value of urokinase plasminogen activator for prostatic carcinoma.
Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.
Prostate cancer cells show elevated urokinase receptor in a mouse model of metastasis.
Prostate-specific antigen activates single-chain urokinase-type plasminogen activator.
Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion.
Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1.
Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3).
Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo.
Regulation of Urokinase Production by Androgens in Human Prostate Cancer Cells: Effect on Tumor Growth and Metastases in Vivo1.
Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Retraction: Demethylation-Linked Activation of Urokinase Plasminogen Activator Is Involved in Progression of Prostate Cancer.
Retraction: RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel.
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies.
Signal transduction-mediated regulation of urokinase gene expression in human prostate cancer.
Skip Regulates TGF- ? 1-Induced Extracellular Matrix Degrading Proteases Expression in Human PC-3 Prostate Cancer Cells.
Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis.
Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening.
suPAR, a soluble form of urokinase plasminogen activator receptor, inhibits human prostate cancer cell growth and invasion.
Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.
Synthesis of thiophene-2-carboxamidines containing 2-aminothiazoles and their biological evaluation as urokinase inhibitors.
Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator.
Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells.
The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer.
The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells.
The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer.
The superoxide scavenger TEMPOL induces urokinase receptor (uPAR) expression in human prostate cancer cells.
The urokinase-type plasminogen activator system in prostate cancer metastasis.
Transforming growth factor beta1 stimulates urokinase plasminogen activator system on prostate cancer cells.
Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells.
uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo.
Urokinase plasminogen activator is necessary but not sufficient for prostate cancer cell invasion.
Urokinase Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Non-invasive Evaluation of Aggressiveness: a Prospective Phase II Clinical Trial Comparing with Gleason Score.
Urokinase-type plasminogen activator expression in human prostate carcinomas.
Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines.
Protein S Deficiency
Mesenteric and portal vein thrombosis in a young patient with protein S deficiency treated with urokinase via the superior mesenteric artery.
[A case of portal and superior mesenteric thrombosis associated with protein S deficiency treated with urokinase via the superior mesenteric vein]
Protein-Losing Enteropathies
Resolution of protein-losing enteropathy with standard high molecular heparin and urokinase after Fontan repair in a patient with tricuspid atresia.
Proteinuria
A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation.
A perspective on chronic kidney disease progression.
Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.
Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria.
Amiloride, a urokinase-type plasminogen activator receptor (uTPA) inhibitor, reduces proteinurea in podocytes.
CD80, suPAR and Nephrotic Syndrome in a case of NPHS2 mutation.
Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy.
Efficacy of cyclosporine A for steroid-resistant severe Henoch-Schönlein purpura nephritis.
Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.
Epidemiology, Major Outcomes, Risk Factors, Prevention and Management of Chronic Kidney Disease in China.
Glomerular filtration barrier dysfunction in a self-limiting, RNA virus-induced glomerulopathy resembles findings in idiopathic nephrotic syndromes.
Immunoglobulin A nephropathy in China: progress and challenges.
Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura.
Plasmin activates epithelial Na+ channels by cleaving the gamma subunit.
Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor.
Resolution of proteinuria secondary to bilateral renal vein thrombosis after treatment with systemic thrombolytic therapy.
Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children.
Sirt6 deficiency exacerbates podocyte injury and proteinuria through targeting Notch signaling.
The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury.
The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.
Urinary plasmin inhibits TRPV5 in nephrotic-range proteinuria.
Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection.
Urokinase-type plasminogen activator contributes to amiloride-sensitive sodium retention in nephrotic range glomerular proteinuria in mice.
[Significance of the markers of endothelial dysfunction and hemorheological disorders for assessing the activity and prognosis of chronic glomerulonephritis]
Pseudomonas Infections
Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection.
Pseudotumor Cerebri
A case of pseudotumor cerebri following glucocorticoid therapy in which warfarin prevented recurrence.
Psoriasis
Expression of plasminogen activator enzymes in psoriatic epidermis.
Immunohistochemical characterization of the plasminogen activator system in psoriatic epidermis.
Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in psoriasis patients and correlation with disease severity.
[Expression of bioinformatically identified genes in skin of psoriasis patients].
Pterygium
Overexpression of collagenase (MMP-1) and stromelysin (MMP-3) by pterygium head fibroblasts.
Overexpression of urokinase-type plasminogen activator in pterygia and pterygium fibroblasts.
Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines.
Ultraviolet-A irradiation upregulated urokinase-type plasminogen activator in pterygium fibroblasts through ERK and JNK pathways.
Pulmonary Arterial Hypertension
Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis.
Pulmonary Atelectasis
[Intrathoracic washing with urokinase was effective for empyema with atelectasis].
Pulmonary Disease, Chronic Obstructive
Efficacy and safety of low-dose urokinase for the treatment of hemodynamically stable AECOPD patients with acute pulmonary thromboembolism.
Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease.
High suPAR and Low Blood Eosinophil Count are Risk Factors for Hospital Readmission and Mortality in Patients with COPD.
Levels of Components of the Urokinase-type Plasminogen Activator System are Related to Chronic Obstructive Pulmonary Disease Parenchymal Destruction and Airway Remodelling.
Role of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD).
Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD.
Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.
Soluble urokinase-type plasminogen activator receptor as a measure of treatment response in acute exacerbation of COPD.
Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD.
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
The role of serum soluble urokinase-type plasminogen activator receptor in stable chronic obstructive pulmonary disease.
The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease.
Urokinase-type plasminogen activator system and human cationic antimicrobial protein 18 in serum and induced sputum of patients with chronic obstructive pulmonary disease.
[Effect of amiloride on the pathology of a rat model of chronic obstructive pulmonary disease]
[Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients]
Pulmonary Edema
A change of position for neurogenic pulmonary edema.
Proteolytic Regulation of Epithelial Sodium Channels by Urokinase Plasminogen Activator: CUTTING EDGE AND CLEAVAGE SITES.
Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema.
Urokinase-type plasminogen activator (uPA) induces pulmonary microvascular endothelial permeability through low density lipoprotein receptor-related protein (LRP)-dependent activation of endothelial nitric-oxide synthase.
Pulmonary Embolism
A controlled clinical trial on the effect of heparin infusion and two regimens of urokinase in acute pulmonary embolism.
A national cooperative trial of thrombolysis in pulmonary embolism: phase I results of urokinase therapy.
A new "wonder" drug to dissolve clots. The results of urokinase therapy in acute myocardial infarction, pulmonary embolism and deep vein thrombosis.
Acute pulmonary embolism treated with thrombolytic agents: current status of tPA and future implications for emergency medicine.
Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.
An evaluation of fibrinolytic therapy of pulmonary thromboembolism using non-invasive examinations and the relationship of urokinase dosage to clinical outcome and coagulation-fibrinolytic changes.
Angiographic observations on the treatment of pulmonary thromboembolism with urokinase.
Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer.
Catheter-directed thrombolysis for thromboembolic disease during pregnancy: a viable option.
Changes in the plasma fibrinolytic system during urokinase therapy: comparison of tissue culture urokinase with urinary source urokinase in patients with pulmonary embolism.
Combined modality of mechanical breakdown and intraembolus thrombolysis in failed systemic thrombolysis of subacute pulmonary embolism patients.
Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up.
Comparative tolerability profiles of thrombolytic agents. A review.
Comparison of urokinase and reteplase thrombolytic treatment in patients with high-risk pulmonary embolism.
Deep venous thrombosis and pulmonary embolism after lung transplantation.
Effect of low-molecular-weight heparin and urokinase on pulmonary arteries involved in pulmonary embolism.
Effect of Recombinant Single-Chain Urokinase-Type Plasminogen Activator on Experimental Pulmonary Embolism.
Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism.
Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial.
Efficacy and safety of low-dose urokinase for the treatment of hemodynamically stable AECOPD patients with acute pulmonary thromboembolism.
Experimental pulmonary embolism: effects of urokinase therapy on organizing thrombi.
Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial.
Hemodynamic effects of bolus infusion of urokinase in pulmonary thromboembolism.
High dose urokinase against massive pulmonary embolism in nephrotic syndrome.
High-dose bolus injection of urokinase. Use during cardiopulmonary resuscitation for massive pulmonary embolism.
High-dose intra-arterial urokinase for the treatment of hepatic artery thrombosis in liver transplantation.
History and physical examination in acute pulmonary embolism in patients without preexisting cardiac or pulmonary disease.
Implications of the urokinase study concerning the surgical treatment of pulmonary embolism.
Interventions in pulmonary embolism.
Intra pulmonary thrombolytic therapy with balloon dilatation in recurrent acute pulmonary embolism.
Intraarterial infusion of urokinase in the treatment of acute pulmonary thromboembolism: preliminary observations.
Intrapulmonary artery infusion of urokinase for treatment of massive pulmonary embolism: a review of 26 patients with and without contraindications to systemic thrombolytic therapy.
Intravascular ultrasound in patients with acute pulmonary embolism after treatment with intravenous urokinase and high-dose heparin.
Life-threatening pulmonary embolism with right-sided heart thrombus. Rapid recovery with recombinant tissue plasminogen activator.
Local low-dose urokinase thrombolysis for the management of hemodynamically stable pulmonary embolism with right ventricular dysfunction.
Low-dose urokinase in major pulmonary embolism.
Low-dose urokinase in massive pulmonary embolism when standard thrombolysis is contraindicated.
Low-dose urokinase in pulmonary embolism.
Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk pulmonary embolism: A retrospective cohort study.
Lung endothelium targeting for pulmonary embolism thrombolysis.
Massive pulmonary embolism: treatment with the hydrolyser thrombectomy catheter.
Mechanical fragmentation and pharmacologic thrombolysis in massive pulmonary embolism.
Midterm Results of Endovascular Treatment for Iliac Vein Compression Syndrome from a Single Center.
P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1.
Pharmacomechanical thrombolysis of experimental pulmonary emboli. Rapid low-dose intraembolic therapy.
Plasminogen and moderate doses of urokinase in the treatment of acute pulmonary embolism.
Possible use of monoclonal antibodies to standardize the production and use of human urokinase.
Preparation and characterization of a disulfide-linked bioconjugate of annexin V with the B-chain of urokinase: an improved fibrinolytic agent targeted to phospholipid-containing thrombi.
Principles of thrombolysis in pulmonary embolism.
Pro-urokinase up-regulates the expression of urokinase-type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells.
Progress in fibrinolysis.
Pulmonary embolism after local urokinase instillation in a Hickman catheter.
Pulmonary embolism and the urokinase pulmonary embolism trial.
Pulmonary embolism from pulse-spray pharmacomechanical thrombolysis of clotted hemodialysis grafts: urokinase versus heparinized saline.
Pulmonary Embolism in 2017: How We Got Here and Where Are We Going?
Pulmonary embolism: a review of medical treatment.
Pulmonary perfusion after rt-PA therapy for acute embolism: early improvement assessed with segmental perfusion scanning.
Pulmonary thromboembolism. 2. New trends in prophylaxis and therapy.
Radiographic, haemodynamic and biochemical findings related to the National Heart and Lung Institute's urokinase pulmonary embolism trial.
Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism.
Recombinant tissue plasminogen activator in patients with pulmonary embolism: correlation of fibrinolytic specificity and efficacy.
Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial.
Role of echocardiography in acute pulmonary embolism.
Streptokinase and urokinase in the treatment of pulmonary thromboemboli; from a national cooperative study.
Successful post-cardiopulmonary resuscitation urokinase therapy for massive perioperative pulmonary embolism - a case report.
Successful urokinase treatment of massive pulmonary embolism in pregnancy.
The Efficacy and Safety of Intermittent Low-Dose Urokinase Thrombolysis for the Treatment of Senile Acute Intermediate-High-Risk Pulmonary Embolism: A Pilot Trial.
The phase II urokinase-streptokinase pulmonary embolism trial: a national cooperative study.
The UKEP study: multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism. The UKEP Study Research Group.
The urokinase pulmonary embolism trial.
The urokinase pulmonary embolism trial. A national cooperative study.
Thrombolysis for pulmonary embolism.
Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.
Thrombolytic therapy with urokinase for pulmonary embolism in patients with stable hemodynamics.
Thrombolytic therapy: overview of results in major vascular occlusions.
Thrombosis of a mechanical tricuspid valve prosthesis and of the left subclavian vein: successful therapy with thrombolysis.
TPA versus urokinase in acute pulmonary embolism: results of a randomized controlled trial.
Treatment of massive pulmonary thromboembolism with low intrapulmonary dosages of urokinase. Short-term angiographic and hemodynamic evolution.
Treatment of pulmonary embolism with urokinase. Results of clinical trial (phase 1).
Treatment of urokinase-related anaphylactoid reaction with intravenous famotidine.
Urokinase & streptokinase in pulmonary embolism.
Urokinase Attenuates Pulmonary Thromboembolism in an Animal Model by Inhibition of Inflammatory Response.
Urokinase for the treatment of acute pulmonary thromboembolism.
Urokinase in pulmonary embolism.
Urokinase in pulmonary thromboembolism.
Urokinase in thromboembolic disease: Pulmonary embolism.
Urokinase pulmonary embolism trial.
Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study.
Urokinase therapy for a catheter-related right atrial thrombus and pulmonary embolism in a 2-month-old infant.
Urokinase therapy in clinical pulmonary embolism. A new thrombolytic agent.
Urokinase therapy in pulmonary thromboembolism.
Urokinase thrombolytic therapy of pulmonary embolism in neurosurgically treated patients.
Urokinase versus tissue plasminogen activator in pulmonary embolism.
[2 cases of pulmonary embolism treated with urokinase]
[A case of pulmonary embolism treated with urokinase]
[A case of pulmonary thromboembolism with heparin-induced thrombocytopenia]
[A case of renal vein thrombosis and pulmonary embolism associated with diffuse membranous glomerulonephritis: the usefulness of low-molecular-weight heparin and urokinase therapy]
[Actual state of thrombolytic treatment of recent vein thrombosis and pulmonary embolism (author's transl)]
[Clinical outcome of catheter fragmentation and aspiration therapy in patients with acute pulmonary embolism]
[Comparison of curative effect and thrombolysis time between r-tPA application and urokinase in the interventional thrombectomy and thrombolysis for acute and severe pulmonary embolism].
[Cost-benefit study of different thrombolytic strategies in treating 156 patients with symptomatic pulmonary thromboembolism].
[Diagnosis and therapy of perioperative lung embolism]
[Diagnostic problems in acute pulmonary embolism]
[Early diagnosis of pulmonary embolism in patients with skin and soft tissue defects after trauma].
[Experimental study of the thrombolytic effects in a canine model of pulmonary thromboembolism induced by autologous radioactive blood clots]
[Hemodynamic course during fibrinolysis in severe pulmonary embolism]
[High-dose short time fibrinolytic treatment with streptokinase of massive lung embolism in the early postoperative period]
[Indications and results of thrombolytic treatment with urokinase of very severe pulmonary embolism]
[Indications for thrombolytics]
[Inefficiency of high doses of urokinase in a massive pulmonary embolism. Possible role of an oral contraceptive]
[Local thrombolysis with urokinase in acute massive pulmonary embolism]
[Long-term results after local thrombolysis in acute massive pulmonary embolism]
[Massive pulmonary thromboembolism. Thrombolytic therapy with urokinase: proposed common protocol]
[Moderate doses of urokinase (UK) in the treatment of myocardial infarct and pulmonary embolism]
[Multicenter clinical trial on the efficacy of thrombolytic therapy with urokinase and/or anticoagulant with low molecular weight heparin in acute pulmonary embolism]
[Multicenter study of 2 urokinase protocols in severe pulmonary embolism. Research Group on Urokinase and Pulmonary Embolism]
[Postoperative pulmonary embolism in neurosurgical practice: report of two cases]
[Pulmonary embolism in neurosurgery. Treatment with urokinase through selective route]
[Pulmonary infarct hardly differentiated from lung cancer--a case report]
[Successful treatment of a fulminant pulmonary embolism using a high-dose bolus injection of urokinase during cardiopulmonary resuscitation]
[Survey of diagnosis and treatment of acute pulmonary embolism in 21 hospitals in China]
[The effect of low molecular heparin and urokinase on MCP-1 of acute experimental pulmonary embolism in rabbits].
[The value of thrombolysis for the treatment of acute pulmonary embolism]
[Therapeutic approach to pulmonary embolism]
[Thrombolysis of rabbit's pulmonary embolism with thrombus-targeted urokinase immune liposome]
[Thrombolytic therapy with urokinase in 8 patients with massive pulmonary thromboembolism]
[Thrombolytic urokinase treatment of very severe pulmonary embolism. Apropos of 6 cases]
[Treatment of acute pulmonary embolism with urokinase compared with the combination plasminogen-urokinase. Apropos of 67 cases]
[Treatment of pulmonary embolism. Current status and future prospects]
[Treatment of recurrent pulmonary thromboembolism with direct infusion of urokinase into the pulmonary artery]
[Treatment of severe pulmonary embolism by the in situ injection of urokinase]
[Ultrahigh-dosage urokinase lysis during pulmonary embolism prophylaxis by means of an extractable caval filter]
[Use of streptokinase and urokinase in deep venous thrombosis and pulmonary embolism: indications and clinical experience]
[Value of moderate doses of urokinase combined with heparin in the treatment of massive pulmonary embolism. A retrospective study of 33 cases]
Pulmonary Fibrosis
Aerosolized urokinase in pulmonary fibrosis.
Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis.
Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?
Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model.
Role of the urokinase-fibrinolytic system in epithelial-mesenchymal transition during lung injury.
Systemic sclerosis-like histopathological features in the myocardium of uPAR-deficient mice.
The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system.
The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability.
The matrix unloaded: aerosolized heparin or urokinase for pulmonary fibrosis.
The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy.
Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes.
UROKINASE RECEPTOR MEDIATES LUNG FIBROBLAST ATTACHMENT AND MIGRATION TOWARDS PROVISIONAL MATRIX PROTEINS THROUGH INTERACTION WITH MULTIPLE INTEGRINS.
[Fibrin deposition and fibrinolysis in the pathogenesis of pulmonary fibrosis]
Purpura
Analysis of urinary and circulating FDP subfragments and subunits: application of the western-blot technique.
Endovascular stent infection.
Pathological improvement of IgA nephropathy and Henoch-Schönlein purpura nephritis with urokinase therapy.
Successful therapy with tonsillectomy for severe ISKDC grade VI Henoch-Schönlein purpura nephritis and persistent nephrotic syndrome.
Purpura Fulminans
Anticoagulant combination therapy of gabexate mesilate and urokinase in purpura fulminans.
[Prevention of distal necrosis in purpura fulminans. Value of sodium nitroprusside and urokinase]
Purpura, Thrombotic Thrombocytopenic
Urokinase treatment for severe neurological complications in a patient with thrombotic thrombocytopenic purpura.
[A case of thrombotic thrombocytopenic purpura (TTP), clinically diagnosed and cured by dipyridamole, urokinase and aspirin]
Pyelonephritis
Pyelonephritis: renal urokinase activity in rats on essential fatty acid diets.
Pyelonephritis: renal urokinase and sialidase (neuraminidase) activity in rats fed a standard laboratory diet.
Successful thrombolytic therapy in two patients with renal vein thrombosis.
The urokinase plasminogen activator receptor is crucially involved in host defense during acute pyelonephritis.
Rectal Neoplasms
Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells.
Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer.
Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer.
Epithelial and stromal cell urokinase plasminogen activator receptor expression differentially correlates with survival in rectal cancer stages B and C patients.
Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers.
Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
uPA and PAI-1 in Rectal Cancer-Relationship to Radiotherapy and Clinical Outcome.
Rectal Prolapse
The pathophysiology of pelvic floor disorders: evidence from a histomorphologic study of the perineum and a mouse model of rectal prolapse.
Renal Insufficiency
Acute renal vein thrombosis: successful treatment with intraarterial urokinase.
Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion.
Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit.
Urinary plasminogen activator activity in progressive renal failure.
[Central venous access for hemodialysis: use and practice with the child in France]
Renal Insufficiency, Chronic
A tripartite complex of suPAR, APOL1 risk variants and ?v?3 integrin on podocytes mediates chronic kidney disease.
Association between Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Biomarkers of Immune Activation and Incident Kidney Failure With Replacement Therapy: Findings From the African American Study of Kidney Disease and Hypertension.
Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.
Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study.
Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients.
Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease.
Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery.
Mechanisms underlying modulation of podocyte TRPC6 channels by suPAR: Role of NADPH oxidases and Src family tyrosine kinases.
Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study.
Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children.
Serum levels of soluble urokinase plasminogen activator receptor in Japanese patients with chronic kidney disease.
Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus.
Soluble Urokinase Receptor and Chronic Kidney Disease.
Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease.
Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study.
Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease.
Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes.
Soluble Urokinase-Type Plasminogen Activator Receptor, Changes of 24-Hour Blood Pressure, and Progression of Chronic Kidney Disease.
uPAR isoform 2 forms a dimer and induces severe kidney disease in mice.
Urokinase and its receptors in chronic kidney disease.
Urokinase excretion in chronic renal diseases of different histological types.
Reperfusion Injury
A Combined Treatment with Taurine and Intra-arterial Thrombolysis in an Embolic Model of Stroke in Rats: Increased Neuroprotective Efficacy and Extended Therapeutic Time Window.
Renal urokinase-type plasminogen activator (uPA) receptor but not uPA deficiency strongly attenuates ischemia reperfusion injury and acute kidney allograft rejection.
[Effects of acupoint-embedment of medicated-thread and acupoint-injection on expression of cortical urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in rats with cerebral ischemia-reperfusion injury].
[Study on effect of shenmai injection in protecting myocardium against ischemia-reperfusion injury in thrombolytic therapy with urokinase for acute myocardial infarction patients evaluated by 99mTc-MIBI myocardial imaging]
Respiratory Distress Syndrome
Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome.
Novel aspects of urokinase function in the injured lung: role of ?2-macroglobulin.
Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients.
Recombinant production of a hybrid plasminogen activator composed of surfactant protein B and low-molecular-weight urokinase.
Serum plasminogen activator urokinase receptor predicts elevated risk of acute respiratory distress syndrome in patients with sepsis and is positively associated with disease severity, inflammation and mortality.
The fibrinolysin system and its relationship to disease in the newborn.
Wood Bark Smoke Induces Lung and Pleural Plasminogen Activator Inhibitor 1 and Stabilizes its mRNA in Porcine Lung Cells.
[Ventilator bundle treatment of acute respiratory distress syndrome and its correlation with biomarkers of inflammation].
Respiratory Insufficiency
Acute hypoxemic respiratory failure following intrapleural thrombolytic therapy for hemothorax.
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Mitral stenosis with bacterial myocarditis in a cat.
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.
[Intensive care of acute respiratory distress syndrome in septic shock--a case report (author's transl)]
Respiratory Tract Infections
Levels of Soluble Urokinase Plasminogen Activator Receptor in Pediatric Lower Respiratory Tract Infections.
Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia.
Retinal Artery Occlusion
Intra-arterial thrombolysis for acute central retinal artery occlusion.
Microcatheter urokinase infusion in central retinal artery occlusion.
Selective thrombolysis of central retinal artery occlusion without long-term systemic heparinization.
[A case of central retinal artery occlusion after anterior posterior fusion of the lumbar spine]
[A case of nonarteritic anterior ischemic optic neuropathy with cilioretinal artery occlusion]
[Fibrinolysis: indications in ophthalmology]
[Local fibrinolytic treatment in occlusions of the central retinal artery]
[Systemic fibrinolytic therapy using urokinase in central retinal artery occlusion. A case study]
Retinal Detachment
Effect of urokinase on posterior penetrating eye injuries.
Retinal Diseases
The Urokinase Receptor-Derived Peptide UPARANT Recovers Dysfunctional Electroretinogram and Blood-Retinal Barrier Leakage in a Rat Model of Diabetes.
Retinal Neovascularization
Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor.
The urokinase/urokinase receptor system in retinal neovascularization: inhibition by A6 suggests a new therapeutic target.
Retinal Vasculitis
[Two cases of frosted retinal angiitis with central retinal vein occlusion]
Retinal Vein Occlusion
[Medical treatment for experimental retinal vein occlusion--thrombolytic effect of nasaruplase]
[The modality of Huoxue-Huayu in treatment of retinal vein occlusion]
[Two cases of frosted retinal angiitis with central retinal vein occlusion]
Retinitis Pigmentosa
The urokinase-type plasminogen activator system as drug target in retinitis pigmentosa: New pre-clinical evidence in the rd10 mouse model.
Retinoblastoma
Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation.
Regulation of the urokinase gene by the retinoblastoma protein.
SerpinB2 is an inducible host factor involved in enhancing HIV-1 transcription and replication.
Rhabdomyosarcoma
Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
Serine enzymes released by cultured neoplastic cells.
Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.
Rhinitis, Allergic
The urokinase system in patients with intermittent and persistent allergic rhinitis.
Sagittal Sinus Thrombosis
Case report: treatment of superior sagittal sinus thrombosis with urokinase.
Expansion of a haematoma after urokinase thrombolysis of superior sagittal sinus thrombosis.
Nonrandomized comparison of local urokinase thrombolysis versus systemic heparin anticoagulation for superior sagittal sinus thrombosis.
Sagittal sinus thrombosis following minor head injury treated with continuous urokinase infusion.
Superior sagittal sinus thrombosis due to lithium: local urokinase thrombolysis treatment.
Urokinase treatment of sagittal sinus thrombosis with venous hemorrhagic infarction.
Sarcoidosis
A case of granulomatous renal sarcoidosis with a dramatic response to corticosteroid and urokinase therapy.
Depressed urokinase activity in bronchoalveolar lavage fluid from patients with sarcoidosis, silicosis or idiopathic pulmonary Rbrosis: relationship to disease severity.
Sarcoma
Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
Clonal variation of expression of the genes coding for plasminogen activators, their inhibitors and the urokinase receptor in HT1080 sarcoma cells.
Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.
Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients.
Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells.
Down-regulation of plasmin receptors on human sarcoma cells by glucocorticoids.
Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma.
One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity.
Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages.
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.
Quercetin inhibits migration and invasion of SAS human oral cancer cells through inhibition of NF-?B and matrix metalloproteinase-2/-9 signaling pathways.
Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.
Targeting angiogenesis for the treatment of sarcoma.
Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors.
Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells.
Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts.
Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas.
Sarcoma, Avian
An inhibitor of plasminogen activator in rabbit endothelial cells.
Direct fluorescent assay of urokinase and plasminogen activators of normal and malignant cells: kinetics and inhibitor profiles.
Plasminogen activator gene expression is induced by the src oncogene product and tumor promoters.
Receptors for plasminogen activator, urokinase, in normal and Rous sarcoma virus-transformed mouse fibroblasts.
Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.
Serine protease and metallo protease cascade systems involved in pericellular proteolysis.
Sarcoma, Ewing
The course of fibrinolytic proteins in children with malignant bone tumours.
Sarcoma, Kaposi
Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi sarcoma cells.
Over-expression of hepatocyte growth factor in human Kaposi's sarcoma.
The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study.
The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
Sarcopenia
Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls.
Schistosomiasis
A case control study on the structural equation model of the mechanism of coagulation and fibrinolysis imbalance in chronic schistosomiasis.
The pathogenesis of accelerated fibrinolysis in hepatosplenic schistosomiasis.
Scleroderma, Diffuse
Neural blockade, urokinase and prostaglandin E1 combination therapy for acute digital ischemia of progressive systemic sclerosis.
Successful treatment of continuous intra-arterial administration of prostaglandin E1, urokinase and heparin for intractable digital ulcers by upper extremity arterial occlusion in diffuse cutaneous systemic sclerosis patient.
Scleroderma, Systemic
A placebo-controlled study on urokinase therapy in systemic sclerosis.
Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis.
Clinical improvement in systemic sclerosis resulting from urokinase therapy explained by light and electron microscopy skin examination.
Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells.
Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression.
Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis.
Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis.
N-Formyl Peptide Receptors Induce Radical Oxygen Production in Fibroblasts Derived From Systemic Sclerosis by Interacting With a Cleaved Form of Urokinase Receptor.
Successful treatment of continuous intra-arterial administration of prostaglandin E1, urokinase and heparin for intractable digital ulcers by upper extremity arterial occlusion in diffuse cutaneous systemic sclerosis patient.
Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor.
Seizures
Deficiency of urokinase-type plasminogen activator and its receptor affects social behavior and increases seizure susceptibility.
Hepatocyte growth factor (HGF) modulates GABAergic inhibition and seizure susceptibility.
Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies.
Treatment of severe intraventricular hemorrhage by intraventricular infusion of urokinase.
Urokinase receptor and tissue plasminogen activator as immediate-early genes in pentylenetetrazole-induced seizures in the mouse brain.
Urokinase-type plasminogen activator deficiency has little effect on seizure susceptibility and acquired epilepsy phenotype but reduces spontaneous exploration in mice.
Seminoma
Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas.
Sepsis
A case of intractable methicillin-resistant Staphylococcus aureus sepsis after an operation for tetralogy of Fallot that was successfully resolved by combined treatment with vancomycin and urokinase.
A Comparative Study of the Diagnostic and Prognostic Utility of Soluble Urokinase-type Plasminogen Activator Receptor and Procalcitonin in Patients with Sepsis and Systemic Inflammation Response Syndrome.
A prospective randomized double-blind trial of bolus urokinase in the treatment of established Hickman catheter sepsis in children.
A prospective randomized trial of urokinase as an adjuvant in the treatment of proven Hickman catheter sepsis.
A Retrospective Study of Preferable Alternative Route to Right Internal Jugular Vein for Placing Tunneled Dialysis Catheters: Right External Jugular Vein versus Left Internal Jugular Vein.
Are urokinase rinses needed to reduce catheter-related bloodstream infections when standard preventive guidelines are observed?
Assessment of Fibrinolysis in Sepsis Patients with Urokinase Modified Thromboelastography.
Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice.
Blood suPAR, Th1 and Th17 cell may serve as potential biomarkers for elderly sepsis management.
Catheter-related sepsis refractory to antibiotics treated successfully with adjunctive urokinase infusion.
Clinical value of plasma soluble urokinase-type plasminogen activator receptor levels in term neonates with infection or sepsis: a prospective study.
Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis.
Diagnostic value of decoy receptor 3 combined with procalcitonin and soluble urokinase-type plasminogen activator receptor for sepsis.
Effect of ascorbate on fibrinolytic factors in septic mouse skeletal muscle.
Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission.
Neutrophils are a main source of circulating suPAR predicting outcome in critical illness.
Plasma soluble vascular endothelial growth factor receptor-1 levels predict outcomes of pneumonia-related septic shock patients: a prospective observational study.
Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis.
Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group.
Prospective analysis of urokinase in the treatment of catheter sepsis in pediatric hematology-oncology patients.
Prospective randomized comparison of valved versus nonvalved peripherally inserted central vein catheters.
Protein kinase C-? mediates sepsis-induced activation of complement 5a and urokinase-type plasminogen activator signaling in macrophages.
Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor.
Role of suPAR and Lactic Acid in Diagnosing Sepsis and Predicting Mortality in Elderly Patients.
Serum Levels of Soluble Urokinase Plasminogen Activator Receptor in Infants with Late-onset Sepsis.
Serum plasminogen activator urokinase receptor predicts elevated risk of acute respiratory distress syndrome in patients with sepsis and is positively associated with disease severity, inflammation and mortality.
Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis.
Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit.
Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients.
Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study.
suPAR as a marker of infection in acute kidney injury - a prospective observational study.
suPAR remains uninfluenced by surgery in septic patients with bloodstream infection.
The effect of perirenal puncture and drainage with urokinase treatment of perirenal hematoma complicated by infection: Two cases' report.
The Prognostic Value of suPAR Compared to Other Inflammatory Markers in Patients with Severe Sepsis.
The role of the soluble urokinase plasminogen activator (suPAR) in children with pneumonia.
The use of soluble urokinase plasminogen activator receptor (suPAR) as a marker of sepsis in the emergency department setting. A current review.
Thrombolysis of occluded synthetic bypass grafts in the lower limb: technical success and 1-year follow-up in 32 patients.
Urokinase lock or flush solution for prevention of bloodstream infections associated with central venous catheters for chemotherapy: a meta-analysis of prospective randomized trials.
Urokinase-type plasminogen activator protects human umbilical vein endothelial cells from apoptosis in sepsis.
[Cannulation of the internal jugular vein with 2 silastic catheters. A new method of vascular access for hemodialysis]
[Diagnostic therapeutic problems of defibrination syndrome in shock, sepsis, and neonatal hypoxia (author's transl)]
[Usefulness of sCD14-ST in the diagnosis of sepsis in patient with renal failure].
Severe Combined Immunodeficiency
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.
Cross-species transmission of gibbon and orangutan hepatitis B virus to uPA/SCID mice with human hepatocytes.
Current status of prediction of drug disposition and toxicity in humans using chimeric mice with humanized liver.
Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes.
Human hepatocyte propagation system in the mouse livers: functional maintenance of the production of coagulation and anticoagulation factors.
Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens.
Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin.
Practical Evaluation of a Mouse with Chimeric Human Liver Model for Hepatitis C Virus Infection Using an NS3-4A Protease Inhibitor.
Shock, Septic
Fibrinolysis and coagulation in patients with infectious disease and sepsis.
The effect of perirenal puncture and drainage with urokinase treatment of perirenal hematoma complicated by infection: Two cases' report.
Sigmoid Neoplasms
Isolated splenic metastasis of sigmoid colon cancer: a case report.
Silicosis
Depressed urokinase activity in bronchoalveolar lavage fluid from patients with sarcoidosis, silicosis or idiopathic pulmonary Rbrosis: relationship to disease severity.
Sinus Thrombosis, Intracranial
Acute thrombosis of the intracranial dural sinus: direct thrombolytic treatment.
An acute cerebral venous sinus thrombosis: successful treatment by combining mechanical thrombolysis with continuous urokinase infusion.
Direct endovascular thrombolytic therapy for dural sinus thrombosis.
Heparin-urokinase treatment in aseptic dural sinus thrombosis.
Intrasinus thrombolysis by mechanical and urokinase for severe cerebral venous sinus thrombosis : a case report.
Mechanical thrombolysis for treatment of acute sinus thrombosis--case report.
Sagittal sinus thrombosis following minor head injury treated with continuous urokinase infusion.
Selective infusion of urokinase and thrombectomy in the treatment of acute cerebral sinus thrombosis.
Thrombolytic therapy in acute stroke.
Treatment of dural sinus thrombosis by urokinase infusion.
Treatment of dural sinus thrombosis using selective catheterization and urokinase.
Treatment of dural sinus thrombosis with local urokinase infusion. Case report.
Urokinase treatment of sagittal sinus thrombosis with venous hemorrhagic infarction.
Use of thrombolytic therapy in cerebral venous sinus thrombosis with ulcerative colitis.
[Effects of injecting urokinase via carotid artery in treatment of cerebral venous sinus thrombosis: an experiment with rabbit models]
[Nephrotic syndrome complicated with intracranial venous thrombosis treated with urokinase: report of 5 cases]
[Nursing care of patients with sinus thrombosis treated with urokinase administered via transcarotid injection]
Sinusitis
Urokinase-type plasminogen activator and plasminogen activator inhibitor antigen in tissue extracts of paranasal sinus mucous membranes affected by chronic sinusitis and antrochoanal polyps.
Skin Diseases
Expression of plasminogen activator enzymes in psoriatic epidermis.
UVB increases urokinase-type plasminogen activator receptor (uPAR) expression.
Skin Neoplasms
Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin.
Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.
Small Cell Lung Carcinoma
Amurubicinol-induced eotaxin-3 expression in human NCI-H69 small cell lung carcinoma cells.
Camptothecin induces urokinase-type plasminogen activator gene-expression in human RC-K8 malignant lymphoma and H69 small cell lung cancer cells.
Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells.
Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells.
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer.
Urokinase combination chemotherapy in small cell lung cancer. A phase II study.
[Effects of MnSOD silence on in vitro tumorigenicity in NCI-H446 cells].
Solitary Kidney
Fibrinolytic therapy for renal vein thrombosis in the child.
Upper tract urokinase instillation for nephrostomy tube patency.
Spasm
Neural blockade, urokinase and prostaglandin E1 combination therapy for acute digital ischemia of progressive systemic sclerosis.
Spinal Dysraphism
Amniotic fluid fibrinolytic system in fetal neural tube defects.
Spondylitis, Ankylosing
Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis.
Squamous Cell Carcinoma of Head and Neck
A novel 3-dimensional culture system as an in vitro model for studying oral cancer cell invasion.
Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - ?1 (TGF-?1) and potential effects on migration and invasion.
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Differential expression levels of urokinase-type plasminogen activator and cathepsin D in locally advanced laryngeal squamous cell carcinoma: clinical implications.
Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin.
Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma.
Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Keratinocytes and head and neck squamous cell carcinoma cells regulate urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in fibroblasts.
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
PLAU1 Facilitated Proliferation, Invasion, and Metastasis via Interaction With MMP1 in Head and Neck Squamous Carcinoma.
Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.
Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma.
RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo.
SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
Silencing of uPAR via RNA interference inhibits invasion and migration of oral tongue squamous cell carcinoma.
Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes.
Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC).
Urokinase receptor up-regulation in head and neck squamous cell carcinoma.
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
Urokinase-type plasminogen activator expression and proliferation stimulation in head and neck squamous cell carcinoma in vitro and in situ.
Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.
[Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma]
[Expressions and clinical significance of urokinase-type activator (uPA) and uPA receptor (uPAR) in laryngeal squamous cell carcinoma]
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[Methylation status of uPA promoter in laryngeal squamous cell carcinoma]
[The expression of urokinase-type plasminogen activator in oral squamous cell carcinoma]
[The relationship between the activation of ERK and the up-regulation of uPA in laryngeal squamous cell carcinoma]
[Urokinase-type plasminogen activator (uPA) and its inhibitor--new prognostic factors in oral squamous cell carcinoma]
ST Elevation Myocardial Infarction
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Long-term outcome of patients with ST-segment elevation myocardial infarction treated with low-dose intracoronary thrombolysis during primary percutaneous coronary intervention: the 5-year results of the DISSOLUTION Trial.
Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction.
Staphylococcal Infections
Persistent catheter-related bacteremia: clearance with antibiotics and urokinase.
Status Epilepticus
Epileptogenesis after traumatic brain injury in Plau-deficient mice.
Urokinase-type plasminogen activator regulates neurodegeneration and neurogenesis but not vascular changes in the mouse hippocampus after status epilepticus.
Stomach Diseases
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer.
Stomach Neoplasms
Cadmium induces urokinase-type plasminogen activator receptor expression and the cell invasiveness of human gastric cancer cells via the ERK-1/2, NF-?B, and AP-1 signaling pathways.
CD87-positive tumor cells in bone marrow aspirates identified by confocal laser scanning fluorescence microscopy.
Clinicopathological significance of urokinase-type plasminogen activator genotypes in gastric cancer.
Correlation between expression of urokinase-type plasminogen activator receptor and metastasis in gastric carcinoma.
Defining the invasive phenotype of proximal gastric cancer cells.
Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer.
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer.
Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis.
Effects of angiopoietin-1 on attachment and metastasis of human gastric cancer cell line BGC-823.
EGF stimulates uPAR expression and cell invasiveness through ERK, AP-1, and NF-kappaB signaling in human gastric carcinoma cells.
EGF-induced urokinase plasminogen activator receptor promotes epithelial to mesenchymal transition in human gastric cancer cells.
Expression of HLA-DR and urokinase-type plasminogen activator in stage IV gastric cancer.
Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer.
Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Extracellular signal-regulated kinase and AP-1 pathways are involved in reactive oxygen species-induced urokinase plasminogen activator receptor expression in human gastric cancer cells.
Fibrinolysis-inhibitory activity of cultured human cancer cell lines.
Helicobacter pylori stimulates urokinase plasminogen activator receptor expression and cell invasiveness through reactive oxygen species and NF-kappaB signaling in human gastric carcinoma cells.
Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer.
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer.
IL-1?-stimulated urokinase plasminogen activator expression through NF-?B in gastric cancer after HGF treatment.
Immunological analysis of plasminogen activators from cultured human cancer cells.
In vitro activity of probiotic Lactobacillus reuteri against gastric cancer progression by downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor gene expression.
Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer.
Lysophosphatidic acid promotes cell invasion by up-regulating the urokinase-type plasminogen activator receptor in human gastric cancer cells.
Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.
MSP-induced RON activation upregulates uPAR expression and cell invasiveness via MAPK, AP-1 and NF-?B signals in gastric cancer cells.
Overexpression of forkhead box M1 and urokinase-type plasminogen activator in gastric cancer is associated with cancer progression and poor prognosis.
Overexpression of urokinase-type plasminogen activator in human gastric cancer cell line (AGS) induces tumorigenicity in severe combined immunodeficient mice.
p75 neurotrophin receptor inhibits invasion and metastasis of gastric cancer.
Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid.
Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
Prognostic factors in gastric cancer.
Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.
Prognostic role of urokinase plasminogen activator receptor in gastric and colorectal cancer: A systematic review and meta-analysis.
Prognostic value of urokinase-type plasminogen activators in gastric-cancer.
Prostaglandin E2 stimulates urokinase-type plasminogen activator receptor via EP2 receptor-dependent signaling pathways in human AGS gastric cancer cells.
Reactive oxygen species regulate urokinase plasminogen activator expression and cell invasion via mitogen-activated protein kinase pathways after treatment with hepatocyte growth factor in stomach cancer cells.
Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines.
Relationship between expression of plasminogen activator system and metastatic ability in human cancers.
Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer.
Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer.
Role of urokinase plasminogen activator receptor in gastric cancer: a potential therapeutic target.
Semaphorin 5A promotes gastric cancer invasion/metastasis via urokinase-type plasminogen activator/phosphoinositide 3-kinase/protein kinase B.
Seroprevalence of Helicobacter pylori/CagA Antibodies in Guatemalan Gastric Cancer Patients: Association of Seropositivity with Increased Plasma Levels of Pepsinogens but not Soluble Urokinase Plasminogen Activator Receptor.
Src/ERK but not phospholipase D is involved in keratinocyte growth factor-stimulated secretion of matrix metalloprotease-9 and urokinase-type plasminogen activator in SNU-16 human stomach cancer cell.
Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells.
The Clinical Study of Urokinase-Type Plasminogen Activator and Vascular Endothelial Growth Factor in Gastric Cancer.
The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells.
The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer.
The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer.
Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
Upregulation of circulating cytokeratin 20, urokinase plasminogen activator and C-reactive protein is associated with poor prognosis in gastric cancer.
Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries.
Urokinase plasminogen activator receptor is upregulated by Helicobacter pylori in human gastric cancer AGS cells via ERK, JNK, and AP-1.
Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma.
Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines.
Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.
[Clinical evaluation of various antineoplastic agents combined with urokinase--a comparison between urokinase from tissue culture (TCUK) and urine-derived urokinase (UUK)]
[Correlation between the expression of urokinase-type plasminogen activator, E-cadherin and malignancy in gastric cancer]
[Effects of S-adenosylmethionine on gastric cancer cell lines SGC-7901 and BGC-823].
[Relationship between urokinase-type plasminogen activator expression and peritoneal metastatic potency in different gastric cancer cell lines]
[uPA expression of gastric cancer cell lines and its correlation with peritoneal seeding]
[Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer]
Stomach Ulcer
Reduced tissue type plasminogen activator activity of the gastroduodenal mucosa in peptic ulcer disease.
Streptococcal Infections
A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection.
Stroke
A Combined Treatment with Taurine and Intra-arterial Thrombolysis in an Embolic Model of Stroke in Rats: Increased Neuroprotective Efficacy and Extended Therapeutic Time Window.
Acute stroke intervention with intraarterial urokinase infusion.
Amino acid supplementation enhances urokinase production by HT-1080 cells.
Angioplasty of the occluded internal carotid artery.
Clinical potential of intra-arterial thrombolytic therapy in patients with acute ischaemic stroke.
Clinical, Biochemical and Neuroimaging Parameters after Thrombolytic Therapy Predict Long-Term Stroke Outcome.
Comparative Analysis of Endovascular Stroke Therapy Using Urokinase, Penumbra System and Retrievable (Solitare) Stent.
Comparative study on the efficacy and safety of alteplase and urokinase in the treatment of acute cerebral infarction.
Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign.
Corrigendum to "Comparative Analysis of Fibrinolytic Properties of Alteplase, Tenecteplase and Urokinase in an in Vitro Clot Model of Intracerebral Haemorrhage. [Journal of Stroke and Cerebrovascular Diseases, Vol. 29, No. 9 (September), 2020: 105073]".
CT after intracranial intraarterial thrombolysis for acute stroke.
Dynamical levels of plasma F(1+2) and D-dimer in patients with acute cerebral infarction during intravenous urokinase thrombolysis.
Early infarct growth predicts long-term clinical outcome after thrombolysis.
Effects of Intra-arterial Urokinase on a Non-human Primate Thromboembolic Stroke Model.
Efficacy of intraarterial thrombolysis of basilar artery stroke.
Emergent middle cerebral artery embolectomy: a useful technique for cranial base surgery.
Emerging technologies in therapeutic ultrasound: thermal ablation to gene delivery.
Endovascular neuroradiological treatment of acute ischemic stroke: techniques and results in 350 patients.
Factors predicting hemorrhagic complications after multimodal reperfusion therapy for acute ischemic stroke.
Fiber-Reinforced Silk Composite for Enhanced Urokinase Production Using High-Density Perfusion Culture and Bioactive Molecule Supplementation.
In vitro simulation of therapeutic plasmatic fibrinolysis.
Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase.
Initial angiographic appearance of intracranial vascular occlusions in acute stroke as a predictor of outcome of thrombolysis: initial experience.
Intra-arterial thrombolysis in 100 patients with acute stroke due to middle cerebral artery occlusion.
Intra-arterial thrombolysis in 24 consecutive patients with internal carotid artery T occlusions.
Intra-arterial thrombolysis in basilar artery occlusion and recent haemorrhagic stroke due to arteriovenous malformation.
Intra-arterial urokinase for acute ischemic stroke: factors associated with complications.
Intraarterial thrombolytic therapy within 3 hours of the onset of stroke.
Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke.
Intracranial thrombolysis via a catheter embedded in the clot.
Intraoperative high-dose regional urokinase infusion for cerebrovascular occlusion after carotid endarterectomy.
Intraoperative intraarterial urokinase in early postoperative stroke following carotid endarterectomy: a useful adjunct.
Intravenous glycoprotein IIb/IIIa inhibitor (tirofiban) followed by intra-arterial urokinase and mechanical thrombolysis in stroke.
Intravenous Glycoprotein IIb/IIIa Inhibitor (Tirofiban) Followed by Low-Dose Intra-Arterial Urokinase and Mechanical Thrombolysis for the Treatment of Acute Stroke.
Intravenous Glycoprotein IIb/IIIa inhibitor (Tirofiban) Followed by Low-dose Intra-arterial Urokinase and Mechanical Thrombolysis for the Treatment of Stroke.
Intravenous thrombolysis guided by a telemedicine consultation system for acute ischaemic stroke patients in China: the protocol of a multicentre historically controlled study.
Intravenous tirofiban with intra-arterial urokinase and mechanical thrombolysis in stroke: preliminary experience in 11 cases.
Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA).
Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan.
Long-term effect of intra-arterial thrombolysis in stroke.
Medical therapy for ischemic stroke.
Multivariable analysis of predictive factors related to outcome at 6 months after intra-arterial thrombolysis for acute ischemic stroke.
Oral urokinase: absorption, mechanisms of fibrinolytic enhancement and clinical effect on cerebral thrombosis.
Outcome evaluation of intravenous infusion of urokinase for acute ischemic stroke.
Outcome in acute stroke with different intra-arterial infusion rate of urokinase on thrombolysis.
Randomized clinical stroke trials in 2007.
Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan.
Rationale and design of a phase 3b, prospective, randomized, open label, blinded-endpoint, multicenter trial of the efficacy and safety of urokinase thrombolysis comparing with antiplatelet agents for patients with minor stroke.
Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Reocclusion and stroke due to immediate plaque protrusion following endovascular treatment of carotid artery successfully treated with intra-arterial urokinase and stent in stent in a patient with Takayasu arteritis with severe disease of all arch vessels.
Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke.
Safety and efficacy of delayed intraarterial urokinase therapy with mechanical clot disruption for thromboembolic stroke.
Safety and Efficacy of Intra-arterial Urokinase After Failed, Unsuccessful, or Incomplete Mechanical Thrombectomy in Anterior Circulation Large-Vessel Occlusion Stroke.
Selective intra arterial thrombolysis in acute carotid territory stroke.
Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
Soluble Urokinase-type Plasminogen Activator Receptor Predicts All-cause 5-Year Mortality in Ischemic Stroke and TIA.
Successful recanalization post endovascular therapy is associated with a decreased risk of intracranial haemorrhage: a retrospective study.
Symptomatic intracranial haemorrhage after intra-arterial thrombolysis in acute ischaemic stroke: assessment of 294 patients treated with urokinase.
Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke.
The beneficial effect of intracarotid urokinase on acute stroke in a baboon model.
The importance of selected markers of inflammation and blood-brain barrier damage for short-term ischemic stroke prognosis.
Thrombolysis in acute stroke without angiographically documented occlusion.
[Intraarterial urokinase infusion therapy for the acute intracranial major artery occlusion]
[New methods of intensive therapy in stroke: hemicraniectomy in patients with complete middle cerebral artery infarction and treatment of intracerebral and intraventricular hemorrhage with urokinase]
[Risk factors for intracerebral hemorrhage after intravenous thrombolysis in acute cerebral infarction]
[Thrombolytic therapy in ischemic infarct]
Stroke, Lacunar
[Clinical effects of urokinase and sodium ozagrel in patients with acute symptomatic lacunar infarction]
Subarachnoid Hemorrhage
Cisternal irrigation therapy with urokinase and ascorbic acid for prevention of vasospasm after aneurysmal subarachnoid hemorrhage. Outcome in 217 patients.
Combined cisternal drainage and intrathecal urokinase injection therapy for prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
Comparison of Intrathecally Administered Urokinase, Tissue-type Plasminogen Activator, and Combination of Urokinase and Lysine-Plasminogen for Clot Lysis after Experimental Subarachnoid Hemorrhage in Dogs.
Development of a kit to treat subarachnoid hemorrhage by intrathecal simple urokinase infusion (ITSUKI) therapy: preliminary results in patients with World Federation of Neurological Surgery (WFNS) grade V subarachnoid hemorrhage.
Effectiveness of the head-shaking method combined with cisternal irrigation with urokinase in preventing cerebral vasospasm after subarachnoid hemorrhage.
Intrathecal urokinase infusion through a microcatheter into the cisterna magna to prevent cerebral vasospasm: experimental study in dogs.
Microthrombosis after experimental subarachnoid hemorrhage: time course and effect of red blood cell-bound thrombin-activated pro-urokinase and clazosentan.
Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Is Not Associated with Neurological Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage.
Stereotactic cisternal lavage in patients with aneurysmal subarachnoid hemorrhage with urokinase and nimodipine for the prevention of secondary brain injury (SPLASH): study protocol for a randomized controlled trial.
The effect of urokinase in preventing the formation of epidural fibrosis and/or leptomeningeal arachnoiditis.
Thrombus in vertebrobasilar dolichoectatic artery treated with intravenous urokinase.
Urokinase cisternal irrigation therapy for prevention of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage: a study of urokinase concentration and the fibrinolytic system.
[Combining exchange of cerebrospinal fluid with small dose of urokinase injection for subarachnoid hemorrhage]
Superior Vena Cava Syndrome
Late vascular occlusion of central lines in pediatric malignancies.
Successful treatment of superior vena cava syndrome with urokinase in an infant with a central venous catheter.
Successful treatment of superior vena cava syndrome with urokinase in an infant.
Successful urokinase therapy for superior vena cava syndrome in a premature infant.
Urokinase. A cost-effective alternative treatment of superior vena cava thrombosis and obstruction.
Syncope
Kawasaki Disease Complicated by Late-Onset Fatal Cerebral Infarction: A Case Report and Literature Review.
Tumor necrosis factor (TNF) stimulates plasminogen activator inhibitor (PAI) production by endothelial cells and decreases blood fibrinolytic activity in the rat.
t-plasminogen activator deficiency
Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity.
Takayasu Arteritis
Reocclusion and stroke due to immediate plaque protrusion following endovascular treatment of carotid artery successfully treated with intra-arterial urokinase and stent in stent in a patient with Takayasu arteritis with severe disease of all arch vessels.
Suction thrombectomy of thrombotic occlusion of the subclavian artery in a case of Takayasu's arteritis.
Telangiectasis
Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis.
Temporomandibular Joint Disorders
Gene expression of fibrinolytic factors urokinase plasminogen activator and plasminogen activator inhibitor-1 in rabbit temporo-mandibular joint cartilage with disc displacement.
[Expression of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in synovial fluid of patients with temporomandibular disorders]
Teratocarcinoma
Teratocarcinoma F9 cells induced to differentiate with sodium butyrate produce both tissue-type and urokinase-type plasminogen activators.
The expression and localization of urokinase-type plasminogen activator and its type 1 inhibitor are regulated by retinoic acid and fibroblast growth factor in human teratocarcinoma cells.
Tetralogy of Fallot
A case of intractable methicillin-resistant Staphylococcus aureus sepsis after an operation for tetralogy of Fallot that was successfully resolved by combined treatment with vancomycin and urokinase.
Thoracic Outlet Syndrome
Treatment of a case of thromboembolism resulting from thoracic outlet syndrome with intra-arterial urokinase infusion.
Thromboangiitis Obliterans
Assessment of plasma prothrombotic factors in patients with Buerger's disease.
Superselective urokinase infusion therapy for dorsalis pedis artery occlusion in Buerger's disease.
[Intrathrombotic injection of urokinase in Buerger's disease]
Thrombocythemia, Essential
Overexpression of PRV-1 gene in polycythemia rubra vera and essential thrombocythemia.
Thrombocytopenia
Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice.
Heparin-induced thrombocytopenia II-induced critical limb ischaemia treated with urokinase and argatroban.
Heparin-induced thrombocytopenia in a glioblastoma multiforme patient with inferior vena cava filter placement for deep venous thrombosis.
Intraoperative urokinase as an alternative to heparin for patients with suspected heparin-induced thrombocytopenia requiring arterial reconstruction: report of a case and review of the literature.
Pulse-spray catheter-directed thrombolysis with urokinase and argatroban for thrombo-occlusion of an inferior vena cava filter due to heparin-induced thrombocytopenia with thrombosis.
Successful treatment of veno-occlusive disease of the liver with urokinase in a patient with non-Hodgkin's lymphoma.
The heparin-induced thrombocytopenia and thrombosis syndrome: treatment with intraarterial urokinase and systemic platelet aggregation inhibitors.
Thrombolytic therapy in heparin-associated thrombocytopenia with thrombosis.
[Calcium heparin-induced immunologic thrombocytopenia complicated with venous gangrene of the legs. Report of a clinical case]
Thromboembolism
Fiber-Reinforced Silk Composite for Enhanced Urokinase Production Using High-Density Perfusion Culture and Bioactive Molecule Supplementation.
Local Intra-Arterial Administration of Urokinase in the Treatment of a Feline Distal Aortic Thromboembolism.
Local urokinase in arterial thromboembolism.
Recombinant tissue plasminogen activator treatment of pulmonary embolism also improves deep venous thrombosis.
Stenting the stent: alternative strategy for treating in-stent restenosis.
Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.
Treatment of a case of thromboembolism resulting from thoracic outlet syndrome with intra-arterial urokinase infusion.
[Possibilities and limits of local intra-arterial fibrinolysis in thromboembolic vascular occlusions of the central nervous system]
[Thrombolysis of cerebral thromboembolism by urokinase in an animal model]
[Thrombolytic therapy in patients with pulmonary artery thromboembolism and deep vein thrombosis].
Thrombophilia
Hypofibrinolysis in patients with hypercoagulability: the roles of urokinase and of plasminogen activator inhibitor.
[A method for determining plasminogen with a Russian chromogenic substrate and its diagnostic significance]
Thrombophlebitis
A case of idiopathic deep vein thrombosis improved with glucocorticoid therapy.
[Non-Hodgkin's lymphoma with marked infiltration in calf muscle]
Thrombosis
A Bi-Functional Anti-Thrombosis Protein Containing Both Direct-Acting Fibrin(ogen)olytic and Plasminogen-Activating Activities.
A chimeric platelet-targeted urokinase prodrug selectively blocks new thrombus formation.
A comparative study of urokinase and heparin in the treatment of deep vein thrombosis.
A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators.
A critical appraisal of the small-diameter portacaval H-graft.
A highly reproducible model of arterial thrombosis in rats.
A new "wonder" drug to dissolve clots. The results of urokinase therapy in acute myocardial infarction, pulmonary embolism and deep vein thrombosis.
A prospective randomized trial of urokinase as an adjuvant in the treatment of proven Hickman catheter sepsis.
A protocol of urokinase infusion and warfarin for the management of the thrombosed haemodialysis catheter.
A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters.
A randomized, placebo-controlled pilot study of patients with spontaneous intraventricular haemorrhage treated with intraventricular thrombolysis.
A targeted antithrombotic conjugate with antiplatelet and fibrinolytic properties which reduces in vivo thrombus formation.
A trial comparing rheolytic thrombectomy with intracoronary urokinase for coronary and vein graft thrombus (the Vein Graft AngioJet Study [VeGAS 2]).
Acute bilateral renal vein thrombosis superimposed on calcified thrombus of the inferior vena cava in a patient with membranous lupus nephritis.
Acute Early Carotid Stent Thrombosis: A Case Series.
Acute extensive portal and mesenteric venous thrombosis after splenectomy: treated by interventional thrombolysis with transjugular approach.
Acute myocardial infarction in a patient with essential thrombocythemia: successful treatment with percutaneous transluminal coronary recanalization.
Acute portal vein thrombosis due to chronic relapsing pancreatitis: a fistula between a pancreatic pseudocyst and the splenic vein.
Acute renal allograft dysfunction in the setting of deep venous thrombosis: a case of successful urokinase thrombolysis and a review of the literature.
Acute renal vein thrombosis: successful treatment with intraarterial urokinase.
Acute symptomatic mesenteric venous thrombosis: treatment by catheter-directed thrombolysis with transjugular intrahepatic route.
Acute thrombosis of a vena cava filter with a clot above the filter. Successful treatment with low-dose urokinase.
Additive fibrinolysis by recombinant tissue-type plasminogen activator (r-t-PA) and recombinant single-chain urokinase type plasminogen activator (r-scu-PA) in rabbit pulmonary thrombosis.
Adenoviral urokinase-type plasminogen activator (uPA) gene transfer enhances venous thrombus resolution.
Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA Trial. TAUSA Investigators. Thrombolysis and Angioplasty in Unstable Angina trial.
Admixture of heparin with urokinase to decrease thrombolysis time and urokinase dose in polytetrafluoroethylene dialysis graft recanalization.
Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis.
Ancrod enhances the thrombolytic effect of streptokinase and urokinase.
Angiographic features in the infarct-related artery after intracoronary urokinase followed by prolonged anticoagulation. Role of ruptured atheromatous plaque and adherent thrombus in acute myocardial infarction in vivo.
AngioJet Aspiration Thrombectomy Combined with Transcatheter Thrombolysis in Treatment of Acute Portal Venous Systemic Thrombosis.
AngioJet rheolytic thrombectomy versus local intrapulmonary thrombolysis in massive pulmonary embolism: a retrospective data analysis.
Anterograde injection of low-dose urokinase salvages free anterolateral thigh flap: A case report of safe and effective treatment.
Anterograde intra-arterial urokinase injection for salvaging fibular free flap.
Antithrombotic benefit of subendothelium-bound urokinase: an experimental study.
Antithrombotic effects by oral administration of novel proteinase fraction from earthworm Eisenia andrei on venous thrombosis model in rats.
Aortic thrombosis in a neonate: failure of urokinase thrombolytic therapy.
Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding.
Approach to thrombotic occlusion related to long-term catheters of hemodialysis patients: a narrative review.
Arterial thrombus dissolution in vivo using a transducer-tipped, high-frequency ultrasound catheter and local low-dose urokinase delivery.
Arthritis simulating thrombosis on urokinase scan.
Augmented pulse-spray thrombolysis with tPA by early pulsed intrathrombic plasminogen enrichment.
Axillary artery compression and thrombosis in throwing athletes.
Beneficial effect of aspirin in maintaining the patency of small-caliber prosthetic grafts after thrombolysis with urokinase or tissue-type plasminogen activator.
Bilateral renal venous thrombosis in a neonate associated with resistance to activated protein C.
Binding of human tissue plasminogen activator (t-PA) to blood clots and clot-lytic activity of clot-bound t-PA.
Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
Bleeding complications after basilar artery fibrinolysis with tissue plasminogen activator.
Blood coagulation changes during effective thrombolysis using urokinase and heparin.
Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
Catheter occlusion by calcium carbonate during simultaneous infusion of 5-FU and calcium folinate.
Catheter-based local thrombolysis with urokinase: comparative efficacy of intraluminal clot lysis with conventional urokinase infusion techniques in an in vivo porcine thrombus model.
Catheter-directed thrombolysis following vena cava filtration for severe deep venous thrombosis.
Catheter-directed thrombolytic therapy combined with angioplasty for hepatic vein obstruction in Budd-Chiari syndrome complicated by thrombosis.
Catheter-directed thrombolytic therapy for thoracic deep vein thrombosis is safe and effective in selected patients with and without cancer.
Central venous line thrombosis in premature infants: a case management and literature review.
Cerebral venous congestion as indication for thrombolytic treatment.
Characterization of wild-type and mutant alpha2-antiplasmins: fibrinolysis enhancement by reactive site mutant.
Chronic and acute consequences of a post-dialysis urokinase lock on permanent hemodialysis catheter function.
Circumferential venolysis and paraclavicular thoracic outlet decompression for "effort thrombosis" of the subclavian vein.
Clinical improvement related to thrombolysis of third ventricular blood clot in a patient with thalamic hemorrhage.
Clinical outcomes of transcatheter selective superior mesenteric artery urokinase infusion therapy
Collateral circulation and outcome after basilar artery thrombolysis.
Combination of Surgical Thrombectomy and Direct Thrombolysis in Acute Abdomen with Portal and Superior Mesenteric Vein Thrombosis.
Combined catheter thrombus fragmentation and fibrinolysis for acute pulmonary embolism.
Combined Low-Frequency Ultrasound and Urokinase-Containing Microbubbles in Treatment of Femoral Artery Thrombosis in a Rabbit Model.
Combined modality of mechanical breakdown and intraembolus thrombolysis in failed systemic thrombolysis of subacute pulmonary embolism patients.
Combined thrombolytic and anticoagulant therapy for venous thrombosis in children.
Combined thrombolytic therapy for atrial thrombus in a preterm infant.
Combined, superselective pharmacological management of large coronary thrombus burden.
Comparative results of thrombolysis treatment with rt-PA and urokinase: a pilot study.
Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.
Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator.
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Comparative tolerability profiles of thrombolytic agents. A review.
Comparison of catheter-directed thrombolysis with and without percutaneous mechanical thrombectomy for subacute iliofemoral deep vein thrombosis.
Comparison of cost effectiveness of streptokinase and urokinase in the treatment of deep vein thrombosis.
Comparison of Direct Iliofemoral Stenting Following AngioJet Rheolytic Thrombectomy vs Staged Stenting After AngioJet Rheolytic Thrombectomy Plus Catheter-Directed Thrombolysis in Patients With Acute Deep Vein Thrombosis.
Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
Comparison of ReoPro((R)) (abciximab) versus intracoronary thrombolysis for early coronary stent thrombosis.
Comparison of retavase and urokinase for management of spontaneous subclavian vein thrombosis.
Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Comparison of the thrombolytic efficacy of defibrase and urokinase on canine coronary artery thrombosis and the mechanism of urokinase-induced hemorrhage.
Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis.
Complex tumors of the glomus jugulare: criteria, treatment, and outcome.
Concentrated sodium chloride catheter lock solution - a new effective alternative method for hemodialysis patients with high bleeding risk.
Congenital protein C deficiency causing major arterial thrombosis in a neonate.
Continuous infusion of low-dose urokinase in the treatment of central venous catheter thrombosis in infants and children.
Continuous local intra-arterial infusion of anticoagulants for digit replantation and treatment of damaged arteries.
Contrast-enhanced sonothrombolysis in a porcine model of acute peripheral arterial thrombosis and prevention of anaphylactic shock.
Copper vapor laser and optical fiber catheter system for liquefaction and removal of thrombus in occluded arteries.
Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis.
Coronary spasm in two sisters.
Coronary thrombolysis and endothelin-1 release.
Coronary thrombolysis. Comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase.
Cost-effectiveness of intra-arterial thrombolytic therapy.
Criteria for use of regional urokinase infusion for deep vein thrombosis.
Crucial Involvement of IL-6 in Thrombus Resolution in Mice via Macrophage Recruitment and the Induction of Proteolytic Enzymes.
Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis.
Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
Defibrotide is equipotent to urokinase in stimulating arterial and venous thrombolysis.
Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema.
Dependence of blood clot lysis on the mode of transport of urokinase into the clot--a magnetic resonance imaging study in vitro.
Diabetes decreases patency of tunneled catheters in hemodialysis patients after first effective thrombolysis with urokinase.
Differential effects of Lys- and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model.
Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.
Dilution of urokinase used to treat thrombus formation in central venous catheters.
Ditazole activity and its interaction with urokinase on experimental thrombosis.
Documentation of successful treatment of prosthetic mitral valve thrombosis with intravenous urokinase infusion for twenty-four hours.
Dural sinus thrombosis and pseudotumor cerebri: unexpected complications of suboccipital craniotomy and translabyrinthine craniectomy.
Early diagnosis and precision treatment of right ovarian vein and inferior vena cava thrombosis following caesarean section: A case report.
Early operative intervention after thrombolytic therapy for primary subclavian vein thrombosis: an effective treatment approach.
Early thrombosis of a tricuspid valve prosthesis: two-dimensional echocardiographic demonstration.
Economic assessment of rheolytic thrombectomy versus intracoronary urokinase for treatment of extensive intracoronary thrombus: Results from a randomized clinical trial.
Effect of drug administration on experimental renal glomerular thrombosis.
Effect of Recombinant Single-Chain Urokinase-Type Plasminogen Activator on Experimental Pulmonary Embolism.
Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Effect of urokinase on fibrinolysis and fibrinogenolysis.
Effectiveness of low dose urokinase on dialysis catheter thrombolysis.
Effects of aspirin and prostaglandin E1 on in vitro thrombolysis with urokinase. Evidence for a possible role of inhibiting platelet activity in thrombolysis.
Effects of streptokinase and urokinase on microarterial thrombosis and haemostasis. An experimental study in rabbits.
Efficacy of angioscopy in determining the effectiveness of intracoronary urokinase and TEC atherectomy thrombus removal from an occluded saphenous vein graft prior to stent implantation.
Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage.
Efficacy of tissue plasminogen activator and urokinase in a canine model of prosthetic graft thrombosis.
Elevation of plasminogen activators in cerebrospinal fluid of mice with eosinophilic meningitis caused by Angiostrongylus cantonensis.
Embolization of cardiac mural thrombus: complication of intraarterial fibrinolysis.
Endoarterial treatment of acute ischemia of the limbs with urokinase. Italian Cooperative Study "Bologna".
Endothelial dysfunction following thrombolysis in vitro.
Endovascular management of acute extensive iliofemoral deep venous thrombosis caused by May-Thurner syndrome.
Endovascular recanalization of chronic long-segment occlusions of the inferior vena cava: midterm results.
Endovascular revascularization of renal artery stenosis: technical and clinical results.
Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis: a prospective study.
Endovascular thrombolysis for symptomatic cerebral venous thrombosis.
Endovascular treatment of acute arterial complications after living-donor liver transplantation.
Endovascular treatment of traumatic dural sinus thrombosis: case report.
Enhanced intracoronary thrombolysis with urokinase using a novel, local drug delivery system. In vitro, in vivo, and clinical studies.
Enhanced Venous Thrombus Resolution in Plasminogen Activator Inhibitor Type-2 Deficient Mice.
Enhancement of fibrinolysis in vitro by ultrasound.
Evaluation of thrombolysis in a porcine model of chronic deep venous thrombosis: an endovascular model.
Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis.
Experience of an implantable central venous access system in a district general hospital.
Experience with subcutaneous infusion ports in three hundred patients.
Experience with the double lumen Silastic catheter for hemoaccess.
Experimental evaluation of small intestinal submucosa as a microvascular graft material.
Experimental study on the comparative thrombolytic effects of intracoronary and intravenous administration of urokinase.
Failure of peripheral arterial thrombolysis due to elevated plasminogen activator inhibitor type 1.
Failure of systemic thrombolytic and heparin therapy in the treatment of neonatal aortic thrombosis.
Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells.
Feasibility examination of isolated zonal thrombolysis using Raman spectroscopy.
Feasibility of low-dose infusion of alteplase for unsuccessful thrombolysis with urokinase in deep venous thrombosis.
Femur fracture with limb shortening causing occlusion of a polytetrafluoroethylene femoral popliteal graft.
Fiberoptic observation of thrombosis and thrombolysis in isolated human coronary arteries.
Fibrin-specific fibrinolysis induced by recombinant staphylokinase.
Fibrinogen-fibrin related antigen pattern in human blood. Incomplete lysis of whole blood clots by urokinase.
Fibrinogenolysis and fibrinolysis in normal volunteers and patients with thrombosis after infusion of urokinase.
Fibrinolysis with intrathrombic injection of urokinase and tissue-type plasminogen activator. Results in a new model of subacute venous thrombosis.
Fibrinolysis: from blood to the brain.
Fibrinolytic therapy for renal vein thrombosis in the child.
Fibrinolytic therapy with streptokinase and urokinase in deep vein thrombosis.
Fibrinolytic Treatment after Transient Ischaemic Attack Caused by Prosthetic Mitral Valve Thrombosis.
Fibrinolytic treatment of portal vein thrombosis after umbilical catheterization using systemic urokinase.
Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis.
Hemorrhagic bullae as a complication of urokinase therapy for hemodialysis catheter thrombosis.
Hemostatic abnormalities in nephrotic syndrome.
Heparin and urokinase in situ for partial thrombosis of indwelling hemodialysis catheters.
Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children.
Heparin, urokinase, and ancrod alter neutrophil function.
High dose urokinase for restoration of patency of occluded permanent central venous catheters in hemodialysis patients.
High-dose intra-arterial urokinase for the treatment of hepatic artery thrombosis in liver transplantation.
High-dose urokinase therapy for the lysis of a central venous catheter-related thrombus in a young patient with Hodgkin's disease.
High-dose urokinase therapy in newborn infants with major vessel thrombosis.
Hydrodynamic thrombectomy system versus pulse-spray thrombolysis for thrombosed hemodialysis grafts: a multicenter prospective randomized comparison.
Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses.
Immediate postoperative thrombolytic therapy: an aggressive strategy for neurologic salvage when cerebral thromboembolism complicates carotid endarterectomy.
Implantation of permanent jugular catheters in patients on regular dialysis treatment: ten years' experience.
In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
In utero brachial artery thrombosis: limb salvage with postnatal urokinase infusion.
In vitro evaluation of the relative thrombolytic efficiency of forced intrathrombic injections: saline versus urokinase.
In vitro model to evaluate the relative efficacy of catheter-directed thrombolytic strategies.
In vitro Simulation of Therapeutic Thrombolysis With Microtiter Plate Clot-Lysis Assay.
In vivo behaviour of vesicular urokinase.
In vivo kinetics and thrombus accumulation of 67Ga-labeled urokinase.
Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects.
Incompatibility of Isovue 370 and papaverine in peripheral arteriography.
Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth.
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase.
Influence of catheter technology and adjuvant medication on acute complications in percutaneous coronary angioplasty.
Inhibition of Plasminogen Activator Inhibitor-1 Activation Suppresses High Fat Diet-Induced Weight Gain via Alleviation of Hypothalamic Leptin Resistance.
Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons.
Insertion of fibrin peptides into urokinase enhances fibrin affinity.
Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.
Interaction analyses of human monocytes co-cultured with different forms of Aspergillus fumigatus.
Interpreting the results of pediatric central venous catheter studies.
Interventional radiologic placement of Hohn central venous catheters: results and complications in 100 consecutive patients.
Intra pulmonary thrombolytic therapy with balloon dilatation in recurrent acute pulmonary embolism.
Intra-arterial reteplase for the treatment of acute limb ischemia.
Intra-arterial thrombolysis in acute basilar artery thromboembolism: the initial Mayo Clinic experience.
Intra-arterial thrombolytic therapy for acute intracranial large artery occlusive disease in patients selected by magnetic resonance image.
Intra-arterial Thrombolytic Therapy for Acute Vertebrobasilar Artery Occlusion.
Intra-arterial urokinase for treatment of retrograde thrombosis following resection of an arteriovenous malformation. Case report.
Intraarterial thrombolysis in a pig model: a preliminary note.
Intraarterial thrombolysis in vertebrobasilar occlusion.
Intraarterially administered abciximab as an adjuvant thrombolytic therapy: report of three cases.
Intracameral urokinase for dissolution of fibrin or blood clots after glaucoma surgery.
Intracoronary thrombus: chronic urokinase infusion and evaluation with intravascular ultrasound.
Intracoronary urokinase as an adjunct to percutaneous transluminal coronary angioplasty in patients with complex coronary narrowings or angioplasty-induced complications.
Intracoronary urokinase for intracoronary thrombus accumulation complicating percutaneous transluminal coronary angioplasty in acute ischemic syndromes.
Intracoronary urokinase in Kawasaki disease: treatment and prevention of myocardial infarction.
Intraluminal thrombus enhances proteolysis in abdominal aortic aneurysms.
Intraoperative infusion of lytic drugs for thrombotic complications of revascularization.
Intraoperative urokinase infusion for embolic stroke during carotid endarterectomy.
Intrathrombic urokinase reverses neonatal renal artery thrombosis.
Intravenous Targeted Microbubbles Carrying Urokinase versus Urokinase Alone in Acute Peripheral Arterial Thrombosis in a Porcine Model.
Intravenous thrombolytic treatment of mechanical prosthetic valve thrombosis: a study using serial transesophageal echocardiography.
Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial.
Involvement of Platelets in Cancers.
Islets surface modification prevents blood-mediated inflammatory responses.
Isolated limb perfusion with urokinase for acute ischemia.
Isolated limb perfusion with urokinase in the treatment of extensive vascular thrombosis of the lower limbs.
K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man.
Late complication of classic Fontan operation: giant right atrial thrombus and massive pulmonary thromboembolism.
Late stent blockage by blood clot successfully treated by urokinase.
Late vascular occlusion of central lines in pediatric malignancies.
Left ventricular thromboembolic occlusion of the popliteal artery treated nonoperatively with local urokinase infusion--a case report.
Life-threatening pulmonary embolism with right-sided heart thrombus. Rapid recovery with recombinant tissue plasminogen activator.
Local fibrinolysis in cerebral venous thrombosis.
Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients.
Local inhibition of thrombosis using urokinase linked to a monoclonal antibody which recognises damaged endothelium.
Local Intra-arterial Thrombolysis during Mechanical Thrombectomy for Refractory Large-Vessel Occlusion: Adjunctive Chemical Enhancer of Thrombectomy.
Local intra-arterial thrombolysis in a 4-year-old male with vertebrobasilar artery thrombosis.
Local intra-arterial thrombolysis with urokinase combined with balloon angioplasty in the lower extremities.
Local intraarterial fibrinolysis of thromboemboli occurring during endovascular treatment of intracerebral aneurysm: a comparison of anatomic results and clinical outcome.
Local intraarterial thrombolysis: in vitro comparison between automatic and manual pulse-spray infusion.
Local intraarterial thrombolysis: in vitro comparison of various infusion catheters.
Local thrombolysis in patients with dural venous thrombosis unresponsive to heparin.
Local thrombolytic therapy as part of a multidisciplinary approach to acute axillosubclavian vein thrombosis (Paget-Schroetter syndrome).
Local thrombolytic therapy for thromboembolic occlusion of the middle cerebral artery.
Local thrombolytic therapy in deep cerebral venous thrombosis.
Local urokinase delivery with the Channel balloon: device safety, pharmacokinetics of intracoronary drug delivery, and efficacy of thrombolysis.
Long-term performance and complications of the Tesio twin catheter system for hemodialysis access.
Long-term results of treatment of benign central venous obstructions unrelated to dialysis with expandable Z stents.
Low-dose antithrombotic treatment in coronary thrombosis of kawasaki disease.
Lysing patterns of retracted blood clots with diffusion or bulk flow transport of plasma with urokinase into clots--a magnetic resonance imaging study in vitro.
Lysis of a right atrial thrombus of more than a week's duration by high dose urokinase in a one-year-old child.
Lysis of intravascular thrombus prior to coronary stenting using the dispatch infusion catheter.
Lysis of intraventricular blood clot with urokinase in a canine model: Part 1. Canine intraventricular blood cast model.
Lysis of intraventricular blood clot with urokinase in a canine model: Part 2. In vivo safety study of intraventricular urokinase.
Lysis of intraventricular blood clot with urokinase in a canine model: Part 3. Effects of intraventricular urokinase on clot lysis and posthemorrhagic hydrocephalus.
Lysis of left ventricular thrombus with urokinase in a patient with alcohol heart disease.
Lytic solution of platelet-rich plasma clots potentiated platelet response to agonists by action on Ca2+ homeostasis.
Magnetic resonance imaging of retracted and nonretracted blood clots during fibrinolysis in vitro.
Maintaining the patency of double-lumen silastic jugular catheters for haemodialysis.
Management and immediate outcome of patients with intracoronary thrombus during percutaneous transluminal coronary angioplasty.
Management of acute superior mesenteric artery occlusion.
Management of complicated coronary angioplasty by intracoronary urokinase and immediate re-angioplasty.
Management of intracoronary thrombosis complicating percutaneous transluminal coronary angioplasty.
Management of venous thromboembolism.
Managing dysfunctional central venous access devices: a practical approach to urokinase thrombolysis.
May-Thurner syndrome, a diagnosis to consider in young males with no risk factors: a case report and review of the literature.
Mechanical fragmentation and pharmacologic thrombolysis in massive pulmonary embolism.
Mechanical thrombectomy of acute iliofemoral deep vein thrombosis with use of an arrow-trerotola percutaneous thrombectomy device.
Mechanical versus chemical thrombolysis: an in vitro differentiation of thrombolytic mechanisms.
Mesenteric and portal vein thrombosis in a young patient with protein S deficiency treated with urokinase via the superior mesenteric artery.
Metformin prevents endotoxin-induced liver injury after partial hepatectomy.
Middle cerebral artery thrombolysis through the contralateral internal carotid artery--case report.
Molecular mechanism of action of newer thrombolytic agents.
Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis.
Multifunctional Thrombin-Activatable Polymer Capsules for Specific Targeting to Activated Platelets.
Multiple coronary artery aneurysms in an adult associated with extensive thrombus formation resulting in acute myocardial infarction: successful treatment with intracoronary urokinase, intravenous heparin, and oral anticoagulation.
Multiple coronary thrombosis in a patient with thrombocytosis.
Multiple stent implantation in single coronary arteries: acute results and six-month angiographic follow-up.
Mutant Prourokinase with Adjunctive C1-Inhibitor Is an Effective and Safer Alternative to tPA in Rat Stroke.
Mycoplasma pneumoniae induced popliteal artery thrombosis treated with urokinase.
Nanoscaled ultrasound contrast agents for enhanced sonothrombolysis.
Neonatal aortic thrombosis treated with intra-arterial urokinase therapy.
Neonatal thrombosis: treatment with heparin and thrombolytics.
Nephrotic syndrome complicated with portal, splenic, and superior mesenteric vein thrombosis.
Neurovascular compression in the thoracic outlet: changing management over 50 years.
Nonsurgical correction for thrombosis of a St. Jude Medical tricuspid prosthesis: report of a case.
Normal saline versus heparin flush for maintaining central venous catheter patency during apheresis collection of peripheral blood stem cells (PBSC).
Novel and emerging therapies: thrombus-targeted fibrinolysis.
Obstructed central venous catheters. Restoring function with a 12-hour infusion of low-dose urokinase.
Optimizing the bolus/infusion ratio for intravenous administration of urokinase in dogs.
Original approach for thrombolytic therapy in patients with Ilio-femoral deep vein thrombosis : 2 years follow-up.
Outcome after Preoperative or Intraoperative Use of Intra-arterial Urokinase Thrombolysis for Acute Popliteal Artery Thrombosis and Leg Ischemia.
Outcome of treatment of deep-vein thrombosis with urokinase: relationship to dosage, duration of therapy, age of the thrombus and laboratory changes.
Outpatient High-Dose Urokinase Infusion Improves Dialysis Catheter Longevity: A Prospective Observational Study.
PAI-1 Leads to G1-Phase Cell-Cycle Progression through Cyclin D3/cdk4/6 Upregulation.
Partial venous thrombosis of the pancreatic allografts after simultaneous pancreas-kidney transplantation.
Patho-physiological studies on lactic acid-induced pulmonary thrombosis in rat. I. Effect of heparin, acetylsalicylic acid, urokinase and tranexamic acid.
Percutaneous aspiration thrombectomy for the treatment of acute lower extremity deep vein thrombosis: is thrombolysis needed?
Percutaneous iliac artery stent: angiographic long-term follow-up.
Percutaneous transhepatic portography for the treatment of early portal vein thrombosis after surgery.
Percutaneous transluminal coronary angioplasty, alone or in combination with urokinase therapy, during acute myocardial infarction.
Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone--a randomized pilot trial (the PROMPT Study). Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis.
Pharmacologic and clinical characteristics of thrombolytic agents.
Pharmacologic treatment of catheter-related thrombus in pediatrics.
Pharmacological thrombolysis: the last choice for salvaging free flaps.
Pharmacomechanical thrombolysis with use of the brush catheter in canine thrombosed femoropopliteal arterial PTFE bypass grafts.
Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution.
Plasminogen acceleration of urokinase thrombolysis.
Plasminogen activation and lysis of blood clots induced by cells in vitro.
Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis.
Platelet-derived porous nanomotor for thrombus therapy.
Platelet-Mimic uPA Delivery Nanovectors Based on Au Rods for Thrombus Targeting and Treatment.
Popliteal artery occlusion caused by cystic adventitial disease: successful treatment by urokinase followed by nonresectional cystotomy.
Popliteal venous aneurysm with pulmonary embolism.
Portal thrombosis due to intrahepatic cholangiocarcinoma following successful treatment for hepatocellular carcinoma.
Portal vein thrombosis after laparoscopic colectomy: thrombolytic therapy via the superior mesenteric vein.
Portal vein thrombosis successfully treated with a colectomy in active ulcerative colitis: report of a case.
Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
Prevention and Treatment of Thrombosis Associated With Long-Term Hemodialysis Catheters.
Prevention of clot formation in cat retinal vein by systemic and subconjunctival urokinase.
Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies.
Prevention of tunneled cuffed catheter dysfunction with prophylactic use of a taurolidine urokinase lock: A randomized double-blind trial.
Preventive effects of batroxobin on experimental canine coronary thrombosis.
Primary subclavian venous thrombosis which developed after sleeping with the arm in an outstretched position: report of a case.
Progress in fibrinolysis.
Prolonged intracoronary urokinase infusion for acute stent thrombosis.
Prolonged intragraft urokinase with a new infusion wire: improved short-term results.
Prolonged intravenous urokinase infusion: an alternative pharmacologic approach in the treatment of thrombus-containing saphenous vein graft stenoses.
Prolonged selective urokinase infusion in totally occluded coronary arteries and bypass grafts: two case reports.
Prospective analysis of urokinase in the treatment of catheter sepsis in pediatric hematology-oncology patients.
Prospective evaluation of a Dacron cuffed hemodialysis catheter for prolonged use.
Prototype therapeutic ultrasound emitting catheter for accelerating thrombolysis.
Pulmonary artery thrombolysis and stenting after a bilateral sequential lung transplantation.
Pulse-spray catheter-directed thrombolysis with urokinase and argatroban for thrombo-occlusion of an inferior vena cava filter due to heparin-induced thrombocytopenia with thrombosis.
Pulse-spray thrombolysis of inferior vena cava thrombosis complicating filter placement.
Pulsed-spray pharmacomechanical thrombolysis: preliminary clinical results.
Purification and characterization of a novel fibrinolytic enzyme from Whitmania pigra Whitman.
Radial Arterial Approach with Adjunctive Urokinase for Treating Occluded Autogenous Radial-Cephalic Fistulas.
Radial arterial approach with adjunctive urokinase for treating occluded autogenous radial-cephalic fistulas.
Radioactive urokinase for blood clot scanning.
Rapid thrombus dissolution by continuous infusion of urokinase through an intracoronary perfusion wire prior to and following PTCA: results in native coronaries and patent saphenous vein grafts.
Recanalization of occluded large arteries with broadened therapeutic window for acute cerebral infarction.
Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
Recombinant tissue plasminogen activator in patients with pulmonary embolism: correlation of fibrinolytic specificity and efficacy.
Reduced fibrinolytic potential in patients with arterial occlusive disease (AOD) in comparison with normal subjects.
Reduction of thrombus formation in vivo using a thrombolytic agent targeted at damaged endothelial cells.
Regional low dosage thrombolytic therapy for peripheral arterial occlusions.
Regional thrombolysis with urokinase for central venous catheter-related thrombosis in patients undergoing high-dose chemotherapy with autologous blood stem cell rescue.
Relationship between clot location and outcome after basilar artery thrombolysis.
Repeated phlebographic examination during and after fibrinolytic therapy with streptokinase and urokinase.
Resolution of proteinuria secondary to bilateral renal vein thrombosis after treatment with systemic thrombolytic therapy.
Restoration of thrombosed Brescia-Cimino dialysis fistulas by using percutaneous transluminal angioplasty.
Right atrial thrombosis in two premature infants: successful treatment with urokinase and heparin.
Role of endothelin in thrombolysis in rat abdominal aorta.
Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis evaluation in transgenic animals.
Role of thrombolysis in free-flap salvage.
Safety and efficacy of abciximab use in conjunction with intracoronary urokinase in patients requiring angioplasty.
Safety and Efficacy of Aspiration Thrombectomy or Pharmacomechanical Thrombectomy after Catheter-Directed Thrombolysis for the Treatment of Acute Iliofemoral Deep Vein Thrombosis.
Safety and efficacy of extended urokinase infusion plus stent deployment for treatment of obstructed, older saphenous vein grafts.
Safety and efficacy of urokinase during elective coronary angioplasty.
Salvage of renal allograft function and lower extremity venous patency with thrombolytic therapy: case report and review of the literature.
Scanning electron microscopy of experimental thrombus formation in canine lateral saphena vein.
Selective infusion of urokinase and thrombectomy in the treatment of acute cerebral sinus thrombosis.
Self-expanding stent for recanalization of acute embolic or dissecting intracranial artery occlusion.
Sodium Citrate Versus Heparin Catheter Locks for Cuffed Central Venous Catheters: A Single-Center Randomized Controlled Trial.
Spontaneous intrajugular migration of long-term central venous access catheters.
Spontaneous Spinal Epidural Hematoma After Normal Spontaneous Delivery with Epidural Analgesia: Case Report and Literature Review.
Streptokinase--a clinically useful thrombolytic agent.
Streptokinase: An Efficient Enzyme in Cardiac Medicine.
Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system.
Success of thrombolysis as a predictor of outcome in acute thrombosis of popliteal aneurysms.
Successful intra-arterial thrombolysis for acute ischemic stroke in the immediate postpartum period: case report.
Successful local low-dose urokinase treatment of acquired thrombosis early after cardiothoracic surgery.
Successful thrombolytic therapy in two patients with renal vein thrombosis.
Successful treatment of an acute thrombosis of an intracranial vertebral artery endarterectomy with urokinase.
Successful treatment of superior vena cava syndrome with urokinase in an infant with a central venous catheter.
Successful use of Tenecteplase in a patient with recurrence of prosthetic mitral valve thrombosis.
Sudden appearance of coronary thrombus observed by angiography--a case report.
Superior sagittal sinus thrombosis: a clinical and experimental study.
Superior sagittal sinus thrombus secondary to occult meningioma: a case report.
Superior vena cava syndrome after heart transplantation: percutaneous treatment of a complication of bicaval anastomoses.
Surgery for effort thrombosis of the subclavian vein.
Synergism of thrombolytic agents in vivo.
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
Synthesis of recombinant human single-chain urokinase-type plasminogen activator variants resistant to plasmin and thrombin.
Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
The beneficial effect of lys-plasminogen upon the thrombolytic efficacy of urokinase in a dog model of peripheral arterial thrombosis.
The biotechnological potential of fibrinolytic enzymes in the dissolution of endogenous blood thrombi.
The effect of intravenous infusion of urokinase on coronary artery thrombolysis in the dog.
The Effectiveness of Subdural Drains Using Urokinase after Burr Hole Evacuation of Subacute Subdural Hematoma in Elderly Patients: A Prelimilary Report.
The effects of thrombus, thrombectomy and thrombolysis on endothelial function.
The efficacy of reteplase in the treatment of thrombosed hemodialysis venous catheters.
The features of thrombus in a microvessel injury model and the antithrombotic efficacy of heparin, urokinase, and prostaglandin E1.
The first 100 cases of intracoronary stent implantation in cardiac center, King Chulalongkorn Memorial Hospital.
The heparin-induced thrombocytopenia and thrombosis syndrome: treatment with intraarterial urokinase and systemic platelet aggregation inhibitors.
The inactivation of single-chain urokinase-type plasminogen activator by thrombin in a plasma milieu: effect of thrombomodulin.
The influence of transport parameters and enzyme kinetics of the fibrinolytic system on thrombolysis: mathematical modelling of two idealised cases.
The inhibitory role of recombinant P-selectin glycoprotein ligand immunoglobulin G on portal vein thrombosis based on a novel rat model.
The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice.
The intracoronary administration of urokinase following direct PTCA for acute myocardial infarction reduces early restenosis.
The preparation of a new self-made microbubble-loading urokinase and its thrombolysis combined with low-frequency ultrasound in vitro.
THE PREVENTION OF ARTERIAL THROMBOSIS BY FIBRINOLYTIC ACTIVATION WITH UROKINASE: AN EXPERIMENTAL STUDY.
The rationale of prevention of thrombosis by enhancing blood levels of single-chain urokinase-type plasminogen activator (scuPA).
The role of intracoronary thrombus in unstable angina: angiographic assessment and thrombolytic therapy during ongoing anginal attacks.
The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis.
The safety and efficacy of pharmaco-mechanical thrombolysis in lower-extremity deep venous thrombosis.
The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.
The tissue plasminogen activator and urokinase response in vivo during natural resolution of venous thrombus.
The transport of 125I-labeled human high molecular weight urokinase across the intestinal tract in a dog model with stimulation of synthesis and/or release of plasminogen activators.
The usefulness of systemic administration of recombinant human tissue-type plasminogen activator in femoral arterial thrombolysis of rabbits.
Thrombolysis Enhancing by Magnetic Manipulation of Fe?O? Nanoparticles.
Thrombolysis for experimental deep venous thrombosis maintains valvular competence and vasoreactivity.
Thrombolysis of occluded infrainguinal bypass grafts.
Thrombolysis of the cervical internal carotid artery before balloon angioplasty and stent placement: report of two cases.
Thrombolysis to treat arterial thrombotic complications of heparin-induced thrombocytopenia.
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.
Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
Thrombolysis with reteplase for recurrent mechanical heartvalve thrombosis.
Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
Thrombolytic and endovascular treatment of peripartum iliac vein thrombosis: a case report.
Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons.
Thrombolytic effect of lonomin V in a rabbit jugular vein thrombosis model.
Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
Thrombolytic Therapy for Acute Myocardial Infarction : A Review.
Thrombolytic therapy for femoral artery thrombosis after left cardiac catheterization in children.
Thrombolytic therapy for prosthetic cardiac valve thrombosis.
Thrombolytic therapy in acute stroke.
Thrombolytic therapy in heparin-associated thrombocytopenia with thrombosis.
Thrombolytic Therapy Using Urokinase for Management of Central Venous Catheter Thrombosis.
Thrombolytic therapy: the treatment of choice for iliac vein thrombosis in the presence of kidney transplant.
Thrombolytic treatment of prosthetic valve thrombosis: a study using Urokinase.
Thrombosis and Urokinase: Proceedings of the Serono Symposia, vol 9.
Thrombosis of a mechanical tricuspid valve prosthesis and of the left subclavian vein: successful therapy with thrombolysis.
Thrombosis of tibial arteries in a patient receiving tamoxifen therapy.
Thrombosis of Tunneled-Cuffed Hemodialysis Catheters: Treatment With High-Dose Urokinase Lock Therapy.
Thrombosis recanalization by paeoniflorin through the upregulation of urokinase?type plasminogen activator via the MAPK signaling pathway.
Thrombotic complications of subclavian apheresis catheters in cancer patients: prevention with heparin infusion.
Thrombus age and tissue plasminogen activator mediated thrombolysis in rats.
Thrombus aspiration as a bailout procedure during percutaneous renal angioplasty.
Thrombus in vertebrobasilar dolichoectatic artery treated with intravenous urokinase.
Thrombus-specific theranostic nanocomposite for codelivery of thrombolytic drug, algae-derived anticoagulant and NIR fluorescent contrast agent.
Thrombus-targeted nanoparticles for thrombin-triggered thrombolysis and local inflammatory microenvironment regulation.
Tissue plasminogen activator: an evaluation of clinical efficacy in acute myocardial infarction.
tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor.
Tracheobronchial Obstruction Due to Blood Clots in Acute Pulmonary Embolism with Cardiac Arrest Managed with Extracorporeal Membrane Oxygenation.
Transcatheter closure of persistent ductus arteriosus with the Amplatzer duct occluder in very young symptomatic children.
Transcatheter regional urokinase therapy in the management of inferior vena cava thrombosis.
Transient left atrial mobile thrombus in acute myocardial infarction--a case report.
Transient left ventricular apical ballooning in a patient with bicuspid aortic valve created a left ventricular thrombus leading to acute renal infarction.
Transradial approach for transcatheter selective superior mesenteric artery urokinase infusion therapy in patients with acute extensive portal and superior mesenteric vein thrombosis.
Treatment for mechanical valve thrombosis in the right heart: combined pharmacological and mechanical thrombolysis.
Treatment of a case of thromboembolism resulting from thoracic outlet syndrome with intra-arterial urokinase infusion.
Treatment of acute myocardial infarction with prolonged intracoronary urokinase delivery through intracoronary infusion catheter.
Treatment of acute stent thrombosis with local urokinase therapy using catheter-based, drug delivery systems: a case report.
Treatment of acute thromboembolic complication after stent-assisted coil embolization of ruptured intracranial aneurysm: a case report.
Treatment of Budd-Chiari syndrome with urokinase following predilation in patients with old inferior vena cava thrombosis.
Treatment of intracoronary thrombus with local urokinase infusion using a new, site-specific drug delivery system: the Dispatch catheter.
Treatment of neonatal aortic thrombosis with urokinase.
Treatment of right atrial thrombus with urokinase.
Treatment of right ventricular thrombus with severe right ventricular dysfunction using urokinase.
Treatment of subclavian-axillary vein thrombosis: long-term outcome of anticoagulation versus systemic thrombolysis.
Treatment of thrombotic saphenous vein bypass grafts using local urokinase infusion therapy with the Dispatch catheter.
Tricuspid valve replacement with the bileaflet St. Jude Medical valve prosthesis.
Two-step targeting of urokinase to plasma clot provides efficient fibrinolysis.
Ultrasound and Intra-Clot Microbubbles Enhanced Catheter-Directed Thrombolysis in Vitro and in Vivo.
Ultrasound with Microbubble Contrast Agent and Urokinase for Thrombosis.
Ultrasound-assisted thrombolysis.
Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma.
Upper tract urokinase instillation for nephrostomy tube patency.
Urokinase and AT-III concentrate treatment in inferior vena cava thrombosis associated with nephrotic syndrome.
Urokinase binding to bovine corneal endothelial cells.
Urokinase dissolution of a right atrial thrombus.
Urokinase in the management of vitreous hemorrhage.
Urokinase in the treatment of shunt malfunctions caused by thrombus.
Urokinase lysis for acute left subclavian artery thrombosis after placement of infusion catheter: report of two cases.
Urokinase perfusion for axillary-subclavian vein thrombosis.
Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism.
Urokinase therapy for a catheter-related right atrial thrombus and pulmonary embolism in a 2-month-old infant.
Urokinase therapy for a catheter-related right atrial thrombus.
Urokinase therapy for a central venous catheter thrombus.
Urokinase therapy for thrombosed hemodialysis access grafts.
Urokinase therapy for thrombosis of tricuspid prosthetic valve.
Urokinase therapy in neonates with catheter related central venous thrombosis.
Urokinase therapy of subclavian-axillary vein thrombosis.
Urokinase thrombolysis as initial therapy for acute and non-acute ischemic extremities.
Urokinase treatment of neonatal aortoiliac thrombosis caused by umbilical artery catheterization: a case report.
Urokinase treatment of pulmonary artery thrombosis complicating the pediatric nephrotic syndrome.
Urokinase treatment of sagittal sinus thrombosis with venous hemorrhagic infarction.
Urokinase treatment preserves endothelial and smooth muscle function in experimental acute arterial thrombosis.
Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial.
Urokinase, tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in severely stenosed and occluded vein grafts with thrombosis.
Urokinase-immobilization suppresses inflammatory responses to polyurethane tubes implanted in rabbit muscles.
Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex.
Urokinase-type plasminogen activator system predicts risk of cardiovascular events in patients with angina pectoris: results of the ECAPTURE study. European Concerted Action on Prevention from Thrombosis by URokinase Enhancement.
Urokinase. A cost-effective alternative treatment of superior vena cava thrombosis and obstruction.
Use of urokinase in dispersal of obstructive postoperative thrombus in the renal pelvis.
Usefulness of Aspiration of Pulmonary Emboli and Prolonged Local Thrombolysis to Treat Pulmonary Embolism.
Usefulness of intracoronary stenting in acute myocardial infarction.
Usefulness of Local Delivery of Thrombolytics Before Thrombectomy in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (the Delivery of Thrombolytics Before Thrombectomy in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention [DISSOLUTION] Randomized Trial).
Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia.
Vertebrobasilar thrombosis in children: report of two cases and recommendations for treatment.
Visible Thrombolysis Acceleration of a Nanomachine Powered by Light-Driving F0F1-ATPase Motor.
[A case of arterial thrombosis successfully treated with a large dosage of urokinase--study on urokinase administration with special reference to alpha2-plasmin inhibitor (author's transl)]
[A case of hypertrophic obstructive cardiomyopathy with left atrial giant thrombus during anti-platelet therapy]
[A case of inferior vena cava thrombosis associated with cholelithiasis demonstrated by ultrasonic examination]
[A case of portal and superior mesenteric thrombosis associated with protein S deficiency treated with urokinase via the superior mesenteric vein]
[A case of renal vein thrombosis and pulmonary embolism associated with diffuse membranous glomerulonephritis: the usefulness of low-molecular-weight heparin and urokinase therapy]
[A combination of arteriovenous impulse system and low-molecular-weight heparins calcium for prophylaxis of deep venous thrombosis following total knee arthroplasty]
[A pilot study on recurrent thrombosis of the coronary vessels. Selective infusion of urokinase is an effective treatment]
[A rat middle cerebral artery thrombosis model for evaluation of thrombolytic and antithrombotic agents]
[A successful thrombolytic therapy for thrombosed ATS valve in the mitral position in a child; report of a case]
[Actual state of thrombolytic treatment of recent vein thrombosis and pulmonary embolism (author's transl)]
[Acute coronary syndrome due to coronary thrombus formed by severe coronary spasm: a case report]
[Acute massive pulmonary embolism--report of a case]
[Addition of antithrombosis in situ in the case of digital replantation: preliminary prospective study of 13 cases].
[An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model]
[Application of percutaneous AngioJet thrombectomy in patients with acute symptomatic portal and superior mesenteric venous thrombosis].
[Atherosclerosis obliterance; thrombolytic therapy]
[Balloon occlusion pulmonary angiography and anticoagulant-antithrombotic therapy in ARDS-associated pulmonary vascular thrombosis]
[Cannulation of the internal jugular vein with 2 silastic catheters. A new method of vascular access for hemodialysis]
[Case of mitral stenosis with regression and elimination of left atrial thrombus after combined therapy of urokinase, dipyridamole and aspirin]
[Catheter-directed thrombolysis for iliofemoral vein thrombosis: report of 13 cases]
[Central venous access for hemodialysis: use and practice with the child in France]
[Cerebral venous thrombosis in a girl carrier of the prothrombin gene mutation 20210G--> A treated by local fibrinolysis of the superior sagittal sinus]
[Clinical analysis of intravenous urokinase treatment of 10 cases with Kawasaki disease complicated with thrombus in coronary aneurysm]
[Clinical application and efficacy of TIPS combined with AngioJet mechanical thrombectomy for liver cirrhosis with extensive portal vein thrombosis].
[Clinical experience in 3 cases, 5 events of thrombosed Björk-Shiley mitral prostheses]
[Clinical experience with the use of implantable vascular systems in advanced heart failure]
[Comparative study of the morphologic behavior of fresh leg and pelvic vein thromboses treated with streptokinase, urokinase and heparin based on phlebography follow-up]
[Comparison of mechanical thrombectomy with transcatheter thrombolysis for acute iliac femoral venous thrombosis].
[Congenital deficiency of factor Xii and spontaenous venous thrombosis treated with urokinase]
[Coronary spasm-induced acute myocardial infarction associated with intracoronary thrombosis]
[Coronary vascular stent implantation--experiences with the first 100 implants]
[Design of Intravascular Ultrasound-enhanced Thrombolysis Excitation System Based on FPGA].
[Early and late results after local streptokinase administration in massive lung embolism]
[Effect of urokinase on morphological changes of vein wall after acute thrombosis in rabbits]
[Effectiveness of double fibrinolytic treatments in subacute deep vein thrombosis of the lower limbs]
[Effort thrombosis of the subclavian vein].
[Experimental and clinical studies on oral urokinase and lysyl-plasminogen. Thrombolytic therapy for cerebral thrombosis]
[Experimental study of the thrombolytic effects in a canine model of pulmonary thromboembolism induced by autologous radioactive blood clots]
[Fibrinogen-guided thrombolysis with urokinase of a portal and mesenterial venous thrombosis during an acute episode of ulcerative colitis]
[Fibrinolytic properties and thrombolytic effect of a novel fibrinolytic enzyme from Streptomyces sp. Y405]
[Fibrinolytic therapy for femoral artery thrombosis after left cardiac catheterization in children].
[Fibrinolytic therapy of deep vein thrombosis of the leg and pelvis with streptokinase and urokinase]
[Fibrinolytic therapy of lower limb deep vein thrombosis with urokinase (author's transl)]
[Fibrinolytic treatment of acute and subacute thromboses of the deep veins of the shoulder girdle (author's transl)]
[Fibrinolytic treatment with urokinase and streptokinase for recurrent thrombosis in two valve prostheses for the aortic and mitral valves during pregnancy]
[High-dose urokinase for thrombolysis following replantation of severed limbs or fingers.]
[In situ thrombolysis in the treatment of venous thrombosis of effort in the arm]
[Intra-arterial lysis therapy in acute limb ischemia. Technical possibilities and limits of indication]
[Intra-arterial urokinase in the treatment of acute thrombosis of the renal artery. A case report]
[Intracoronary thrombolytic therapy in Kawasaki disease and the usefulness of two-dimensional echocardiography in detecting intracoronary thrombi]
[Intracoronary thrombolytic treatment with urokinase in myocardial infarct: clinical angiographic findings and effects on left ventricular function]
[Late effect of intracoronary urokinase. Apropos of a case of recurrent coronary thrombosis after angioplasty]
[Local intravenous fibrinolysis in deep cerebral vein thrombosis]
[Local low-dose thrombolytic treatment with sequential urokinase-plasminogen in deep central venous thrombosis]
[Local therapeutic fibrinolysis in ischemic cerebrovascular insults: initial findings in 6 patients]
[Loco-regional transcatheter thrombolysis]
[Low dose thrombolytic treatment for revascularisation in arterial occlusion (author's transl)]
[Neonatal subrenal abdominal aortic thrombosis. Recovery following urokinase]
[Popliteal aneurysm and leg ischemia: thrombolysis first]
[Portal vein thrombosis associated with idiopathic hypereosinophilic syndrome].
[Preparation of thrombus-targeted urokinase liposomes and its thrombolytic effect in model rats]
[Prevention of catheter-induced thromboses by low molecular weight heparins]
[Primary nephrotic syndrome treated with urokinase--a report of 20 cases]
[Pulmonary artery thrombosis during hormonal contraceptive therapy. Treatment with urokinase]
[Recurrent thrombosis of an aortic valve prosthesis in a pregnant woman. Treatment with urokinase]
[Role of thrombolytic treatment in thrombosis of valvular prostheses. Apropos of 2 cases and review of the world literature]
[Selective thrombolytic therapy for deep venous thrombosis by using a small caliber catheter passed through a temporary vena cava filter]
[Septic portal vein thrombosis. Its successful therapy by local fibrinolysis and a transjugular portasystemic stent-shunt (TIPS)]
[Severe acquired protein S deficiency with thrombophlebitis after febrile infection in a 7-year-old girl]
[Simultaneous urokinase perfusion in renal artery and vein in a case of renal vein thrombosis]
[Subacute thrombosis of the abdominal aorta with suprarenal involvement and successful treatment with pharmacomechanical fibrinolysis]
[Successful fibrinolytic treatment with urokinase six weeks after leg and pelvic vein thrombosis (author's transl)]
[Successful lysis of a septic thrombosis of the superior vena cava using recombinant tissue-plasminogen activator]
[Successful lysis of iliofemoral and inferior vena cava thrombi in heparin-induced type-II thrombocytopenia]
[Successful lysis therapy in acute unilateral renal vein thrombosis]
[Successful replantation of circularly severed palm and multiply severed fingers. A case report]
[Successful treatment of a right atrial thrombus secondary to central venous catheterization]
[Successful treatment of superior mesenteric artery thrombosis with local high-dose urokinase therapy]
[t-PA in thrombolytic therapy of acute myocardial infarct]
[Tesio twin catheter system for hemodialysis tunnelized using an echo-guided technique. Retrospective analysis of 210 catheters]
[The fibrinolytic treatment with urokinase of acute arterial thrombosis]
[The functional expression of humanized ScFv-urokinase fusion protein in Escherichia coli]
[The use of endoprosthesis in superior vena cava syndrome caused by lung neoplasms]
[Thrombolytic therapy in patients with pulmonary artery thromboembolism and deep vein thrombosis].
[Thrombolytic therapy of thrombosed Björk-Shiley aortic valve prosthesis--report of four cases]
[Thrombolytic therapy with urokinase in two systemic lupus erythematosus patients with deep vein thrombosis]
[Thrombolytic therapy. Effect of urokinase on experimental thrombosis (author's transl)]
[Thrombolytic treatment with urokinase (author's transl)]
[Thrombosis of the renal veins in a premature infant. Treatment with heparin and urokinase]
[Thrombosis on a mitral valve prosthesis: treatment with urokinase and color-Doppler monitoring]
[Thrombus age as a determinant of lysis efficacy of in vitro produced platelet-fibrin thrombi]
[TIPSS in the Budd-Chiari syndrome with portal vein thrombosis]
[Treatment of a large intracoronary thrombus with urokinase and a chimeric monoclonal platelet aggregation inhibitor]
[Treatment of massive arterial thrombosis caused by thrombocytopenia induced by heparin with local thrombolysis]
[Treatment of obstruction and thrombosis due to central venous catheterization]
[Treatment of thrombosis of the central retinal vein with urokinase. Complete cure]
[Treatment possibilities for extensive pulmonary embolism as an alternative to the Trendelenburg operation]
[Treatment with urokinase of systemic arterial thrombosis in the newborn infant]
[Urokinase in a premature infant: its use in a case of right atrial thrombosis secondary to catheterization of the umbilical vein]
[Urokinase recanalization of extensive thrombosis of the superior vena cava secondary to an implantable perfusion device]
[Urokinase therapy of deep vein thrombosis (author's transl)]
[Urokinase therapy of deep vein thrombosis]
[Urokinase therapy of recurrent thrombosis of tricuspid prosthetic valve]
[Use of urokinase in the occlusion of the vascular access routes in chronic hemodialysis. 7 years' experience]
[Water-soluble modified derivatives of urokinase: fibrinolytic activity and other properties]
Thrombotic Microangiopathies
Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target?
Thrombotic Stroke
Circadian fluctuations in the efficacy of thrombolysis with streptokinase.
Investigational use of tPA in acute stroke.
The beneficial effect of intracarotid urokinase on acute stroke in a baboon model.
Thymoma
Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Thyroid Cancer, Papillary
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
In papillary thyroid carcinoma BRAF(V) (600E) is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells.
The Urokinase Plasminogen Activator System in Metastatic Papillary Thyroid Carcinoma: A Potential Therapeutic Target.
Thyroid Diseases
[Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases]
Thyroid Neoplasms
Human thyroid carcinoma cell invasion is controlled by the low density lipoprotein receptor-related protein-mediated clearance of urokinase plasminogen activator.
Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study.
The urokinase plasminogen activating system in thyroid cancer: clinical implications.
Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity.
Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients.
Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study.
Toxemia
The role of placental urokinase inhibitor in toxemia of pregnancy.
[Fibrinolysis in pregnancy toxemia]
[Fibrinolytic therapy for toxemia of late pregnancy--experimental studies of pregnant rabbits treated with urokinase]
Tricuspid Atresia
Resolution of protein-losing enteropathy with standard high molecular heparin and urokinase after Fontan repair in a patient with tricuspid atresia.
Triple Negative Breast Neoplasms
Engineered Antibody Fragment against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography.
MicroRNA-645 targets urokinase plasminogen activator and decreases the invasive growth of MDA-MB-231 triple-negative breast cancer cells.
N-Alkylisatin-Loaded Liposomes Target the Urokinase Plasminogen Activator System in Breast Cancer.
Urokinase-type plasminogen activator receptor inhibits apoptosis in triple-negative breast cancer through miR-17/20a suppression of death receptors 4 and 5.
Tuberculoma
[Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients]
Tuberculosis
Concurrent upregulation of urokinase plasminogen activator receptor and CD11b during tuberculosis and experimental endotoxemia.
Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.
Serum levels of soluble urokinase plasminogen activator receptor (suPAR) as a marker of tuberculosis treatment efficacy.
Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection.
Soluble urokinase plasminogen activator receptor levels in tuberculosis patients at high risk for multidrug resistance.
Soluble urokinase-type plasminogen activator receptor as a biomarker of treatment response in childhood tuberculosis.
The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau.
Utility of the Plasma Level of suPAR in Monitoring Risk of Mortality during TB Treatment.
Tuberculosis, Meningeal
Use of urokinase in the treatment of tuberculous meningitis hydrocephalus.
Tuberculosis, Pleural
Intrapleural urokinase directly under medical thoracoscopy for the diagnosis of tuberculous pleurisy.
Treatment of free-flowing tuberculous pleurisy with intrapleural urokinase.
[The study of intrapleural urokinase in the prevention of pleural thickening and loculated effusions by tuberculous pleurisy]
Tuberculosis, Pulmonary
Elevated levels of soluble urokinase receptor in serum from mycobacteria infected patients: still looking for a marker of treatment efficacy.
Sedimentation rate and suPAR in relation to disease activity and mortality in patients with tuberculosis.
[An attempt to enhance the antituberculous effect of chemotherapeutics by the combined administration of urokinase for pulmonary tuberculosis (author's transl)]
Tuberous Sclerosis
Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Typhoid Fever
Plasminogen- 125 I responses in dogs to a single injection of urokinase and typhoid vaccine and to vascular injury.
u-plasminogen activator deficiency
A urokinase-type plasminogen activator deficiency diminishes the frequency of intestinal adenomas in Apc(Min/+) mice.
Plasmin and matrix metalloproteinases in vascular remodeling.
Regulation of epithelial sodium channels in urokinase plasminogen activator deficiency.
Urokinase-type plasminogen activator deficiency (uPA-KO) prevented carotid artery ligation-induced vascular remodeling in mice.
Urokinase-type plasminogen activator deficiency has little effect on seizure susceptibility and acquired epilepsy phenotype but reduces spontaneous exploration in mice.
Urokinase-Type Plasminogen Activator Deficiency in Bone Marrow-Derived Cells Augments Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms.
Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice.
Upper Extremity Deep Vein Thrombosis
Comparison of retavase and urokinase for management of spontaneous subclavian vein thrombosis.
Continuous infusion of low-dose urokinase in the treatment of central venous catheter thrombosis in infants and children.
Thrombolytic Therapy Using Urokinase for Management of Central Venous Catheter Thrombosis.
Uremia
Impact of low-dose urokinase in peritoneal dialysis on serum oxidative stress, nitric oxide and endothelin in cerebral infarction complicated with uremia.
The serum levels of MMP-9, MMP-2 and vWF in patients with low doses of urokinase peritoneal dialysis decreased uremia complicated with cerebral infarction.
Ureteral Obstruction
Serine proteases, inhibitors and receptors in renal fibrosis.
Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.
[Role of integrin-linked kinase in renal tubular epithelial-mesenchymal transition and the regulatory effect of urokinae on its expression in mice with obstructive nephropathy]
Urinary Bladder Neoplasms
An ATF24 peptide-functionalized ?-elemene-nanostructured lipid carrier combined with cisplatin for bladder cancer treatment.
Anticancer drug sensitivity in vitro in the bladder cancer cell line, KK-47 and prophylactic use of carbazilquinone and urokinase in bladder cancer.
Apigenin Suppresses the IL-1?-Induced Expression of the Urokinase-Type Plasminogen Activator Receptor by Inhibiting MAPK-Mediated AP-1 and NF-?B Signaling in Human Bladder Cancer T24 Cells.
Association of Urokinase Gene 3'-UTR T/C polymorphism with bladder cancer.
CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer.
Combined intravesical therapy with doxorubicin (adriamycin) and urokinase in the management of superficial bladder tumours.
Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel marker for bladder cancer.
Expression of UPA and UPAR is associated with the clinical course of urinary bladder neoplasms.
Fibrinolysis-inhibitory activity of cultured human cancer cell lines.
First-in-human uPAR PET: Imaging of Cancer Aggressiveness.
Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets.
Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.
Immunological analysis of plasminogen activators from cultured human cancer cells.
Intravesical therapy of noninvasive bladder tumors (stage Ta) with doxorubicin and urokinase.
Is interferon gamma one key of metastatic potential increase in human bladder carcinoma?
mTORC2 activation is regulated by the urokinase receptor (uPAR) in bladder cancer.
Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer.
Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer.
Re: Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Re: urokinase and urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Safety, dosimetry and tumor detection ability of 68Ga-NOTA-AE105 - a novel radioligand for uPAR PET imaging: first-in-humans study.
Sinulariolide Suppresses Cell Migration and Invasion by Inhibiting Matrix Metalloproteinase-2/-9 and Urokinase through the PI3K/AKT/mTOR Signaling Pathway in Human Bladder Cancer Cells.
The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.
The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer.
The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer.
The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).
The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report.
uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.
Urokinase (u-PA) and the u-PA receptor. Modulation of in vitro invasiveness of human bladder cancer cell lines.
Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Urokinase inhibitor in patients with bladder cancer.
Urokinase-type plasminogen activator and its receptor in bladder cancer.
[Effect of polyphenols from the Mediterranean diet on proliferation and mediators of in vitro invasiveness of the MB-49 murine bladder cancer cell line]
[Urokinase-type plasminogen activator antigen as a prognostic factor in bladder cancer]
Urinary Calculi
Meta-analysis of the urokinase gene 3'-UTR T/C polymorphism and susceptibility to urolithiasis.
Urinary Tract Infections
Plasma soluble urokinase plasminogen activator receptor in children with urinary tract infection.
Urolithiasis
ApaL1 urokinase and Taq1 vitamin D receptor gene polymorphisms in first-stone formers, recurrent stone formers, and controls in a Caucasian population.
Association of calcium urolithiasis with urokinase P141L and 3'-UTR C>T polymorphisms in a Japanese population.
Association of urokinase gene 3'-UTR T/C polymorphism with calcium oxalate urolithiasis in children.
Effects of bacteria involved with the pathogenesis of infection-induced urolithiasis on the urokinase and sialidase (neuraminidase) activity.
Erratum: interleukin-1?, calcium-sensing receptor, and urokinase gene polymorphisms in korean patients with urolithiasis.
In vivo effects of urease-producing bacteria involved with the pathogenesis of infection-induced urolithiasis on renal urokinase and sialidase activity.
Interleukin-1?, calcium-sensing receptor, and urokinase gene polymorphisms in korean patients with urolithiasis.
Meta-analysis of the urokinase gene 3'-UTR T/C polymorphism and susceptibility to urolithiasis.
The effect of calcium and magnesium ions on urinary urokinase and sialidase activity.
Urokinase alteration and its correlation with disease severity and oxidative/nitrosative stress in buffalo calves with obstructive urolithiasis.
Urokinase gene 3'-UTR T/C polymorphism is associated with urolithiasis.
Urologic Diseases
Immunohistochemical staining of urokinase plasminogen activator-like and urokinase plasminogen activator receptor-like proteins in the urinary tract of healthy dogs.
[Urinary urokinase and blood fibrinolytic activity in patients with nephrolithiasis and other urinary tract diseases]
Urologic Neoplasms
Extract from Serenoa repens suppresses the invasion activity of human urological cancer cells by inhibiting urokinase-type plasminogen activator.
Inhibition of aminopeptidase N (AP-N) and urokinase-type plasminogen activator (uPA) by zinc suppresses the invasion activity in human urological cancer cells.
Urticaria
Blood urokinase plasminogen activator system in chronic urticaria.
Uterine Cervical Neoplasms
A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix.
Biochemical markers as a predictor for lymph-node involvement in patients with cervical-cancer of the uterus.
Clinical significance of urokinase-type plasminogen activator (uPA) in invasive cervical cancer of the uterus.
Construction of Urokinase-Type Plasminogen Activator Receptor-Targeted Heterostructures for Efficient Photothermal Chemotherapy against Cervical Cancer To Achieve Simultaneous Anticancer and Antiangiogenesis.
Downregulation of Extracellular Matrix Metalloproteinase Inducer by scFv-M6-1B9 Intrabody Suppresses Cervical Cancer Invasion Through Inhibition of Urokinase-Type Plasminogen Activator.
Effect of a synthetic inhibitor of urokinase plasminogen activator on the migration and invasion of human cervical cancer cells in vitro.
Evaluating the value of uPAR of serum and tissue on patients with cervical cancer.
Fisetin Inhibits Migration and Invasion of Human Cervical Cancer Cells by Down-Regulating Urokinase Plasminogen Activator Expression through Suppressing the p38 MAPK-Dependent NF-?B Signaling Pathway.
Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway.
Hypoxia inducible factor-1 mediates upregulation of urokinase-type plasminogen activator receptor gene transcription during hypoxia in cervical cancer cells.
Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer.
Knockdown of Pentraxin 3 suppresses tumorigenicity and metastasis of human cervical cancer cells.
Prognostic significance of uPA and uPAR expression in patients with cervical cancer undergoing radiotherapy.
Prostaglandin E2 receptor 3 (EP3) signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor (uPAR).
[Urokinase-type plasminogen activator as a predictor for lymph nodes metastasis of uterine cervical cancer]
Uterine Neoplasms
Clinical significance of urokinase-type plasminogen activator (uPA) in invasive cervical cancer of the uterus.
Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
Vaccinia
Controlled gamma-irradiation mediated pathogen inactivation of human urokinase preparations with significant recovery of enzymatic activity.
Varicose Ulcer
Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Growth factors, tissue and urokinase-type plasminogen activators in venous ulcers.
Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds.
The soluble urokinase plasminogen activator receptor and its fragments in venous ulcers.
Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers.
Varicose Veins
Matrix metalloproteinase-9 and urokinase-type plasminogen activator in varicose veins.
Vascular Calcification
Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-?B pathway in osteoclasts.
Urokinase receptor mediates osteogenic differentiation of mesenchymal stem cells and vascular calcification via the complement C5a receptor.
Vascular Diseases
ALKBH1 reduces DNA N6-methyladenine to allow for vascular calcification in chronic kidney disease.
Influence of homocysteine on fibrin network lysis.
Local thrombolytic therapy for cerebrovascular disease: current Oregon Health Sciences University experience (July 1991 through April 1995).
Obstructive vascular disease treated by urokinase.
Transgenic chickens expressing human urokinase-type plasminogen activator.
Urokinase receptor associates with myocardin to control vascular smooth muscle cells phenotype in vascular disease.
[Middle cerebral arterial occlusion secondary to brain tumor -- case report (author's transl)]
Vascular Malformations
Cellular markers that distinguish the phases of hemangioma during infancy and childhood.
Vascular System Injuries
A targeted antithrombotic conjugate with antiplatelet and fibrinolytic properties which reduces in vivo thrombus formation.
Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes.
Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro.
Native atherosclerosis and vein graft arterialization: association with increased urokinase receptor expression in vitro and in vivo.
Plasmin and matrix metalloproteinases in vascular remodeling.
Plasminogen- 125 I responses in dogs to a single injection of urokinase and typhoid vaccine and to vascular injury.
Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury.
Urokinase activates the Jak/Stat signal transduction pathway in human vascular endothelial cells.
Vasospasm, Intracranial
Case presentations of neuroradiologic interventions for acute cerebrovascular disease.
Clot-clearance rate in the sylvian cistern is associated with the severity of cerebral vasospasm after subarachnoid hemorrhage.
Effect on cerebral vasospasm of coil embolization followed by microcatheter intrathecal urokinase infusion into the cisterna magna: a prospective randomized study.
Effectiveness of the head-shaking method combined with cisternal irrigation with urokinase in preventing cerebral vasospasm after subarachnoid hemorrhage.
Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage.
Intrathecal urokinase infusion through a microcatheter into the cisterna magna to prevent cerebral vasospasm: experimental study in dogs.
Microcatheter intrathecal urokinase infusion into cisterna magna for prevention of cerebral vasospasm: preliminary report.
Surgical procedure and results of cisternal washing therapy for the prevention of cerebral vasospasm following SAH.
[Combined modality therapy for cerebral vasospasm: fibrinolytic therapy using urokinase and intravascular surgery]
Venous Thromboembolism
Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism.
Venous Thrombosis
A comparative study of urokinase and heparin in the treatment of deep vein thrombosis.
A new "wonder" drug to dissolve clots. The results of urokinase therapy in acute myocardial infarction, pulmonary embolism and deep vein thrombosis.
Acute renal allograft dysfunction in the setting of deep venous thrombosis: a case of successful urokinase thrombolysis and a review of the literature.
Adenoviral urokinase-type plasminogen activator (uPA) gene transfer enhances venous thrombus resolution.
Blood coagulation changes during effective thrombolysis using urokinase and heparin.
Bolus recombinant urokinase versus heparin in deep venous thrombosis: a randomized controlled trial.
Catheter-directed thrombolysis for thromboembolic disease during pregnancy: a viable option.
Catheter-Directed Thrombolysis With a Continuous Infusion of Low-Dose Alteplase for Subacute Proximal Venous Thrombosis: Efficacy and Safety Compared to Urokinase.
Catheter-directed thrombolysis with a continuous infusion of low-dose urokinase for non-acute deep venous thrombosis of the lower extremity.
Combined thrombolytic and anticoagulant therapy for venous thrombosis in children.
Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Comparison of cost effectiveness of streptokinase and urokinase in the treatment of deep vein thrombosis.
Comparison of Direct Iliofemoral Stenting Following AngioJet Rheolytic Thrombectomy vs Staged Stenting After AngioJet Rheolytic Thrombectomy Plus Catheter-Directed Thrombolysis in Patients With Acute Deep Vein Thrombosis.
Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis.
Criteria for use of regional urokinase infusion for deep vein thrombosis.
Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
Deep venous thrombosis associated with protein C and/or S deficiency: management with catheter-directed thrombolysis.
Direct thrombolysis of superior sagittal sinus thrombosis with coexisting intracranial hemorrhage.
Efficacy and safety of repeated boluses of urokinase in the treatment of deep venous thrombosis.
Enhanced Venous Thrombus Resolution in Plasminogen Activator Inhibitor Type-2 Deficient Mice.
Evaluation of thrombolysis in a porcine model of chronic deep venous thrombosis: an endovascular model.
Feasibility of continuous, catheter-directed thrombolysis using low-dose urokinase in combination with low molecular-weight heparin for acute iliofemoral venous thrombosis in patients at risk of bleeding.
Feasibility of low-dose infusion of alteplase for unsuccessful thrombolysis with urokinase in deep venous thrombosis.
Fibrinolysis with intrathrombic injection of urokinase and tissue-type plasminogen activator. Results in a new model of subacute venous thrombosis.
Fibrinolytic therapy with streptokinase and urokinase in deep vein thrombosis.
Free tissue transfer in pediatric patients.
Iliofemoral deep venous thrombosis: aggressive therapy with catheter-directed thrombolysis.
Increase in the degree of phosphorylation of circulating fibrinogen under thrombolytic therapy with urokinase.
Intermittent pneumatic compression of the foot and calf improves the outcome of catheter-directed thrombolysis using low-dose urokinase in patients with acute proximal venous thrombosis of the leg.
Isolated straight sinus and deep cerebral venous thrombosis: successful treatment with local infusion of urokinase. Case report.
Late vascular occlusion of central lines in pediatric malignancies.
Localisation of deep-venous thrombosis using technetium-99m-labelled urokinase.
Long-term follow-up of upper extremity implanted venous access devices in oncology patients.
Management of pelvic venous stenosis with intravascular stainless steel stents.
Mechanical thrombectomy of acute iliofemoral deep vein thrombosis with use of an arrow-trerotola percutaneous thrombectomy device.
Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis.
Mycoplasma pneumoniae-induced cerebral venous thrombosis treated with urokinase.
Outcome of treatment of deep-vein thrombosis with urokinase: relationship to dosage, duration of therapy, age of the thrombus and laboratory changes.
Proceedings: Thrombolytic therapy of deep venous thromboses with urokinase.
Progress in fibrinolysis.
Repeated phlebographic examination during and after fibrinolytic therapy with streptokinase and urokinase.
Safety and Efficacy of Low Dosage of Urokinase for Catheter-directed Thrombolysis of Deep Venous Thrombosis.
Sequential Release Platform of Heparin and Urokinase with Dual Physical (NIR-II and Bubbles) Assistance for Deep Venous Thrombosis.
Simultaneous renal arterial and venous thrombosis associated with idiopathic nephrotic syndrome: treatment with intra-arterial urokinase.
Spontaneous Spinal Epidural Hematoma After Normal Spontaneous Delivery with Epidural Analgesia: Case Report and Literature Review.
Successful local arterial urokinase infusion to reverse late postoperative venous thrombosis of a renal graft.
Sustained improvement of pulmonary hemodynamics in patients at rest and during exercise after thrombolytic treatment of massive pulmonary embolism.
Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
The complete recanalization of PICC-related venous thrombosis in cancer patients: A series of case reports.
The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis.
The safety and efficacy of pharmaco-mechanical thrombolysis in lower-extremity deep venous thrombosis.
The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.
Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
Thrombolytic therapy for inferior vena cava thrombosis in paroxysmal nocturnal hemoglobinuria.
Ultrasound with Microbubble Contrast Agent and Urokinase for Thrombosis.
Urokinase in iliofemoral venous thrombosis.
Urokinase in the management of acute arterial and venous thrombosis.
Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism.
Urokinase protocol for free-flap salvage following prolonged venous thrombosis.
Urokinase therapy in neonates with catheter related central venous thrombosis.
Urokinase treatment for arteriovenous fistulae declotting in dialyzed patients.
Urokinase-coated chitosan nanoparticles for thrombolytic therapy: preparation and pharmacodynamics in vivo.
Use of urokinase in pregnancy.
Use of urokinase in pregnancy. Two success stories.
[Actual state of thrombolytic treatment of recent vein thrombosis and pulmonary embolism (author's transl)]
[Color-coded Doppler sonography for phlebothrombosis]
[Comparison of mechanical thrombectomy with transcatheter thrombolysis for acute iliac femoral venous thrombosis].
[Congenital deficiency of factor Xii and spontaenous venous thrombosis treated with urokinase]
[Dosage of urokinase in venous thrombosis of the lower extremities]
[Effects of potentiation and rapid action in models of venous thrombosis in dogs upon combined administration of the plasminogen tissue activator and urokinase modified by fibrinogen]
[Efficacy and value of fibrinolytic agents in chronic proximal venous thrombosis of the lower limbs]
[Efficacy of regional administration of urokinase and argatroban via small saphenous vein catheter for treatment of acute deep venous thrombosis in the lower limb.]
[Experience with urokinase in chronic arterial occlusive disease and long-standing phlebothrombosis]
[Experiences with streptokinase and urokinase therapy of different dosages in deep venous thrombosis]
[Extensive cerebral venous thrombosis resistant to heparin: local fibrinolysis with urokinase]
[Fibrinogen-guided thrombolysis with urokinase of a portal and mesenterial venous thrombosis during an acute episode of ulcerative colitis]
[Fibrinolytic therapy of deep vein thrombosis of the leg and pelvis with streptokinase and urokinase]
[Fibrinolytic therapy of deep venous thrombosis. Streptokinase, urokinase, plasminogen substitution]
[Fibrinolytic therapy of lower limb deep vein thrombosis with urokinase (author's transl)]
[Fibrinolytic therapy with streptokinase and urokinase in deep venous thrombosis]
[Fibrinolytic treatment with urokinase in older phlebothrombosis (author's transl)]
[Fibrinolytic treatment with urokinase of post acute phlebothromboses (author's transl)]
[Indications and implementation of fibrinolytic therapy with streptokinase and urokinase in deep venous thrombosis]
[Individualized endovascular treatment of cerebral venous thrombosis: analysis of 168 patients]
[Local low-dose thrombolytic treatment with sequential urokinase-plasminogen in deep central venous thrombosis]
[Loco-regional fibrinolysis with urokinase in the treatment of deep venous thromboses]
[Loco-regional thrombolytic therapy with urokinase in deep venous thrombosis of the legs. Our experience]
[Nephrotic syndrome complicated with intracranial venous thrombosis treated with urokinase: report of 5 cases]
[Primary nephrotic syndrome treated with urokinase--a report of 20 cases]
[Studies on thrombolytic therapy for venous thrombosis in the extremities--dynamics of plasmin inhibitor and FDP following administration of urokinase (author's transl)]
[Thrombolysis using urokinase in acute phlebothrombosis]
[Thrombolysis with Urokinase after anaphylaxis caused by streptokinase treatment (author's transl)]
[Thrombolytic agents]
[Thrombolytic efficacy of a Lys-plasminogen-urokinase combination: studies in experimental animals and humans]
[Thrombolytic therapy in patients with pulmonary artery thromboembolism and deep vein thrombosis].
[Thrombolytic therapy with urokinase in two systemic lupus erythematosus patients with deep vein thrombosis]
[Treatment of obstruction and thrombosis due to central venous catheterization]
[Urokinase dosage in deep venous thromboses]
[Urokinase in deep venous thrombosis]
[Urokinase therapy of deep vein thrombosis (author's transl)]
[Urokinase therapy of deep vein thrombosis]
[Use of streptokinase and urokinase in deep venous thrombosis and pulmonary embolism: indications and clinical experience]
[Value of color-coded duplex sonography in diagnosis of acute and chronic venous diseases of the lower extremity]
[Venous thrombolysis and venous angioplasty]
Ventricular Dysfunction, Right
Local low-dose urokinase thrombolysis for the management of hemodynamically stable pulmonary embolism with right ventricular dysfunction.
Treatment of right ventricular thrombus with severe right ventricular dysfunction using urokinase.
Ventricular Fibrillation
A novel modified tissue-type plasminogen activator (t-PA), E6010, gradually increases coronary blood flow after thrombolysis compared with native t-PA, urokinase and balloon catheter occlusion-reperfusion.
Ventricular fibrillation after intrapleural urokinase.
Vertebral Artery Dissection
[A case of basilar artery occlusion of traumatic vertebral artery dissection successfully managed by endovascular treatment]
Vertebrobasilar Insufficiency
Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor.
Thrombus in vertebrobasilar dolichoectatic artery treated with intravenous urokinase.
Viremia
Immunological predictors of survival in HIV type 2-infected rural villagers in Guinea-Bissau.
Virus Diseases
Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.
The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in Crimean-Congo hemorrhagic fever.
Vision Disorders
Statistical analysis of visual prognosis following stellate ganglion block treatment on patients with retinal vessel obstruction.
Vitreous Detachment
The efficacy of plasminogen-urokinase combination in inducing posterior vitreous detachment.
The role of recombinant lysine-plasminogen and recombinant urokinase and sulfur hexafluoride combination in inducing posterior vitreous detachment.
[Preparation of high-purity and safe autologous plasmin and its clinical application]
Vitreous Hemorrhage
Intravitreal urokinase in the treatment of vitreous hemorrhage.
Urokinase in experimental vitreous hemorrhage.
Urokinase in the management of vitreous hemorrhage.
[Intravitreal urokinase for vitreous hemorrhage]
[Subconjunctival injection of urokinase in the treatment of diabetic vitreous hemorrhage]
von Willebrand Diseases
Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activators according to the synthesis of von Willebrand factor.
Warts
[Immunohistologic alterations of epidermal cytokeratins following cryotherapy]
Whooping Cough
Activation of the {beta}-catenin/T-cell-specific transcription factor/lymphoid enhancer factor-1 pathway by plasminogen activators in ECV304 carcinoma cells.
Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of CD14 and urokinase receptor.
Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of Mac-1(CD11b/CD18) and urokinase receptor (CD87).
Pro-collagen I COOH-terminal trimer induces directional migration and metalloproteinases in breast cancer cells.
Urokinase/urokinase receptor and vitronectin/alpha(v)beta(3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways.
Xeroderma Pigmentosum
Insulin-like growth factors II exon 9 and E-cadherin-Pml I but not myeloperoxidase promoter-463, urokinase-ApaL I nor xeroderma pigmentosum polymorphisms are associated with higher susceptibility to leiomyoma.
UV irradiation induces the murine urokinase-type plasminogen activator gene via the c-Jun N-terminal kinase signaling pathway: requirement of an AP1 enhancer element.